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Abstract
Objective: To examine the psychological processes that occur whilst people are 
taking obesity medication orlistat and to assess longer term changes in weight, 
beliefs and behaviour over an 18 month period.
Background: Orlistat functions by reducing fat absorption. Research indicates 
that orlistat can have a significant impact on weight loss however there is some 
variability in outcomes and it is still not clear where the variability arises from. 
Method: A questionnaire was completed at baseline (n=1582), 6 (n=572), 12 
(n=443) and 18 months (n=519) to explore predictors of change in weight, beliefs 
and behaviour. The data was analysed at baseline (n=1582), 0 to 6 months. 
(n=572), 0 to 18 months (n=519) and the process of change over the 18 months 
(n=296). 10 individuals who failed to lose weight after 18 months were 
interviewed. The qualitative data was analysed using I PA to examine 
participants’ explanations for their weight loss failure.
Results: The results show a significant decline in weight over the first 6 months 
(4.5kg), then a gradual regain. Successful weight loss was related to significant 
event motivations, adhering to orlistat, eating less fat and greater perceived 
control over their weight. Orlistat functioned by educating them in what foods ' 
should not be eaten through the side effects and showed them that their weight 
could be controlled. To reduce failure, people needed to have a shift in identity 
towards someone who no longer expected to fail and to endorse the efficacy of 
their current method of weight loss whilst overcoming barriers.
Conclusion: Successful weight loss was related to a significant event motivation 
and believing their weight is controllable. The additional impact of orlistat is that it 
promotes healthy eating and shows their weight can be controlled, which 
facilitates long term weight loss and maintenance.
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Chapter 1 
Literature Review
1.1 Introduction
The main aim of this thesis is to examine the psychological processes that occur 
whilst people are taking obesity medication, specifically orlistat (120mg, Xenicai) 
and the Impact of this on weight loss and changes in beliefs and behaviours in 
the longer term. This literature review will consist of two sections. The first will 
describe the background to the thesis and will examine the definitions, 
prevalence, conséquences and causes of obesity. It will then discuss obesity 
management including dietary interventions, behavioural interventions, surgical 
interventions and pharmacological interventions. Orlistat will then be addressed 
specifically by describing what it is, how it works, its effectiveness for weight 
loss, weight maintenance and how it in works in practice. This review will then 
discuss how orlistat has been applied with other interventions along with 
examining cessation of orlistat, potential abuse and cost-effectiveness.
The second section will then locate the use of orlistat within a 
psychological framework. First it will describe the psychological implications of 
orlistat and how this relates to psychological theory. Next weight loss 
maintenance will be discussed along with behaviour change. Finally, adherence 
will be explored along with the doctor patient relationship, illness beliefs and 
coherence and how this relates to improving effectiveness, along with 
measurement of illness beliefs. The review will conclude with the aims of the 
thesis.
1.2 Definition of obesity, prevalence and consequences
Obesity is a condition involving excessive fat in the body and has significant 
health consequences. It is the result of undesirable weight gain caused by 
people consuming more energy than they expend (WHO Regional Office for
Europe, 2009), but is not simply a result of an unhealthy lifestyle, it is a condition 
that poses a significant health risk.
Obesity is a highly and increasingly prevalent chronic condition that is 
associated with significant morbidity and mortality. Obesity is associated with an 
increased risk of diseases that are a major cause of morbidity and mortality, 
including type 2 diabetes, coronary heart disease (CHD), hypertension, many 
cancers and osteoarthritis (National Institute for Clinical Excellence, 2006).
Obesity is a growing concern as its prevalence is increasing year on year. 
It is estimated that in 2010, in England alone, around 6,658,953 men will be 
obese, a rise from 4,302,588 in 2003 and around 5,984,653 women will be 
obese, a rise from 4,754,080 in 2003 (Zaninotto et al., 2006). Therefore almost 
two-thirds of adults are either overweight or obese with the Health Select 
Committee (2004) reporting the economic burden and cost of obesity in England 
being between £3.3 and £3.7 billion per year, which includes £49 million for 
treating obesity, £1.1 billion for treating the consequences of obesity, and 
indirect costs of £1.1 billion for premature death and £1.45 billion for sickness 
absence. The cost of obesity plus overweight is estimated between £6.6 and 
£7.4 billion per year (National Institute for Clinical Excellence, 2006) and the 
overall costs to society forecast to reach £50 billion per year by 2050 on current 
trends (Foresight, 2007).
Body mass index (BMI) is one measure of obesity widely used and is 
calculated by weight in kilograms divided by the square of the height in meters. 
The World Health Organisation (WHO) criteria for being overweight is defined as 
a BMI of between 25 to 29.9 kg/m^ and obesity is 30 kg/m^ or above. The obese 
range is also sub categorised in mild 30 to 34.9 kg/m^, moderate 35 to 39.9 
kg/m^ and severe 40 kg/m^ or above.
Along with the health implications of obesity there are also many social 
implications. Research shows that a fat person is judged and stigmatised by 
society along with being perceived as lazy, incompetent and lacking self 
discipline which can lead to significant discrimination for accessing employment, 
health care and education opportunities (Puhl & Brownell, 2001). These social 
issues were explored in a recent qualitative study by Throsby (2007). In this 
study people who had been (or still are) very overweight and had undergone 
weight loss surgery to lose weight were interviewed in terms of how they 
accounted for their size. The participants described three main discourses to 
account for their size and to resist the construction of their fatness as a moral 
failure; they described the fat-prone body, childhood weight gain and life events 
interrupting their weight management attempts. By the participants deciding to 
undergo surgery they are endorsing the belief that their weight problem and thus 
their fat body is a problem to be solved. Through the main discourses these 
participants described, they can be seen to be distancing themselves from the 
belief that their weight problem is something they have chosen to let happen to 
them through a lack of self-discipline and will power.
There are also the psychological consequences of being overweight. 
Much research has indicated an association between obesity and psychiatric 
disorders. Simon et al. (2006) conducted a cross-sectional epidemiological 
survey of US adults and found obesity was associated with significant increases 
in lifetime diagnosis of major depression, bipolar disorder and panic disorder or 
agoraphobia. Obesity was associated with an approximate 25% increase in the 
probability of mood and anxiety disorders. Other research has found that poor 
mental health is not an inevitable consequence of obesity. Hill and Williams 
(1998) examined the effect of obesity on the psychological health of a non- 
clinical sample of obese women and found that in terms of measures of mental 
health the heaviest women did not differ, however they did express the greatest 
dissatisfaction with their body weight, shape and appearance and had the lowest 
self-esteem. This therefore indicates there are some negative psychological
consequences associated with obesity. There are also issues around dieting 
and the psychological impact of this. Ross (1994) described being overweight as 
being negatively associated with perceived physical health which in turn is 
negatively associated with depression. Furthermore dieting to lose weight has its 
own consequences. Ross described being overweight as positively associated 
with dieting: dieting is positively associated with depression and dieting explains 
much of the positive association between being overweight and depression. 
Ross also suggested that being overweight is more distressing for the well 
educated than the poorly educated, as there is a significant interaction between 
being overweight and education. This seems to indicate that dieting to lose 
weight may be more distressing than being overweight and the more educated 
the individual is, the more distressed they become about being overweight.
1.3 Causes
As discussed obesity is a growing concern as the number of people classed as 
overweight and obese is on the increase. The causes behind the onset of 
excess weight will now be explored. There are many physiological theories that 
address the causes of obesity including genetics, metabolic rate theory, fat cell 
theory and appetite regulation. Genetic theories address the observation that 
obesity appears to run in families. Studies have found that having one obese 
parent in a family increases the chances of having an obese child and this is 
further increased with two obese parents in the family (Maes, Neale & Eaves, 
1997). However this may be due to genetics or the fact that families tend to live 
in similar environments, therefore twin studies have been carried out to explore 
this further. Stunkard et al. (1990) examined the BMI of 93 pairs of identical 
twins reared apart and they found that genetic factors accounted for 66-70% in 
the variance in their body weight. This result seems to suggest a genetic 
component in obesity, however it is worth noting this effect was greater in lighter 
twins than heavier twins. Another way to address the genetic component of 
obesity is to use adoptee studies. Stunkard et al. (1986) compiled information 
about 540 adult adoptees in Denmark, including information on their adopted
parents and biological parents. The results of this indicated a strong relationship 
between the weight class of the adoptee and their biological parents’ weight 
class but no relationship with their adoptive parents’ weight class. This finding 
was consistent across all weight classes and these results suggest a strong role 
for genetics in obesity.
Other physiological theories include the metabolic rate theory which 
suggests that ‘resting metabolic rate', which is the energy expended by the body 
as it carries out all the chemical and biological processes to being alive, is highly 
heritable (Bouchard et al., 1990). Also that low metabolic rates may be 
associated with obesity as people with lower metabolic rates burn less calories 
when resting therefore require less food to carry on living. Another theory is the 
fat cell theory which stipulates that obese people tend to have more fat cells, 
which may be determined by genetics, therefore with more fat cells they have 
more fat cells to fill up and thus put on weight. Research has also focussed on 
appetite regulation. This physiological theory suggests a genetic predisposition 
to appetite control with a lack of leptin which is responsible for telling the brain to 
stop eating. This theory is still in the early stages and more research is required 
to determine whether appetite regulation has a genetic predisposition which 
needs to be addressed (Ogden, 2007). Kopelman (2000) suggests that even 
though obesity appears to run In families the influence of genetics may be 
exacerbated by non-genetic factors. Apart from rare obesity-related syndromes, 
such as Prader-Willi syndrome which is characterised by upper-body obesity 
and is associated with familial inheritance, genetics seems to work by making 
the individual susceptible to obesity. This genetic inheritance increases the risk 
of developing obesity, but is not essential for its development and nongenetic 
factors such as environmental circumstances also play a role.
As discussed obesity is seen to run in families, which may suggest 
genetics as playing a role in the onset of obesity but environment may also be a 
factor. Horst et al. (2007) examined environmental correlates of obesity-related
dietary behaviours in youth in a systematic review. Their review found the most 
consistent associations were between parental intake and children’s fat, 
fruit/vegetable intakes, parent and sibling intake with adolescent’s energy and 
fat intakes and parental education with adolescent’s fruit/vegetable intake. Most 
consistent associations were found for parental influences which were parental 
intake and education. They found parental intake and to a lesser extent 
availability and accessibility were associated with intakes in adolescents and 
children. There was a positive association between an authoritative parenting 
style and adolescent’s fruit and vegetable intake. Finally there was a positive 
association for specific parenting practices and children’s energy and fat intakes. 
The findings of this review indicate that parental behaviour is associated with 
child and adolescent intakes therefore interventions should be designed to take 
behaviour of parents into account or desensitize adolescents from the undesired 
behaviour of their parents.
There are also the potential behavioural causes of obesity. These include 
physical activity and eating behaviour. Research has suggested that increases 
in the prevalence of obesity have coincided with a decrease in physical activity. 
A survey in 1992 (Allied Dunbar National Fitness Survey) found that only 20% of 
men and 10% of women were employed in active occupations and further 
research has shown that most peoples leisure time is dominated by inactivity 
(Central Statistical Office, 1994). A study that examined the relationship
between inactivity and obesity was conducted by Prentice and Jebb (1995) who
examined population data on changes in physical activity from 1950 to 1990, 
this was measured by car ownership and television viewing, and compared this 
with changes in the prevalence of obesity. They found a strong association 
between increases in both car ownership and television watching and an 
increase in obesity. However this data is only examines the association
therefore causality can not be assumed. But this study does show there is a
relationship between lack of exercise and obesity. Furthermore as the World 
Health Organisation report (2003) the rising obesity epidemic reflects the
profound changes in society and behavioural patterns with a large shift towards 
less physically demanding work worldwide. Less physical activity is also 
attributed to increased use of automated transport, technology in the home and 
more passive leisure pursuits. These societal changes are driving the obesity 
epidemic.
Obesity and overweight is the result of an energy imbalance between 
calories consumed and calories expended (WHO, 2006), therefore along with 
physical activity, eating behaviour is also a key determinant of obesity. It has 
been shown, from data in the UK National Food Survey, that food intake over 
the past 50 years changes with overall calorie consumption increasing between 
1950 and 1970, but since 1970 there has been a decrease in the amount we eat 
(Ogden, 2007). Furthermore Prentice and Jebb (1995) also examined the 
association between changes in food intake, through energy intake and fat 
intake, and changes in obesity. They found no association between increases in 
obesity and changes in food intake. However their study also indicated that the 
ratio between carbohydrate consumption and fat consumption had changed, 
where we now eat less carbohydrate but proportionally more fat. It has been 
suggested that relatively lower carbohydrate consumption is related to lower 
levels of obesity (Bolton-Smith & Woodward, 1994). This was examined through 
one study (Blundell & Macdiarmid, 1997) examining fat proportion in relation to 
obesity. This study found that high fat eaters who derived more than 45% of 
their energy from fat were 19 times more likely to be obese than those who 
derived less than 35% of their energy from fat. Therefore it seems that obese 
people do not necessarily eat more than the non-obese, however they do seem 
to eat more fat compared to carbohydrate, therefore the proportion of fat in their 
diet is higher. This seems to indicate an Intervention aimed at reducing fat intake 
would have successful outcomes if applied to the obese population. Overall 
global increases in overweight and obesity are in line with a global shift in diet 
towards increased consumption of energy-dense foods that are high in fat and 
sugars but low in vitamins, minerals and other micronutrients (WHO, 2006).
Therefore it appears that behavioural factors play an important role in the onset 
of obesity.
1.4 Obesity management
Several different approaches are used to aid weight loss. These include 
traditional methods of behaviour change such as diet and exercise, surgical 
approaches and medication. Many interventions, both behavioural and medical, 
have been applied to try and help patients reduce their weight. These different 
methods will now be discussed.
1.4.1 Dietary interventions
One traditional method of weight loss is through dietary modification. This is the 
most commonly used method of weight loss for people of all ranges of weight 
class, from normal weight individuals who would like to lose a few pounds to 
morbidly obese individuals who need to lose significant amounts of weight. One 
review of four popular diets was conducted by Dansinger et al. (2005). They 
assessed the adherence rates and effectiveness of Atkins, Zone, Weight 
Watchers and Ornish diets for weight loss and cardiac risk factor reduction. The 
study involved a single centre randomised trial that included overweight or 
obese people, with a mean BMI of 35, with known hypertension, dyslipidemia or 
fasting hyperglycemia. 160 participants were randomly assigned to a diet group 
of either Atkins, which is carbohydrate restriction. Zone, which is macronutrient 
balance. Weight Watchers, which is calorie restriction or Ornish, which is fat 
reduction. After 2 months of maximum effort, participants were allowed to select 
their own level of dietary adherence.
The mean weight loss at 1 year was 2.1kg for Atkins, 3.2kg for Zone, 3kg 
for Weight Watchers and 3.3kg for Ornish. This is a modest weight loss over a 1 
year period. Completion rates were not very high either with 53% for Atkins, 
65% for Zone, 65% for Weight Watchers and 50% for Ornish. They assumed no 
changes from baseline for those who discontinued the study, therefore there
were greater effects observed in study completers which may not have been 
accurate. All diets significantly reduced the low-density iipoprotein/high-density 
lipoprotein (HDL) cholesterol ratio by approximately 10% with no significant 
effects on blood pressure or glucose at 1 year. Weight loss was associated with 
self-reported dietary adherence levels, but not with diet type. For all diets 
decreasing levels of total/HDL cholesterol, C-reactive protein and insulin were 
significantly associated with weight loss with no significant difference between 
diets.
The results of this study (Dansinger et al., 2005) indicate that no specific 
diet is better than the others but that it may be more of a case of selecting a diet 
to suit the preferences and cardiovascular risk profiles of the patient that will 
lead to greater adherence and success. In the current study the adherence may 
have been improved if the participants were allowed to choose the diet that best 
suits them. Another limitation of this study is that the numbers of participants 
involved and the high attrition rate meant that the numbers were not great 
enough to detect a difference between the diet types; this would need further 
research with a larger sample size. The study also does not examine long term 
safety risks or occasional adverse events, as it was relatively short in duration. 
However in the short term the study indicates no safety risks. Overall this study 
indicates that diets can produce modest weight loss and reduction in several 
cardiac risk factors at 1 year. Dietary adherence was generally low, but 
increased adherence was associated with greater weight loss and cardiac risk 
factor reduction for all diets.
Ayyad and Andersen (2000) conducted a systematic review of studies 
that examined long-term efficacy of dietary treatment of obesity. Studies were 
included if they were a dietary treatment, involved adults, the follow up period 
was greater than 3 years, the follow up rate was greater than 50% of the original 
study group, information on one of the success criteria including maintenance of 
all weight initially lost or maintenance of at least 9 to 11 kg of initial weight loss.
and obesity complications of the patient group not over-represented. 17 
publications were included, follow up was from 3-14 years with a mean initial 
weight loss from 4 to 28kg. Overall 15% of followed up patients fulfilled one of 
the criteria for success with success rates appearing stable for up to 14 years of 
observation. The results of this systematic review showed that diet combined 
with group therapy lead to better long-term success rates than diet alone or diet 
combined with behaviour modification. Active follow-up was generally 
associated with better success rates than with passive follow up. Conventional 
diet (CD) appeared most efficacious combined with group therapy, whereas very 
low calorie diet (VLCD) was most efficacious if combined with behaviour 
modification and active follow up.
Overall this review suggests median success rates of 15%, however even 
though many of these people would still be classed as overweight there are still 
some health benefits to be achieved from the weight loss achieved. It is likely 
that those who drop out are likely to have poor outcomes, therefore by excluding 
this data the results may be skewed. However when this review included the 
patients lost to follow up as failures the overall success rate was reduced to 
13%. The review highlights there is a possible adjuvant effect of group therapy, 
behaviour modification and active follow-up in success rates. This review 
indicates the fact that there is limited literature on long-term weight 
maintenance. Therefore overall dietary interventions can be a useful tool for 
weight loss however results tend to be modest and additional interventions can 
improve outcomes.
1.4.2 Behavioural interventions
Another traditional method of weight loss is exercise. Shaw et al, (2006) 
conducted a review of studies examining exercise for overweight or obesity as a 
means of achieving weight loss, using randomised control clinical trials. This 
review found that when compared with no treatment, exercise resulted in small 
weight losses across studies. Furthermore exercise combined with diet resulted
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in more weight loss than diet alone. Also increasing exercise intensity increased 
the magnitude of weight loss. Therefore vigorous activity appears more effective 
than moderate or light intensity exercise in inducing weight loss. However high 
intensity exercise was only significantly better than low intensity exercise at 
inducing weight loss when undertaken without dietary change. When dietary 
change was included exercise intensity did not significantly affect weight loss 
magnitude. Therefore it appears that the effect of exercise on weight loss is 
outweighed by the magnitude of effect of dietary change. Thus suggesting diet is 
significantly more effective at facilitating weight loss than exercise.
Shaw et al.’s (2006) review also suggests exercise interventions have a 
positive effect on cardiovascular risk factors. Participants taking part in exercise 
interventions alone reduced systolic and diastolic blood pressure, cholesterol, 
triglycerides and fasting serum glucose, along with increased HDL (serum high- 
density lipoprotein) levels. Significant changes when compared with no 
treatment were seen in diastolic blood pressure, triglycerides, HDL and glucose. 
These changes were independent of significant weight loss. An issue with this 
review, and the studies included in this review, is that outcomes measures were 
short term changes, there was no data on long term effects, which is important 
for assessing effect of exercise on mortality. Also many studies were not 
included in the review due to large losses to follow-up; this means some useful 
studies were not included in the review. Overall the review supports exercise as 
a weight loss intervention and is particularly effective when combined with 
dietary change. Furthermore exercise is also associated with improvements in 
cardiovascular risk factors even when no weight is lost.
A study that explored this in more detail was conducted by Jeffery et al. 
(2003). They explored whether prescribing higher physical activity goals improve 
outcomes. They assigned participants to either a standard behaviour therapy 
(SBT) with an energy expenditure (EE) goal of 1000 kcal/week, or to a high 
physical activity (HPA) treatment with a goal of 2500 kcal/week. The HPA
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received other interventions to aid them in reaching the higher activity levels, 
including them recruiting 1-3 exercise partners into the study, personal 
counselling from an exercise coach and small monetary incentives. The HPA 
group achieved higher mean physical activity levels than the SBT group at 6, 12 
and 18 months. Furthermore their mean weight loss was significantly higher at 
12 and 18 months. The fact that weight loss did not significantly differ at 6 
months may be due to the participants in the HPA treatment group only 
gradually increasing their activity levels and they only achieved their highest 
levels at the 6 month time point. It is also important to note that the weight loss 
may have been due to the other interventions applied to the HPA group as they 
received additional support that the SBT group did not. However the two groups 
did not differ in their dietary intake therefore it does appear that it is the physical 
activity levels that seemed to have played a major role in the achieved weight 
loss. This study suggests that along with exercise being a useful tool to aid 
weight loss, higher intensity physical activity can promote long term weight loss 
better than conventional recommendations.
Research therefore shows that behavioural interventions can be 
beneficial for weight loss and for reducing cardiovascular risk factors. However 
non-pharmacological methods of obesity treatment, which include dietary 
modification and exercise, have demonstrated short-term efficacy. Around one 
third to two thirds of weight loss is regained within one year and by 5 years 
almost all is regained (NIH, 1993). For a more long term solution there is the 
option of bariatric surgery.
1.4.3 Surgical interventions
Bariatric surgery refers to surgical alteration of the stomach or intestine in order 
to produce weight loss (Crookes, 2006). Bariatric surgery is now an operation 
that can be performed reliably, usually laparoscopically, with low mortality. 
Bariatric surgery comes in several different forms; there is vertical banded 
gastroplasty (VBG), which involves partitioning the stomach into a small
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restrictive pouch which then empties into the residual stomach via a calibrated 
and banded outlet. There is the Roux-en-Y gastric bypass (RNYGBP), which 
involves forming a small gastric pouch by division of the upper stomach, which 
the jejunum is joined on to, so that food bypasses the stomach and upper small 
bowel (Leff & Heath, 2009). There is also the biliopancreatic diversion with and 
without duodenal switch. The biliopancreatic diversion (BPD) is a form of 
RNYGBP construction, but the bypassed segment of intestine includes the 
portion of duodenum at the point of entry of biliary and pancreatic secretions. 
Furthermore the BPD was developed to include the duodenal switch (BPD-DS) 
where the Roux limb is anastomosed not to the stomach but to the duodenum 3- 
5 cm beyond the pylorus. The duodenal switch is combined with a linear 
(sleeve) gastrectomy, removing the dilatable storage portion of the stomach and 
leaving only a narrow tube based on the lesser curve. Finally there is the 
adjustable gastric band, also known as the Swedish band. This is a purely 
restrictive operation, with the aim of reducing hunger and provides the feeling of 
satiety after eating a small meal. It has lower risk but is somewhat less effective. 
This involves a band being placed around the upper part of the stomach which is 
connected to a port under the skin into which saline can be injected or 
withdrawn to inflate or deflate the band, respectively (Leff & Heath, 2009).
Weight loss after bariatric surgery is generally expressed as percentage 
of excess weight lost (%EWL), with successful weight loss after bariatric surgery 
being around 50% EWL (Dietel & Shahi, 1992). In one meta-analysis (Buchwald 
et al, 2004) the effect of these operations were summarized and the mean 
%EWL at the time point for which co morbidities were assessed were reported. 
For the gastric banding the mean EWL was 47.5%, for the RNYGBP 61.6%, for 
the gastroplasty 68.2% and for BPD with or without DS 70.1%. Weight loss 
outcomes did not differ significantly for assessments at 2 years or less 
compared with those at 2 years or more. In terms of absolute weight loss this 
averaged at 46.4 kg for BPD, 43.5 kg for RNYGBP, 39.8 kg for gastroplasty and 
28.6 kg for gastric banding. This data shows that surgical intervention is a useful
tool for weight loss, however there is still some variability in terms of success in 
weight loss, which means is is useful to look at the experiences of those 
experiencing weight loss surgery and look at the key variables that may affect 
outcomes.
Karlsson et al. (2007) report a 10 year study of obese participants 
involved in surgical or conventional treatment for their weight problem and the 
changes in health related quality of life (HRQL) from weight loss. Surgical 
treatment included fixed or variable banding, vertical banded gastroplasty or 
gastric bypass. Conventional treatment was that offered by their regular health­
care centre, this was not standardised and treatments varied according to local 
practices. The results of this study show that changes in HRQL over the 10 
years mostly followed phases of weight loss, weight regain and weight stability. 
Improvements and deteriorations in HRQL were associated with the extent of 
weight loss or regain. They found that for positive long-term effects on HRQL 
maintained weight loss of 10% is sufficient. Overall they found that long-lasting 
weight loss in the obese population has general positive outcome on HRQL. 
Furthermore bariatric surgery is a favourable treatment with long-term weight 
loss and improvements in HRQL in most patients. However this is not 
guaranteed as some patients do struggle to control and maintain this weight loss 
over time.
A study which examined patient's experiences of obesity surgery was 
conducted by Ogden, Clement! and Ayiwin (2006) through a series of in-depth 
interviews. Through Interpretative Phenomenlogical Analysis (IPA) they found 
four main themes emerged from the interviews. The first was personal weight 
histories; patients had described how they decided upon obesity surgery from 
numerous failed attempts at more traditional solutions, such as dieting, and 
reported a long history of weight cycling. The next theme was the decision 
making process including general motivations, such as concerns about their 
health and weight and specific triggers, such as symptoms which highlight the
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problems associated with excess weight. Thirdly the impact of surgery on their 
eating behaviour and their relationship with food. They described how the 
reduction in the size of their stomach had enforced a change in their eating as a 
result of the negative feedback associated with the consequences of overeating, 
such as nausea and pain. This had resulted in new eating preferences and food 
became less of a focus with a reduction in hunger which meant they felt they 
had regained control over what and when they ate. Finally the impact of weight 
loss was a main theme with an increase in self-esteem, health status, quality of 
life, energy, renewed confidence and relationships with others improved.
Through the interviews the central theme which became apparent 
through all the four themes was control. The surgery itself imposed control and 
limited choice on what the individual ate through the reduction in size of the 
stomach. However paradoxically this imposed control gave the patients back 
control over their eating and gave them a renewed sense of control. Patients 
reported feeling out of their control with eating which is why they had gained the 
weight and felt the need to pass over the control to an external source to deal 
with the problem. Although paradoxically by going through surgery and having a 
physical limitation on what they can physically eat they felt a sense of regaining 
control over their eating and their weight with a renewed sense of control over 
their lives in general. This contradicts the belief that patients need choice to 
facilitate a feeling of control. The surgery had removed the choice from patients 
in terms of what and how much they eat, but this had improved their feelings of 
control, therefore the relationship between choice and control is not as 
straightforward. Even though obesity is seen as a behavioural problem with a 
behavioural solution, non behavioural solutions, such as surgery, can also 
facilitate weight loss and shifts In the patients’ cognitions. Therefore surgical 
interventions have great success and are part of the solution for the obesity 
epidemic, but there is also a less invasive medical solution which is 
pharmacological interventions.
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1.4.4 Pharmacological interventions
Another medical intervention for weight loss is obesity medication or drug 
therapy. Obesity medication is a method to aid weight loss that is usually applied 
before surgical intervention and after traditional diet and exercise methods have 
failed. Drug therapy is recommended for individuals with a BMI of greater than 
30 kg/m^ or a BMI of 27 to 30 kg/m^ with one or more obesity related disorders 
(Royal College of Physicians of London, 2003). Drug therapy should also be 
used in conjunction with non-pharmacological therapy. The American Food and 
Drugs Administration (FDA) and the European agency for the Evaluation of 
Medicinal Products (EMEA) both demand that any anti-obesity drugs should 
produce a significantly greater weight loss compared to placebo^ The FDA 
specify that the drug should produce 5% greater placebo-subtracted weight loss, 
also significantly more people should have lost 5% or more of their initial body 
weight compared to placebo. The FDA also demand that the drug reduces total 
body fat mass and alters the distribution of body fat. The EMEA demand that 
anti-obesity medication should elicit 10% or more of their initial body weight from 
baseline and that significantly more people should lose 10% or more of their 
initial weight than the placebo group. The secondary outcome for an anti-obesity 
drug trial is that the weight loss is sustained and provides a significant reduction 
in risk factors for obesity related co-morbidities. Furthermore that the drug 
induced weight loss has a positive impact on health related quality of life 
(Halford, 2006).
There are three main types of obesity medication. Firstly there are 
inhibitors of intestinal fat absorption such as orlistat. Secondly there are 
medications that act to suppress appetite, increase satiety, or increase 
thermogenesis, primarily by modifying central nervous system 
neurotransmission of norepinephrine, dopamine and serotonin. This type 
includes sibutramine which inhibits re-uptake of serotonin and norepinephrine. It 
is the most commonly prescribed medication and primarily acts to suppress 
appetite. Sibutramine is the only centrally acting anti-obesity compound
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approved for use in most countries. Finally there are inhibitors of the 
endocannabinoid system such as rimonabant. Rimonabant reduces food intake, 
hunger and body weight in obese people. Three medications which were 
approved for long term use were orlistat, sibutramine and rimonabant (Padwal et 
al., 2003). However as of June 2008 EMEA withdrew its guidance on the use of 
rimonabant for the treatment of overweight and obese patients. They have 
recommended the suspension of the marketing authorisation for rimonabant 
(Acomplia) in Europe, this was because they reported that the benefits of 
rimonabant no longer outweigh its risks. Acomplia has always noted in its 
product information there may be possible psychiatric side effects, in particular 
depression, however studies have indicated an approximate doubling of the risk 
of psychiatric disorders in patients taking Acomplia compared to those taking 
placebo. They recommend that prescribers should not issue any prescriptions 
for Acomplia and should review the treatment of patients currently taking it. It is 
also important to note that orlistat (marketed as Alii, 60mg, and Xenical, 120mg) 
is currently undergoing a safety review by the FDA, They are currently 
examining a few reports (32, worldwide) of serious liver damage, most 
commonly jaundice, weakness and abdominal pain. However the FDA’s analysis 
is ongoing and no definite association between liver injury and orlistat has been 
established. Furthermore the FDA current advice is for health professionals to 
not change their prescribing practices with orlistat. Patients and consumers 
currently taking orlistat are advised to continue with their treatment, however if 
they experience any symptoms possibly associated with taking orlistat they 
should consult their health care professional (US Food and Drug Administration 
(FDA), 2009).
Many interventions have been applied to assist obese individuals to lose 
weight. A systematic review, by Avenell et al. (2004a) examined randomized 
control trials, lasting for 1 year or more, using weight reducing diets combined 
with drug therapy, exercise, behaviour therapy or a combination of these. The 
results of this review indicated that adding orlistat to diet was associated with
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weight change of -3.26kg for up to 24 months with significant beneficial changes 
in total and LDL cholesterol, blood pressure and glycémie control. Adding 
sibutramine to diet related to weight change of -4.18kg by 12 months with 
significant beneficial effects on high density lipoprotein cholesterol (HDL) and 
triglycerides (TGs), but an increase in diastolic blood pressure. Adding exercise, 
such as walking, jogging and cycling, to diet, or to diet and behaviour therapy, 
lead to improved weight loss for up to 36 months and improved HDL, TGs and 
blood pressure. Finally adding behaviour therapy to diet, or to diet and 
sibutramine together, was associated with improved weight loss up to 18 
months.
Avenell et ai. (2004a) highlight some issues to be aware of with the two 
obesity medications included, which needed to be considered. Sibutramine has 
beneficial effects on weight and risk factors but it also has the potential to 
increase blood pressure and is associated with constipation. Orlistat had 
beneficial effects on weight and risk factors but it was also associated with 
gastrointestinal adverse events related to the action of the drug with a greater 
need for vitamin supplements. Overall this review found that long term weight 
loss can be improved by adding orlistat, sibutramine, exercise or behaviour 
modification to weight reducing diets.
Phelan and Wadden (2002) reviewed combining behavioural and 
pharmacological treatments for obesity. They review adding pharmacological 
treatments, such as orlistat and sibutramine, to a modest programme of lifestyle 
modification. The studies they reviewed indicated that the addition of medication 
generally improves short term and long term weight loss in comparison to 
lifestyle modification alone. Also long term use of medication appears to 
facilitate weight maintenance. The best results were obtained when medications 
were combined with an intensive group program of lifestyle modification. The 
two approaches may have an additive effect. Behavioural treatment seems to 
help the participants’ control the external environment, which is food related, and
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pharmacotherapy seems to control the internal environment by reducing hunger, 
cravings or nutrient absorption. However this review highlights that more 
research is needed to determine the types of lifestyle interventions that 
maximise the medication effects.
The effectiveness of obesity medication is important in terms of 
achievable weight loss along with the other health benefits as the outcome 
variable. In a recent updated meta-analysis (Rucker et al, 2007) of double blind 
randomised placebo controlled trials of approved anti-obesity drugs, including 
orlistat, sibutramine and rimonabant, used in adults aged over 18 years for one 
to four years, this was addressed. This review found that compared with placebo 
orlistat reduced weight by 2.9kg, sibutramine by 4.2kg and rimonabant by 4.7kg. 
This review showed that with active drug treatment patients were significantly 
more likely to reach 5% and 10% weight loss thresholds. In terms of other health 
benefits orlistat reduced incidence of diabetes, improved concentrations of total 
cholesterol and low density lipoprotein (LDL) cholesterol, blood pressure and 
giycaemic control in patients with diabetes but increased gastrointestinal side 
effects and slightly lowered concentrations of high density lipoprotein (HDL). For 
sibutramine they found lowered concentrations of HDL cholesterol and 
triglycerides but raised blood pressure and pulse rate. Finally for rimonabant 
studies showed improved concentrations of HDL cholesterol and triglycerides, 
blood pressure and giycaemic control in patients with diabetes but increased risk 
of mood disorders. All three of the anti-obesity medications reviewed had 
advantages and disadvantages, therefore the decision to prescribe them 
involves careful assessment of these risks and benefits. Rucker et al highlight 
that the average weight loss with drug treatment is modest and most patients 
will remain considerably obese or overweight. Furthermore the drugs 
themselves are costly with 28 days treatment costing around £40-55 in the UK. 
Therefore the decision to prescribe anti-obesity medication needs to be a 
balanced decision; it needs to be considered who it would be potentially useful 
in, when to avoid use and other factors such as what factors need to be
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monitored, such as blood pressure or mood disorders. The results of this meta­
analysis also need to be considering in terms of the context of the environment. 
These patients were involved in a clinical trial which means there were 
numerous highly trained staff to deal with any problems or queries. The same 
results may not be achieved when applied to a general practice setting as GP’s 
are generally very busy and would not have the same amount of time nor the 
same expertise as thé staff working in the trial, therefore these drugs need to be 
examined in a general practice setting.
Frost et al. (2002) conducted an intensive lifestyle intervention combined 
with the choice of pharmacotherapy to improve weight loss and cardiac risk 
factors in the obese. They used contractual methods with more time with the 
dietician, offering pharmacotherapy where appropriate and emphasis on 
achieving realistic weight loss of 10% in a 6 month period through a lifestyle 
clinic. They also employed cognitive behavioural strategies focusing on changes 
in dietary intake and physical activity levels. 26 patients completed the 
programme with 18 taking orlistat and 8 remaining on lifestyle advice only. The 
results of the study indicated clinically significant benefits for exercise tolerance, 
waist measurement and total cholesterol. The lifestyle clinic alone produced a 
weight loss of 5% at 6 months, which is clinically significant. The lifestyle clinics 
involve 340 minutes of dietician contact time over a 6 month period, which is 
significantly more than current clinical practice (approx 80 minutes), with an 
average weight loss of 7.8kg. The clinics also show greater successes with 
weight loss and greater improvements in health risk factors. The results also 
indicate that investment in more dietician time for patients results in greater 
weight loss and lifestyle changes for better weight loss in the short term. Further 
research needs to be conducted to see if this benefit is continued and reflected 
in the longer term.
The lifestyle clinic is a structured weight loss intervention and allows for a 
more holistic treatment of the patient which takes into account the needs and
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requirements of the individual attempting weight loss. The lifestyle clinic also 
prepares the individual for weight loss maintenance when the programme 
comes to an end. The clinic’s programme addresses the factors involved in the 
individuals’ weight gain and strategies to avoid certain foods or situations. 
Furthermore physical activity is addressed in terms of setting goals and it is 
encouraged as a daily habit for a lifetime. The drug therapy that was offered to 
the patients in the clinic was shown to be a useful tool as part of the treatment in 
the lifestyle clinic. It is important to highlight that the data in this study was based 
on audit data which limits the conclusions that can be drawn. The results from 
this study indicate that lifestyle clinics, which incorporate appropriate 
pharmacotherapy, can facilitate beneficial changes in lifestyle which lead to 
weight loss and a positive impact on morbidity risk factors which demonstrated 
an improvement on current NHS services available.
Padwal, Li and Lau (2003) conducted a review of long term 
pharmacotherapy for obesity and overweight. They compared the effects and 
safety of approved anti-obesity medications in clinical trials of at least 1 year 
duration. They examined double-blind, randomised controlled weight loss and 
weight maintenance trails of approved anti obesity agents. Only orlistat and 
sibutramine studies met their criteria and were included in the review. All 
patients received lifestyle modification as a co-intervention in the trails. Study 
attrition rates were high which averaged at 33% during the weight loss phase for 
orlistat trials and 43% in sibutramine studies.
Padwal, Li and Lau (2003) found that compared to placebo, orlistat 
treated patients lost 2.7kg more weight and patients taking sibutramine 
experienced 4.3kg greater weight loss. The number of patients achieving 10% or 
greater weight loss was 12% higher with orlistat and 15% higher with 
sibutramine therapy, with weight maintenance results reflecting a similar patter. 
In terms of side effects, those on orlistat reported gastrointestinal side effects 
and taking sibutramine was associated with small increases in blood pressure
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and pulse rate. However with most studies the gastrointestinal symptoms that 
were associated with orlistat treatment were reported as mild and transient and 
decreased as patients adjusted to a low fat diet. The numbers of patients 
discontinuing therapy due to these adverse effects appeared small. They also 
suggest if sibutramine is prescribed, blood pressure monitoring is required. 
Furthermore orlistat treated patients showed improvements in total cholesterol, 
low-density lipoprotein cholesterol, blood pressure and glycémie control and 
slightly lower high-density lipoprotein levels. Sibutramine therapy showed small 
improvements in high-density lipoprotein cholesterol and triglyceride levels.
High attrition rates were observed in both treatment and control groups. 
In some studies, to address this, authors carried forward the last observation to 
the end of the study, however this may have biased the results in either direction 
as depending when the patient dropped out it may mean the results are over or 
underestimated. Furthermore another limitation of the studies included in this 
review is that weight was often measured at the beginning of the run-in phase 
rather than the point of randomisation to drug therapy or placebo. This may have 
inflated the amount of weight loss reported however this was the procedure for 
both treatment and control groups therefore the comparative weight differences 
are still of interest. Also only those who complied with the initial run-in phase 
were included for randomisation, therefore the results may be biased and only 
represent obese patients able to comply with diet and treatment in the run-in 
phase which may not be representative of the obese population in general. An 
interesting point for continuing prescription of drug therapy in the general 
population is that responders can be identified within the first several months of 
therapy as near maximal weight loss was achieved by 6 months in most trails. 
This review indicates that both orlistat and sibutramine appear modestly 
effective in promoting weight loss. Even though the weight loss appears modest 
it has been show that this weight loss is of health benefit, with significant 
reduction in the incidence of diabetes (Torgerson et al., 2004). Also all studies in 
this review showed a positive treatment effect.
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1.5 Orlistat - What is it and how does it work?
Orlistat (Xenical) is one of the most commonly prescribed obesity medications 
which acts on the gastrointestinal system and works by reducing fat absorption. 
It blocks absorption of fat in the gut and the availability of fat soluble vitamins 
(vitamins"A, D, E and K) therefore it is also recommended that patients taking 
orlistat also take a vitamin supplement (National Institute for Clinical Excellence, 
2001). It helps block about one-third of the fat in the food eaten from being 
absorbed in the body and is eliminated in bowel movements. Current 
recommendations suggest that it is used for patients who have a history of failed 
weight loss attempts using behavioural methods and who can demonstrate 
some degree of weight loss in the month before treatment (National Institute of 
Clinical Excellence, 2001). Patients need to reduce their daily calorie intake by 
500 to 1000 calories to achieve weight loss in overweight and considerably 
overweight people. In addition to reducing calorie intake, they also need to 
watch the number of fat grams they consume whilst on orlistat. The Dietary 
Guidelines for Americans recommend that fat in their diets is limited to about 
30% of their daily calories, e.g. 40 grams of fat in a 1200-calorie diet. Current 
recommendations are that adults have to have lost at least 2.5kg by diet and 
exercise in the month prior to their first prescription. When orlistat is taken in 
conjunction with high fat foods there are unpleasant side effects including liquid 
stools, an urgency to go to the toilet and anal leakage, this is because the drug 
prevents the fat consumed from being absorbed by the body.
1.5.1 Or! istat for weîg ht loss
As discussed above in terms of effectiveness of orlistat the review by Padwal, Li 
and Lau (2003) found weight loss was 2.7kg or 2.9% greater in orlistat treated 
patients. Furthermore with regard to secondary outcomes the results indicated 
that orlistat reduced cholesterol and blood pressure levels and improved 
glycémie control when compared to placebo. This review also addressed 
attrition rates. The review of randomised control trials found average attrition
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rates for orlistat was 33% (11 studies, n=6021). it has been suggested in 
pharmacoepidemiological studies that in clinical practice attrition rates are even 
higher (64-77%) (Vray et al, 2005). These findings indicate that variability is an 
issue. This has been addressed in guidelines for treatment of obesity (National 
Institute for Clinical Excellence, 2001). If, at 3 months, individuals have not lost 
more than 5% of their body weight from the start of drug treatment, then 
physicians are advised not to continue treatment. Furthermore if at 6 months 
weight loss is not at least 10% of body weight then treatment should not 
continue. Treatment of obesity with orlistat does not usually continue beyond 12 
months and never beyond 24 months (National Institute for Clinical Excellence, 
2001). Although anecdotal reports show that patients are often put on and off 
the drug several times. Variability is a key concern as it is of interest as to who 
takes it as prescribed and who does not, also who orlistat works for and who it 
does not.
A randomised placebo trial of orlistat as an aid to weight loss and weight 
loss maintenance in obese patients was conducted by Sjostrom et al. (1998). 
They assessed the efficacy and tolerability of orlistat in promoting weight loss 
and preventing weight regain in obese patients over a 2 year period. 688 
patients completed 4 weeks on a single blind, placebo lead in period on a 
hypocaloric diet (600 kcal/day deficit). They were then assigned double-blind 
treatment with orlistat or placebo for 1 year alongside the hypocaloric diet. In a 
further 52 week double-blind period patients were assigned to either a placebo 
or orlistat group with a weight maintenance diet (eucaloric). The results showed 
that from the beginning of the lead-in period to the end of year 1 the orlistat 
group lost, on average, more weight than the placebo group. Also in year 2, 
patients who continued on orlistat regained, on average, half as much weight as 
those who switched to the placebo group. Patients who were switched from 
placebo at year 1 to orlistat at year 2 lost an additional 0.9kg during year 2, 
compared to a mean regain of 2.5kg for those who remained on placebo. 
Therefore in year 2 weight regain was reduced greater by orlistat compared to
24
placebo and those who ceased taking orlistat experienced a marked rebound 
effect in terms of their weight. The total cholesterol, low density lipoprotein (LDL) 
cholesterol, LDL/high-density lipoprotein ratio, and concentrations of glucose 
and insulin decreased more in the orlistat group compared to the placebo group. 
Plasma total cholesterol and LDL-cholesterol concentrations fell further in the 
orlistat than would be expected from weight loss alone, which may be a result of 
the way orlistat works as it reduces the energy uptake from fat.
Orlistat works directly and specifically at the site of fat breakdown in the 
stomach and small intestine, therefore systemic absorption is negligible and 
potential for systemic adverse events seems to be small. Gastrointestinal 
adverse events were more common in the orlistat group; however this was 
expected due to the pharmacological mode of action of the drug. Also these 
were more common in the orlistat group in year 1 but were lower in those who 
continued on orlistat in year 2. Another issue with orlistat is that it decreases the 
absorption of fat-soluble vitamins, however in this study most remained within 
normal range and few individuals with low values needed supplementation. This 
study has shown that when orlistat is taken with an appropriate diet it can 
promote clinically significant weight loss and reduce weight regain in obese 
patients over a 2 year period. Furthermore it enables several beneficial changes 
in several cardiovascular risk factors.
A recent systematic review of the clinical effectiveness of orlistat for the 
management of obesity was published by O’Meara et al. (2004). They reviewed 
randomized control trials evaluating the effectiveness of orlistat for weight loss 
or maintenance of weight loss in individuals who are overweight or obese. They 
found statistically significant differences in favour of orlistat for weight loss and 
changes in risk factors. Flowever a smaller effect size was observed in patients 
with type 2 diabetes. This may have been due to weight gain from anti-diabetic 
medication, changes in energy intake or altered regulation of energy balance. 
The review also suggests some of the weight loss in patients treated with orlistat
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may be due to them altering their dietary fat intake to avoid the unpleasant 
consequences of fatty stools. They mention this needs to be addressed in 
further research and it has been qualitatively assessed by Ogden and Sidhu 
(2006), which is described later. They identify that trials tend to recruit between 
the ages of 18 to 75 years, therefore there is both a younger and older group 
that have not been addressed and this needs to be rectified in future research 
as obesity is also prevalent in these groups. There is also the issue of adhering 
to the same selection criteria as in clinical practice, which is specified in UK 
national prescribing guidelines. However most trials did not require patients to 
lose the required 2.5kg before treatment commenced through diet and exercise, 
with the discontinuation of treatment if they do not achieve losing 5% of their 
initial body weight by 12 weeks. This conflict with clinical practice means the 
results from the trials may not be generalised to clinical practice.
O’Meara et al also identify that analysis in 1999 (Foxcroft & Ludders) 
estimated the average annual cost of orlistat treatment for 100 patients (treated 
for 2 years) was £73,436. Furthermore the number of QALY gained in 1 year of 
100 patients treated with orlistat, compared to placebo was estimated at 1.601. 
They identified that orlistat was more cost-effective in patients with additional 
risk factors. They highlight taking orlistat is associated with higher incidence of 
gastrointestinal adverse events compared with placebo. Overall they concluded 
that orlistat is more effective than placebo in promoting weight loss, 
maintenance of weight loss and improving cardiovascular risk factor profiles. 
Furthermore they highlight the issue that baseline profile parameters of patients 
seen in clinical practice should be taken into account when treatment with 
orlistat is considered.
As described earlier very little orlistat is absorbed into the body and it has 
no systemic action however it may modulate feeding behaviour. Due to the 
adverse consequences of eating fatty foods whilst taking orlistat people may 
alter their food choices in order to avoid these effects. However it has also been
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shown that orlistat treatment can lead to significant increase in the consumption 
of carbohydrate (Ullrich et al. 2003). Those taking orlistat who lost the least 
weight were those who increased their carbohydrate consumption the most.
Orlistat works by reducing fat absorption, therefore the advice given to 
patients taking it is to reduce fat intake, however total calories and amount of 
carbohydrate that is consumed is also important to address with patients who 
are trying to lose weight. Ullrich et al. (2003) examined total energy and 
macronutrient intake in terms of change in eating habit and weight loss whilst on 
orlistat. 56 patients consumed a hypocaloric diet, with orlistat for 72 weeks with 
a maximal fat allowance of 30% of energy intake. They were also given an 
educational programme on dietary advice. Food diaries were completed as a 
measure of food intake. After the initial 6 month period the recommended 
energy content of their diet permitted at least weight maintenance. The average 
weight loss was 8.5kg and energy intake during the study was less than 1500 
kcal/day. The results identified 3 main groups according to weight loss achieved, 
those who lost less than 5%, those who lost more than 5% but less than 10% 
and those who lost more than 10%. Fat intake was in line with the 
recommended range in all groups during the first 6 months, but only in group 3 
after that. All groups increased their carbohydrate consumption and this was 
greatest in group 1, which could account for the rapid regain of weight initially 
lost. The food diaries indicate the educational programme with an emphasis on 
low fat intake was successful as all groups adhered to their fat allowance in the 
first 6 months. Flowever after the initial weight loss their fat allowance was 
adapted, only one third adhered to the new lower levels. However no group 
increased their fat intake above the initial recommendation, which they suggest 
may be due to orlistat and the adverse events that are associated with 
consuming too much fat. Group 1 were unable to reduce their body weight 
consistently during the study and analysis of food diaries suggested this may be 
due to over-consumption of carbohydrates which prevented maintenance of 
reduced body weight. Only those who maintained their fat intake substantially
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lower than the initial recommendation were able to reduce and maintain their 
body weight, despite the increase in carbohydrates. The results of this study 
show that orlistat along with a low fat intake can lead to weight loss in the short 
term. However in terms of long term success patients who are struggling to keep 
the weight off must also address their carbohydrate consumption which should 
be restricted along with fat intake to ensure weight loss and weight 
maintenance. Therefore educational programmes on eating behaviour should 
not solely focus on fat intake when an individuals’ weight has reached a plateau 
or they are beginning to regain weight, they should also be educated on 
carbohydrate consumption which may need to be limited in order to ensure long 
term success of weight reduction.
1.6.2 Orlistat for weight maintenance
One study which looked at the effectiveness of orlistat after an initial weight loss 
was conducted by Hill et al. (1999). They conducted a randomised, double-blind, 
placebo-controlled, one year study of obese subjects who had already loss > 8% 
of their initial body weight during a 6 month prescribed hypoenergetic diet. 729 
subjects were assigned randomly to either orlistat or placebo 3 times daily for 1 
year in combination with a maintenance diet to prevent weight regain. The 
results showed that after 1 year subjects treated with orlistat 3 times a day 
regained less weight compared to placebo treated subjects. Furthermore orlistat 
treatment was associated with significantly greater reductions in total and LDL- 
cholesterol concentrations than with placebo treatment. The results from this 
study indicate that orlistat combined with a weight maintenance diet can be used 
to help maintain weight loss and facilitate long-term improvements in obesity 
related disease risk factors.
Richelsen et al. (2007) examined the effect of orlistat on weight regain 
and cardiovascular risk factors after a very low energy diet (VLED). The study 
involved abdominally obese patients being randomised to placebo or orlistat 
groups over a 3 year period. Initially they induced weight loss through an 8 week
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VLED, then those who lost more than 5% of their body weight (n=309) were 
randomised to lifestyle counselling for 3 years together with either orlistat 120mg 
or matching placebo capsules. The key areas of interest were whether they 
maintained the greater than 5% weight loss after 3 years and differences in 
development of type 2 diabetes between orlistat and placebo groups.
The VLED induced a mean weight loss of 14.4kg among those who were 
subsequently randomised. After 3 years the mean weight gain was lower with 
orlistat compared with placebo. Also more participants achieved the 5% weight 
loss with orlistat compared to placebo. Waist circumference was significantly 
more reduced in the orlistat group and incidences of new cases of type 2 
diabetes were significantly reduced with orlistat compared to placebo. The extra 
weight loss and maintenance shown in this study reflects other studies findings 
such as XENDOS (Torgerson et al., 2004). However the impact of this weight 
loss and use of orlistat was not apparent in the cardiovascular risk factors 
suggested in other research (Sjostrom et al., 1998).
A limitation of this study is that they only randomised those who had 
initially lost at least 5% of their weight during the VLED, which was 80% of those 
who started on the VLED. This means only those who were successful in their 
initial weight loss were randomised into the study and as many people who 
attempt weight loss are not successful initially the data may not be 
representative of those who attempt weight loss. However one of the criteria for 
continuing to be prescribed orlistat at 3 months, as described earlier, is that they 
lose at least 5% of their body weight, which fits in with this study. Therefore the 
results of this study may be applied more accurately to responders of orlistat 
treatment. This study indicates that adding orlistat to lifestyle counselling was 
associated with greater maintenance of an initial weight loss over 3 years and 
that this was associated with reduced occurrence of type 2 diabetes. This 
suggests an initial large weight loss followed by intensive, frequent and
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prolonged therapy of both pharmacological and behavioural, is a useful tool in 
weight loss and maintenance.
1.5.3 Orlistat in practice
Linne, Rooth and Rossner (2003) commented that in primary care success rates 
of orlistat are limited by failure to follow prescribing recommendations. In clinical 
trials, as described above, orlistat is shown to be successful at weight loss and 
maintenance. However in these clinical trials there are specialist, well trained 
staff with advanced experience of using the drug and of working with the obese 
population. In a GP practice time is often limited and GPs have to deal with the 
obese patients alongside other patients with acute or chronic conditions. 
Therefore the obese patient may not get the same amount of time and attention 
that they require. Lindgarde (2000) described that orlistat has some success in 
the primary healthcare setting however Linne et al looked at what is going on 
when it does not work. They sent questionnaires to patients who had been 
referred to an obesity unit and in the referral letter the GP had written that 
‘treatment with orlistat did not work’ (n=70). They found that only in a few cases 
were the patients given information to facilitate weight loss concomitant with 
orlistat. Furthermore in many cases patients had not been checked as to 
whether they had lost the required 2.5kg to be eligible to receive orlistat initially 
then they had not been monitored to ensure they had lost the required 5% 
weight loss to continue to be treated with orlistat after 3 months. These findings 
highlight the concern that for orlistat to be a useful tool for weight loss, those 
prescribing the treatment need to give the patient appropriate information along 
with monitoring their progress for improved success rates.
Orlistat has more recently been made available over the counter (OTC) in 
the UK and has been available for longer in the United States (US). One study 
which explored orlistat in an OTC setting in the US was conducted by Schwartz 
et al. (2008). They examined how consumers would use orlistat (60mg) in terms 
of compliance, behaviour change and weight loss without physician supervision.
They conducted a 3 month naturalistic study in an OTC setting in 18 pharmacies 
in the US. Consumers over the age of 18 years were able to buy orlistat 
packages containing orlistat 60mg plus educational material with lifestyle 
information and tools to encourage weight loss. They collected data at pharmacy 
visits and during telephone interviews at 14, 30, 60 and 90 days after enrolment. 
237 subjects purchased orlistat, used the product and completed at least one 
interview.
Their results indicated that most followed dosing directions and also took 
a daily multivitamin. They also reported taking less than the recommended dose 
when they skipped a meal or had a meal containing minimal or no fat, rather 
than taking less to avoid the side effects. Around 80% used the educational 
material, most reported following a diet and around 50% reported taking part in 
more exercise than at enrolment. Most reported being satisfied or very satisfied 
with their weight loss, with median weight loss achieved being around 5% after 
60 days on orlistat. The most common adverse events were gastrointestinal, 
which is common when taking orlistat due to the way it works, furthermore most 
did not interrupt or discontinue orlistat due to these events. The study was 
conducted in a natural setting which gives a valuable insight into the success of 
this drug in actual use and reflects those who may purchase orlistat in an OTC 
environment. However the results may still be biased as those who took part in 
the interviews may have been different to those who would not. Also only those 
who returned to the pharmacy for a repeat purchase would provide the weight 
loss data and it may be the case that those who tend to return for a further 
purchase are those who are successful, because those who were not successful 
would not be motivated to returned for a repeat purchase. Simply the fact that 
they were asked questions about how they took orlistat may alter their 
behaviour, such as they may not have initially thought to take the multivitamin 
however after being asked how often they took a multivitamin it may have 
triggered them to take it. Overall they found subjects taking orlistat in this 
environment showed positive behavioural changes in diet and physical activity
along with weight loss during the study. The study shows that orlistat available in 
an OTC setting with self-instructional lifestyle materials and without physician 
supervision can be used appropriately and safely with high consumer 
satisfaction, and is an appropriate weight loss therapy.
1.5.4 Orlistat combined with other interventions
Toplak et al. (2005) examined weight reduction with orlistat in obese participants 
receiving a mildly or moderately reduced energy diet. They explored the effect of 
two different levels of either 500 or 1000 kcal/day energy deficit in weight loss in 
those taking orlistat over a 1 year period, worldwide. If patients did not achieve 
>5% weight loss after 3 and 6 month assessments then they were taken off 
orlistat and were not allowed to proceed to study completion (n=70). Energy 
intake was measured through self-reported diet diaries and dietary 
recommendations were reinforced at 6 and 9 months. The mean difference in 
energy intake between the two groups at weeks 24 and 52 was 111 and 95 
kcal/day respectively. 295 of the 430 patients who took part in this study 
achieved >5% weight loss at both 3 and 6 months. By 52 weeks weight loss was 
similar for both groups. At 12 months of treatment with orlistat, 84% of the 500 
kcal/day deficit group and 85% of the 1000 kcal/day deficit group achieved >5% 
weight loss, and 50% and 53% respectively achieved >10% weight loss. Both 
groups, at 52 weeks, showed similar significant improvements in blood pressure, 
lipid levels and waist circumference. Furthermore a significant reduction in waist 
circumference with orlistat treatment was observed. They found that patient 
compliance to diet improves as the severity of energy restriction decreases as 
those prescribed the mildly reduced energy diet gravitated towards the energy 
intake level of moderately reduced energy diet and patients prescribed the 
moderately reduced energy diet gravitated towards the mildly reduced energy 
diet. However self reported diet diaries tend to under estimate energy intake so 
a more objective measure would provide more accurate data on this. It is clear 
that prescribing a moderately reduced energy diet can lead to long term 
adherence as patients will adapt this to a diet that is manageable to them. Only
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those who had achieved >5% weight loss by 3 months remained on orlistat 
therefore these participants were not receiving the same support in their weight 
loss either through medication or the regular visits to the doctor.
The study by Toplak et ai. indicated that orlistat is associated with 
clinically beneficial weight loss, regardless of whether the energy deficit in their 
diet was 500 or 1000 kcal/day. Of those who achieved >5% weight loss at 3 
months and remained on orlistat plus diet achieved long-term, clinically 
beneficial weight loss. This suggests that those who achieve >5% weight loss at 
3 months which is at least maintained by 6 months would benefit greatest from 
orlistat treatment in combination with diet. However as patients who had not 
achieved this weight loss by 3 months were taken off orlistat it is not clear 
whether they would also benefit in the long term with longer treatment with 
orlistat plus diet, although as discussed in other studies early response is a good 
indicator of treatment success and long-term effectiveness.
Torgerson et al. (2004) conducted a randomised study of orlistat in 
addition to lifestyle changes for prevention of type two diabetes in obese 
patients (XENDOS). The aim of the study was to determine whether adding 
orlistat to lifestyle changes can lead to a greater decrease in body weight and 
the incidence of type two diabetes in obese patients. The study was a 4 year, 
double-blind, prospective study with 3305 patients randomised to lifestyle 
changes plus either orlistat 120mg or placebo, three times a day. Both groups 
were prescribed intensive lifestyle changes in addition to receiving orlistat or 
placebo. Patients were either normal or had impaired glucose tolerance (IGT). 
Primary endpoints were time to onset of type two diabetes and change in body 
weight. Retention rates in those taking orlistat were 52% and for the placebo 
group it was 34% after 4 years.
More people completed treatment when taking orlistat compared to those 
taking placebo. After 4 years treatment there was a higher incidence of type two
diabetes in the placebo group compared to those taking orlistat. A reduction in 
the incidence of type two diabetes was only apparent in those with IGT. Mean 
weight loss after 4 years was significantly higher in those taking orlistat 
compared to those taking placebo. Cardiovascular risk factors were improved in 
those taking orlistat, with sustained and significantly better improvements than 
with placebo. Furthermore this study demonstrated the long term safety of 
orlistat along with it being well tolerated. It is also worth noting that they found a 
significant decrease in the level of fat soluble vitamins in the orlistat group 
compared to placebo. However the mean level remained within its reference 
range at all times during the 4 year study for both orlistat and placebo group. 
Those prescribed orlistat by their GP or as ‘Alii’ over the counter are 
recommended to also take a vitamin supplement to address this. Withdrawal 
from the treatment program was higher for those taking placebo, this may have 
been due to the greater weight loss in the orlistat group. This study indicated 
that compared with lifestyle changes alone, orlistat along with lifestyle changes 
resulted in a greater reduction in the incidence of type two diabetes over 4 years 
and produced greater weight loss in an obese population, along with 
improvements in cardiovascular risk factors.
Poston et al. (2006) examined the effectiveness of a primary care 
orientated brief counselling intervention for obesity with and without orlistat. 
They randomly assigned patients to a brief counselling intervention alone, in 
combination with orlistat and drug-alone in a 12 month randomised-control trial. 
The brief counselling sessions were implemented by well-trained dieticians and 
followed a standardised protocol. There were 136 completers with data at 
baseline, 6 months and 12 months and there were 250 participants in the 
sample in total. For the completers; those in the drug only and the drug plus 
brief counselling groups lost more weight than the brief counselling only group at 
6 months, but there were no significant group differences at 12 months. The 
results of this study show that pharmacotherapy alone or combined with brief 
counselling resulted in modest weight loss that had minimal impact on
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cardiovascular parameters, but were still greater than counselling alone. 
However the results of this evaluation suggest that such minimal interventions 
result in minimal benefits. Drug therapy seems to only facilitate modest weight 
losses which were substantially less than that achieved when pharmacotherapy 
is combined with a more intensive lifestyle intervention programme (Wadden et 
al., 2005). Therefore a compromise between the two may be worthwhile.
Poston et al also assessed treatment exposure and medication 
adherence. They found that patients who completed the trial received most or all 
of the treatment (therefore attended more than 85% of visits) and used the 
medication. This study used dieticians to provide the brief counselling 
component, which may be difficult to implement in primary care and may be 
more easily implemented if primary care doctors, nurses or other staff were 
trained to implement this. In terms of attrition this was highest in the brief 
counselling only group, suggesting this type of intervention alone is not 
acceptable to most patients seeking treatment for weight loss. This study 
indicates that minimal interventions alone are not sufficient for weight loss and 
weight loss maintenance. More intensive lifestyle interventions along with 
pharmacotherapy seem a more appropriate method for obesity management. 
However for more effective use of time in a primary care setting an effective 
level of intensity needs to be determined in order to balance the needs for 
simplicity, cost and time sensitivity.
Initial weight loss goals and expectations can play an important role in the 
process of weight loss. A recent study that examined weight loss in a program 
with orlistat and telephone-counselling was conducted by Munsch et al. (2007). 
They explored the effectiveness of a short term telephone counselling program 
with orlistat and the influence of pre-treatment characteristics on weight loss 
goals and achieved weight change. During treatment patients lost on average 
7.7% of their initial weight during the 33.6 weeks of treatment. Weight loss goals 
that the patients had reported were 17.8% of initial weight. At the end of the
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program the majority of patients judged their weight change as successful even 
though the average weight change was 9.8%. The initial counselling in the study 
was to facilitate patients setting feasible weight loss goals, therefore this seems 
to have been effective in diminishing unrealistic outcome expectation. Desired 
weight loss was positively related to weight at the start of the program and age. 
Achieved weight loss was positively related to weight at the start of the program. 
They also found that setting high weight loss goals was a positive predictor of 
weight loss, therefore the higher the desired weight loss the greater the 
subsequent weight loss. Although, as patients are taking part in a weight loss 
program, they may expect unrealistic weight loss goals. Also it should be made 
clear that this study was not randomised in term of medication or not and 
counselling or not. Furthermore as the patients are taking part in a study they 
may be more motivated therefore may achieve higher than expected weight 
loss.
The research indicates that orlistat combined with other interventions has 
some success. The additional interventions reduce some of the variability in 
success. However it is still not clear where the variability arises from.
1.5.5 Cessation of orlistat, potential abuse and cost effectiveness
As obesity is a growing concern, treatment options need to be used that are 
effective in terms of weight loss but also cost-effective. Hertzman (2005) 
examined the cost-effectiveness of orlistat in a one year weight-management 
responder program treating overweight and obese patients in Sweden. They 
explored the cost-effectiveness of orlistat plus diet versus diet only program, in 
terms of quality-adjusted life-years (QALYs) gained. The amount of patients who 
had lost more than 5% in weight at 3 months was nearly twice as high with 
orlistat compared to the diet only group, this was also the case at 12 months. 
They estimated that the use of orlistat combined with diet in a 12 month program 
increased the number of QALYs and reduced the cumulative incidence of 
diabetes when compared with the diet only group. Furthermore the incremental
cost-effectiveness ratio for those on orlistat alongside a dietary program was the 
same as many other well accepted healthcare treatment programs. They also 
suggest that the appropriate alternative to orlistat would be no diet at all 
because patients who have failed numerous attempts at weight loss through diet 
programs need a new treatment to sufficiently motivate them to try and lose 
weight again. It is important to highlight that this study focussed on the Swedish 
healthcare perspective, however it does give an insight in to cost-effectiveness 
of orlistat and may translate some way in other European healthcare markets. 
Furthermore the data from this study was based on a responder program 
therefore they achieved greater than 5% weight loss by month 3. This study 
indicated that a treatment responder approach means patients who orlistat 
would be beneficial for, would be identified early on which would result in more 
efficient use of healthcare resources along with reduced budgetary impact.
Losing weight has been found to improve cardiovascular risk factors 
along with subsequent cost and clinical effects (Oster et al., 1999). There are 
other important factors to address in terms of benefits of losing weight. Findings 
have shown that reduction in health-related quality of life can be more severe for 
obese patients compared to those with other chronic conditions such as 
rheumatoid arthritis, and are on a par with patients with a relapse in cancer 
(Sullivan et al., 1993)
Orlistat has been shown to be a useful aid to weight loss and weight loss 
maintenance, however it is also interesting to examine people after cessation of 
treatment with orlistat. Woo et al. (2007) examined the effectiveness of a 
lifestyle modification programme for weight maintenance in obese subjects after 
cessation of treatment with orlistat. 55 subjects with and without diabetes 
mellitus were randomly assigned to either the intervention group of a lifestyle 
modification programme or usual care at the end of a 6 month treatment period 
with orlistat. The lifestyle modification programme was led by a nutritionist and 
consisted of dietary management, physical activity, peer group support and
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discussion: using techniques of self-monitoring, stimulus control and cognitive 
restructuring. Many medical and psychological measures were assessed before 
and after the intervention period. The results of this study found that the 
intervention group maintained their weight loss along with favourable profiles, 
but most measures deteriorated in the usual care group, which were more 
apparent in diabetic subjects. Furthermore the amount of weight regain was 
comparable to that lost during orlistat treatment. However it is worth noting that 
this study only involved a small number of participants (n=55) and duration was 
only 6 months. Therefore it is unclear whether motivation in a lifestyle change 
programme would last for longer periods. For most patients there is a tendency 
to rely on drugs, with less emphasis on lifestyle modification, as there are less 
barriers to taking a pill compared to changing lifestyle. Weight loss can still be 
achieved with orlistat without significant lifestyle changes, but weight loss 
maintenance is the main aim and this requires the lifestyle change for success. 
Lifestyle change advice can come from many different sources including 
doctors, nurses, dieticians or multidisciplinary professionals, individually or in a 
group, therefore this is something that can be applied to many patients after 
care. The lifestyle programmes need to incorporate an element of behaviour 
change. This study indicated that a nutritionist-led lifestyle modification 
programme for obese subjects is effective in weight maintenance after treatment 
with orlistat and without this programme the benefits of the drug treatment were 
lost. Furthermore the magnitude of effect of the lifestyle modification programme 
is comparable to that observed with orlistat.
In terms of the use of orlistat it is important to discuss the potential abuse 
of this drug. In the current longitudinal study presented in this thesis only those 
who had been prescribed orlistat by their GP were included however there are 
other methods of acquiring this medication which may lead to abuse. There are 
not many cases of abuse reported in literature however one case report 
(Cochrane & Malcolm, 2002) reports the case of a normal-weight woman with an 
eating disorder and stimulant dependence. This woman was a normal weight
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bulimic patient who uses orlistat when she cannot use laxatives or cannot 
secretly vomit. This patient bought orlistat off the internet but had also been 
prescribed it from weight loss centres. The patient on occasion took orlistat after 
she had binged and purged on high fat foods, she did this to decrease 
absorption of any remaining fat.
This case study highlights the issues around the availability of 
medications on the internet. With diet drugs being advertised in the press, 
knowledge about new and available diet drugs is more wide spread. Previously 
there would be no further course of action if a GP refused a patient a drug they 
requested, for whatever reason, however now if the patient has money and 
computer literacy there is the opportunity to acquire these drugs on the internet. 
Furthermore in terms of orlistat, patients with eating disorders with fear of fat in 
their bodies may seek out orlistat as it would be an attractive drug for them to 
abuse. This potential for abuse within those with eating-disorders needs to be 
addressed when these patients are being treated and questioning patients about 
this should be included in the patient evaluations. In terms of patients without 
eating disorders there is also the potential that normal weight people may seek 
out orlistat on the internet in order to lose or maintain their weight, this is 
something that needs to be examined and any potential abuse would need to be 
addressed. In the longitudinal study presented in this thesis, only those 
prescribed orlistat by their GP were included.
1.6 Summary
So far this review has explored definitions of obesity, its prevalence and the 
consequences of being obese. The causes of obesity were examined in terms of 
physiological and behavioural theories. The management of obesity was 
discussed in relation to dietary, behavioural, surgical and pharmacological 
interventions. As the main focus of this thesis is the experiences of those taking 
orlistat, this specific obesity medication was then examined in more detail. 
Orlistat was explored in relation to what it is and how it works along with how it
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performs for weight loss and weight maintenance. Orlistat is available over the 
counter (60mg) and through prescription with the general practitioner (120mg), 
therefore the efficacy of orlistat in practice, along with its efficacy when 
combined with other interventions was examined. Outcomes were explored in 
terms of cessation of orlistat, therefore the impact after they stop taking it, along 
with other key areas that were important to address including potential abuse 
and cost effectiveness. From this review it can be concluded that dietary, 
behavioural, surgical and pharmacological interventions all have varying 
degrees of success. But the common theme among all these methods of weight 
loss is variability in outcomes. The reasons behind this variability and the 
mechanisms involved need to be explored which is the main purpose of this 
thesis.
This summary highlights the background in the literature regarding 
obesity along with treatment options for individuals, in particular the obesity 
medication orlistat. The way this background literature is embedded in 
psychological theory is also important to address. Therefore the remainder of 
this literature review will examine the psychological implications of orlistat and 
how the mechanisms of orlistat relate to psychological theory. Psychological 
aspects of weight loss maintenance and behaviour change will be addressed 
along with adherence literature relating to other medications. The participants’ 
included in this thesis were prescribed orlistat by their GP therefore the doctor- 
patient relationship will be explored. The way individuals conceptualise their 
weight problem will be explored thus illness beliefs and coherence literature will 
be discussed to give a background to the current study, along with the literature 
on measurement of illness perceptions. Finally psychological theory and 
predictors of success will be explored in relation to improving effectiveness in 
weight loss.
The first section of this literature review gave the background to obesity 
and its treatment options. The next section will discuss psychological theory and
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background literature to provide a setting for the current thesis and series of 
studies.
1.7 Psychological implications of orlistat
As discussed above orlistat works by reducing fat absorption and when taken in 
conjunction with high fat foods there are quite unpleasant side effects. Therefore 
the experiences of patients who have taken the drug need to be explored to see 
how it has affected their subsequent behaviour. One study that looked at the 
experiences of those patients taking orlistat was conducted by Ogden and Sidhu 
(2006). This study was qualitative and involved in depth interviews. There were 
a small number of participants (n=12), to enable in-depth analysis of their 
experiences of being prescribed orlistat in the past year. The interviews involved 
questions about previous weight history and experiences of taking orlistat. The 
results of the study found four broad themes. Firstly participants described their 
model of the causes of their obesity, which varied from a medical model where 
genetics or illnesses were the issue, to a more behavioural model where their 
eating and exercise behaviour were the main factor. Secondly they described 
their motivations for weight loss, these ranged from routine consequences of 
being overweight to major life crises. Another theme was the side effects of 
taking orlistat, which included very graphic descriptions. Finally there was the 
issue of how they managed the side effects and made sense of them. Some 
treated them as an educational tool to make the link between food eaten and 
weight, whilst others saw them as a necessary evil to be tolerated.
The way the four broad themes interacted with weight loss showed the 
differences between those who did and those who did not lose weight. Those 
who lost weight associated obesity with a more behavioural model, the 
motivations to lose the weight were dramatic life crises, they conceptualised the 
side effects as an education, they adhered to the medication and made 
behavioural changes. Whereas those with no weight loss had a more medical 
model of obesity, their motivations were just the routine consequences of weight
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loss, the side effects were seen as something to be tolerated, this all combined 
with non adherence and no changes in behaviour. Therefore for some the 
negative experiences of the medication led to non-adherence and no 
subsequent behaviour change, with these people initially being motivated to lose 
weight due to every day consequences of being overweight. Those who had 
experienced a major life crisis seemed able to tolerate the side effects more 
leading to adherence with the side effects causing a shift in beliefs about causes 
and solutions. The side effects and subsequent shift enabled the connection to 
be made between food consumed and body weight, leading to behaviour 
change and weight loss. This adherence and behaviour change led to less side 
effects which related to continuing adherence being more acceptable and 
bearable. The life crises seemed to have given the initial momentum to the 
process of change through medication.
In summary, Ogden and Sidhu (2006) suggested that whilst orlistat can 
help some to lose weight, others see no change, and that this is due to a 
combination of factors. The initial motivation is important, along with why they 
think they are overweight and how the side effects are conceptualised. In 
particular it suggested that orlistat, through the highly visual side effects, 
changes people's beliefs about the cause of their obesity which makes them 
more likely to change their behaviour. Therefore taking orlistat and subsequent 
weight loss are the result of experiencing the side effects and the realisation that 
their weight problem is caused by their own behaviour. These are all issues that 
need to be addressed in a quantitative large scale study. This will give a clearer 
picture of the mechanisms involved.
In terms of the psychological implications of orlistat Garrow (1998) 
discussed orlistat in an article in the BMJ when it was first licensed for 
prescription in the UK. He commented that the weight loss achieved whilst on 
orlistat is statistically significant but that diet accounts for more than half of the
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loss. He comments that some of the weight loss in those taking orlistat can be 
explained by them reducing their fat intake in their diets to avoid the adverse 
events associated with taking orlistat and consuming high fat foods. Therefore 
Garrow suggests whilst on orlistat those who eat high fat foods have a powerful 
incentive to reduce fat intake, as it seems the drug will succeed by inducing 
obese people to keep to a low fat reducing diet. This is in line with Ogden and 
Sidhu’s study that found orlistat to have an “antabuse effect” (Finer, 2002) with 
those who use the side effects to educate them into what foods are high in fat 
and learn to avoid them and be successful in weight loss. This shows from the 
beginning of orlistat being used as a tool for weight loss there was an 
understanding of the psychological implications of the mechanisms of the drug 
which have an impact on behaviour change.
As a background to the psychological implications of orlistat for weight 
loss the relevant psychological theories will be described including the self- 
regulatory model of illness behaviour, the health belief model and the stages of 
change model, together with a focus on key processes such as illness 
representations, visual feedback and the doctor-patient relationship and key 
outcomes including adherence, coherence, weight loss and behaviour change.
1.8 Theories
There are several theories that attempt to explain illness behaviours and 
behaviour change. In this review the theories that will be explored are the self- 
regulatory model of illness behaviour, the health belief model and the stages of 
change model.
1.8.1 Self-regulatory model of illness behaviour
A key theory of illness behaviour is Leventhal's self-regulatory model of illness 
behaviour (Leventhal et al. 1992). This model has three main stages; 
interpretation, coping and appraisal. Interpretation involves symptom perception 
and social messages, which indicates they may be ill due to deviating from the
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norm. Within this stage, interpretation includes representation of the health 
threat which involves identity, cause, consequences, time line and cure 
(solution) or control. It also includes the emotional response to the health threat 
which involves fear, anxiety and depression. The next stage of coping entails 
approach coping and/or avoidance coping. Finally there is the appraisal stage 
where the individual assesses whether their coping strategy was effective and if 
not then they go back to stage 1 and begin the process again.
1.8.2 Health belief model
Another model of behaviour is the health belief model (Becker, 1974; 
Rosenstock, 1974). This model has five main components that predict the 
likelihood that the behaviour will occur. There is susceptibility to illness, severity 
of the illness, the costs involved in carrying out the behaviour, the benefits of 
carrying out the behaviour and cues to action, which may be internal or external. 
The health belief model also later included the construct of health motivation, 
which reflects the individual’s readiness to be concerned about health matters. 
Furthermore the construct of perceived control was added (Becker & 
Rosenstock, 1987) to the model to incorporate the belief the individual has that 
they can control the behaviour.
1.8.3 Stages of change model
A further model of behaviour change, which is very popular with application to 
smoking cessation, is the transtheoretical model of behaviour change 
(Prochaska & DiClemente, 1982), which is also known as the stages of change 
model. This suggests that behaviour change is based on 5 key stages which are 
pre-contemplation, contemplation, preparation, action and maintenance. Pre­
contemplation refers to those who do not intend to make any changes, 
contemplation is when someone is considering change, preparation is where 
they make small changes, action refers to actively engaging in a new behaviour 
and maintenance refers to sustaining the change over time. These stages make 
up the stages of change model but they do not always flow in a linear fashion
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but are more dynamic and not 'all or nothing’. Through this model there is also a 
cost-benefits analysis where the individual weighs up the costs or benefits of a 
particular behaviour and focuses primarily on either one depending on which 
stage of change they are at. This model has been applied to several health 
related behaviours including smoking cessation and screening behaviour, thus 
as it is being applied to change in behaviour it could also be applied to change in 
diet and exercise behaviour.
1.9 Processes
As the theories above describe; illness behaviour and behaviour change is a 
multi-factorial process. Some of the processes involved in behaviour change, 
include illness representations, visual feedback and the doctor-patient 
relationship, which will now be discussed.
1.9.1 Illness representations
Leventhal et al. (1984, 1992 & 1997) suggested that illness representations are 
illness specific. Petrie and Weinman (2006) address the issue that illness 
representations directly influence a person’s emotional response and coping 
behaviour. When an individual is diagnosed with an illness they form a cognitive 
model to make sense of their illness as part of their coping strategies. Illness 
representations guide individuals coping strategies along with illness specific 
behaviours such as adherence to treatment. This means that when individuals 
are seeking help for a health problem a greater awareness of the patients’ 
beliefs can improve communication in the medical consultation and also the 
treatment and therefore illness outcomes. It is also important to be aware that 
illness perceptions can be changed, which can be addressed to help improve 
patient care and their adjustment to illness.
French, Cooper and Weinman (2006) conducted a systematic review of 
literature on illness representations in terms of attendance at cardiac 
rehabilitation following acute myocardial infarction (AMI). Through this literature
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they wanted to assess whether illness representations predict attendance at the 
clinic and what factors moderate this relationship. They found that four main 
illness perceptions predicted attendance at the clinic, which were positive 
identity, cure/control, consequences and coherence. The strongest predictor of 
attendance of AMI patients at cardiac rehabilitation clinic was cure/control. 
Therefore this review found that AMI patients who view their condition as 
controllable, as symptomatic, with severe consequences and if they feel they 
understand their condition then they are more likely to attend the clinic. They 
also note that it may not be a single illness perception that predicts attendance, 
rather a combination of beliefs that are a more useful predictor of attendance. As 
discussed in other studies it has been shown that illness beliefs do not always 
remain stable therefore an intervention to address the patients beliefs, before 
treatment begins, may improve attendance.
As shown above illness representations are an important factor in health 
related behaviour change. It is therefore important to explore changing illness 
representations in a health context. Petrie et al. (2002) examined whether a brief 
hospital intervention designed to alter patients’ perceptions about their 
myocardial infarction (Ml) would result in better recovery and reduced disability. 
They assigned patients to either usual care from rehabilitation nurses or 
received an intervention designed to alter their perceptions about their Ml. 
Patients were assessed in hospital before and after the intervention and at 3 
months after discharge from hospital. The results from this study indicated that 
the intervention caused significant positive changes in the patients’ views of their 
Ml also that those in the intervention group reported they were better prepared 
for leaving hospital and subsequently returned to work at a significantly faster 
rate than the control group who received usual care. The intervention group had 
significantly modified their perceptions of how long their illness would last and 
the personal consequences of the Ml on their life compared with the control 
group. The intervention group was also more optimistic that their illness could be 
controlled or cured compared to the control group. Furthermore at the 3 month
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follow up the Intervention group reported significantly lower rates of angina 
symptoms than the control group. The intervention significantly increased the 
patients’ intentions to go to the rehabilitation program which resulted in higher 
attendance at rehabilitation however there were no significant differences in 
rehabilitation attendance between the intervention and control group.
Petrie at al.’s (2002) study showed an intervention can improve patients 
understanding of their illness by modifying any misconceptions and negative 
beliefs the individual may have early in the recovery process. Furthermore by 
addressing these issues immediately after a major life event, such as a heart 
attack, the individual is more amenable to an intervention that encourages 
changes in behaviour. This element relates back to the health belief model 
(Becker, 1974; Rosenstock, 1974) with the cue to action of a major life event, 
such as a heart attack, predicting the likelihood of that behaviour. Petrie et al. 
(2002) showed that an in-hospital intervention to change patients’ illness 
perceptions can result In positive outcomes such as in this case with improved 
functional outcomes after Ml. This study shows that illness perceptions can 
change with an intervention and this needs to be explored in terms of illness 
beliefs regarding obesity. In the study by Ogden and Sidhu (2006) they identified 
in their exploratory study that orlistat may function by changing beliefs about the 
causes and solutions to their weight problem. This needs to be examined in a 
larger scale to determine if this is the case.
In order to assess these illness beliefs they need to be measured, the 
literature on this will now be discussed. The way an illness develops can vary 
from person to person, even when they have the same condition. The self 
regulatory model by Leventhal et al. has been used as a theoretical basis to 
explore how patients create models or representations of their illness and how 
this relates to coping strategies. One questionnaire that addressed this was the 
illness perception questionnaire (IPQ) proposed by Weinman et al. (1996). This 
questionnaire was a method for assessing the cognitive representations of
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illness. The IPQ is commonly used as a quantitative method assessing the five 
main cognitive illness representations in Leventhal’s self-regulatory model which 
are identity, consequences, cause, timeline and cure or control. Identity refers to 
the label the individual uses to describe the illness and symptoms of that illness, 
consequences refers to the expected effects and outcome of the illness, cause 
relates to the individuals belief about the cause of the illness, timeline relates to 
the patients beliefs about how long the illness will last and cure or control relates 
to whether the individual feels they can recover from the illness or control it.
The illness perception questionnaire was a popular measure of illness 
representations but it was felt that there were a few issues with two of the 
subscales along with the issue that it only addressed the cognitive components 
of patients’ representations without addressing the emotional response 
generated by the illness. Therefore the IPQ was revised in 2002 (Moss-Morris et 
al.) to address internal consistency in the subscales cure/control and timeline, 
along with assessing cyclical timeline perceptions, illness coherence and 
emotional representations.
From the revised IPQ a more recent measure which assesses illness 
perceptions in a brief format was suggested by Broadbent et al. (2006). They felt 
a shorter more simple measure of illness perceptions would be more useful. 
They suggested a nine-item scale designed to rapidly assess the cognitive and 
emotional representations of illness. The nine items included the five cognitive 
illness representations which were consequences, timeline, personal control, 
treatment control and identity. Along with two emotional representation items 
which were concern and emotions. There was one item addressing illness 
comprehensibility. Finally there was an open-ended response to an item which 
addressed causal factors in their illness and they were asked to list the three 
most important factors. The R-IPQ assessed whether a patient’s illness 
representation provided a coherent understanding of the illness, a type of meta­
cognition reflecting the way the patient evaluates the coherence or usefulness of
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his or her illness representation. The brief IPQ is a quick assessment tool that 
assesses illness perception, which is particularly helpful in Illness populations, 
large-scale studies and in repeated measures research design. Therefore this 
was one of the measures used in the longitudinal study in this thesis as this 
study assesses an illness population of overweight and obese individuals, along 
with it being a large-scale study with repeated measures. This measure 
facilitated inclusion of psychological theory Into the studies presented in this 
thesis. Along with measuring illness perceptions, reducing variability and 
improving effectiveness will also be explored. Another process involved in 
behaviour change is visual feedback which will now be discussed.
1.9.2 Visual feedback
There has been some research on visual feedback in terms of smoking 
cessation. Bovet et al. (2002) examined the impact of giving smokers ultrasound 
photographs of their own atherosclerotic plaques to improve smoking cessation. 
They selected smokers from the general population who were randomly 
allocated to undergo high-resolution B-mode ultrasonography of their carotid 
and femoral arteries with all smokers receiving quit-smoking counselling. 
Smokers with >1 atherosclerotic plaque were given two photographs of a plaque 
with a relevant explanation. Quit rates were assessed by telephone 6 months 
later, therefore relying on self reports which have their limitations in terms of 
inaccuracies due to imprecision of recall or giving socially desirable answers. 
Group A included those who did not undergo ultrasonography. Of the 74 
smokers submitted to ultrasonography, 20 had no plaque (group B) and 54 had 
>1 plaque (group C). Quit rates were highest in those submitted to 
ultrasonography (group B and C) and in those receiving photographs (group 0). 
The results indicated the photographs with relevant explanation resulted in a 
higher quit rate at 6 months compared to providing counselling only. This study 
suggests a role for visual feedback in behaviour change and it appears to be a 
useful tool to facilitate the process of change in smoking cessation and have 
been explained within the framework of the stages of change model. The role of
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Visual feedback in changing other behaviours, such as dietary behaviour 
change, also needs to be examined.
In terms of the stages of change model (Prochaska, DiClemente & 
Norcross, 1992) where health behaviour change is related to the stage of 
change the person is in, efficacy of smoking cessation interventions may be 
related to the stage of readiness to change. Bovet et al. (2002) suggest 
demonstrating atherosclerotic plaques to smokers could facilitate the transition 
from the “early” stages to the “action” stages. However It is important to note that 
the follow-up in this study was only 6 months therefore the results may be 
overoptimistic in terms of quit rates. Bovet et al. (2002) demonstrated providing 
smokers with photographs of ultrasonic images demonstrating their own 
atherosclerotic lesions were an effective addition to physician’s advice to quit 
smoking. This study highlights the impact of visual feedback in changing 
behaviours and whether orlistat works in the same way to change behaviour 
needs to be explored. The side effects from eating fatty foods while taking 
orlistat is oily stools and urgency to go to the toilet, which is the visual feedback 
that may assist in changing diet behaviour to stop the side effects. Whether this 
is the outcome required for sustained weight loss will be examined.
1.9.3 Doctor-patient relationship
The doctor patient interaction is an important aspect to discuss in terms of 
illness behaviour and behaviour change. General practitioner’s (GP’s) are 
normally the first port of call for patients seeking help with their behaviour that is 
affecting their health, such as smoking or a weight problem. In terms of a weight 
problem the patient may go to their GP for diagnosis, advice and treatment, 
therefore it is important to address the GP’s beliefs about obesity. One 
qualitative study which looked at the views of GP’s treating obese patients was 
conducted by Epstein and Ogden (2005). They interviewed 21 GP’s about 
recent obese patients and obesity in general. The GP’s in this study reported 
that they believed that obesity was the responsibility of the patient, rather than a
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medical problem requiring a medical solution. However they also believed that 
patients wish to hand responsibility for their weight problem over to the GP. This 
contradiction caused conflict for the GP as they reported they did not believe 
current treatment options were effective. They felt that this contradiction would 
create a problem with the doctor-patient relationship. Therefore in order to 
resolve this conflict the GP’s reported offering treatments to patients that they 
believed were inappropriate or ineffective and offered patients support for other 
associated problems. This study provided an interesting insight into the beliefs 
of GP’s who treat obese patients, however as it was an exploratory qualitative 
study the sample size was small therefore generalisability was limited. This 
study indicated that GP’s are still sceptical about whether treating obesity comes 
under their professional domain and whether they can actually offer any 
treatments that can help with the patient’s weight problem. This suggests 
effective treatment interventions should be made known to GP’s so they can 
offer them to their patients without feeling sceptical about the outcome and will 
be willing to give help and support through the treatment. This study highlights 
the importance of addressing GP’s views in terms of obesity to aid them in 
providing their patients with adequate care and treatment.
Both the GP and the patients’ beliefs are important for successful 
treatment. One study that examined both GP and patients beliefs about obesity 
was conducted by Ogden et al. (2001). They examined GP and patient beliefs 
about causes, consequences and solutions to obesity. The reason behind this 
study was that differences in beliefs, between GP and patients, may lead to 
unsuccessful management of obesity. The study involved questionnaires being 
completed by both GP’s and patients. The results showed that patients 
endorsed a more medical model in terms of cause by attributing obesity to a 
gland or hormone problem, slow metabolism and stress. However GP’s 
endorsed a more behavioural model by blaming obesity on eating too much. 
When it came to consequences, the GP’s felt diabetes was the most important 
consequence whereas the patients reported difficulty getting to work as more
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important. For solutions to obesity both populations reported the same beliefs for 
a range of methods. In terms of who would be more helpful, the GP felt it was 
the patient themselves whereas the patient believed the GP or counsellor to be 
more helpful. The patients seemed to endorse a more self serving model thus 
blaming internal factors for the etiology of obesity and external factors for its 
solution. Whereas the GP’s views seem to reflect a more victim blaming model 
reporting both internal and controllable explanations for both causes and 
solutions. The results indicated that the patients would have a preference for a 
professional based intervention whereas the GP would favour a patient based 
approach. This indicated that patients may seek new drug therapies, such as 
orlistat, as a more favourable solution whereas GP’s may not. This study 
demonstrated that there are differences in beliefs for the GP and the patient and 
this conflict may lead the success rates of treatments to be poor as one of them 
will be involved in a treatment that contradicts their beliefs. This lack of 
coherence between the GP and patient would be a real problem that needs to 
be addressed to improve treatment of obesity. Therefore an intervention to 
address this would mean the GP or patients’ model of obesity would need to be 
changed or GP’s would need to be encouraged to tolerate differences with their 
patients.
Another study that examined both GP and lay people’s beliefs was 
conducted by Ogden and Flanagan (2008) who examined GP’s and lay people’s 
beliefs about causes and solutions to obesity. The results indicated that GP’s 
generally believe that obesity is caused by psychological and behavioural 
factors and are ambivalent about the majority of possible solutions. When they 
compared GP’s with lay people they found that GP’s have a greater 
endorsement of behavioural, structural, social and psychological causes of 
obesity, whereas lay people are more likely to endorse a biological model. The 
GP’s also showed consistency in their beliefs about causes and solutions, 
whereas the lay people did not. Therefore if the GP’s believed in social factors 
as the cause then they also endorsed policy change as a solution. It is also an
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issue that many GP’s are pessimistic about most solutions to obesity, this is not 
encouraging if the patients are seeking their help in finding a solution to their 
weight problem. GP’s may simply prescribe patients with an obesity medication 
to get the patient out of their office and they may not give the patient suitable 
advice to ensure success with adherence and weight loss outcomes.
Harvey et al. (2002) conducted an updated systematic review of 
interventions to improve health professionals’ management of obesity. The aim 
of the review was to determine the existence and effectiveness of interventions 
to improve health professionals’ management of obesity and to update a 
previous systematic literature review. The review included intervention studies 
with participants who were trained health professionals along with overweight 
and obese patients. The measurements in the studies included were objective 
measures of health professionals’ practice and behaviours, and patient 
outcomes such as satisfaction, behaviour, psychological factors, disease status, 
risk factors and measures of body weight, fat or BMI. 18 studies were included 
in total however heterogeneity and limited quality, small sample sizes and high 
drop out rates in these studies made it difficult to draw firm conclusions to inform 
recommendations for improving health professionals’ obesity management. The 
review did highlight that some initiatives do seem promising. Reminder systems 
appear promising in changing doctors’ practice and brief training interventions 
seem to be a cheap and quick intervention which is promising for changing 
practice in the short term. Shared care between GP’s and hospital services 
showed positive effects in the short term and inpatient care showed benefits 
even in the long term however the cost of such an approach may be prohibitive, 
also dietician-led treatment may be worth further investigations. They discussed 
how further research into cost effectiveness for improving the management of 
obesity is needed. They generally found that people tended to put weight back 
on over time, but not back to the original baseline weight and participants’ 
generally weighed less in the long term compared to the outset.
Research shows that the doctor patient relationship is important to 
address in order to have an impact on patient outcomes. The research indicated 
that both the patient and doctors beliefs are important in behaviour change, 
therefore illness beliefs in the obese population need to be explored.
1.10 Outcomes
Outcomes are important to discuss in relation to illness behaviour and 
behaviour change. The outcomes are the main aim of behaviour change. The 
processes discussed above have an impact on the outcomes and the outcomes, 
specifically adherence, coherence, weight loss and behaviour change, will now 
be examined. Behaviour change is the focus of many psychological theories as 
it is important in weight loss with adherence to medication and lifestyle changes 
being part of what is required to maintain weight loss.
1.10.1 Adherence
Adherence refers to the patient taking medication as prescribed and therefore in 
the case of orlistat that is three times a day with each meal. However also in 
more broad terms it refers to the individual eating a low fat diet and exercising 
more as is recommended while trying to lose weight. Overall, low adherence 
with prescribed treatments is very common (McDonald et al., 2002) and this 
non-adherence not only reduces the treatment benefits, as in the case of orlistat 
it would be less weight is lost, but it also biases both the health professionals 
and patients perception of the effectiveness of the treatment. Therefore 
adherence is important to discuss in the context of the doctor-patient 
relationship as non adherence may arise from the practitioner failing to discuss 
the treatment regimen with a patient, presents inconsistent instructions, uses 
technical language that is unintelligible, fails to establish rapport and or fails to 
monitor the patient’s performance of the regimen on subsequent visits 
(Svarstad, 1976).
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Adherence is a complex issue with psychological constructs that play a 
part. Leventhal et al. (1992) discussed adherence as having a broad range of 
determinants that affect how adherent the patient is. These include identity, 
cause, consequences, timeline, cure or control, along with fear, anxiety and 
depression. These are key determinants of adherence from the perspective of 
the patient psychology and are part of the process that affects adherence.
An extension to the self-regulatory model of illness behaviour included 
treatment beliefs, this would mean that adherence to medication is related to 
illness perceptions along with beliefs about treatment. Horne and Weinman 
(2002) developed this extension from a study into the role of illness perceptions 
and treatment beliefs in explaining non-adherence to preventer medication. 
They used a cross-sectional design using questionnaires to assess perceptions 
of asthma, beliefs about preventer inhalers and reported adherence to them. 
The study found that non-adherent behaviours were associated with doubts 
about the necessity of medication and concerns about potential adverse side 
effects and with consequences of illness being perceived more negatively. The 
study further supported the inclusion of treatment beliefs into adherence as 
illness perceptions influenced adherence both directly and indirectly via 
treatment beliefs, which subsequently was the strongest predictors. This study 
showed beliefs about treatment are an important component along with illness 
perceptions in treatment adherence. Thus both beliefs about causes and 
solutions for an illness are important and for treatment to be successful the 
treatment of the illness needs to be coherent with the illness perceptions for a 
successful outcome. Thus consistency relates to adherence to medication and 
behaviour change. Also as discussed previously French, Cooper and Weinman 
(2006) found that four main illness perceptions predicted attendance at the 
clinic, which were positive identity, cure/control, consequences and coherence. 
Whether the same illness beliefs also have an effect on adherence to obesity 
medication in the short and longer term needs io be examined. Furthermore 
whether orlistat has an effect on these illness perceptions and whether they
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change over time which may lead to a healthier lifestyle in terms of diet and 
exercise will be explored.
Adherence is also addressed through the health belief model. The health 
belief model suggests that adherence is a function of motivation and response 
selection, with motivation conceived as a product of the perception of 
vulnerability to the disease times the perception on its negative consequences. 
Also response selection is a function of the perceived benefits and costs of each 
of the available self-protective actions. In the case of obesity and orlistat the 
health belief model would predict that the individual who fails to see themselves 
as vulnerable to the consequences of obesity would be less motivated to adhere 
to their medication along with the healthy lifestyle regimen than someone who 
accepts this vulnerability. However someone who is motivated may be non 
adherent if they perceive the costs and benefits of orlistat treatment as 
unfavourable in comparison to some other method even if that method is 
ineffective. The cues to actions in the health belief model are reflected in Ogden 
and Sidhu’s study of the experiences of patients taking orlistat. One of the major 
themes that arose in these interviews were motivations for weight loss such as a 
major life crisis. This major cue to action made them able to tolerate the side 
effects more leading to adherence, with the side effects causing a shift in beliefs 
about causes and solutions. The side effects and subsequent shift enabled the 
connection to be made between food consumed and body weight, leading to 
behaviour change and weight loss. This adherence and behaviour change led to 
fewer side effects which related to continuing adherence being more acceptable 
and bearable. The life crises seemed to have given the initial momentum to the 
process of change through medication.
1.10.2 Coherence
Both Ogden and Sidhu (2006) and Ogden and Hills (2008) identify that 
perceived cause of their problem is an important factor in behaviour change, 
along with coherence of beliefs about causes and solutions to the weight
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problem. As Ogden and Sidhu suggested, when obesity medication works it 
does so by creating coherence between causes and solutions to the individual’s 
weight problem. This focus on beliefs about causes and solutions along with 
coherence maps onto Leventhal’s self-regulatory model of illness behaviour 
(Leventhal et al., 1984, 1992, 1997). In particular this model gives a theoretical 
framework to dealing with illness through cognitions and behaviour change and 
indicated the importance of coherence between illness beliefs and treatment 
beliefs in order to facilitate behaviour to change.
Coherence is also an issue in terms of consistency in beliefs between 
causes and solutions. Ogden and Jubb (2008) examined consistency in beliefs 
in terms of different problems which included depression, obesity and sleep 
problems along with whether they were consistent with each other in terms of 
cause and solution. They examined whether these beliefs were open to change 
and whether this change applied to both causes and solutions. They found that 
the beliefs about causes and solutions were different for the different problems 
indicating beliefs are illness specific. This fit in with the argument put forward by 
Leventhal et al. (1984, 1992, 1997) that illness representations are illness 
specific and therefore beliefs are not consistent across problem type. 
Furthermore beliefs are consistent for a specific illness regarding causes and 
solutions; thus if they report a psychological cause they would also report a 
psychological solution. This study found that beliefs can be manipulated and can 
change. They found that after manipulation, a shift in beliefs about cause results 
in a parallel shift in beliefs about solution. Consistent models are seen as better 
predictors of changes in patient outcomes. The results of this study have 
important implications in terms of both patient and GP’s beliefs. GP’s beliefs are 
important to address as consistency in cause and solutions may limit their 
perspective on what constitutes an effective solution, they may neglect 
alternative solutions which do not fall into their model of causality. Also if there is 
lack of coherence between GP and patient beliefs this can be manipulated to 
ensure coherence and lead to more successful treatment. Patients’ beliefs can
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be manipulated to ensure consistency in beliefs about causes and solutions to 
their illness to co-inside with the treatment they are receiving to improve 
adherence to medication they may receive from their GP.
1.10.3 Behaviour change
Behaviour change has been addressed in early research into different models of 
helping and coping, which argued that there can be a distinction made between 
attribution of responsibiiity for a problem and attribution of responsibility for a 
solution. This was put forward by Brickman et al. (1982) and consequently they 
put forward four general models. Firstly the moral model, where the individual is 
held responsible for both the problem and the solution, therefore they require 
motivation. Next the compensatory model which postulates the individual is not 
responsible for the problem but is responsible for the solution and therefore 
needs power. There is the medical model where the individual is not responsible 
for the problem nor the solution and therefore needs treatment. Finally there is 
the enlightenment model where the individual is responsible for the problem but 
is unable or unwilling to provide a solution and therefore needs discipline. 
Brickman et al. suggested the wrong choice of model will undermine effective 
helping and coping. They also raise the question whether some models are 
uniformly better than others.
In relation to behaviour change in terms of orlistat Ogden and Sidhu (2006) 
suggested the highly visual side-effects of the weight loss drug, such as oily 
stools and anal leakage, can change people's beliefs about the cause of their 
obesity which makes them more likely to change their behaviour. Also Ogden 
and Flills (2008) study highlighted the factors of motivations to change, imposed 
control and having a behavioural model of their problem as being key concepts 
in sustained behaviour change. These factors appear to be key predictors of 
change, which would be useful to assess in terms of the motivations for starting 
to take orlistat at baseline and how this affects subsequent behaviour change.
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1.10.4 Weightless
The main outcome that will be addressed in this thesis is weight loss. In terms of 
this outcome Ogden and Sidhu’s study (2006) found that those who had a more 
behavioural model of their obesity were more likely to be successful in their 
weight loss than those who had a medical model. The issue of consistent or 
inconsistent beliefs about causes and solutions also appears to be of some 
importance. A study on successful weight loss and maintenance by Ogden 
(2000) concluded people with success stories in weight loss were more likely to 
believe their behaviour was fundamental to both the cause and the solution of 
their weight problem. In addition Ogden and Sidhu (2006) reported consistent 
beliefs about causes and solutions related to the effectiveness of weight loss 
medication.
Weight loss in the various treatment programs varies from person to 
person. This variability, along with predictors of success, will be addressed In 
the current thesis. Stotland and Larocque (2005) examined early treatment 
response as a predictor of ongoing weight loss in obesity treatment. They 
examined early treatment response in obesity treatment, defined as early 
change in BMI and early change in eating behaviour, as a predictor of ongoing 
weight loss. They conducted measures of eating behaviour, emotional factors 
and BMI over 9 months. 344 female participants with a BMI of at least 25, 
putting them at least in the overweight category, were put on a very low calorie 
or low calorie diet. The analysis from this study indicated four key predictors of 
ongoing weight loss. The four significant predictors were early BMI change, type 
of diet, number of weigh-ins and early change in uncontrollable eating. 
Participants who displayed a strong reduction in uncontrolled eating during the 
first 5 weeks of treatment were subsequently more successful in losing weight 
when compared to those who did not show the same changes in behaviour. 
Greater early weight loss was also a positive factor for ongoing weight loss and 
early improvements in eating behaviour were equally if not more important than 
early weight loss in predicting subsequent weight change. These results showed
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that early weight loss without comparable improvements in eating control are 
less likely to result in favourable long term outcomes compared to patients 
whose early weight loss is accompanied by an equal amount of improvement in 
eating control. Early BMI change was significantly predicted by type of diet, with 
those on the very low calorie diet showing greater weight loss than those on the 
low calorie diet. Type of diet was also a predictor of ongoing BMI change. The 
number of weigh-ins, therefore the regularity of attendance in the clinic, was a 
significant positive predictor of ongoing weight change and early BMI change 
was positively related to later BMI change. This study indicated early 
improvements in eating behaviour and weight have an additive effect in 
predicting ongoing weight change. Therefore it is important to monitor early 
treatment response in obesity treatment to ensure resources are well placed or 
interventions can be applied to keep patients on track with their weight loss, as 
poor early response is likely to result in poor later response.
Ogden and Sidhu (2006) illustrate ways in which orlistat works in terms of 
aiding weight loss. Research has also explored how behaviour change and 
subsequent weight loss is maintained. Ogden and Hills (2008) conducted 
interviews with 34 ‘success stories’ who had either lost weight-through changes 
in diet and exercise (n=24) or stopped smoking (n=10) and maintained this for at 
least 3 years. The main finding of this study was that this sustained behaviour 
change was triggered by a significant life crisis relating to their health, 
relationships or salient milestones. The initial change was translated into 
sustained change if three conditions were met, which were the function of the 
unhealthy behaviour was disrupted, the individual perceived that their choice 
over carrying out the unhealthy behaviour was reduced and they adhered to a 
behavioural model of their problem. Furthermore these conditions enabled a 
process of reinvention whereby the participants shifted their identity to a new 
healthier self. This shows the key factors involved in maintaining weight loss 
through sustained behaviour change. However this study was exploratory
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therefore had a small sample size and this needs to be examined on a larger 
scale.
Maintaining weight loss in the long term is important to address as most 
people who lose weight tend to regain it. It is important to explore why people 
regain weight and how weight maintenance can be promoted. Elfhag and 
Rossner (2005) reviewed weight loss literature to highlight potential factors of 
importance in weight maintenance. Their definition of weight maintenance was 
when intentional weight loss was maintained for at least 6 months. They found 
that successful weight maintenance was associated with more initial weight loss, 
reaching a seif-determined goal weight, being physically active, eating regular 
meals including breakfast and healthy eating, control of over-eating and self­
monitoring of behaviours. They further established weight maintenance was 
associated with an internal motivation to lose weight, social support, self 
efficacy, better coping strategies and ability to handle life stresses, autonomy, 
assuming responsibility in life with overall more psychological strength and 
stability. In contrast to these findings for weight maintenance they described 
potential risk factors for regaining weight which include history of weight cycling, 
uninhibited eating, binge eating, more hunger, emotional eating and more 
passive reactions to problems. It is important to highlight that in this review the 
majority of participants involved were women. Also the methods of weight loss 
tended to be traditional methods such as behaviour modification treatments or 
individual dieting efforts. Therefore there are limitations to generalising the 
findings beyond women in these traditional weight loss conditions. But the 
findings do highlight factors that could be helpful in improving the efficacy of 
weight loss methods and maintenance.
Douketis et al. (2005) conducted a systematic review of long term weight 
loss studies in obese adults. They reviewed studies of over 2 years in duration 
that investigated dietary or lifestyle, pharmacologic and surgical weight loss 
methods to assess weight loss and the effect of this on cardiovascular risk
61
factors. Along with how these findings can be applied to clinical practice. The 
results of this review indicated that dietary or lifestyle therapy provided less than 
5kg weight loss after two to four years, pharmacologic therapy provided 5-10kg 
weight loss after 1 to 2 years and surgical therapy provided 25-75kg weight loss 
after 2 to 4 years. They suggested that greater weight loss occurs when weight 
loss medication is added to lifestyle or dietary therapy, however it appears 
continuous drug therapy is required to maintain this weight loss and weight 
regain may occur if drug therapy is terminated. It indicated that weight loss of 
less than 5% of baseline weight improved lipid levels and glycémie and blood 
pressure control however these improvements in cardiovascular risk factors 
were not consistent and these benefits were intervention specific and mainly 
occurred in those with concomitant cardiovascular risk factors. Therefore the 
impact of weight loss on cardiovascular risk factors is greatest in those with 
impaired glucose tolerance, type 2 diabetes or hypertension. This may be 
because changes in risk factors are more likely in those with abnormal baseline 
levels.
Limitations of the studies included in the review are that they had 
inadequate study duration as few studies had follow up of longer than 3 years. 
Drop out rates were high, therefore some studies chose to carry forward last 
observations for analysis which may have skewed the results and overestimated 
weight loss efficacy and cardiovascular risk factor improvements. There was a 
lack of appropriate usual care group who received placebo, with only a few 
studies including this. Although the reality of the usual care group would be no 
treatment at all rather than a placebo, which would need to be taken into 
account when examining the results. Finally there was a lack of reporting 
outcomes in high risk subgroups, unless the study was limited to high-risk 
subjects. These limitations restrict the applicability of the studies to clinical 
practice therefore more research is required in this area. Overall Douketis et al. 
highlight that dietary or lifestyle and pharmacologic weight loss interventions 
resulted in modest weight loss and improve cardiovascular risk factors, although
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these improvements were more likely in those with cardiovascular risk. The 
review also highlights the difficulties in achieving weight loss and suggests 
obesity prevention should be a worthwhile area of research.
Prevention of weight gain is an important aspect to address along with 
weight loss, as it is a useful prevention strategy. Hardeman et al. (2000) 
conducted a systematic review of interventions aimed at prevention of weight 
gain. They included 9 interventions primarily aimed at prevention of weight gain 
and they had mixed methods. The results of the review indicated that where diet 
and exercise were described in the interventions positive effects were usually 
obtained but this was only measured through self-reports. A more objective 
measure would ensure effectiveness was more precisely demonstrated and 
measured. Furthermore it would be easier to replicate interventions if they were 
more explicitly described. Also differentiating between exercise, which requires 
conscious decision-making and making plans, and physical activity, which is 
usual activities such as walking and climbing stairs and can be habitual. Overall 
they found weight loss to be mixed and follow ups were mostly short term. 
Future interventions would benefit from a longer follow up period. They found 
higher drop out rates in thinner, lower-income participants which is an area that 
would need to be addressed in future interventions aimed at prevention of 
weight gain. Effectiveness of the interventions was greatest in older, male, high- 
income participants. Smaller effects were found on weight gain among low- 
income participants, students and smokers.
This review found overall interventions to prevent weight gain displayed 
varying degrees of effectiveness. Other limitations to the interventions were that 
they required randomised controi design and bigger sample sizes. Other reviews 
(Health Promotion Effectiveness Reviews, 1997 & 1998) have reported that 
interventions appear more effective with the use of behaviour change theories, 
feedback on behaviour change and individual exercise programmes. 
Furthermore other reviews (Health Promotion Effectiveness Reviews, 1997,
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Kalichman, Carey & Johnson, 1996) suggested that interventions that use 
psychological methods in developing interventions may make them more 
effective. Hardeman et al. highlight the importance of reviewing previous 
literature to ensure previous pitfalls are not repeated. Furthermore it indicated 
that interventions to prevent weight gain can be more effective when based on 
psychological models and behaviour change methods. The psychological 
mechanisms involved in successful weight loss and prevention of weight regain 
are important to address with an evidence base of psychological theory. 
Therefore previous research and psychological theory will find reflection in the 
research presented in this thesis.
1.11 Overview
This literature review described obesity, its consequences and treatments. This 
was then embedded in psychological theory as theoretical underpinnings to the 
current thesis.
In terms of describing obesity a definition of obesity was described along 
with its prevalence and consequences followed by physiological and behavioural 
theories of cause. Obesity management was then explored in terms of dietary, 
behavioural, surgical and pharmacological interventions. As the main topic of 
this thesis is peoples’ experiences of orlistat this particular pharmacological 
interventions was explored in more detail. What orlistat is and how it works 
along with its use for weight loss and weight maintenance was described. The 
practical implications of orlistat in practice along with its success when combined 
with other interventions and the implications of cessation of orlistat were 
examined. The potential abuse and cost effectiveness of orlistat were also 
explored.
Orlistat was discussed in relation to the psychological implications and 
mechanisms of orlistat which were related to psychological theory. Previous 
research only addressed this qualitatively therefore there is the need to address
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this quantitatively. Psychological theory was explored, specifically the self- 
regulatory model, the health belief model and the stages of change model. The 
processes of behaviour change were then examined in terms of illness 
representations, visual feedback and the doctor-patient relationship. The 
outcomes of these processes were then described, in particular adherence, 
coherence, weight loss and behaviour change, were examined.
Variability in success in relation to taking orlistat has been explored 
qualitatively on a small scale but this needs to be examined quantitatively in 
relation to adherence and illness beliefs on a larger scale. This thesis will 
address the gaps in the literature and aims to add to the limited literature on the 
psychological implications of orlistat as an intervention for weight loss. The 
specific aims of this thesis will now be discussed in more detail.
1.12 Alms of this thesis
This thesis aims to address the psychological processes involved in behaviour 
change and weight loss whilst individuals are taking the obesity medication 
orlistat (120mg) and the impact of this on weight loss and changes in beliefs and 
behaviours in the longer term. It aims to provide insights into the mechanisms of 
change per se and how these are facilitated by orlistat using a quantitative 
longitudinal design with follow ups at 6, 12 and 18 months and further qualitative 
interviews with a sample of participants. This will be examined in the short term 
over 6 months and the longer term over 18 months. The process of change will 
be examined along with the experiences of those who have failed to lose weight 
or maintain the initial weight lost. The aims of each study will now be described:
Study 1: Baseline behaviour, cognitions and experiences of taking orlistat. 
(Chapter 3):
1. To describe participants’ demographics (e.g. profile characteristics,
weight, BMI), beliefs (e.g. beliefs about causes, solutions and
motivations, illness perceptions, side effects, implications, imposed
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control) and behaviour (e.g. adherence, eating behaviour, exercise, help 
seeking and methods of weight loss) at baseline.
2. To examine coherence in beliefs about causes and solutions of 
obesity.
3. To examine the role of demographics, cognitions and behaviour, 
illness perceptions and eating behaviour at baseline in explaining 
outcomes (BMI, healthy eating, unhealthy eating and adherence).
Study 2: Short term changes in Individuals taking orlistat, from baseline to 
six months follow up. (Chapter 4):
1. To describe participants’ demographics, beliefs and behaviour at 
baseline and 6 month follow up.
2. To explore the changes over time in weight, beliefs and behaviour.
3. To examine predictors of patient outcomes.
4. To examine experiencing side effects with the impact on 
adherence and diet change.
5. To examine the changes in endorsing a behavioural solution and 
the relationship to losing weight.
6. To examine changes in beliefs about medical solutions to their 
weight problem and relationship to losing weight.
7. To explore changes in adherence and losing weight.
Study 3: Long term behaviour change and weight loss since taking
orlistat, from baseline to 18 month follow up. (Chapter 5):
1. To describe participants’ demographics, beliefs and behaviour at 
baseline and 18 month follow up.
2. To explore the changes over time in weight, beliefs and behaviour.
3. To examine predictors of patient outcomes.
4. To examine the changes in endorsing a behavioural solution and
the relationship to losing weight.
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5. To examine changes in beliefs about medical solutions to their 
weight problem and relationship to losing weight.
Study 4: The process of behaviour change since beginning to take orlistat, 
from baseline through 6,12 and 18 month follow up. (Chapter 6):
1. To describe participants’ demographics, beliefs and behaviour at 
baseline, 6 month, 12 month and 18 month follow up.
2. To explore the changes over time in weight, beliefs and behaviour.
3. To examine predictors of patient outcomes.
Study 5: Experiences of those who have failed to lose weight In the long 
term (18 months) after drug therapy: A qualitative study (Chapter 7):
1. To explore people’s experiences of taking orlistat who fail to lose
weight in the long term using I PA analysis.
1.13 Hypotheses to be tested in the quantitative studies:
Primary hypotheses:
1. Those that show a greater weight loss, over the short and long term, will 
have more significant life events motivations along with endorsing a behavioural 
model to their obesity at baseline.
2. Those that change from endorsing a medical model to their weight to a 
behavioural model will lose more weight than those who maintain their 
endorsement of a medical model.
3. Those that adhere to orlistat, eat healthier food and exercise more will 
lose more weight.
Secondary hypotheses:
1. Participants will be consistent in their beliefs about causes and solutions 
to their weight problem.
2. Of those who experience side effects from taking orlistat, those who fully 
adhere will also change their eating behaviour.
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3. Those who endorse a more behavioural model to their weight problem 
will be more successful in losing weight than those who endorse a more medical 
model.
4. Those who report more routine motivations to begin losing weight will be 
less successful in losing weight than those who report more significant event 
motivations.
5. Those who fully adhere to orlistat will lose more weight than those who 
selectively adhere.
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Chapter 2 
Method for the longitudinal study
2.1 Design
The study used a longitudinal design with questionnaires concerning 
experiences of taking orlistat in terms of weight, beliefs and behaviour. Data 
was collected at baseline, 6 month, 12 month and 18 month follow up.
2.2 Sample
The sample included people who had registered on the Xenical support 
system (MAP), which is a telephone helpline that offers information, advice 
and support to people who are taking orlistat. Patient’s prescribed orlistat by 
their GP are given the MAP details and can elect to register with them for 
further support. When they rang MAP to register they were asked if they 
would like to take part in this study and if they gave consent their name and 
address were passed on to the researcher and they were sent an information 
sheet and questionnaire in the post. Those who returned the baseline 
questionnaire were sent the follow up at 6 months; those who returned a 
completed questionnaire at 6 months were sent a further questionnaire at 12 
months. All those who returned a completed questionnaire at baseline were 
sent a follow up questionnaire at 18 months. The University Ethics committee 
approved the study (see appendix 1).
2.3 Inclusion/Exclusion Criteria
Participants were included if they initially rang up to register on the MAP 
program within a four month period, were 18 or over and were prescribed 
orlistat by their GP.
2.4 Procedure
MAP gained initial consent from participants to pass on their contact details 
to take part in the study. An information sheet (see appendix 2) and 
questionnaire were then sent out to participants by post with a freepost 
envelope for them to return it in. Participants who returned the baseline
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questionnaire (n=1582) were then sent a follow up questionnaire at 6 months 
by post, with a freepost envelope and/or by email with a link to the 
questionnaire online, if they provided their email address at baseline. A 
reminder email was sent after 1 month, with the link to the questionnaire 
online, to those who had not yet completed the questionnaire and had 
provided an email address. Those who returned the follow up questionnaire 
at 6 months (n=572), online or by post, were sent a further questionnaire at 
12 months, by post, with a freepost envelope and/or by email with a link to 
the questionnaire online, if provided. A reminder email was sent after 1 
month, with the link to the questionnaire online, to those who had not yet 
completed the questionnaire and had provided an email address. All those 
who returned a completed questionnaire at baseline were sent a follow up 
questionnaire at 18 months by post or email. Those who had not yet 
completed the questionnaire after one month were sent a reminder email, if 
one had been provided (see table 2.1 for participant flow).
Table 2.1: Participant flow
Baseline 6 months 12 months 18 months
Returns Sent = 4704 
Returned = 1582 
Response rate = 34%
Sent = 1582 
Returned = 572 
Response rate = 36%
Sent = 572 
Returned = 443 
Response rate = 77%
Sent = 1582 
Returned = 519 
Response rate = 33%
Numbers 
in the 
studies
Chapter 3 
Baseline
Chapter 4 
Shoit term 
(0-6 months)
Chapter 5 
Long term 
(0-18 months)
Chapter 6 
Process
(0-6-12-18 months)
n = 1582 n = 572 
Percentage of 
baseline = 36%
n = 519 
Percentage of 
baseline = 33%
n = 296 
Percentage of 
baseline = 19%
2.5 Measures at baseline
The questionnaire was based on previous qualitative research (Ogden & 
Sidhu, 2006; Ogden & Hills, 2008). The questionnaire examined people’s 
profile characteristics, beliefs and behaviour in the past month (see appendix 
3 for questionnaire). All participants were asked to complete a baseline 
questionnaire consisting of:
Demographics
I. Profile characteristics
II. Time taking orlistat
III. Weight history
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Beliefs
IV. Beliefs about causes, solutions and motivations
V. Illness perceptions
VI. Side effects, implications and behaviour change 
Behaviour
VII. Adherence and imposed control
VIII. Eating behaviour
IX. Exercise
X. Help seeking
XI. Methods of weight loss
These will now be described in detail.
Demographics
2.5.1 Profile characteristics
Participants were asked to describe their age, sex, ethnic group (white/black 
African/black Caribbean/Asian/other), work status (full/part time/not working), 
marital status(married/divorced/separated/living with partner/single/widowed) 
and highest level of education (less than Secondary school/Secondary 
school graduate/Some college/College g raduate/U nderg rad uate 
degree/Masters degree/Doctoral or Professional Degree) (Argyle, 1994).
2.5.2 Weight history
The first questions in this section asked participants to describe their present 
weight and height; as a means to calculate their BMI scores. They were then 
asked a further 9 questions regarding their weight histories including their 
highest and lowest weight and most weight lost (what weight would you like 
to be, how long did/have you maintained this weight loss for, are you 
currently trying to lose weight, how old were you when you first became 
overweight, how old were you when you first tried to lose weight, how many 
years have you been trying to lose weight for) (Ogden, 2000).
2.5.3 Taking orlistat
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Participants were asked how long they had been taking orlistat for, whether it 
was the first time they had been prescribed orlistat and if not how many times 
they been prescribed it before.
Beliefs
2.5.4 Beliefs about causes, so lu tions  and m otiva tions
I. Causes
Participants rated 6 statements regarding the possible causes of their weight 
problem on a scale ranging from not at all (1) to totally (5). These items were 
chosen as 3 were behavioural causes (eating too much, not enough exercise 
and eating the wrong foods) and 3 were medical causes 
(genetics/inheritance, glands/hormone problem and slow metabolism) which 
fit into previous qualitative research as being the main causes people relate 
their obesity to.
II. Solutions
They rated 8 statements regarding the possible solutions to their weight 
problem on the same scale, which included 3 diet solutions (eating fewer 
calories, healthy eating and eating less fat), 3 exercise solutions (exercise, 
being more active and physical activity) and 2 medical solutions (medication 
and surgery) which were based on previous qualitative research (Ogden & 
Sidhu, 2006; Ogden & Hills, 2008).
III. Motivations
They then rated 9 statements on what motivated them to start taking orlistat 
on a scale ranging from not at all (1) to totally (5), which included 3 everyday 
consequences of being obese (low self-esteem, lack of confidence and 
feeling unattractive), 3 significant life events (major medical problem, 
significant event e.g. birthday, relationship breakdown) and 3 health related 
issues (feeling unhealthy, feeling breathless and pains in your knees) which 
have been identified in previous qualitative research (Ogden & Sidhu, 2006; 
Ogden & Hills, 2008).
2.5.5 Illness perceptions
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The next section was the brief illness perception question (Broadbent et al., 
2006), which rapidly assesses the cognitive and emotional representations of 
illness. The questions were altered to refer to their weight problem and 
orlistat as a treatment. This was made up of 8 items assessing 
consequences (how much does your weight affect your life), timeline (how 
long do you think your weight problem will continue), personal control (how 
much control do you feel you have over your weight), treatment control (how 
much do you think taking orlistat can help your weight), identity (how much 
do you experience symptoms from your weight), concern (how concerned are 
you about your weight), understanding (how well do you feel you understand 
your weight) and emotional response (how much does your weight affect you 
emotionally), which were rated on a 10 point scale.
2.5.6 Side effects, Implications and behaviour change
I. Experiences
Participants were asked how often they had experienced common side 
effects of taking orlistat, they were asked to rate 5 main side effects (liquid 
stools, an urgency to go to the toilet, diarrhoea, bloating and wind) on a scale 
ranging from never (1) to constantly (5).
II. Impact on cognitions
They were then asked to rate 6 statements about how the side effects 
changed the way they thought on a scale ranging from not at all (1) to totally 
(5), these statements included 3 behavioural consequences (they have 
helped me to think about my diet, they have helped me to think why I’m 
overweight and they have made me realise what is in different foods) and 3 
medical consequences (they are just something I have to put up with, they 
are a necessary part of weight loss and they are a necessary part of taking 
the drug).
III. Impact on behaviour
Participants were asked to rate 6 statements regarding how the side effects 
have made them change their behaviour. There were 3 statements regarding 
behavioural changes (eat healthier, reduce fat intake and change the way 
you eat) and 3 statements regarding how they manage their medication (stop
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taking orlistat, take orlistat only occasionally, not take orlistat if you want to 
eat fattier foods), these statements were rated on a scale ranging from not at 
all (1) to totally (5). These constructs relate to previous research of people’s 
experiences of taking orlistat (Ogden & Sidhu, 2006).
Behaviour
2.5.7 Adherence and im posed contro l
I. Imposed control
They were asked to rate 3 statements on imposed control of orlistat (limits 
what you can eat, limits what you want to eat and makes you eat food you do 
not enjoy), these statements were rated on a scale ranging from not at all (1) 
to totally (5).
II. Adherence
They were also asked to rate 3 statements on adherence to medication (I 
take it religiously, I miss doses sometimes and I stop taking it before a fatty 
meal), these were rated on the same scale from not at all (1) to totally (5). 
These constructs relate to previous qualitative research (Ogden & Sidhu, 
2006).
2.5.8 Eating behaviour
The next part asked about their current diet in the past month. The eating 
behaviour questionnaire was developed from the World Health Organisation 
2001/02 protocol (Currie et al, 2001), the food frequency questionnaires 
found in Inchley et al (2001), the seven day food diary (Gregory et al, 2000) 
and consumer market research report data (Mintel, 2003).
I. Snacks
The first question asked how often they snacked on 4 healthy snacks (rice 
cakes, crackers or breadsticks, raw vegetables and salad, fruit and cereal 
bars) and 4 unhealthy snacks (chips, crisps or savoury snacks, cakes, 
biscuits and other sweet pastries, confectionery) on a 8 point scale ranging 
from never or less than once a month (1) to more than 3 times a day, every 
day (8).
II. Meals
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The participants were then asked 4 items about meals eaten at home and 
meals out (cooked meals at home, ate processed foods, ate ready meals and 
ate takeaways) on the same scale as the previous question.
III. Cooking methods
They were then asked about the cooking methods they usually used, they 
were asked to rate 3 healthy (boil, steam and dry fry) and 3 unhealthy 
methods (deep fry in oil/fat, shallow fry in oil/fat and roast/bake) on a 5 item 
scale ranging from never (1) to often (5).
IV. Fat
They were then asked how often they consumed 3 high fat (full cream milk, 
full fat butter/margarine and full fat cheese (hard)) and 3 low fat items (semi­
skimmed/skimmed milk, low fat butter/margarine and low fat cheese) on a 8 
item scale ranging from never (1) or less than once a month to more than 3 
times a day, every day (8).
V. Fruit and vegetables
Participants were asked how many portions of fruit and vegetables they 
usually have on an average day over the past month from 0 to 7 plus.
2.5.9 Exercise
Participants were also asked to indicate on a 5 point scale ranging from 
sedentary (no exercise) (1) to regular vigorous exercise (i.e., work or 
recreation for 30 minutes) (5) how active they have been over the past month 
(Adapted from Ebrecht et al, 2004).
2.5.10 Help seeking
I. Professionals
Participants were asked how much contact they had had with health 
professionals to help them to lose weight on a 5 point scale ranging from 
none (1) to frequently (5) (these included 7 health professionals which were 
GP, dietician, psychologist, practice nurse, hospital doctor, counsellor and 
slimming club organiser).
II. MAP
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The participants’ in this study had signed up to MAP, a telephone support 
group, who called the participants’ to offer support and advice, therefore how 
often they received this and how they evaluated this support was explored. 
Participants were asked how often they had contacted the MAP telephone 
support service on a 8 item scale ranging from never or less than once a 
month (1) to more than 3 times a day, everyday (8). They were then asked 
their experience of the telephone support service through rating 6 statements 
(helpful, caring, personal, informative, understanding and supportive) on a 
scale ranging from not at all (1) to totally (5).
2.5.11 Methods of weight loss
Participants were asked if they had tried any other methods of weight loss 
(calorie controlled diet, food avoidance, food weighing, low fat diet, healthy 
eating, high fibre diet, exercise, weighing yourself, counselling, cognitive 
behavioural therapy and self help group) on a 5 point scale ranging from 
never (1) to very often (5). They were then asked if they had had weight loss 
surgery and whether they intended to have it in the future. This was to 
address all the participants’ behaviour to facilitate weight loss which may 
have had an impact on their experiences of taking orlistat.
2.6 Measures at follow up
All participants were then asked to complete a follow up questionnaire at 6,
12 and 18 months. The follow up questionnaire followed a similar format as 
the baseline questionnaire but there were a few changes. The sections that 
remained the same as baseline were beliefs about causes and solutions; 
illness perceptions, eating behaviour, exercise and methods of weight loss. A 
couple of other sections remained the same but participants’ were told not to 
complete them if they were no longer taking orlistat, these were adherence 
and imposed control and side effects, implications and behaviour change. 
The sections that changed were:
2.6.1 Profile characteristics
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The only question that was repeated at follow up in this section was current 
weight.
2.6.2 Taking orlistat
At follow up participants were asked if they were still taking orlistat or not and 
if they were no longer taking orlistat they were asked why they stopped, with 
the option to respond yes or no to 3 statements, which were because the 
doctor told me to, because it wasn't helping and because I didn’t like the side 
effects. If respondents stopped taking orlistat more than a month ago they 
were asked to skip the rest of this section. The rest of this section was the 
same as baseline.
2.6.3 Help seeking
The questions regarding seeing health professionals about their weight 
remained the same as baseline however when asked about MAP they were 
asked if they still had contact with MAP. If they stated yes they were asked 
the same questions as baseline. If they responded no then they were asked 
to skip the rest of the questions on MAP.
2.7 Data reduction and reliability
Data was reduced if several items in the same section referred to the same 
concept. When the items were grouped together, the mean was calculated by 
adding the scores from all items and the dividing them by the number of 
items (to one decimal place). These items and concepts will be described. 
Reliability was assessed using Cronbach’s alpha (a).
2.7.1 Beliefs
For causes of their weight problem 3 were grouped as behavioural causes 
(eating too much, not enough exercise and eating the wrong foods; a=.726) 
and 3 were grouped as medical causes (genetics/inheritance, 
glands/hormone problem and slow metabolism; a=.653). Under solutions to 
their weight problem 6 were grouped as behavioural solutions (eating fewer 
calories, healthy eating, eating less fat, exercise, being more active and
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physical activity; a=.861) and 2 were grouped as medical solutions 
(medication and surgery; r=.407).
2.7.2 Motivations
Under motivations to start taking orlistat 3 items were grouped as everyday 
consequences of being obese (low self-esteem, lack of confidence and 
feeling unattractive; a=.922), 3 were identified as significant life events (major 
medical problem, significant event e.g. birthday and relationship breakdown; 
a=-.134) and 3 were grouped as symptoms (feeling unhealthy, feeling 
breathless and pains in your knees; a=.630).
2.7.3 Experience of side effects
The 5 items describing the side effects of taking orlistat were grouped 
together to describe the side effects score, these items were liquid stools, an 
urgency to go to the toilet, diarrhoea, bloating and wind (a=.847).
For the cognitions of the side effects 3 items were grouped as 
behavioural consequences (they have helped me to think about my diet, they 
have helped me to think why I’m overweight and they have made me realise 
what is in different foods; a=.840) and 3 were grouped as medical 
consequences (they are just something I have to put up with, they are a 
necessary part of weight loss and they are a necessary part of taking the 
drug; a=.757).
Under behavioural implications of the side effects 3 items were 
averaged to form behavioural changes (eat healthier, reduce fat intake and 
change the way you eat; a=.902) and 3 statements were averaged to form 
adherence behaviour change (stop taking orlistat, take orlistat only 
occasionally, not take orlistat if you want to eat fattier foods; a=.743).
2.7.4 Taking Orlistat
3 items were averaged to describe imposed control of orlistat, which were 
limits what you can eat, limits what you want to eat and makes you eat food
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you do not enjoy (a=.749). For adherence, items I miss doses sometimes 
and I stop taking it before a fatty meal were reversed scored then those two 
plus the item I take it religiously were averaged to describe adherence 
(a=.689).
2.7.5 Behaviour
In the diet section of the questionnaire several items were combined for 
analysis. 4 healthy items including rice cakes, crackers or breadsticks; raw 
vegetables and salad; fruit and cereal bars were averaged to form a new 
variable of healthy snack (a=.544). 4 items including chips; crisps or savoury 
snacks; cakes, biscuits and other sweet pastries, and confectionery were 
averaged to form a new variable of unhealthy snack (a=.740).
The items ate processed foods, ate ready meals and ate takeaways 
were averaged to form a new variable of unhealthy meal (a=.602). A new 
variable of healthy cooking was formed by calculating the mean for the boil, 
steam and dry fry items (a=.413). The items deep fry in oil/fat, shallow fry in 
oil/fat and roast/bake were averaged to form the variable of unhealthy 
cooking (a=.466).
Items full cream milk, full fat butter/margarine and full fat cheese 
(hard) were combined and the mean calculated to form the variable of high 
fat food (a=.403). Items semi-skimmed/skimmed milk, low fat 
butter/margarine and low fat cheese were averaged to form the variable of 
low fat food (a=.3B9).
2.7.6 Historical factors
For past methods of weight loss; calorie controlled diet, food avoidance, food 
weighing, low fat diet, healthy eating and high fibre diet were combined and 
the mean calculated to form the diet item (a=.777). The items counselling, 
cognitive behavioural therapy and self help group were combined and the 
mean calculated to describe psychological methods (a=.468).
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2.7.7 Telephone support service
Finally in terms of grouping variables under the section on MAP, the 
telephone support group, all 6 items (helpful, caring, personal, informative, 
understanding and supportive) assessing the quality of support were 
combined and the mean calculated to give an overall score of how positive 
they felt about MAP (a=.975).
Note: The majority of the Cronbach’s alpha are at an acceptable level in such 
a large sample size with some at a lower level. This low level is due to the 
respondents not necessarily responding the same to all items that make up 
the constructs that are being assessed for reliability, however the constructs 
may still make sense. For example they would not necessarily eat the same 
amount of milk, butter and cheese but these could be categorised as high fat 
foods. The main construct of concern was the significant event item. The 
Cronbach’s alpha implies there is a problem with the construct, when the 
major medical problem item was removed the Cronbach’s alpha increased to 
.218, however this did not alter the results of the multiple regressions where 
the grouped variable was used. Also the multiple regressions were re-run 
with the individual item of significant event and the results of the multiple 
regression also did not differ.
2.8 Grouping responses.
For descriptive purposes only some of the items scored on a 5 point likert 
scale were grouped as follows:
NOTE: These were not used in any other analysis.
2.8.1 Beliefs and motivations
Questions on causes and solutions to weight problems and motivations for 
weight loss were scored on a scale of 1 to 5. These responses were grouped 
as 1 to 2.4 as ‘no’ (1), 2.5 to 3.4 as ‘not sure’ (2) and 3.5 to 5 as ‘yes’ (3).
2.8.2 Experience of side effects and taking orlistat
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Questions on side effects, cognitions of the side effects, behavioural 
implications of the side effects and imposed control were also on a scale 
from 1 to 5 and recoded in the same manner. The grouped item of adherence 
was recoded as 1 to 3.4 as ‘no’ and 3.5 to 5 as ‘yes’.
2.8.3 IPQ
For the IPQ items were scored on a scale from 0 to 10 which were recoded 
for scores of 0 to 3 as ‘low’, 4 to 6 as ‘not sure’ and 7 to 10 as ‘high’.
2.8.4 Behaviour
For the diet section the items in snacks, meal at home/out, and fat were on a 
scale from ‘never or less than once a month’ to ‘more than 3 times a day, 
everyday’. Responses were grouped into never or less than once a month to 
less than once a week as ‘no’; once a week to 2 to 4 days a week as 
‘sometimes’ and 5 to 6 days a week to more than 3 times a day, every day as 
‘never’. For the section on home cooking and eating out items were scored 
on a 5 point response scale from never to often. Never and seldom were 
recoded as ‘no’, occasionally was recoded at ‘sometimes’ and frequently and 
often were recoded as ‘often’.
For the exercise section responses were on a scale from sedentary to 
regular vigorous exercise. The responses were recoded so sedentary and 
occasional mild exercise were defined as ‘sedentary’; regular mild exercise 
was recoded as ‘regular mild’ group and occasional vigorous exercise and 
regular vigorous exercise were defined as ‘vigorous’.
2.8.5 Historical factors
For the section of past weight loss methods items were scored on a 5 item 
scale from never to very often, these responses were recoded as none to 
rarely as ‘never’; sometimes remained as ‘sometimes’ and often to very often 
were recoded as ‘very often’.
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For the section on help seeking the items were scored on a 5 item 
scale from none to frequently. Responses of none to rarely were recoded as 
'none', sometimes remained as ‘sometimes’ and regularly to frequently were 
recoded as ‘frequently’.
2.8.6 Telephone support service
In the section on MAP, the telephone support service, the first item on how 
much contact they have with MAP was scored on a 8 item scale from never 
or less than once a month (1) to more than 3 times a day every day (8).
These responses were recoded as never or less than once a week as ‘0>1 
days a week’; once a week to 2-4 days a week as ‘1-4 days a week’; and 5-6 
days a week, once a day everyday, 2-3 times a day everyday and more than 
3 times a day everyday were recoded as ‘5 days a week<3 times a day 
everyday’.
Finally the items on how they found the service were scored on a 5 
item scale from not at all (1) to totally (5). These were recoded from 1 to 2.4 
as ‘not at all’ ; 2.5 to 3.4 as ‘somewhat’ and 3.5 to 5 as ‘totally’.
2.9 Outlier management
The variables were changed into z-scores (standardised values). Participants 
with z-scores greater than 3.29 were removed and then it was checked that 
less than 1% had scores greater than 2.58 and 5% had values greater than 
1.96 (Field, 2005). This consisted of n=7 (total n=1582) for study 1, n=4 (total 
n=572) for study 2, n=7 for study 3 (total n=519) and n=4 for study 4 (total 
n=296). Therefore outliers were removed from continuous variables used in 
the multiple regressions.
82
Chapter 3
Study 1: Baseline behaviour, beliefs and experiences of taking orlistat.
3.1 Introduction
3.1.1 Background
Drug therapy is one method used for weight loss in over weight and obese 
individuals. It is recommended for individuals with a BMI of greater than 30 
kg/m^ or a BMI of 27 to 30 kg/m^ with one or more obesity related disorders (US 
Guidelines, 1998) and should also be used in conjunction with continuing non- 
pharmacoiogical therapy of diet and exercise. Current recommendations also 
suggest that it is used for patients who have a history of failed weight loss 
attempts using behavioural methods and who can demonstrate some degree of 
weight loss (at least 2.5kg) in the month before treatment (National Institute of 
Clinical Excellence, 2001). Whilst taking orlistat patients need to reduce their 
daily calorie intake by 500 to 1000 calorie to achieve weight loss along with 
monitoring the number of fat grams they consume to ensure the fat in their diets 
is limited to about 30% of their daily calorie intake.
Orlistat works by reducing fat absorption by blocking about one-third of 
the fat in the food eaten from being absorbed in the body and being eliminated 
in bowel movements. When orlistat is taken in conjunction with high fat foods 
there are unpleasant side effects because the drug prevents the fat consumed 
from being absorbed by the body. A qualitative study that examined the 
experiences of those patients taking orlistat was conducted by Ogden and Sidhu 
(2006). They conducted interviews with those who had been prescribed orlistat 
in the past year and discussed previous weight history and experiences of taking 
orlistat. The main themes that came out of these interviews were participant’s 
model of obesity, their motivations for weight loss, the impact of the highly visual 
side effects of taking orlistat and their management of the side effects. Further it 
was argued that the experiences of those taking orlistat provide insights into two 
central behaviours; those of adherence to medication and behaviour change. In
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particular, it was argued that the side effects can function by encouraging a 
more behavioural model of the causes of obesity by highlighting the link 
between fat eaten and body fat stored. That in turn can make the participant 
more likely to try to adopt a lower fat healthier diet; by creating coherence 
between beliefs about causes and solutions with a focus on behaviour, which 
means subsequent changes in behaviour are more likely to occur. These 
themes find reflection in Leventhal’s self regulatory model and his emphasis on 
illness cognitions and in particular, coherence (Leventhal et al., 1982) and in 
addition are in line with research emphasising the role of visual feedback and 
the impact of visual stimuli on an individual’s beliefs and behaviours (Bovet et 
al., 2002). These themes, however, came from a small qualitative study with 
limited generalisability. The present study therefore aimed to explore them 
quantitatively in a much larger national sample. The data presented in this 
chapter reflects the baseline data of the longer longitudinal study that followed 
participants up over an 18 month period (this longitudinal data is reported in 
chapters 4, 5 & 6).
3.1.2 Aims
The aim of this current study was to describe and explore the experiences of 
those taking orlistat when they first signed up to the MAP program in a large 
scale national postal questionnaire. This questionnaire aimed to examine beliefs 
and current behaviour in addition to how the beliefs and behaviours are related. 
Specifically the aims of this study are:
1. To describe participants’ demographics (e.g. profile characteristics, 
weight, BMI), beliefs (e.g. beliefs about causes, solutions and motivations, 
illness perceptions, side effects implications and imposed control) and behaviour 
(e.g. adherence, eating behaviour, exercise, help seeking and methods of 
weight loss) at baseline.
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2. To examine coherence in beliefs about causes and solutions of 
obesity.
3. To examine correlates of outcomes including the role of 
demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline in explaining BMI, 
healthy eating, unhealthy eating and adherence.
3.2 Methods
3.2.1 Design
The study used a cross sectional design with questionnaires concerning 
participant demographics, experiences of taking orlistat and beliefs about the 
causes and solutions of obesity.
3.2.2 Sample
The sample included people who had registered on the Xenical support system 
(MAP), which is a telephone helpline that offers information, advice and support 
to people who are taking orlistat. Patients prescribed orlistat by their GP are 
given the MAP details and can elect to register with them for further support. 
When they rang MAP to register they were asked if they would like to take part 
in this study and if they gave consent their name and address were passed on to 
the researcher and they were sent an information sheet and questionnaire in the 
post. 4704 questionnaires were sent out in the post and 1582 were returned 
completed (response rate = 34%). The University Ethics committee approved 
the study.
3.2.3 Procedure
MAP gained initial consent from participants to pass on their contact details to 
take part in the study. An information sheet and questionnaire were then sent 
out to participants by post with a freepost envelope for them to return it in.
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3.2.4 Measures
The questionnaire was based on previous qualitative research (Ogden & Sidhu, 
2006 and Ogden & Hills, 2008). The questionnaire examined people’s weight, 
motivations, beliefs about obesity, side effects of orlistat, diet and exercise in the 
past month along with profile characteristics. All participants were asked to 
complete a questionnaire consisting of the sections titled; demographics, weight 
history, historical factors, taking orlistat. beliefs, motivations, IPQ, experience of 
side effects, behaviour and telephone support service (see method section, 
chapter 2, for further details).
3.2.5 Inclusion/Exclusion Criteria
Participants were included if they rang up to register on the MAP program within 
a four month period, were 18 or over and were prescribed orlistat by their GP.
3.2.6 Data analysis
The data was analysed to:
1. To describe participants’ demographics, beiiefs and behaviour
in terms of:
Demographics
i. Profile characteristics, weight and BMI.
ii. Time taking orlistat
iii. Weight history 
Beliefs
iv. Beliefs about causes, solutions and motivations
V. Illness perceptions
vi. Side effects, implications and behaviour change 
Behaviour
vii. Adherence and imposed control
viii. Eating behaviour
ix. Exercise
X. Help seeking
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xi. Methods of weight loss 
For the multiple regressions outliers were removed.
2. To examine coherence in beliefs about causes and so lu tions o f 
obesity. ‘If, then’ analyses were conducted to explore whether people held 
consistent beliefs about causes and solutions to their weight problems.
3. To examine correlates o f outcomes.
The role of demographics, beliefs (cognitions and illness perceptions) and 
behaviour (exercise, adherence and eating behaviour) at baseline in explaining 
a number of outcomes was assessed using Multiple Regression analysis as 
follows:
i. Explaining BMI from:
Demographics 
Beliefs and behaviour 
Illness beliefs 
Eating behaviour
ii. Explaining healthy eating from:
Demographics 
Beliefs and behaviour 
Illness beliefs
iii. Explaining unhealthy eating from:
Demographics 
Beliefs and behaviour 
Illness beliefs
iv. Explaining exercise from:
Demographics 
Beliefs and behaviour 
Illness beliefs 
Eating behaviour
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V. Explaining adherence from:
Demographics 
Beliefs and behaviour 
Illness beliefs 
Eating behaviour
Data transformation 
Demographics
For the multiple regressions age, sex and education remained as they were and 
ethnicity, job and marital status were recoded. Ethnicity was recoded into white 
(n=1498) and other (n=69). Job was recoded into working (n=817) or not 
working (n=707). Marital status was recoded into living with someone (n=1092) 
and living alone (n=440).
Coherence
For causes of their weight problem 3 were grouped as behavioural causes 
(eating too much, not enough exercise and eating the wrong foods) and 3 were 
grouped as medical causes (genetics/inheritance, glands/hormone problem and 
slow metabolism). For solutions to their weight problem 6 were grouped as 
behavioural solutions (eating fewer calories, healthy eating, eating less fat, 
exercise, being more active and physical activity) and 2 were grouped as 
medical solutions (medication and surgery). Using median split these were split 
into yes and no, with the yes responses being used in the “if then” analysis.
3.3 Results
3.3.1 Describing participants demographics, beliefs and behaviour
Descriptive analysis was conducted to explore participants’ demographics, 
beliefs and behaviour.
Demographics
I. Profile characteristics, w eight and BMI.
Participants’ demographics were described in terms of profile characteristics, 
weight and BMI. Participants’ demographics are shown in table 3.1.
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Table 3.1; Demographics
Variable
Age (yrs) Mean = 48.5 SD -  13.1
(n=1558) Range = 1 8 -8 7
Sex Male = 280 (17.9%)
(n=1564) Female = 1284 (82.1%)
Ethnicity White = 1497 (95.6%) Black Caribbean = 19 (1.2%)
(n=1566) Black African = 9 (0.6%) Asian = 21 (1.3%) 
Other = 20 (1.3%)
Job Full time = 499 (32.8%) Part time = 318 (20.9%)
(n=1523) Not Working = 706 (46.4%)
Marital Status Married = 930 (60.7%) Divorced = 189 (12.3%)
(n=1531) Living with Partner = 162 (10.6%)
Single = 191 (12.5%) Widowed = 59 (3.9%)
Education Less than secondary = 193 (12.2%)
(n=1499) Secondary School Grad = 512 (32.4%)
Some College = 374 (23.6%)
College Grad = 218 (13.8%)
Graduate = 109 (6.9%) Postgraduate = 33 (2.1%) 
Doctorate or Professional Degree = 61 (3.9%)
Height (m) Mean =1 .66  SD = 0.09
(n=1523) Range = 1.27 - 2.08
Weight (kg) Mean = 98.9 SD = 18.8
(n=1498) Range = 57.15 -  177.00
BMI Mean = 36.04 SD = 5.905
(n=1480) Range = 20.25 -  56.25
The results showed that the majority of participants were women, white, not 
working, married and secondary school graduates. The mean age was 48.5 
years. The mean height was 1.66 (m) and mean weight 98.9 (kg). The mean 
BMI was 36.04.
II. Time taking orlistat
Participants’ time taking orlistat was assessed in terms of length of time taking 
orlistat, whether it was their first time taking it and if not how many times they 
had taken it previously. Participants’ time taking orlistat is shown in table 3.2. 
Table 3.2: Taking orlistat
Length of time taking orlistat Mean 9.29 SD 11.60
(weeks) Range 1-156
First time? Yes No
n=1317 (83.8%) n=255 (16.2%)
If no how many times before Mean 1.42 SD 0.68
Range 1-6
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The results show on average participants had been on orlistat just over 2 
months, for the majority it was the first time they had taken orlistat, but of those 
who had taken it before on average they had taken it once before.
III. Weight history
Participants’ weight histories are described in table 3.3.
Table 3.3: Weight history
Highest weight ever Mean 108.01 SD 22.03
(kg) Range 55.34-280.77
Lowest weight since 18 yrs Mean 68.34 SD 16.02
(kg) Range 31.75-134.26
Desired weight Mean 71.65 SD 12.00
(kg) Range 40-150
Most weight lost Mean 17.85 SD 10.99
(kg) Range 0-88.9
How long maintained Mean 20.95 SD 31.48
(months) Range 0-360
Currently trying to lose weight Yes No
n=1533 (99.5%) n=7 (0.5%)
Age first overweight Mean 25.39 SD 13.19
(yrs) Range 0-72
Age first tried to lose weight Mean 28.09 SD 13.15
(yrs) Range 0-75
Years trying to lose weight Mean 16.60 
Range 0-77
SD 12.56
The results showed on average the participants highest ever weight was 
108.01kg and their lowest weight since 18 years old was 68.34kg. The average 
weight they would like to be was 71.65kg. The average amount of most weight 
lost was 17.85kg and the average time it was maintained for was 20.95 months. 
Almost 100% of participants were currently trying to lose weight. The average 
age participants became overweight was 25.39 yrs and the average age they 
first tried to lose weight was 28.09yrs, with the average length of time 
participants had been trying to lose weight as 16.6 years.
Beliefs
IV. Beliefs about causes, solutions and motivations
Participants’ beliefs about their weight were assessed in terms of beliefs about 
causes, solutions and motivations to lose weight; these are shown in table 3.4.
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Table 3.4: Beliefs
Variable No Not sure Yes
Behavioural cause n=207 n=442 n=615
(16.4%) (35%) (48.7%)
Medical cause n=722 n=259 n=123
(65.4%) (23.5%) (11.1%)
Behavioural solution n=37 n=219 n=981
(394) (17.7%) (79.3%)
Medical solution n=472 n=554 n=174
(39.3%) (46.2%) (14.5%)
Routine motivation n=421 n=216 n=599
(34.1%) (17.5%) (48.5%)
Significant event motivation n=1016 n=126 n=30
(86.7%) (10.8%) (2.6%)
Symptom motivation n=435. n=314 n=511
(34.5%) (24.9%) (40.6%)
The results showed that the majority felt their weight problem had a behavioural 
cause and that the solution was behavioural. Also the main motivations for 
losing weight were the routine everyday consequences of being overweight, but 
symptoms of being overweight were also a factor.
V. Illness perceptions
Participants’ illness beliefs, as measured by the IPQ, are shown in table 3.5. 
Table 3.5: Brief Illness Perception Questionnaire
Item Low Not sure High
Consequences n=67 n=345 n=1146
(4.3%) (22.1%) (73.6%)
Timeline n=114 n=659 n=786
(7.3%) (42.3%) (50.4%)
Personal control n=348 n=683 n=532
(22.3%) (43.7%) (34%)
Treatment control n=87 n=323 n=1153
(5.6%) (20.7%) (73.8%)
Identity n=286 n=568 n=698
(18.4%) (36.6%) (45%)
Concern n=24 n=168 n=1376
(1.5%) (10.7%) (87.8%)
Understanding n=139 n=370 n=1055
(8.9%) (23.7%) (67.5%)
Emotional response n=189 n=282 n=1093
(12.1%) (18%) (69.9%)
The results indicate that the IPQ items that were scored high by most 
participants were consequences, timeline, treatment control, identity, concern.
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understanding and emotional response. The only factor that most scored as not 
sure was personal control.
VI. Side effects, implications and behaviour change
Participants’ descriptions of the side effects of orlistat, the implications of these 
side effects and the subsequent behaviour change are shown in table 3.6.
Table 3.6; Side effects
Variable No Not sure Yes
Side effects n=673 n=456 n=180
(51.4%) (34.8%) (13.8%)
Behavioural implications n=233 n=300 n=824
(17.2%) (22.1%) (60.7%)
Medication implications n=783 n=256 n=244
(61%) (20%) (19%)
Diet behaviour change n=120 n=187 n=1109
(8.5%) (13.2%) (78.3%)
Adherence behaviour change n=1202 n=51 n=33
(93.5%) (4%) (2.6%)
The results show that most participants had not experienced many side effects. 
But that the side effects they did experience had behavioural implications, which 
also made them change their diet behaviour.
Behaviour
VII. Adherence and imposed control
Participants’ description of their adherence to orlistat and the imposed control of 
orlistat on their diet are shown in table 3.7.
Table 3.7: Adherence and control
No Some Yes
Imposed control n=716 n=403 n=255
52.1% 29.3% 18.6%
Adherence n=0 n=23 n=802
2.8% 97.2%
The results show most participants felt orlistat did not impose control on their 
eating behaviour. Also the majority of participants reported that they totally 
adhered to their medication.
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VIII. Eating behaviour
Participants’ description of their current eating behaviour is shown in table 3.8.
Table 3.8: Eating behaviour
Variable No Sometimes Often
Healthy snack n=153 n=944 n=386
(10.3%) (63.7%) (24.4%)
Unhealthy snack n=1220 n=252 n=10
(82.3%) (17%) (0.7%)
Home cooked meal n=22 n=218 n=1320
(1.4%) (14%) (84.6%)
Takeaway/processed/ready meal n=1092 n=362 n=14
(74.4%) (24.7%) (1%)
Healthy cooking n=246 n=502 n=703
(17%) (34.6%) (48.4%)
Unhealthy cooking n=1163 n=280 n=30
(79%) (19%) (2%)
High fat food n=1262 n=154 n=8
(88.6%) (10.8%) (0.6%)
Low fat food n=109 n=708 n=653
(7.4%) (48.2%) (44.4%)
Fruit and vegetables Mean: 4.25 SD: 1.57 Range: 0-7
The results showed that most participants often ate healthy snacks, home 
cooked meals and cooked healthily, but never ate high fat foods and only 
sometimes ate low fat foods. The average amount of fruit and vegetables eaten 
on an average day was 4.25 portions {note: this is high but self reported).
IX. Exercise
The amount of exercise participants described is shown in table 3.9. 
Table 3.9: Exercise
Variable Sedentary Regular mild Vigorous
Exercise n=505 n=514 n=541
(32.4%) (32.9%) (34.7%)
On average participants described their activity levels as vigorous exercise over 
the past month, which Involved work or recreation for 30 minutes or more.
X. Help seeking
The amount of contact participants’ reported having with health professionals is 
shown in table 3.10.
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Table 3.10: Help seeking
Profession None Sometimes Frequently
Practice nurse n=796 n=286 n=376
(54.6%) (19.6%) (25.8%)
GP n=560 n=502 n=420
(37.8%) (33.9%) (28.3%)
Hospital doctor n=1260 n=78 n=61
(90.1%) (5.6%) (4.4%)
Dietician n=1112 n=191 n=141
(77%) (13.2%) (9.8%)
Counsellor n=1334 n=42 n=22
(95.4%) (3%) (1.6%)
Psychologist n=1375 n=9 n=15
(98.3%) (0.6%) (1.1%)
Slimming club n=750 n=352 n=369
organiser (51%) (23.9%) (25.1%)
0>1 day a week 1-4 days a week 5 days a week<3 times a day everyday
Contact MAP n=1498 n=51 n=3
(96.5%) (3.3%) (0.2%)
Not at all Somewhat Totally
MAP positive n=94 n=243 n=982
(7.1%) (18.4%) (74.5%)
The results in table 3.10 show that in general the participants in this study who 
were taking orlistat did not take part in help seeking behaviour very often 
regarding their weight. In particular the results show that the majority of 
participants had never had contact with a professional to help them lose weight. 
But of those who had seen a professional frequently about their weight, practice 
nurse and slimming club organiser were the most common. Also GP’s were 
sometimes seen.
Most participants had not contacted MAP after registration, but did find 
the telephone support service totally positive. This may have been more due to 
the fact that MAP staff actually called the patients regularly to monitor progress 
and answer any questions the patient may have, therefore the patients did not 
feel the need to make additional phone calls to MAP to discuss any issues that 
may have arisen.
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XI. Methods of weight loss
The methods of weight loss participants’ described is shown in table 3.11, 
Table 3.11: Methods of weight loss
Never Sometimes Very Often
Diet n=436 n=614 n=327
(31.7%) (44.6%) (23.7%)
Exercise n=335 n=637 n=505
(22.7%) (43.1%) (34.2%)
Weighing yourself n=316 n=341 n=810
(21.5%) (23.2%) (55.2%)
Psychological n=1361 n=40 n=16
(96%) (2.8%) (1.1%)
Yes Maybe No
Had surgery n=5 n=1527
(0.3%) (99.7%)
Would have surgery in the future n=93 n=54 n=1363
(6.2%) (3.6%) (90.3%)
The results showed that most participants’ methods of weight loss were diet, 
exercise and that they weighed themselves very often. The majority had not had 
surgery and most would not have it in the future.
3.3.2 Coherence in beliefs about causes and solutions to their weight 
problem.
The extent to which participants’ beliefs about causes and solutions were 
coherent at baseline was explored. The 3 behavioural cause items and 3 
medical cause items along with the 6 behavioural solution items and 2 medical 
solution items were grouped and the yes responses for both are shown in table 
3.12.
Table 3.12: Coherence between beliefs about causes and solutions
Causes
Medical Behavioural
Solutions Medical
Behavioural
n =104 
12.6%  
n = 94 
11.4%
n = 167 
20 .2% 
n = 460 
55.8%
These results indicate that the majority of the people in this sample indicated 
that they held a belief in both a behavioural cause and solution to their weight
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problem. The next highest percentage was those who held a behavioural cause 
but a medical solution to their weight problem. This shows most people were 
coherent in their beliefs about the cause and solution to their weight problem but 
that there was also conflict when taking orlistat for their weight problem as they 
endorsed a behavioural cause to their weight problem but were using a medical 
intervention as a solution.
3.3.3 To examine correlates of outcomes
The data was analysed to explore the role of demographics, beliefs (cognitions 
and illness perceptions) and behaviour (exercise, adherence and eating 
behaviour) at baseline in explaining BMI, healthy eating, unhealthy eating, 
exercise and adherence, through a series of multiple regressions.
I. Explaining BMi
The data was analysed to explore the role of demographics, beliefs (cognitions 
and illness perceptions) and behaviour (exercise, adherence and eating 
behaviour) at baseline in explaining BMI.
Demographics
Demographics at baseline and the variance they accounted for in BMI are 
shown in table 3.13.
Table 3.13: BMI and demographics
Variables Standardised R. coefficient P
Age -.103 .001 *
Sex -.036 .188
Ethnicity .041 .139
Job -.064 .029 *
Marital Status -.030 .282
Education -.075 .009 *
Adjusted = .014
The results show that a higher BMI at baseline was explained mostly by lower 
age along with less education and working less accounting for 1.4% of the 
variance (F=4.169, p=.0001).
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Beliefs and behaviour at baseiine
The role of beliefs and behaviour at baseline in explaining BMI are shown in 
table 3.14.
Table 3.14: BMI and beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause .129 .006 *
Medical cause .079 .043 *
Behavioural solution -.017 .703
Medical solution .053 .180
Significant event motivation .053 .182
Routine motivation .007 .853
Symptom motivation .147 .0001 *
Healthy food -.006 .870
Unhealthy food .037 .386
Exercise -.107 .006 *
Side effects -.039 .364
Behavioural cognitions -.118 .015 *
Medication cognitions .083 .043 *
Diet behaviour change .024 .631
Adherence behaviour change .007 .874
Imposed control -.010 .804
Adherence .076 .096
Adjusted R"= = .071
The results showed that a higher BMI was explained mostly by greater symptom 
motivations also by a greater endorsement of behavioural causes, less exercise, 
less belief in the side effects making them think about their behaviour, a greater 
belief that the side effects were just part of the drug and a greater endorsement 
of medical cause to their weight, accounting for 7.1% of the variance (F=4.116,
p=.0001).
Illness beliefs at baseline
illness beliefs at baseline and the variance they accounted for in BMI are shown 
in table 3.15.
Table 3.15: BMI and illness perceptions
Variables Standardised ft coefficient P
Consequences .025 .476
Timeline .148 .0001 *
Personal control -.040 .168
Treatment Control -.036 .206
Identity .107 .0001 *
Concern .136 .0001 *
Understanding -.035 .216
Emotional Response -.046 .146
Adjusted R  ^ = .076
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The results (see table 3.15) showed that a higher BMI was explained by greater 
timeline, greater identity and more concern, accounting for 7.6% of the variance 
(F=15.498, p=.0001).
Eating behaviour at baseiine
Eating behaviour at baseline and the variance they accounted for In BMI are 
shown in table 3.16.
Table 3.16: BMI and eating behaviour
Variables Standardised ft coefficient P
Healthy snack -.035 .284
Unhealthy snack .012 .723
Home cooked meal -.021 .509
Unhealthy meal .050 .134
Healthy cooking -.012 .705
Unhealthy cooking .017 .589
High fat -.015 .647
Low fat .000 .994
Fruit and vegetables .022 .513
Adjusted = -.003
Results showed that this model accounted for 0.3% of the variance in eating 
behaviour and BMI (F=.618, p=.782), but none of the factors were significant.
Summary of correlates of BMI
For beliefs and behaviours, a higher BMI was explained by greater symptom 
motivations, a greater endorsement of behavioural causes, less exercise, less 
belief in the side effects making them think about their behaviour, a greater 
belief that the side effects were just part of the drug and a greater endorsement 
of medical cause to their weight, but these only accounted for 7.1% of the 
variance. For illness beliefs, a higher BMI was explained by greater timeline, 
greater identity and more concern, accounting for 7.6% of the variance. In terms 
of demographics, a higher BMI was explained by lower age, less education and 
working less, but this model only accounted for 1.4% variance.
II. Explaining healthy eating
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The data was then analysed to explore the role of demographics, beliefs 
(cognitions and illness perceptions) and behaviour (exercise and adherence) at 
baseline in explaining healthy eating.
Demographics
Demographics at baseline and the variance they accounted for in healthy eating 
are shown in table 3.17.
Table 3.17; Healthy eating and demographics
Variables Standardised ft coefficient P
Age .079 .009 *
Sex .111 .0001 *
Ethnicity .065 .021 *
Job -.048 .108
Marital Status .115 .0001 *
Education .032 .277
Adjusted = .033
The results show that healthy eating at baseline was explained mostly by being 
female and living with someone, but also being older and white, accounting for 
3.3% of the variance (F=8.022, p=.0001).
Beliefs and behaviour at baseline
The role of beliefs and behaviour at baseline in explaining healthy eating are 
shown in table 3.18.
Table 3.18: Healthy eating and beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause -.040 .363
Medical cause -.037 .318
Behavioural solution -.003 .946
Medical solution -.040 .292
Significant event motivation .054 .151
Routine motivation .007 .865
Symptom motivation .076 .048 *
Exercise 114 .002 *
Side effects -020 .623
Behavioural cognitions -.042 .361
Medication cognitions -.078 .043 *
Diet behaviour change .160 .0001 *
Adherence behaviour change -.049 .247
Imposed control -.066 .080
Adherence .092 .029 *
Adjusted R"^  = .068
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The results showed that healthy eating was explained mostly by a greater belief 
in the side effects making them change their diet behaviour, also by more 
exercise, greater adherence, less of a belief that the side effects were just part 
of the drug and greater symptom motivation, accounting for 6.8% of the variance 
(F=4.707, p=.0001).
Illness perceptions at baseline
Illness perceptions at baseline and the variance they accounted for in healthy 
eating are shown in table 3.19.
Table 3.19: Healthy eating and illness perceptions
Variables Standardised ft coefficient P
Consequences -.022 .544
Timeline -.028 .329
Personal control .040 .193
Treatment Control .098 .001 *
Identity -.037 .246
Concern .024 .497
Understanding .076 .012 *
Emotional Response .018 .591
Adjusted R*^  = .023
The results showed that healthy eating was explained mostly by greater 
treatment control and also more understanding of their weight, accounting for 
2.3% of the variance (F=4.813, p=.0001).
Summary of correlates of healthy eating
In relation to demographic characteristics, healthy eating at baseline was 
explained most by being female and living with someone, then by being older 
and white, accounting for 3.3% of the variance. For beliefs and behaviour, 
healthy eating was explained mostly by a greater belief in the side effects 
making them change their diet behaviour, also more exercise, greater 
adherence, less belief that the side effects were just part of the drug and a 
greater symptom motivation; accounting for 6.8% of the variance. Finally for 
illness beliefs, healthy eating was explained by greater treatment control and
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more understanding of their weight, but this only accounted for 2.3% of the 
variance.
III. Explaining unhealthy eating
The data was analysed to explore the role of demographics, beliefs (cognitions 
and illness perceptions) and behaviour (exercise and adherence) at baseline in 
explaining unhealthy eating.
Demographics
Demographics at baseline and the variance they account for in unhealthy eating 
are shown in table 3.20.
Table 3.20: Unhealthy eating and demographics
Variables Standardised ft coefficient P
Age -.135 .0001 *
Sex -.080 .006 *
Ethnicity -.076 .009 *
Job .014 .649
Marital Status -.030 .298
Education .034 .253
Adjusted = .030
The results show that unhealthy eating at baseline was explained mostly by 
being younger, also more likely male and less likely to be white, accounting for 
3% of the variance (F=7.131, p=.0001).
Beliefs and behaviour at baseline
The role of beliefs and behaviour at baseline in explaining unhealthy eating are 
shown in table 3.21. The results showed that unhealthy eating was explained by 
more side effects, less belief in the side effects changing their diet behaviour 
and less adherence, also a greater belief that the side effects were due to their 
behaviour, a greater the belief that the side effects were just part of the drug and 
less symptom motivation, accounting for 20.8% of the variance (F=14.339,
p=.0001).
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Table 3.21: Unhealthy eating and beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause .074 .072
Medical cause -.028 .412
Behavioural solution -.024 .539
Medical solution .033 .355
Significant event motivation -.037 .279
Routine motivation .036 .311
Symptom motivation -.089 .012 *
Exercise -.050 .133
Side effects .222 .0001 *
Behavioural cognitions .121 .005 *
Medication cognitions .099 .006 *
Diet behaviour change -.274 .0001 *
Adherence behaviour change -.002 .966
Imposed control -.016 .640
Adherence -.201 .0001 *
Adjusted R'^  = .208
Illness perceptions at baseline
Illness perceptions at baseline and the variance they account for in unhealthy 
eating are shown in table 3.22.
Table 3.22: Unhealthy eating and illness perceptions
Variables Standardised ft coefficient P
Consequences .006 .865
Timeline .047 .109
Personal control -.061 .049 *
Treatment Control -.128 .0001 *
Identity .069 .030 *
Concern -.087 .013 *
Understanding -.072 .017 *
Emotional Response .053 .113
Adjusted R'^  = .049
The results showed that unhealthy eating was explained mostly by less 
treatment control, also less concern, less understanding for their weight, more 
identity and less personal control, accounting for 4.9% of the variance (F=9.199,
p=.0001).
Summarv of correlates of unhealthv eating
Of the demographics, unhealthy eating at baseline was explained by
lower age, being male and being white, accounting for 3% of the variance. For
beliefs and behaviour, unhealthy eating was explained by less belief in the side
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effects changing their diet behaviour, less adherence, more side effects, a 
greater belief that the side effects were due to their behaviour, a greater belief 
that the side effects were just part of the drug and less symptom motivation, with 
these variables accounting for 20.8% of the variance. For illness beliefs, 
unhealthy eating was explained by less treatment control, less concern, less 
understanding for their weight, more identity and less personal control which 
accounted for 4.9% of the variance.
IV. Explaining exercise
The data was analysed to explore the role of demographics, beliefs (cognitions 
and illness perceptions) and behaviour (adherence and eating behaviour) at 
baseline in explaining exercise.
Demographics
Demographics at baseline and the variance they account for in exercise are 
shown in table 3.23.
Table 3.23: Exercise and demographics
Variables Standardised ft coefficient P
Age -.138 .0001 *
Sex .061 .021 *
Ethnicity -.049 .063
Job .115 .0001 *
Marital Status .041 .118
Education .051 .058
Adjusted = .058
The results show that exercise at baseline was explained mostly by lower age 
and more likely working, also being female, accounting for 5.8% of the variance 
(F=15.449, p=.0001).
Beliefs and behaviour at baseline
The role of beliefs and behaviour at baseiine in explaining exercise are shown in 
table 3.24. The results showed that exercise was explained mostly by less 
symptom motivations to lose weight, also by greater routine motivations to lose
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weight, more healthy eating, less endorsement of a behavioural cause to their 
weight problem, greater belief that the side effects were due to their behaviour 
and less endorsement of a medical solution to their weight problem, accounting 
for 7.8% of the variance (F=4.827, p=.0001).
Table 3.24; Exercise and beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause -.118 .009 *
Medical cause .004 .909
Behavioural solution .033 .444
Medical solution -.094 .016 *
Significant event motivation -.057 .133
Routine motivation .129 .001 *
Symptom motivation -.160 .0001 *
Healthy food .111 .003 *
Unhealthy food -.053 .196
Side effects -.067 .116
Behavioural cognitions .115 .015 *
Medication cognitions .010 .798
Diet behaviour change .034 .479
Adherence behaviour change .024 .580
Imposed control .042 .277
Adherence -.021 .639
Adjusted R"^  = .078
Illness perceptions at baseline
illness perceptions at baseline and the variance they account for in exercise are 
shown in table 3.25.
Table 3.25: Exercise and illness perceptions
Variables Standardised ft coefficient P
Consequences -.107 .001 *
Timeline -.093 .001 *
Personal control .049 .084
Treatment Control -.001 .980
Identity -.122 .0001 *
Concern .014 .668
Understanding .001 .975
Emotional Response .111 .0001 *
Adjusted R'' = .041
The results showed that exercise was explained mostly by less identity and 
greater emotional response to their weight problem, also by less consequences 
and less timeline, accounting for 4.1% of the variance (F=8.924, p=.0001).
104
Eating behaviour at baseline
Eating behaviour at baseline and the variance they account for in exercise are 
shown in tabie 3.26.
Table 3.26; Exercise and eating behaviour
Variables Standardised ft coefficient P
Healthy snack .122 .0001 *
Unhealthy snack -.037 .261
Home cooked meal .046 .131
Unhealthy meal -.031 .330
Healthy cooking .039 .200
Unhealthy cooking -.055 .071
High fat .023 .455
Low fat -.059 .048 *
Fruit and vegetables -.037 .248
Adjusted = .024
The results showed that exercise was explained mostly by more healthy snacks 
and also less low fat foods, accounting for 2.4% of the variance (F=4.254,
p = .0 0 0 1 ).
Summarv of correlates of exercise
In terms of demographics, exercise at baseline was explained by lower age, 
working and being female accounting for 5.8% of the variance. Of the beliefs 
and behaviours examined, exercise was explained by less symptom motivations 
to lose weight, greater routine motivations to lose weight, healthier eating, less 
endorsement of a behavioural cause to their weight problem, a greater belief 
that the side effects were due to their behaviour and less endorsement of a 
medical solution to their weight problem, which accounted for 7.8% of the 
variance. For illness beliefs, exercise was explained by less identity, greater 
emotional response, fewer consequences and less timeline for their weight 
problem, accounting for 4.1% of the variance. Finally of the eating behaviour, 
exercise at baseiine was explained by more healthy snacks and less low fat 
foods, but only accounted for 2.4% of the variance.
V. Explaining adherence
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The data was analysed to explore the role of demographics, beliefs (cognitions 
and illness perceptions) and behaviour (exercise and eating behaviour) at 
baseline in explaining adherence.
Demographics
Demographics at baseline and the variance they account for in adherence are 
shown in table 3.27.
Table 3.27: Adherence and demographics
Variables Standardised (i coefficient P
Age .110 .0001 *
Sex -.008 .788
Ethnicity -.015 .601
Job -.032 .296
Marital Status .089 .003 *
Education -.143 .0001 *
Adjusted = .047
The results showed that adherence at baseline was explained mostly by being 
older and having less education, also more likely to live with someone, 
accounting for 4.7% of the variance (F=10.325, p=.0001).
Beliefs and behaviour at baseline
The role of beliefs and behaviour at baseline in explaining adherence are shown 
in table 3.28.
Table 3.28: Adherence and beliefs/behaviour
Variables Standardised fi coefficient P
Behavioural cause -.017 .654
Medical cause .029 .373
Behavioural solution .048 .199
Medical solution -.004 .896
Significant event motivation .059 .070
Routine motivation -.033 .325
Symptom motivation -.026 .445
Healthy food .032 .317
Unhealthy food -.160 .0001 *
Exercise -.015 .639
Side effects -.021 .560
Behavioural cognitions -.009 .815
Medication cognitions .054 .113
Diet behaviour change .059 .148
Adherence behaviour change -.500 .0001 *
Imposed control -.051 .120
Adjusted R"^  = .326
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The results showed that adherence was explained by a less unhealthy food and 
a lower belief that the side effects made them change their adherence 
behaviour, accounting for 32.6% of the variance (F=23.035, p=.0001).
Illness perceptions at baseline
Illness perceptions at baseline and the variance they accounted for in adherence 
are shown in table 3.29.
Table 3.29: Adherence and illness perceptions
Variables Standardised (i coefficient P
Consequences .024 .528
Timeline -.032 .286
Personal control -.008 .802
Treatment Control .198 .0001 *
Identity -.018 .572
Concern .103 .005 *
Understanding -.004 .887
Emotional Response -.149 .0001 *
Adjusted R = .060
The results showed that adherence was explained mostly by greater treatment 
control and less emotional response to their weight problem, also by more 
concern, accounting for 6% of the variance (F=10.332, p=.0001).
Eating behaviour at baseline
Eating behaviour at baseline and the variance they accounted for in adherence 
are shown in table 3.30.
Table 3.30: Adherence and eating behaviour
Variables Standardised fi coefficient P
Healthy snack -.003 .931
Unhealthy snack -.149 .0001 *
Home cooked meal .042 .188
Unhealthy meal -.120 .0001 *
Healthy cooking .023 .465
Unhealthy cooking -.043 .176
High fat -.074 .023 *
Low fat -.015 .636
Fruit and vegetables .098 .003 *
Adjusted R'^  = .099
107
The results showed that adherence was explained mostly by less unhealthy 
snacks and less unhealthy meals, also by more fruit and vegetables and less 
high fat, accounting for 9.9% of the variance (F=13.422, p=.0001).
Summary of correlates of adherence
In terms of demographics, adherence at baseline was explained by higher age, 
less education and living with someone; accounting for 4.7% of the variance. Of 
the beliefs and behaviours examined, adherence at baseline was explained by 
less unhealthy food and less belief in the side effects making them change their 
adherence behaviour, accounting for 32.6% of the variance. For illness beliefs, 
adherence at baseline was explained by greater treatment control, less 
emotional response to their weight problem and more concern, accounting for 
6% of the variance. Finally in relation to eating behaviour, adherence at baseline 
was explained by less unhealthy snacks, less unhealthy meals, more fruit and 
vegetables and less high fat, accounting for 9.9% of the variance.
3.4. Discussion
This study provides cross sectional data on those who are starting to take 
orlistat and have signed up to the MAP programme. This study aimed to 
describe the characteristics, beliefs and behaviour of people who had recently 
started taking orlistat. The predictors of outcomes were also explored, along with 
examining coherence in beliefs about causes and solutions of obesity.
The results of this study reflect the baseline data of a longitudinal study 
which follows participants, who signed up to the MAP program, over an 18 
month period. In this discussion a summary of results will be described, these 
will be related to background literature and the implications of these results will 
be discussed.
Summary of results
1. To describe participants’ demographics, beliefs and behaviour.
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Demographics
I. Profile characteristics, weight and BMI
The majority of participants’ were women, white, not working, married and were 
secondary school graduates. The mean age was 48.5 years; mean height was 
1.66m and mean weight 98.9kg. The mean BMI was 36.04.
li. Time taking orlistat
On average the participants had been on orlistat just over 2 months, it was the 
first time they had taken orlistat and of those who had taken it before they had 
taken it once before on average.
ill. Weight history
On average the participants highest ever weight was 108.01kg and their lowest 
weight since 18 years old was 68.34kg. The average weight they would like to 
be was 71.65kg. The average amount of most weight lost was 17.85kg and the 
average time it was maintained for was 20.95 months. Almost 100% of 
participants were currently trying to lose weight. The average age participants 
became overweight was 25.39 yrs and the average age they first tried to lose 
weight was 28.09yrs, with the average length of time participants had been 
trying to lose weight as 16.6 years.
Beliefs
IV. Beliefs about causes, solutions and motivations
The results showed participants mostly felt their weight problem had a 
behavioural cause and the solution was behavioural. Also the main motivations 
for losing weight were mostly just the routine everyday consequences of being 
overweight, but symptoms of being overweight were also a factor
V. Illness perceptions
Most participants reported high consequences, timeline, treatment control, 
identity, concern, understanding and emotional response to their weight 
problem. The only factor that most scored as not sure was personal control.
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VI. Side effects, implications and behaviour change
The results showed that most participants had not experienced many side 
effects. But that the side effects they did experience made them think about their 
behaviour and change their diet behaviour.
Behaviour
VII. Adherence and imposed control
The results showed most participants felt orlistat did not impose control on their 
eating behaviour. Also the majority of participants reported that they totally 
adhered to their medication.
VIII. Eating behaviour
Most participants reported often eating healthy snacks, often ate home cooked 
meals, often cooked healthily, never ate high fat foods and only sometimes ate 
low fat foods. The average amount of fruit and vegetables eaten on an average 
day was 4.25 portions, which is high but is self reported.
IX. Exercise
On average participants described their activity levels as vigorous exercise over 
the past month, which involved work or recreation for 30 minutes or more.
X. Heip seeking
In general the participants in this study did not seek help very often regarding 
their weight. In particular, the majority of participants had never had contact with 
a professional to help them lose weight. But of those who had seen a 
professional frequently about their weight, practice nurse and slimming club 
organiser were the most common. Also GP’s were sometimes seen. Most 
participants had not contacted MAP after registration, but did find the telephone 
support service positive. This may have been due to the fact that MAP staff 
called the patients regularly to monitor progress and answered any questions
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the patient may have had; therefore the patients did not feel the need to make 
additional phone calls to MAP to discuss any issues that may have arisen.
XI. Methods of weight loss
Most participants reported sometimes dieting, sometimes exercising and very 
often weighed themselves as a method of weight loss. The majority had not had 
surgery and most would not have it in the future.
The descriptive analysis gives a clear picture of the people in the sample 
that had recently started taking orlistat and joined MAP, the telephone support 
group. Coherence in beliefs regarding causes and solutions to their weight 
problem was also examined.
2. Coherence in beliefs about causes and solutions of obesity.
The extent of coherence between beliefs about causes and solutions to their 
weight problems was explored. The results indicated the majority of participants 
were consistent in their beliefs in that they believed their weight problem had a 
behavioural cause and a behavioural solution. Another aim of study 1 was to 
explore predictors of outcomes.
3. Predictors of outcomes.
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline were examined in terms 
of the variance they accounted for in predicting BMI, healthy eating, unhealthy 
eating, exercise and adherence. The items are ordered in terms of significance.
I. Predicting BMI
Illness beliefs accounted for 7.6% of the variance in BMI with a higher BMI being 
explained by greater timeline, greater identity and more concern. Beliefs and 
behaviours accounted for 7.1% of the variance in BMI with a higher BMI being
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explained by greater symptom motivations, a greater endorsement of 
behavioural causes, less exercise, less belief in the side effects making them 
think about their behaviour, a greater belief that the side effects were just part of 
the drug and a greater endorsement of medical cause to their weight. 
Demographics only accounted for 1.4% variance in BMI with a higher BMI being 
explained by lower age, less education and working less.
II. Predicting healthy eating
Beliefs and behaviour accounted for 6.8% of the variance in healthy eating with 
healthy eating being explained by a greater belief in the side effects making 
them change their diet behaviour, more exercise, greater adherence, less belief 
that the side effects were just part of the drug and a greater symptom 
motivation. Demographic characteristics accounted for 3.3% of the variance in 
healthy eating at baseline, with healthy eating being explained by being female, 
living with someone, being older and white. Illness beliefs only accounted for 
2.3% of the variance in healthy eating with healthy eating being explained by 
greater treatment control and more understanding of their weight.
III. Predicting unhealthy eating
Beliefs and behaviour accounted for 20.8% of the variance in unhealthy eating 
with unhealthy eating being explained by less belief in the side effects changing 
their diet behaviour, less adherence, more side effects, a greater belief that the 
side effects were due to their behaviour, a greater belief that the side effects 
were just part of the drug and less symptom motivation. Illness beliefs 
accounted for 4.9% of the variance in unhealthy eating with unhealthy eating 
being explained by less treatment control, less concern, less understanding for 
their weight, more identity and less personal control. Demographics accounted 
for only 3% of the variance in unhealthy eating at baseline with unhealthy eating 
being explained by being younger, male and white.
IV. Predicting exercise
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Beliefs and behaviours accounted for 7.8% of the variance in exercise with 
exercise being explained by less symptom motivations to lose weight, greater 
routine motivations to lose weight, healthier eating, less endorsement of a 
behavioural cause to their weight problem, a greater belief that the side effects 
were due to their behaviour and less endorsement of a medical solution to their 
weight problem. Demographics accounted for 5.8% of the variance in exercise 
with exercise at baseline being explained by lower age, working and being 
female. Illness beliefs accounted for 4.1% of the variance in exercise with 
exercise being explained by less identity, greater emotional response, fewer 
consequences and less timeline for their weight problem. Eating behaviour only 
accounted for 2.4% of the variance in exercise at baseline with exercise being 
explained by more healthy snacks and less low fat foods.
V. Predicting adherence
Beliefs and behaviours accounted for 32.6% of the variance in adherence at 
baseline, with adherence being explained by less unhealthy food and less belief 
in the side effects making them change their adherence behaviour. 
Demographics accounted for 4.7% of the variance in adherence at baseline, 
with adherence being explained by higher age, less education and living with 
someone. Illness beliefs accounted for 6% of the variance in adherence at 
baseline, with adherence being explained by greater treatment control, less 
emotional response to their weight problem and more concern. Eating behaviour 
accounted for 9.9% of the variance in adherence at baseline, with adherence 
being explained by less unhealthy snacks, less unhealthy meals, more fruit and 
vegetables and less high fat.
Through this analysis the key factors that account for variance in 
outcomes has been explored. Therefore the results highlight the key 
components of demographics, beliefs (cognitions and illness perceptions) and 
behaviours (eating behaviour) at baseline that are important. There is also the
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issue of coherence of beliefs about causes and solutions to their weight problem 
which previous research has suggested is important in behaviour change.
Links to literature
The results showed participants mostly felt their weight problem had a 
behavioural cause and the solution was behavioural. Also the main motivations 
for losing weight were mostly just the routine everyday consequences of being 
overweight, but symptoms of being overweight were also a factor. Motivations 
for losing weight are important factors in weight loss, as Ogden and Sidhu 
(2006) found that those who decided to lose weight due to routine 
consequences were less likely to lose weight than those who had a significant 
life event. This will be explored in other chapters.
The majority of participants in this study did not experience many side 
effects from the drug which indicates they must have been sticking to the low 
calorie diet, which in time would lead to successful weight loss. However Ogden 
and Sidhu (2006) found the side effects to be an educational tool which help 
change people’s beliefs about the causes of their weight problem from a medical 
to a behavioural model. But the current participants mostly endorsed a 
behavioural model already, therefore the side effects may not be as much of an 
important factor in this population. The current study also indicated the 
participants did not alter their adherence to orlistat to fit in with their eating 
behaviour; therefore they did not stop taking the drug when they wanted to eat a 
fatty meal. However these responses may be more socially desirable than 
reality. There is also the factor of behaviour change which should become clear 
in the follow up studies following the participants every 6 months over an 18 
month period.
Most participants felt orlistat did not impose control on their eating 
behaviour and they reported complete adherence to their medication.
Adherence is commonly very low with prescribed treatments (McDonald et al..
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2002) therefore the finding that most people in this sample are totally adhering is 
encouraging in terms of treatment benefits. Adherence needs to be examined 
over the whole period that the participants are taking orlistat which will be 
explored in future chapters.
The average amount of fruit and vegetables reported to be eaten on an 
average day was 4.25 portions, which is in line with the Government 
recommendations of an intake of at least five portions of fruit or vegetables per 
person per day to help reduce the risk of some cancers, heart disease and many 
other chronic conditions (Department of Health, 2009). However as this is self 
reported this may not be accurate and may be biased by what they feel they 
should be eating.
The majority of participants were consistent in their beliefs regarding the 
cause and solution to their weight problem. This consistency in beliefs reflects 
Ogden and Jubb (2008) who found that beliefs about causes and solutions are 
consistent, therefore if they report a psychological cause they would also report 
a psychological solution. Which also fits in with Leventhal et al. (1984, 1992, 
1997) who described coherence in illness beliefs, as in a belief in a behavioural 
cause is consistent with a belief in a behavioural solution to their weight 
problem. Ogden and Jubb (2008) found that beliefs can be manipulated and can 
change, therefore this will be explored in further studies to examine whether the 
participants change their beliefs about causes and solutions to their weight 
problem after treatment with orlistat.
The results indicated that some felt their weight problem had a 
behavioural cause but a medical solution. This could be related to the fact that 
these participants are currently using a medical intervention to help them lose 
weight. It also fits in with what patients would have been told by their doctor 
before starting to take orlistat. They have to change their diet to reduce the 
amount of calories and fat otherwise they will experience the highly visual side
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effects. They are made aware that it is their behaviour that has caused their 
weight problem but are offered a medical solution to try and solve the problem. 
Ogden and Sidhu (2006) found that a belief in a behavioural model led to 
successful weight loss which indicates that the majority of the people in this 
study should be successful in weight loss, but it may also rely on a combination 
of other factors such as motivation to start losing weight, side effects, adherence 
and behaviour change, which needs to be explored through follow up.
The issues of causes and consequences also reflects back to Brickman 
et al. (1982). They put forward four general models for helping and coping; the 
moral model, compensatory model, medical model and enlightenment model. 
They raise the issue of whether some models are uniformly better than others. 
This is an issue that should be explored and this will be examined in further 
chapters when the model an individual holds is related to how successful they 
are at weight loss.
The majority of participants believed their problem had a behavioural 
cause and a behavioural solution, which indicates consistency in their beliefs 
however some felt it was a behavioural cause but a medical solution. 
Participants will be compared in terms of consistent and inconsistent beliefs 
regarding causes and solutions which will be examined in relation to who is 
more successful in addressing their weight problem and whether this leads to 
successful weight loss and maintenance. This consistency or inconsistency may 
also relate to the participants’ adherence to medication as in previous research 
where adherence to asthma medication was related to whether their beliefs 
about the cause of their problem were consistent with their beliefs about 
treatment (Horne, 1997; Horne & Weinman, 1999, 2002).
The beliefs about causes and consequences of their weight problem are 
also related to Leventhal’s self-regulatory model of illness behaviour. The 
current study included items of the brief illness perception questionnaire
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(Broadbent et al., 2006). Participants reported the items that were scored high 
by most participants were consequences, timeline, treatment control, identity, 
concern, understanding and emotional response to their weight. The only factor 
that was not scored high was personal control which was mostly scored as not 
sure. This indicated that they perceived their weight problem as severely 
affecting their life, will last forever, that orlistat can be extremely helpful, they 
experienced many severe symptoms from their weight problem, they are 
extremely concerned, they understand their weight problem very clearly and are 
extremely affected emotionally. The only factor which does not fall in line is 
personal control, the participants felt they were unsure as to whether they had 
control over their weight problem. High scores on the IPO indicate the 
participants interpreted their illness as a problem that they need to cope with. 
Some felt unsure about having personal control for their weight problem which 
may be a key issue to follow up over the longer term, because if they do not 
have self efficacy they may feel there is nothing they can do, therefore do not 
change their behaviour to lose weight. As Brickman et al. (1982) suggested, 
they may fall into the enlightenment model where they are responsible for the 
problem but unable or unwilling to provide a solution and therefore need 
discipline. Thus they may feel it is their behaviour that led to their weight 
problem but don’t feel they can do anything about it. They may need to be 
empowered and enlightened to help them to change their behaviour and lose 
weight.
Conclusion
The current study shows that this sample had good indicators for future success 
in weight loss and they are taking orlistat as prescribed.
Understanding weight loss
The majority endorsed a behavioural model of both the cause and solution to 
their weight problem, which may be a good Indicator for weight loss. However 
the majority also reported being unsure as to whether they had personal control
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over their weight, which may be an indicator that they will not change their 
behaviour and lose weight.
The additional impact of oriistat
There were some who endorsed a behavioural cause but a medical solution. 
This may be the impact of orlistat in that they were currently using a medical 
intervention to facilitate their weight loss. This needs to be explored over time to 
examine the impact of these inconsistent beliefs on weight loss. Adhering to 
orlistat was related to less unhealthy food and less changing their adherence 
due to the side effects, therefore orlistat functioned by facilitating healthier food 
choices if the individual did not alter their adherence due to the side effects and 
instead changed their diet. These will be key factors to address in the long term 
to explore their impact on weight loss.
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Chapter 4
Study 2: Shortterm changes in individuals taking orlistat. 
From baseline to six months follow up.
4.1 introduction
In study 1 consistency in beliefs about causes and solutions to their weight 
problem were found in most participants. It was also shown that those who 
adhered most did not selectively adhere and ate a healthier diet. These factors 
will now be examined to explore their impact on short term changes in weight 
and the impact of orlistat over the short term.
4.1.1 Background
Individuals are usually prescribed orlistat for 3 months in the first instance and 
therapy may continue beyond 3 months only if the person has lost at least 5% of 
their initial body weight since starting drug treatment (NICE, 2006). For the drug 
treatment to continue for longer than 12 months (usually for weight 
maintenance) this should only be considered after discussing potential benefits 
and limitations with the patient. The first study in this thesis examined the 
baseline beliefs and behaviours of those taking orlistat. The present study aimed 
to explore the short term changes that occur whilst people are taking orlistat. In 
addition, this chapter will also examine adherence to orlistat in the short term 
from when individuals first start taking orlistat. Previous studies (Linne, Rooth & 
Rossner, 2003) indicate that success rates of orlistat in primary care are limited 
by failure to follow prescribing recommendations. Adherence to orlistat will be 
examined at 6 month follow up and this will be compared to adherence at 
baseline, this will also be explored in term of success in weight loss. This maps 
onto Horne and Weinman’s (2002) extension to Leventhal et al.’s (1984, 1992, 
1997) self-regulatory model of illness behaviour, which included treatment 
beliefs along with illness perceptions as relating to adherence to medication.
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Therefore illness beliefs need to be explored in terms of short term changes 
whilst on orlistat.
Furthermore as Ogden and Sidhu (2006) described, the side effects of 
orlistat seem to change people’s models of obesity and subsequent behaviour, 
the present study aimed to empirically test this in the short term in a large scale 
quantitative study with a focus on beliefs, behaviour and changes in BMI and 
weight. Also how people who take orlistat experience the side effects and how 
they feel this impacts on their thought processes and behaviour. Whether the 
visual feedback of experiencing the side effects of orlistat, where they see the 
fat they have just consumed, has the same impact as photographs in Bovet et 
al.’s study (2002) for smoking cessation needs to be explored. In Bovet et al.’s 
study those who received visual feedback of the ultrasound photographs of their 
own atherosclerotic plaques were more likely to quit smoking. Therefore whether 
people seeing the fat they have consumed will lead them to change their beliefs 
and behaviour to reduce fat intake and lose weight will be examined.
4.1.2 Aims
The aim of this study is to examine the short term changes in weight, beliefs and 
behaviour. These short term changes will be examined between the first 3 
months of the participants starting to take orlistat and the subsequent 6 months. 
Specifically the aims of this study are:
1. To describe participants’ demographics, taking orlistat and 
methods of weight loss at baseline and 6 month follow up.
2. To explore the changes over time in weight, beliefs and behaviour.
3. To examine predictors of outcomes including the role of 
demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline in explaining BMI, 
healthy eating, unhealthy eating and adherence.
4. To examine experiencing side effects with the impact on 
adherence and diet change.
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5. To examine the changes in endorsing a behavioural solution and 
the relationship to losing weight.
6. To examine changes in beliefs about medical solutions to their 
weight problem and relationship to losing weight.
7. To explore changes in adherence and losing weight.
4.2 Methods
4.2.1 Design
The study used a longitudinal design with questionnaires concerning 
experiences of taking orlistat and beliefs and behaviours at baseline and six 
month follow up.
4.2.2 Sample
The sample included people who had registered on the Xenical support system 
(MAP). Individuals who returned the baseline questionnaire (see chapter 3) were 
sent a further questionnaire at six months. Only those who completed the 
baseline questionnaire within the first three months of them starting to take the 
medication and returned the 6 month follow up questionnaire were included in 
this study.
572 participants returned both the baseline within the first three months of 
them starting to take orlistat and 6 month follow up questionnaires, which was a 
response rate of 36% of total baseline responders. The University Ethics 
committee approved the study. The data presented here reflects the short term 
follow up, at baseline and six months, of the longer longitudinal study that 
followed participants up over an 18 month period.
4.2.3 Procedure
MAP gained initial consent from participants to pass on their contact details to 
take part in the study. An information sheet and questionnaire were then sent
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out to participants by post with a freepost envelope for them to return it in.
Participants who returned the baseline questionnaire were sent a shorter follow 
up questionnaire at six months by post with a freepost envelope or by email if it 
had been provided when they returned the baseline questionnaire.
4.2.4 Measures
The questionnaires were based on previous qualitative research (Ogden &
Sidhu, 2006; Ogden & Hills, 2008) and also included the brief IPO (Broadbent et 
al. 2006). The questionnaires examined people’s weight, motivations, beliefs 
about obesity, side effects, diet and exercise in the past month along with profile 
characteristics. All participants were asked at baseline to complete a 
questionnaire consisting of the sections titled; demographics, weight history, 
historical factors, taking orlistat, beliefs, motivations, IPO, experience of side 
effects, behaviour and telephone support service (see chapter 2 for full details).
The follow up questionnaire, which was sent at six months, consisted of some of 
the same sections as the baseline questionnaire. The sections in the follow up 
questionnaire were; beliefs, taking orlistat, behaviour, IPO, current weight and 
telephone support service (see chapter 2 for further details).
4.2.5 Inclusion/Exclusion Criteria
Participants were included if they rang up to register on the MAP program within 
a four month period, were 18 or over and were prescribed orlistat by their GP.
They completed the baseline questionnaire within the first three months of 
starting to take orlistat and also returned the follow up questionnaire at six 
months.
4.2.6 Data analysis
The data will be analysedM  /
1. To describe partic ipants’ demographics at baseline and 6 month 
fo llow  up.
Descriptive analysis will be conducted to explore:
122
I. Profile characteristics.
II. Taking orlistat
III. Methods of weight loss
Further descriptive analysis of beliefs (causes, solutions, motivations, illness 
perceptions, side effects, implications and behaviour change) and behaviour 
(adherence, imposed control, eating behaviour, exercise and help seeking) are 
in appendix 5.
For the multiple regressions outliers were removed.
2. To explore the changes over time In weight, beliefs and behaviour.
Repeated measures AN OVA's will be conducted to explore the changes in: 
Weight
i. Weight change 
Beliefs
ii. Beliefs about causes and solutions
iii. Illness perceptions
iv. Side effects, implications and behaviour change 
Behaviour
V. Adherence and imposed control
vi. Eating behaviour
vii. Exercise
viii. Help seeking
ix. Methods of weight loss
3. To examine predictors of outcomes.
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline will be explored and 
multiple regressions will be conducted to explore the variance they account for 
in:
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I. Predicting changes in BMI from:
Demographics
Baseline, 6 month follow up and changes in beliefs/behaviour 
Baseline, 6 month follow up and changes in illness perceptions 
Baseline, 6 month follow up and changes in eating behaviour
II. Predicting changes in healthy eating from:
Demographics
Baseline, 6 month follow up and changes in beliefs/behaviour 
Baseline, 6 month follow up and changes in illness perceptions
III. Predicting changes in unhealthy eating from:
Demographics
Baseline, 6 month follow up and changes in beliefs/behaviour 
Baseline, 6 month follow up and changes in illness perceptions
IV. Predicting changes in adherence from:
Demographics
Baseline, 6 month follow up and changes In beliefs/behaviour 
Baseline, 6 month follow up and changes in illness perceptions 
Baseline, 6 month follow up and changes in eating behaviour
4. To examine experiencing side effects with the impact on adherence
and diet change using “if then” analysis.
5. To examine the changes in endorsing a behavioural solution and the
relationship to losing weight.
6. To examine changes in beliefs about medical solutions to their
weight problem and the relationship to losing weight.
7. To explore changes in adherence and losing weight.
Data transformation
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Demographics
For the multiple regressions age, sex and education remained as they were and 
ethnicity, job and marital status were recoded. Ethnicity was recoded into white 
(n=549) and other (n=16). Job was recoded into working (n=288) or not working 
(n=268). Marital status was recoded into living with someone (n=398) and living 
alone (n=162).
Side effects
The responses to the items whether the side effects made them change their 
diet and change their adherence were grouped as yes if they reported 2.5 or 
greater on the scales. Participants were separated into experiencing side effects 
or not using median split. Those who responded yes were then examined in 
terms of their adherence which was split into groups of yes or no using median 
split. For diet change, baseline scores of unhealthy eating were subtracted from 
follow up scores, this gave the diet change score which was split into yes or no 
using median split. These were then put into a chi-squared analysis.
Behavioural so lu tion
For the behavioural solutions 6 items (eating fewer calories, healthy eating, 
eating less fat, exercise, being more active and physical activity) were grouped 
and an average score calculated at baseline and 6 month follow up. Using a 
median split these were split into behavioural solution or not at both time points, 
then these were put in the “if then” analysis to explore whether they lost weight. 
Medical so lution
For the medical solutions 2 items (medication and surgery) were grouped and 
an average score calculated at baseline and 6 month follow up. Using median 
split these were split into medical solution or not at both time points, then these , 
were put in the “if then” analysis to explore whether they lost weight.
Adherence
For adherence 2 items were reversed scored (I miss doses sometimes and I 
stop taking it before a fatty meal) and combined with another item (I take it 
religiously) to calculate an average score for adherence. These were then split
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into adherence or not at baseline and 6 month follow up using median split. 
These were then put in the “if then” analysis to explore whether they lost weight.
4.3 Results
4.3.1 Description of demographics.
I. Profile characteristics
The results were analysed to describe the participants’ demographic 
characteristics, these are shown in table 4.1.
Table 4.1: Demographics
Variable
Age (yrs) Mean = 50.20 SD = 13.02
(n=561) Range = 1 9 - 8 1
Sex Male = 98 (17.4%) Female = 464 (82.6%)
(n=567)
Ethnicity White = 544 (97.1%) Black Caribbean = 4 (0.7%)
(n=560) Black African = 2 (0.4%)
Asian = 5 (0.9%) Other = 5 (0.9%)
Job Full time = 173 (31.3%) Part time =115 (20.8%)
(n=552) Not Working = 264 (47.8%)
Marital Status Married = 331 (59.6%) Divorced = 66 (11.9%)
(n=555) Living with Partner = 65 (11.7%)
Single = 70 (12.6%) Widowed = 23 (4.1%)
Education < secondary = 68 (12.4%)
(n=548) Secondary School Grad = 178 (32.5%)
Some College = 134 (24.5%)
College Grad = 78 (14.2%)
Graduate = 54 (9.9%) Postgraduate = 12 (2.2%) 
Doctorate or Professional Degree = 24 (4.4%)
Height (m) Mean =1.65  SD = 0.09
(n=554) Range = 1.37 -1 .96
Baseline weight (kg) Mean = 99.14 SD = 18.63
(n=537) Range = 59.42 -  177
6 month weight (kg) Mean = 94.80 SD = 18.77
(n=532) Range = 54.88 -  175
Baseline BMI Mean = 36.11 SD = 5.69
(n=533) Range = 26.43 -  54.67
6 month BMI Mean = 34.55 SD = 5.88
(n=516) Range = 24.74 - 58.48
Weight lost baseline- Mean = 4.10 SD = 6.20
6 month (kg) (n=502) Range = -17.93 -  24.49
The mean age in this sample was 50.2 years. The majority of respondents were 
female, white, not working, married and secondary school graduates. Mean BMI
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at baseline was 36.11 and at 6 month follow up was 34.55, with the mean weight 
lost being 4.10 kg.
Representativeness of the sample
Table 4.2: Responders compared to non-responders at baseline
Variable Responders Non-responders U  2': P
Age X =  50.20 
SD = 13.02 
n -  561
X = 47.61 
S D = 13.10 
n = 992
3.78 .0001 "
Sex Male = 98 (17.4%) 
Female = 464 (82.6%)
Male =181 (18.2%) 
Female = 816 (81.8%)
.126 .723
Ethnicity White = 544 (97.1%)
Black Caribbean = 4 (0.7%) 
Black African = 2 (0.4%) 
Asian = 5 (0.9%)
Other = 5 (0.9%)
White =  949 (94.8%)
Black Caribbean = 14 (1.4%) 
Black African = 7 (0.7%) 
Asian = 16 (1.6%)
Other = 1 5  (1.5%)
4.75 .314
Job Full time = 173 (31.3%)
Part time = 115 (20.8%)
Not Working = 264 (47.8%)
Full time = 325 (33.6%)
Part time = 202 (20.9%)
Not Working = 439 (45.4%)
.999 .607
Marital
Status
Married = 331 (59.6%)
Divorced = 66 (11.9%)
Living with Partner = 65 (11.7%) 
Single = 70 (12.6%)
Widowed = 23 (4.1%)
Married = 597 (61.5%) 
Divorced = 122 (12.6%)
Living with Partner = 97 (10%) 
Single = 119 (12.3%) 
Widowed = 36 (3.7%)
1.524 .822
Education < stçand.aiy = 68 (12.4%)
Secondary School Grad = 178 (32,5%)
Some College = 134 (24.5%)
College G rad = 78 (14.2%)
Graduate =  54 (9.9%)
Postgraduate = 12 (2.2%)
Doctorate or Professional Degree =  24 (4.4%)
125 (13.2%)
Secondary School Grad =  332 (35.1%)
Some College = 238 (25.1%)
College Grad = 140 (14.8%)
Graduate = 54 (5.7%)
Postgraduate = 21 (2.2%)
Doctorate or Professional Degree = 37 (3.9%)
9.454 150
BMI x = 36.18 
SD =  5.84 
n = 528
X = 35.99 
SD = 6.01 
n = 947
.608 .544
In terms of the representativeness of the data, the only difference was that those 
who responded were significantly older than non-responders.
li. Taking orlistat
The results were analysed to describe whether the participants’ were still taking 
orlistat by 6 months and if they were not why they stopped, this is shown in table 
4.3.
Table 4.3; Taking orlistat
Still taking orlistat at 6 month Yes No
(n=568) n= 337 (59.3%) n= 231 (40.7%)
Because doctor told me to Yes No
(n=201) n= 79 (39.3%) n= 122 (60.7%)
Because wasn't helping Yes No
(n=195) n= 91 (46.7%) n= 104 (53.3%)
Because didn’t like side effects Yes No
(n=200) n= 63 (31.5%) n= 137 (68.5%)
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At 6 month follow up the amount still taking orlistat were 59.3%, with the main 
reason for not still taking it was because it wasn’t helping.
III. Methods of weight loss
Participants’ described the different methods they had tried to lose weight at 
baseline and 6 month follow up, which are described in table 4.4.
Table 4.4: Methods of weight loss
Baseline 6 month follow up
Never Sometimes Very Often Never Sometimes Very Often
Diet n=119 n=277 n=106 n=100 n=257 n=127
(23.7%) (55.2%) (21.1%) (20.7%) (53.1%) (26.2%)
Exercise n=135 n=225 n=175 n=111 n=183 n=243
(25.2%) (42.1%) (32.7%) (20.7%) (34.1%) (45.3%)
Weighing n=116 n=130 n=290 n—140 n=137 n=247
yourself (21.6%) (24.3%) (54.1%) (26.7%) (26.1%) (47.1%)
Psychological n=500 n=11 n=3 n=484 n=9 n=5
(97.3%) (2.1%) (0.6%) (97.2%) (1.8%) (1.0%)
Yes Maybe No Yes Maybe No
Had surgery n=4 n=552 n=5 n=562
(0.7%) (99.3%) (0.9%) (99.1%)
Would have n=30 n=17 n=502 n=30 n=9 n=526
surgery in the (5.5%) (3.1%) (91.4%) (5.3%) (1.6%) (93.1%)
future
When asked about methods of weight loss tried in the past month the majority 
reported sometimes using a diet at baseline and 6 month follow up, sometimes 
doing exercise at baseline and very often at 6 month follow up, very often 
weighing themselves at baseline and 6 month follow up and never using 
psychological methods at baseline and 6 month follow up. The majority reported 
they had not had weight loss surgery at baseline and 6 month follow up and 
most did not want it in the future at baseline and 6 month follow up.
4.3.2 Changes over time
The descriptive analysis gave a description of the sample, next the variables 
that change over the 6 month period will be explored.
Weight
I. Weight change
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Participants’ weight and BMI at baseline and 6 month follow up are shown in 
table 4.5.
Table 4.5: Weight change
Baseline 6 month follow 
up
F P Direction
Weight x=99.2739 x=94.7555 169.191 0.0001 * 1 > 2
SD=18.85814 SD=18.65881
BMI x=36.1434 x=34.4916 161.013 0.0001 * 1 > 2
SD=5.83013 SD=5.86957
The results show that there was a significant decrease in weight and BMI from 
baseline to 6 month follow up.
Beliefs
II. Causes and solutions
Participants’ endorsement of behavioural and medical causes and solutions to 
their weight problem and how they changed over time are described in table 4.6. 
There was a significant decrease in endorsement of behavioural solutions to 
their weight problem from baseline to 6 month follow up.
Table 4.6: Beliefs
Baseline 6 month 
follow up
F P Direction
Behavioural cause x=3.448 x=3.398 1.500 0.221
SD=0.9327 SD=0.9314
Medical cause x=2.274 x=2.271 0.005 0.944
SD=0.9602 SD=0.9791
Behavioural solution x=4.212 x=4.073 16.087 0.0001 * 1 > 2
SD=0.7394 SD=0 7982
Medical solution x=2.563 x=2.495 2.231 0.136
SD=0.9476 SD=0.9466
III. Illness beliefs
Participants illness beliefs at baseline and 6 month follow up are shown in table 
4.7. There was a significant decrease in consequences of their weight problem 
and significant increase in timeline of their weight problem from baseline to 6 
month follow up. There was a significant decrease in treatment control and 
significant decrease in concern for their weight problem from baseline to 6
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month follow up. Furthermore there was a significant increase in emotional 
response to their weight problem from baseline to follow up.
Table 4.7: Illness perceptions
Baseline 6 month 
follow up
F P Direction
Consequences x=7.40 x=6.98 19.410 0.0001 * 1 > 2
SD=2.091 SD=2.405
Timeline x=6.55 x=6.82 6.201 0.013 * 1 < 2
SD=2.200 SD=2.568
Personal control x=5.48 x=5.70 3.343 0.068
SD=2.384 SD=2.476
Treatment control x=7.79 x=7.02 41.681 0.0001 * 1 > 2
SD=2.273 SD=3.019
Identity x=5.87 x=5.73 1.476 0.225 1 > 2
SD=2.507 SD=2.713
Concern x=8.60 x=8.28 12.842 0.0001 * 1 > 2
SD=1.813 SD=2.094
Understanding x=7.38 x=7.18 2.824 0.093
SD=2.419 SD=2.536
Emotional response x=6.83 x=7.03 3.988 0.046 * 1 < 2
SD=2.951 SD=2.936
IV. Side effects, cognitions and behaviour change
Participants’ described whether they experienced any side effects of taking 
orlistat along with the impact of these side effects on cognitions and behaviour 
at baseline and 6 month follow up, which is shown in table 4.8.
Table 4.8: Side effects
Baseline 6 month 
follow up
F P Direction
Side effects x=2.339 x=2.354 0.099 0.753
SD=0.8403 SD=0.8016
Behavioural cognitions x=3.479 x=3.752 15.161 0.0001 * 1 < 2
SD=1.2605 SD=1.0486
Medication cognitions x=2.268 x=2.247 0.108 0.743
SD=1.1608 SD=0.9788
Diet behaviour change x=4.062 x=3.876 9.100 0.003 * 1 > 2
SD=1.1090 SD=1.0399
Adherence behaviour x=1.247 x=1.521 36.215 0.0001 * 1 < 2
change SD=0.5956 SD=0.8407
The results show that there was a significant increase in the side effects making 
them think about their eating behaviour from baseline to follow up. There was 
also a significant decrease in the side effects making them change their diet
130
behaviour and a significant increase in the side effects making them selectively 
adhere from baseline to follow up.
Behaviour
V. Adherence and imposed control 
Participants described whether they adhered to orlistat as prescribed and 
whether taking orlistat imposed control on what they ate, which is shown in table 
4.9.
Table 4.9: Medication
Baseline 6 month 
follow up
F P Direction
Adherence 
Imposed control
x=4.822
SD=0.3782
x=2.388
SD=0.9552
x=4.663 
SD=0.4728 
x=2.315 
80=0 9529
21.451
1.653
0.0001 * 
0.199
1 > 2
The results show a significant decrease in adherence from baseline to follow up.
VI. Eating behaviour
Participants’ eating behaviour at baseline and 6 month follow up along with the 
changes are shown in table 4.10.
Table 4.10: Eating behaviour
Baseline 6 month 
follow up
F P Direction
Healthy snack x=3.884 x=3.574 47.274 0.0001 * 1 > 2
80=1.0199 80=1.0576
Unhealthy snack x=1.77B x=2.182 143.429 0.0001 * 1 < 2
80=0.7433 80=0.8580
Healthy meal x=5.81 x=5.67 6.341 0.012 * 1 > 2
80=1.153 80=1.257
Unhealthy meal x=1.870 x=2.049 28.722 0.0001 * 1 < 2
80=0.7969 80=0.8741
Healthy cooking x=3.459 x=3.341 9.300 0.002 * 1 > 2
80=0.8862 80=0.8953
Unhealthy cooking x=2.035 x=2.142 18.731 0.0001 * 1 < 2
80=0.5476 80=0.5535
High fat food x= 1.423 x=1678 57.847 0.0001 * 1 < 2
80=0.6661 80=0.8798
Low fat food x=4.275 x=4.297 0.161 0.688
80=1.2478 80=1.331
Fruit and x=4.34 x=4.52 6.019 0.014 * 1 < 2
vegetables 80=1.504 80=1.684
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The results show a significant decrease in healthy snacks, healthy meals and 
healthy cooking, along with an increase in unhealthy snacks, unhealthy meals, 
unhealthy cooking, high fat food and fruit and vegetables from baseline to follow 
up.
VII. Exercise
Participants’ described the intensity of exercise they took part in at baseline and 
6 month follow up and the significance of any changes are shown in table 4.11. 
Table 4.11: Exercise
Baseline 6 month F P
follow up
Exercise x=3.19 x=3.12 2.401 0.122
SD=1.158 SD=1.165
There was no significant difference in exercise from baseline to follow up.
VIII. Help seeking
Participants’ reported the frequency they saw health professionals at baseline 
and 6 month follow up with the significance of any changes shown in table 4.12. 
Table 4.12: Help seeking
Baseline 6 month 
follow up
F P Direction
Practice nurse x=2.30 x=2.13 6.302 0.012 * 1 > 2
SD=1.328 SD=1.452
GP x=2.80 x=2.30 64.000 0.0001 * 1 > 2
SD=1.129 SD=1.401
Hospital doctor x=1.27 x=1.13 17.069 0.0001 * 1 > 2
SD=0.685 SD=0.537
Dietician x=1.76 x=1.32 89.220 0.0001 * 1 > 2
SD=1.100 SD=0.872
Counsellor x=1.12 x=1.08 2.228 0.136 1 > 2
SD=0.474 SD=0.451
Psychologist x=1.05 x=1.01 7.804 0.005 * 1 > 2
SD=0.317 SD=0.113
Slimming club x=2.58 x=147 264.180 0.0001 * 1 > 2
organiser SD=1.418 SD=1.121
Contact MAP x=1.37 x=122 26.723 0.0001 * 1 > 2
SD=0.573 SD=0.454
MAP positive x=4.177 x=3.985 14.553 0.0001 * 1 > 2
SD=0.9797 SD=1.1608
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The results showed a significant decrease in seeing a practice nurse, GP, 
hospital doctor, dietician, psychologist, slimming club organiser, contacting MAP 
and perceiving MAP to be positive from baseline to follow up.
IX. Methods of weight loss
Participants’ described the methods of weight loss they had tried to lose weight 
at baseline and follow up, which are shown in table 4.13, along with the 
significance of any changes that occurred. The results show a significant 
increase in exercise, decrease in weighing themselves and decrease in 
psychological help as methods of weight loss from baseline to follow up.
Table 4.13: Methods of weight loss
Baseline 6 month 
follow up
F P Direction
Diet x=2.975 x=3.053 3.515 0.061
SD=0.8345 SD=0.8309
Exercise x=3.14 x=3.42 25.195 0.0001 * 1 < 2
SD=1.083 SD=1.183
Weigh yourself x=3.47 x=3.31 5.462 0.020 * 1 > 2
SD=1.283 SD=1.360
Psychological x= 1.306 x=1.238 6.197 0.013 * 1 > 2
SD=0.5096 SD=0.4915
4.3.3 Predictors of change
The data was examined in terms of how key variables account for variance in 
outcomes. Demographics, beliefs (cognitions and illness perceptions) and 
behaviour (exercise, adherence and eating behaviour) at baseline were 
analysed through multiple regressions in relation to BMI, healthy eating, 
unhealthy eating and adherence change.
I. Predictors of short term change in BMI
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline were analysed to 
examine their impact on BMI change from baseline to 6 month follow up.
Demographics
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Table 4.14: BMI change (T1 minus T2) and demographics
Variables Standardised fi coefficient P
Age .076 .144
Sex .012 .792
Ethnicity -.024 .606
Job -.019 .702
Marital Status -.008 .872
Education -.053 .275
Adiusted R"' = -.001
Results showed that this model accounted for 0.1% of the variance in 
demographics and change in BMI from baseline to 6 month follow up and none 
of the factors were significant, nor was the overall model (F=.928, p=.475).
Baseline beliefs/behaviour
Table 4.15: BMI change (T1 minus T2) and baseline beliefs/behaviour
Variables Standardised 13 coefficient P
Behavioural cause -.018 .841
Medical cause .021 .783
Behavioural solution -.018 .839
Medical solution .160 .030 *
Routine motivation -.238 .003 *
Significant event motivation -.055 .468
Symptom motivation .082 .294
Healthy food .075 .325
Unhealthy food -.082 .313
Exercise .009 .908
Side effects -.150 .090
Behavioural cognitions -.169 .095
Medication cognitions .017 .823
Diet behaviour change .241 .015 *
Adherence behaviour change -.081 .274
Imposed control .016 .825
Adherence .015 .848
Adjusted R"^  = .114
The results showed that a decrease in BMI by 6 month follow up was mostly 
predicted by lower endorsement of routine motivations at baseline, then by 
greater change in diet following the side effects and greater endorsement of a 
medical solution, accounting for 11.4% of the variance (F=2.440, p=.002).
Follow up beliefs and behaviour
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Table 4.16: BMI change (T1 minus T2) and 6 month follow up beliefs/behaviour
Variables Standardised fJ coefficient P
Behavioural cause .187 .074
Medical cause -.073 .401
Behavioural solution -.154 .159
Medical solution .086 .342
Healthy food -.050 .553
Unhealthy food -.269 .005 *
Exercise .105 .207
Side effects -.114 .220
Behavioural cognitions .061 .622
Medication cognitions -.083 .349
Diet behaviour change .136 .282
Adherence behaviour change -.077 .367
Imposed control -.101 244
Adherence .048 .578
Adjusted R = .148
The results showed that a decrease in BMI by 6 month follow up was predicted 
by less unhealthy food at 6 month follow up, accounting for 14.8% of the 
variance (F=2.737, p=.001).
Change in beliefs and behaviour
Table 4.17: BMI change (T1 minus T2) and change in beliefs/behaviour (T1 minus T2)
Variables Standardised 13 coefficient P
Behavioural cause .066 .576
Medical cause -001 .991
Behavioural solution .084 .517
Medical solution .162 .153
Healthy food .173 .162
Unhealthy food .315 .006 *
Exercise -.094 .415
Side effects -.053 .676
Behavioural cognitions -.460 .001 *
Medication cognitions -.372 .004 *
Diet behaviour change .191 .164
Adherence behaviour change -.038 .745
Imposed control .199 .098
Adherence -099 .403
Adjusted R^ ' = .181
The results showed that a decrease in BMI by 6 month follow up was mostly 
predicted by a greater belief in the side effects making them think about their 
eating behaviour, a greater belief in the side effects just being part of taking the
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drug and then by a decrease in unhealthy food from baseline to 6 month follow 
up, accounting for 18.1% of the variance (F=2.231, p=.016).
Baseline Illness perceptions
Table 4.18: BMI change (T1 minus T2) and baseline illness perceptions
Variables Standardised 13 coefficient P
Consequences -.068 .258
Timeline -.030 .532
Personal control .032 .530
Treatment Control .158 .001 *
Identity .040 .455
Concern .090 .123
Understanding .056 .253
Emotional Response -.074 .189
Adjusted R = .044
The results showed that a decrease in BMI was predicted by greater treatment 
control for their weight problem at baseline, accounting for 4.4% of the variance 
(F=3.703, p=.0001).
Follow up illness perceptions
Table 4.19: BMI change (T1 minus T2) and 6 month follow up illness perceptions
Variables Standardised 13 coefficient P
Consequences .018 .781
Timeline -.129 .008 *
Personal control .146 .002 *
Treatment Control .282 .0001 *
Identity -.040 .439
Concern -.078 .183
Understanding .067 .127
Emotional Response -.033 .568
Adjusted R = .197
The results showed that a decrease in BMI by 6 month follow up was mostly 
predicted by greater treatment control over their weight, then by more personal 
control over their weight and also by less of a belief that their weight problem 
would last a long time at 6 month follow up, accounting for 19.7% of the variance 
(F=15.887, p=.0001).
Change in illness perceptions
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Table 4.20: BMI change (T1 minus T2) and change in illness perceptions (T1 minus T2)
Variables Standardised fi coefficient P
Consequences -.004 .936
Timeline .141 .002 *
Personal control -.132 .004 *
Treatment Control -.198 .0001 *
Identity .107 .024 *
Concern .126 .013 *
Understanding -037 .417
Emotional Response .100 .037 *
Adjusted R = .145
The results showed that a decrease in BMI by 6 month follow up was predicted 
mostly by greater treatment control, then less belief that their weight problem will 
last a long time, greater personal, less concern, less identity and being less 
emotional about their weight problem from baseline to 6 month follow up, 
accounting for 14.5% of the variance (F=10.802, p=.0001).
Baseline eating behaviour
Table 4.21: BMI change (T1 minus T2) and baseline eating behaviour
Variables Standardised 13 coefficient P
Healthy snack -.020 .702
Unhealthy snack -.162 .005 *
Home cooked meal .041 .427
Unhealthy meal .013 .811
Healthy cooking -.043 .407
Unhealthy cooking .012 .818
High fat -.111 .040 *
Low fat -.030 .557
Fruit and vegetables .148 .005 *
Adjusted R"^  = .059
The results showed that a decrease in BMI by 6 month follow up was predicted 
mostly by less unhealthy snacks and more fruit and vegetables, then less high 
fat at baseline, accounting for 5.9% of the variance (F=3.736, p=.0001).
Follow up eating behaviour
The results showed that a decrease in BMI by 6 month follow up was predicted 
most by less unhealthy snacks, then by less high fat and less low fat at 6 month 
follow up, accounting for 14.2% of the variance (F=8.682, p=.0001).
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Table 4.22: BMI change (T1 minus T2) and 6 month follow up eating behaviour
Variables Standardised 13 coefficient P
Healthy snack .062 .225
Unhealthy snack -.218 .0001 *
Home cooked meal .004 .939
Unhealthy meal -.063 .204
Healthy cooking .022 .651
Unhealthy cooking -.060 .228
High fat -.167 .001 *
Low fat -.137 .006 *
Fruit and vegetables -.008 .866
Adjusted R = .142
Change in eating behaviour
Table 4.23: BMI change (T1 minus T2) and change in eating behaviour (T1 minus T2)
Variables Standardised 13 coefficient P
Healthy snack -.076 .164
Unhealthy snack .092 .112
Home cooked meal .019 .714
Unhealthy meal .070 .185
Healthy cooking -.102 .059
Unhealthy cooking .004 .939
High fat .150 .008 *
Low fat .157 .005 *
Fruit and vegetables .130 .015 *
Adjusted R^  = .066
The results showed that a decrease in BMI by 6 month follow up was predicted 
most by less low fat, then by less high fat and fruit and vegetables from baseline 
to 6 month follow up, accounting for 6.6% of the variance (F=3.773, p=.0001).
Summary of predictors of BMI
The variables will be described in order of significance of their model. A 
decrease in BMI was predicted by greater treatment control for their weight 
problem at baseline, accounting for 4.4% of the variance. Also a decrease in 
BMI was predicted by greater treatment control over their weight, more personal 
control over their weight and also by less of a belief that their weight problem 
would last a long time at 6 month follow up, accounting for 19.7% of the 
variance. A decrease in BMI was also predicted by greater treatment control,
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less belief that their weight problem will last a long time, greater personal, less 
concern, less identity and being less emotional about their weight problem from 
baseline to 6 month follow up, accounting for 14.5% of the variance. A decrease 
in BMI by 6 month follow up was predicted by less unhealthy snacks, more fruit 
and vegetables and less high fat at baseline, accounting for 5.9% of the 
variance. A decrease in BMI was predicted most by less unhealthy snacks, less 
high fat and less low fat at 6 month follow up, accounting for 14.2% of the 
variance. Furthermore a decrease in BMI was predicted most by less low fat, 
less high fat and fruit and vegetables from baseline to 6 month follow up, 
accounting for 6.6% of the variance. Those models all had the same level of 
significance, with a slightly lower significance was a decrease in BMI by 6 month 
follow up was predicted by less unhealthy food at 6 month follow up, accounting 
for 14.8% of the variance. Then a decrease in BMI by 6 month follow up was 
predicted by lower endorsement of routine motivations, greater change in diet 
following the side effects and greater endorsement of a medical solution at 
baseline, accounting for 11.4% of the variance. Finally a decrease in BMI by 6 
month follow up was predicted by a greater belief in the side effects making 
them think about their eating behaviour, a greater belief in the side effects just 
being part of taking the drug and a decrease in unhealthy food from baseline to 
6 month follow up, accounting for 18.1% of the variance.
II. Predictors In short term changes In healthy eating
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline were analysed to 
examine their impact on change in healthy eating from baseline to 6 month 
follow up.
Demographics
The results show that a decrease in healthy eating by 6 month follow up was 
predicted most by lower age and then by more education accounting for 1.7% of 
the variance (F=2.230, p=.039).
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Table 4.24: Change in healthy eating (T1 minus T2) and demographics
Variables Standardised 13 coefficient P
Age -.115 .029 *
Sex -.072 .140
Ethnicity .030 .542
Job -.018 .723
Marital Status -.037 .451
Education .100 .042 *
Adjusted = .017
Baseline beliefs and behaviour
Table 4.25: Change in healthy eating (T1 minus T2) and baseline beliefs/behaviour
Variables Standardised 13 coefficient P
Behavioural cause -.153 .084
Medical cause -.122 .116
Behavioural solution .123 .166
Medical solution .002 .977
Routine motivation -.108 .195
Significant event motivation -.048 .533
Symptom motivation .042 .599
Exercise .095 .201
Side effects .113 .190
Behavioural cognitions .167 .100
Medication cognitions -.039 .619
Diet behaviour change .024 .807
Adherence behaviour change .062 419
Imposed control -.140 .064
Adherence -.031 .685
Adiusted R'^  = .026
Results showed that this model accounted for 2.6% of the variance in cognitions 
and behaviour at baseline and change in healthy eating from baseline to 6 
month follow up but none of the factors were significant (F= 1.356, p=.174).
Follow up beliefs and behaviour
The results showed that a decrease in healthy eating by 6 month follow up was 
predicted by higher endorsement of the side effects just being part of taking the 
drug at 6 month follow up, accounting for 0.8% of the variance, but the overall 
model was not significant (F=1.099, p=.366).
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Table 4.26: Change in healthy eating (T1 minus T2) and 6 month follow up beliefs/behaviour
Variables Standardised 13 coefficient P
Behavioural cause .041 .689
Medical cause .140 .120
Behavioural solution .045 .679
Medical solution -.107 .253
Exercise .027 .753
Side effects -.092 .322
Behavioural cognitions .084 .483
Medication cognitions .223 .015 *
Diet behaviour change -.089 .476
Adherence behaviour change .074 .404
Imposed control -.124 .163
Adherence .008 .929
Adjusted R = .008
Change in beliefs and behaviour
Table 4.27: Change in healthy eating (T1 minus T2) and change in beliefs/behaviour (T1 minus 
T2)
Variables Standardised 13 coefficient P
Behavioural cause -.064 .569
Medical cause .146 .171
Behavioural solution .068 .574
Medical solution -.053 .611
Exercise -.073 .482
Side effects -.001 .990
Behavioural cognitions .277 .028 *
Medication cognitions .243 .038 *
Diet behaviour change .015 .905
Adherence behaviour change .034 .753
Imposed control -.260 .022 *
Adherence .176 .099
Adjusted R^  = .165
The results showed that a decrease in healthy eating by 6 month follow up was 
predicted most by an increase in orlistat imposing control on what they ate, then 
by a decrease in the belief that the side effects made them think about their 
eating behaviour and a decrease in the side effects just being part of the drug, 
accounting for 16.5% of the variance (F=2.477, p=.008).
Baseline illness perceptions
The results showed that a decrease in healthy eating by 6 month follow up was 
predicted by the belief that they had less personal control over their weight
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problem at baseline, accounting for 1.5% of the variance, but the overall model 
was not significant (F=1.806, p=.074).
Table 4.28: Change in healthy eating (T1 minus T2) and baseline illness perceptions
Variables Standardised (i coefficient P
Consequences .061 .322
Timeline -.074 .141
Personal control -113 .035 *
Treatment Control -.026 .628
Identity .030 .594
Concern -.107 .071
Understanding -.006 .912
Emotional Response -.019 .739
Adjusted R = .015
Follow up Illness perceptions
Table 4.29: Change in healthy eating (T1 minus T2) and 6 month follow up illness perceptions
Variables Standardised 13 coefficient P
Consequences 021 .778
Timeline .034 .548
Personal control -.109 .041 *
Treatment Control 018 .737
Identity -.054 .351
Concern .065 .353
Understanding .024 .639
Emotional Response -084 .225
Adjusted R = -.002
The results showed that an increase in healthy eating from baseline to 6 month 
follow up was predicted by less belief in having personal control over their 
weight problem at 6 month follow up, accounting for 0.2% of the variance, but 
the overall model was not significant (F=.910, p=.508).
Change in illness perceptions
Table 4.30: Change in healthy eating (T1 minus T2) and change in illness perceptions (T1 minus 
T2)
Variables Standardised 13 coefficient P
Consequences .066 .232
Timeline -.073 .150
Personal control .003 .959
Treatment Control -.056 .266
Identity .041 .425
Concern -.140 .011 *
Understanding -.045 .374
Emotional Response .029 .572
Adjusted R = .008
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The results showed that a decrease in healthy eating by 6 month follow up was 
predicted by an increase in concern over their weight problem, accounting for 
0.8% of the variance, but the overall model was not significant (F=1.441, 
p=.177).
Summary of predictors of healthy eating
The models are summarised in terms of which were more significant. Less 
healthy eating from baseline to 6 months was predicted by an increase in 
imposed control of orlistat, less belief in the side effects changing the way they 
thought about their behaviour and a decrease in the side effects making them 
change the way they think about the medication from baseline to 6 month follow 
up, accounting for 16.5% of the variance. With slightly less significance a 
decrease in healthy eating from baseline to 6 months was predicted by lower 
age and more education at baseline, accounting for 1.7% of the variance.
III. Predictors of short term changes in unhealthy eating
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline were analysed to 
examine their impact on unhealthy eating change from baseline to 6 month 
follow up.
Demographics
Table 4.31: Change in unhealthy eating (T1 minus T2) and demographics
Variables Standardised (3 coefficient P
Age .084 .117
Sex -.054 .275
Ethnicity -.069 .170
Job -.023 .665
Marital Status -.032 .523
Education .042 .410
Adjusted = .004
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The results showed that this model accounted for 0.4% of the variance in 
demographics and change in unhealthy eating from baseline to 6 month follow 
up but none of the factors were significant.
Baseline beliefs and behaviour
Table 4.32: Change In unhealthy eating (T1 minus T2) and baseline beliefs/behaviour
Variables Standardised (3 coefficient P
Behavioural cause .017 .850
Medical cause .038 .630
Behavioural solution -.046 .606
Medical solution .137 .069
Routine motivation -.047 .581
Significant event motivation -.099 .202
Symptom motivation -.054 .502
Exercise .042 .578
Side effects .022 .795
Behavioural cognitions -.125 .227
Medication cognitions .141 .073
Diet behaviour change .142 .157
Adherence behaviour change -.018 .812
Imposed control -.060 .433
Adherence -.017 .829
Adjusted R = .007
Results showed that this model accounted for 0.7% of the variance in cognitions 
and behaviour at baseline and change in unhealthy eating from baseline to 6 
month follow up but none of the factors were significant.
Follow up beliefs and behaviour
Table 4.33: Change in unhealthy eating (T1 minus T2) and 6 month follow up beliefs/behaviour
Variables Standardised 13 coefficient P
Behavioural cause -.072 .489
Medical cause .046 .603
Behavioural solution .048 .652
Medical solution .002 .986
Exercise -.134 .112
Side effects -.241 .009 *
Behavioural cognitions -.065 .582
Medication cognitions .136 .135
Diet behaviour change .040 .745
Adherence behaviour change .066 .446
Imposed control -.022 .805
Adherence .081 .341
Adjusted R^  = .019
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The results showed that a decrease in unhealthy eating by 6 month follow up 
was predicted by experiencing fewer side effects at 6 month follow up, 
accounting for 1.9% of the variance, but the model was not significant (F=1.244, 
p=.259).
Change in beliefs and behaviour
Table 4.34: Change in unhealthy eating (T1 minus T2) and change in beliefs/behaviour (T1 
minus T2)
Variables Standardised (3 coefficient P
Behavioural cause -.036 .756
Medical cause .026 .812
Behavioural solution .213 .095
Medical solution .027 .805
Exercise .126 244
Side effects .278 .025 *
Behavioural cognitions .047 .711
Medication cognitions .036 .767
Diet behaviour change -101 .428
Adherence behaviour change -.104 .354
Imposed control .004 .969
Adherence -.143 .206
Adjusted = .042
The results showed that a decrease in unhealthy eating by 6 month follow up 
was predicted by a decrease in side effects, accounting for 4.2% of the variance, 
but the model was not significant (F=1.343, p=.211).
Baseline illness perceptions
Table 4.35: Change in unhealthy eating (T1 minus T2) and baseline illness perceptions
Variables Standardised (3 coefficient P
Consequences -.031 .626
Timeline .084 .099
Personal control -.040 .460
Treatment Control -.054 .321
Identity .045 .430
Concern .102 .090
Understanding .027 .608
Emotional Response -.116 .047 *
Adjusted R"^  = .009
The results showed that a decrease in unhealthy eating by 6 month follow up 
was predicted by less emotional response to their weight problem at baseline.
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accounting for 0.9% of the variance, but the model was not significant (F=1.460, 
p=.170).
Follow up illness perceptions
Table 4.36: Change in unhealthy eating (T1 minus T2) and 6 month follow up illness perceptions
Variables Standardised (3 coefficient P
Consequences .047 .526
Timeline -.067 .252
Personal control .135 .014 *
Treatment Control -.086 .105
Identity .061 .305
Concern -.002 .975
Understanding -.054 .308
Emotional Response -.081 .232
Adjusted R =.013
The results showed that a decrease in unhealthy eating by 6 month follow up 
was predicted by more personal control over their weight problem at 6 month 
follow up, accounting for 1.3% of the variance, but the model was not significant 
(F=1.703, p=.096).
Change in illness perceptions
Table 4.37: Change in unhealthy eating (T1 minus T2) and change in illness perceptions (T1 
minus T2)
Variables Standardised (3 coefficient P
Consequences -.021 .713
Timeline .147 .005 *
Personal control -.168 .001 *
Treatment Control .047 .350
Identity .009 .870
Concern .075 .180
Understanding .062 .223
Emotional Response -.052 .323
Adjusted R  ^ = .036
The results showed that a decrease in unhealthy eating by 6 month follow up 
was predicted most by greater personal control over their weight problem and 
then by less of a belief that their weight problem will last a long time by 6 month 
follow up, accounting for 3.6% of the variance (F=2.890, p=.004).
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Summary of predictors of unhealthy eating
Some models and variables were not significant but for others the variables 
were significant but the overall model was not. The models and variables that 
were significant indicated that a decrease in unhealthy eating by 6 month follow . 
up was predicted by greater personal control over their weight problem and less 
of a belief that their weight problem will last a long time by 6 month follow up, but 
these only accounted for 3.6% of the variance.
IV. Predictors o f sho rt term  changes In adherence
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) at baseline were analysed to 
examine their impact on adherence change from baseline to 6 month follow up. 
Demographics
Table 4.38: Change in adherence (T1 minus T2) and demographics
Variables Standardised 13 coefficient P
Age .041 .644
Sex .132 .105
Ethnicity .060 .471
Job .056 .524
Marital Status .030 .719
Education .075 .369
Adjusted = -.010
Results showed that this model accounted for 1% of the variance in 
demographics and change in adherence from baseline to 6 month follow up but 
none of the factors were significant.
Baseline beliefs and behaviour
The results showed that a decrease in adherence by 6 month follow up was 
predicted most by less endorsement of a behavioural cause to their weight 
problern and then by less of a belief that orlistat imposed control on their eating 
at baseline, accounting for 13.3% of the variance (F= 1.960, p=.025).
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Table 4.39; Change in adherence (T1 minus T2) and baseline beliefs/behaviour
Variables Standardised 13 coefficient P
Behavioural cause -.290 .017 *
Medical cause -.194 .076
Behavioural solution .213 .067
Medical solution -.025 .819
Routine motivation -.018 .871
Significant event motivation .156 .171
Symptom motivation -.047 .658
Healthy food -.060 .583
Unhealthy food .093 .409
Exercise .127 .217
Side effects .113 .369
Behavioural cognitions .153 .290
Medication cognitions -.170 .141
Diet behaviour change .126 .352
Adherence behaviour change -.149 .148
Imposed control -.225 .037 *
Adjusted = .133
Follow up beliefs and behaviour
Table 4.40: Change in adherence (T1 minus T2) and 6 month follow up beliefs/behaviour
Variables Standardised (3 coefficient P
Behavioural cause .193 .106
Medical cause .042 .680
Behavioural solution -.205 .106
Medical solution -.079 .473
Routine motivation .093 .381
Significant event motivation .123 .232
Symptom motivation .018 .871
Healthy food -.189 .067
Unhealthy food .043 .688
Exercise .141 .153
Side effects .035 .762
Behavioural cognitions .336 .023 *
Medication cognitions -.216 .056
Diet behaviour change -.059 .675
Adherence behaviour change .003 .976
Imposed control -.202 .052
Adjusted R^  = .108
The results showed that a decrease in adherence by 6 month follow up was 
predicted by a greater belief that the side effects made them think about their 
eating behaviour, accounting for 10.8% of the variance (F=1.825, p=.039).
Change in beliefs and behaviour
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Table 4.41: Change in adherence (T1 minus T2) and change in beliefs/behaviour (T1 minus T2)
Variables Standardised fJ coefficient P
Behavioural cause -.126 .289
Medical cause -.177 .118
Behavioural solution .179 .163
Medical solution .015 .893
Healthy food .189 .120
Unhealthy food -.118 .290
Exercise .059 .594
Side effects .175 .172
Behavioural cognitions -.123 .365
Medication cognitions .016 .898
Diet behaviour change .183 .166
Adherence behaviour change -.113 .332
Imposed control -.160 .194
Adjusted = .083
Results showed that this model accounted.for 8.3% of the variance in change in 
cognitions and behaviour and change in adherence from baseline to 6 month 
follow up but none of the factors were significant.
Baseline illness perceptions
Table 4.42: Change in adherence (T1 minus T2) and baseline illness perceptions
Variables Standardised 13 coefficient P
Consequences .021 .830
Timeline -.202 .015 *
Personal control -.060 .497
Treatment Control .027 .755
Identity -.072 .455
Concern .067 .523
Understanding .088 .327
Emotional Response .089 .358
Adiusted R'^  = .020
The results showed that a decrease in adherence by 6 month follow up was 
predicted by less of a belief that their weight problem would continue for a long 
time, accounting for 2% of the variance, but the overall model is not significant 
(F=1.397, p=.202).
Follow up illness perceptions
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Table 4.43: Change In adherence (T1 minus T2) and 6 month follow up illness perceptions
Variables Standardised 13 coefficient P
Consequences -.095 .411
Timeline -.164 .078
Personal control .026 .782
Treatment Control .005 .961
Identity -.033 .746
Concern .104 .356
Understanding -.090 .306
Emotional Response .100 .346
Adjusted R = -.006
The results showed that this model accounted for 0.6% of the variance in illness 
beliefs at 6 month follow up and change in adherence from baseline to 6 month 
follow up but none of the factors were significant.
Change in illness perceptions
Table 4.44: Change in adherence (T1 minus T2) and change in illness perceptions (T1 minus 
T2)
Variables Standardised (3 coefficient P
Consequences .099 .301
Timeline -.050 .571
Personal control -078 .355
Treatment Control -020 .808
Identity -.037 .684
Concern .019 .841
Understanding .151 .105
Emotional Response .013 .895
Adjusted R'^  = -.010
The results showed that this model accounted for 1% of the variance in illness 
beliefs from baseline to 6 month follow up and change in adherence from 
baseline to 6 month follow up but none of the factors were significant.
Baseline eating behaviour
The results showed that a decrease in adherence by 6 month follow up was 
predicted by healthier cooking at baseline, accounting for 5.9% of the variance 
(F=1.991, p=.045).
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Table 4.45: Change in adherence (T1 minus T2) and baseline eating behaviour
Variables Standardised fi coefficient P
Healthy snack -.095 .259
Unhealthy snack .150 .112
Home cooked meal -.050 .582
Unhealthy meal -.042 .642
Healthy cooking .241 .005 *
Unhealthy cooking -.145 .088
High fat .015 .867
Low fat -.163 .066
Fruit and vegetables -019 .830
Adjusted R = .059
Follow up eating behaviour
Table 4.46: Change in adherence (T1 minus T2) and 6 month follow up eating behaviour
Variables Standardised ft coefficient P
Healthy snack -.035 .692
Unhealthy snack 189 .038 *
Home cooked meal -.167 .053
Unhealthy meal -.052 .523
Healthy cooking .157 .068
Unhealthy cooking .098 .259
High fat .031 .718
Low fat -.244 .005 *
Fruit and vegetables .096 .282
Adjusted R = .077
The results showed that a decrease in adherence by 6 month follow up was 
predicted most by less low fat, then by more unhealthy snacks at 6 month follow 
up, accounting for 7.7% of the variance (F=2.370, p=.016).
Change in eating behaviour
Table 4.47: Change in adherence (T1 minus T2) and change in eating behaviour (T1 minus T2)
Variables Standardised ft coefficient P
Healthy snack .030 .744
Unhealthy snack -.063 .534
Home cooked meal .013 .882
Unhealthy meal .075 .410
Healthy cooking .144 .113
Unhealthy cooking -.204 .032 *
High fat -.094 .321
Low fat .053 .575
Fruit and vegetables -.065 .484
Adjusted R"^  = .022
151
The results showed that a decrease in adherence by 6 month follow up was 
predicted by an increase in unhealthy cooking, accounting for 2.2% of the 
variance, but the overall model was not significant (F=1.316, p=.236).
Summary of predictors of adherence
The model with the highest significance identified a decrease in adherence was 
predicted by less low fat and more unhealthy snacks at 6 months, accounting for 
7.7% of the variance. Next a decrease in adherence was predicted by less 
endorsement of a behavioural cause and imposed control at baseline, 
accounting for 13.3% of the variance. Then a decrease in adherence was 
predicted by a greater belief in the side effects changing their diet behaviour at 6 
months, accounting for 10.8% of the variance and healthier cooking at baseline, 
accounting for 5.9% of the variance.
4.3.4 To examine experiencing side effects with the impact on adherence 
and diet change.
I. Self reported frequency of diet change due to the side effects
Participants reported at baseline whether they experienced side effects or not 
and whether these side effects made them change their diet and change their 
adherence. The table below shows the self reported effects of the side effects. 
Participants were grouped as yes if they reported 2.5 or greater on the scales. 
Table 4.48: Self reported impact of the side effects at baseline
Yes No
Diet behaviour change n = 462 n = 57
89% 11%
Adherence behaviour change n = 33 n = 449
5.8% 78.5%
These results show that the majority of people reported that the side effect made 
them change their diet behaviour but not change adherence. This will now be 
examined in terms of the actual behaviour they reported.
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II. To objectively examine experiencing side effects with the impact on 
adherence and diet change.
Participants reported whether they experienced side effects and adhered at 
baseline along with their eating behaviour at baseline and 6 month follow up. 
Participants were separated into experiencing side effects or not using median 
split, this is shown below.
Table 4.49: Experience of side effects at baseline
Yes No
Side effects at baseline n = 241 237
50.4% 49.6%
Those who responded yes were then examined in terms of their adherence at 
baseline and their diet behaviour change. Adherence was split into groups of 
yes or no using median split. For diet change, baseline scores of unhealthy 
eating were subtracted from follow up scores, this gave the diet change score 
which was split into yes or no using median split. These were then put into a chi- 
squared analysis, which is shown below.
Table 4.50: Impact of side effects on adherence and change in unhealthy eating
Change in unhealthy eating
Yes No
Baseline Yes n = 21 n = 165 186
adherence 7.6% 59.8%
No n = 12 n = 78 90
4.3% 28.3%
33 243 276
These results indicate that those who experienced side effects at baseline and 
adhered at baseline were more likely to not be associated with changing their 
diet behaviour. But this was also the case for those who did not adhere at 
baseline. Therefore overall of those who experienced side effects at baseline, 
they were not likely to change their diet behaviour. This is shown in the chi- 
squared analysis, which found that the participants adherence at baseline had 
no association with a change in their eating behaviour from baseline to 6 month 
follow up ( (1, n=276) = .24, p>.5).
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4.3.5 Changes in endorsing a behavioural solution and losing weight.
Changes in endorsing a behavioural solution to their weight problem or not and 
the relationship to losing weight was explored.
Table 4.51: Endorsing a behavioural solution at baseline and 6 month follow up
Baseline
6
month
follow
up
Behavioural solution 
Not behavioural solution
Behavioural solution
n= 154
38%
n= 61
15.1%
Not behavioural solution 
n= 57 211
14.1%
n= 133 ' 194
32.8%
215 190 405
The majority of participants endorsed a behavioural solution to their weight 
problem at baseline and 6 month follow up. The second highest majority were 
those who did not endorse a behavioural solution at baseline and 6 month follow 
up. This indicates that the majority of people tended to remain consistent with 
their beliefs over time. The participants endorsement of a behavioural solution at 
baseline had a significant association with endorsing a behavioural solution or 
not at 6 month follow up (1, N=405) = 70.04, p<.0001).
Whether endorsing a behavioural solution at both time points related to 
them losing weight from baseline to 6 month follow up was examined.
Table 4.52: Impact on endorsing a behavioural solution and weight loss
T1 Behavioural 
solution
T2 Behavioural 
solution
T1 Not behavioural 
solution 
T2 Behavioural 
solution
T1 Behavioural 
solution
T2 Not behavioural 
solution
T1 Not behavioural 
solution
T2 Not behavioural 
solution
Lost weight n= 78 n= 25 n= 25 n= 48
T1 to T2 56.1% 52.1% 43.9% 40%
Not lost weight n= 61 n= 23 n= 32 n= 72
T1 to T2 43.9% 47.9% 56.1% 60%
The results indicate that if an individual had a behavioural solution at both time 
points they were more likely to lose weight. Furthermore if they changed from 
not endorsing a behavioural solution at baseline to endorsing a behavioural 
solution at 6 month follow up they were also more likely to lose weight.
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Table 4.53: Correlation of the impact on endorsing a behavioural solution and weight loss
T1 Behavioural 
solution 
T2 Behavioural 
solution
T1 Not behavioural 
solution
T2 Not behavioural 
solution
Lost weight 
T1 to T2
78 48 126
Not iost weight 
T1 to T2
61 72 133
139 120 259
The majority of participants who endorsed a behavioural solution at both time 
points lost weight and the majority of those who did not endorse a behavioural 
solution at both time points did not lose weight. The participants endorsement of 
a behavioural solution or not at both time points had a significant association 
with losing weight or not (1, N=259) = 6.70, p<.01).
4.3.6 Changes in beliefs about a medical solution to their weight problem 
and the relationship to losing weight
Changes in endorsing a medical solution to their weight problem or not and the 
relationship to losing weight was explored.
Table 4.54: Endorsing a medical solution at baseline and 6 month follow up
Baseline
Medical solution Not medical solution
6 Medical solution n= 152 n= 60 212
month 39.4% 15.5%
follow Not medical solution n= 63 n= 111 174
up 16.3% 28.8%
215 171 386
The majority of participants endorsed a medical solution at baseline and 6 
month follow up. Furthermore the second majority did not endorse a medical 
solution at baseline and 6 month follow up. This reflects that people tend to 
remain consistent in their beliefs over time. The participants endorsement of a 
medical solution at baseline had a significant association with endorsing a 
medical solution or not at 6 month follow up (1, N=386) = 48.78, p<.0001).
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Whether endorsing a medical solution to their weight problem at baseline 
and 6 month follow up, related to them losing weight from baseline to 6 
month follow up was examined.
Table 4.55: Impact of endorsing a medical solution and weight loss
T1 Medical 
solution 
T2 Medical 
solution
T1 Not medical 
solution
T2 Medical solution
T1 Medical solution 
T2 Not medical 
solution
T1 Not medical 
solution
T2 Not medical 
solution
Lost weight n= 78 n= 26 n= 27 n= 39
T1 to T2 55.3% 48.1% 48.2% 39.8%
Not lost weight n= 63 n= 28 n= 29 n= 59
T1 to T2 44.7% 51.9% 51.8% 60.2%
Only those who had a medical solution at baseline and 6 month follow up were 
more likely to lose weight.
Table 4.56: Correlation of the impact on endorsing a medical solution and weight loss
T1 Medical solution 
T2 Medical solution
T1 Not medical solution 
T2 Not medical solution
Lost weight 
T1 to T2
78 39 117
Not lost weight 
T1 to T2
63 59 122
141 98 239
The majority of participants who endorsed a medical solution at both time points 
lost weight and the majority of those who did not endorse a medical solution at 
both time points did not lose weight. The participants endorsement of a medical 
solution or not at both time points had a significant association with losing weight 
or not (1, N=239) = 5.58, p<.05).
4.3.7 Change in adherence and the relationship to losing weight
Table 4.57: Adherence at baseline and 6 month follow up
Baseline
Adhere Not adhere
6 Adhere n= 80 n= 9 89
month 48.5% 5.5%
follow Not adhere n= 42 n= 34 76
up 25.5% 20.6%
122 43 165
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The majority of participants adhered to orlistat at both baseline and 6 month 
follow up. The next highest majority were those who adhered at baseline and 
selectively adhered at 6 month follow up. The participants adherence at baseline 
had a significant association with whether they adhered or not at 6 month follow 
up (1, N=165) = 25.51, p<.0001).
Whether adhering to o rlis ta t at baseline and 6 month fo llow  up related to 
them losing w eight from  baseline to  6 month fo llow  up was examined.
Table 4.58: Impact of adherence on weight loss
T1 Adhere 
T2 Adhere
T1 Not adhere 
T2 Adhere
T 1 Adhere 
T2 Not adhere
T 1 Not adhere 
T2 Not adhere
Lost weight n= 52 n= 4 n= 29 n= 15
T1 to T2 72.2% 57.1% 78.4% 50%
Not lost weight n= 20 n= 3 n= 8 n= 15
T1 to T2 27.8% 42.9% 21.6% 50%
The highest majority of those who lost weight adhered at baseline but only 
selectively adhered at 6 month follow up. The second highest majority adhered 
at both baseline and 6 month follow up.
Table 4.59: Correlation of adherence and weight loss
T1 Adhere 
T2 Adhere
T1 Adhere 
T2 Not adhere
Lost weight 
T1 to T2
52 29 81
Not lost weight 
T1 to T2
20 8 28
72 37 109
The majority of participants who adhered at baseline lost weight regardless of 
whether they adhered at 6 months. The participants adherence at both time 
points had no significant association with losing weight or not (1, N=109) = 
.49. p>.05).
4.4 D iscussion
In this discussion the results will be summarised, this will include a description of 
the sample in relation to demographics. The changes over time and predictors of
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change in key variables will be discussed. The relationship between 
experiencing side effects with baseline adherence and diet change will be 
explored. Changes in endorsing a behavioural solution and the relationship to 
losing weight, changes in beliefs about medical solutions to their weight problem 
and relationship to losing weight and changes in adherence and losing weight 
will be examined. These results will be discussed in terms of previous literature 
and the implications of the results.
1. A description of participants’ demographics, beliefs and behaviour 
at baseline and 6 month follow up.
I. Profile characteristics
The mean age in this sample was 50.20 years with most participants’ being 
female, white, not working, married and secondary school graduates. Mean BMI 
at baseline was 36.11 and at 6 month follow up was 34.55, with the mean weight 
lost being 4.10 kg.
II. Taking orlistat
At 6 month follow up the amount still taking orlistat were 59.3%, with the main 
reason for not still taking it was because it wasn’t helping. Therefore it appears 
the majority did not endorse orlistat as a solution to their weight problem and 
therefore did not continue with the treatment.
III. Methods of weight loss
When asked about methods of weight loss tried in the past month the majority 
reported sometimes using a diet at baseline and 6 month follow up, sometimes 
doing exercise at baseline and very often at 6 month follow up, very often 
weighing themselves at baseline and 6 month follow up and never using 
psychological methods at baseline and 6 month follow up. The majority reported 
they had not had weight loss surgery at baseline and 6 month follow up and 
most did not want it in the future at baseline and 6 month follow up.
158
Participants were described in terms of their profile characteristics; taking 
orlistat and methods of weight loss at baseline and 6 month follow up. This 
analysis simply described these constructs at the two time points, these 
constructs were also analysed to explore changes over time.
2. To explore the changes over time in weight, beliefs and behaviour.
i. Weight
Over the 6 month period, overall, the participants weighed significantly less and 
their BMI decreased.
ii. Beliefs
During the 6 months from baseline to follow up there was an overall significant 
decrease in the endorsement of a behavioural solution to their weight problem.
In terms of illness beliefs there was a significant change in many variables over 
the 6 month period. There was a significant increase in timeline and emotional 
response, therefore there was a greater belief that their weight problem would 
continue for a long time and there was an increase in their weight affecting them 
emotionally. There was also a significant decrease in consequences, treatment 
control, identity and concern for their weight. Therefore overall most participants 
reported their weight as having less of an effect on their life, less of a belief that 
orlistat would help their weight problem, experiencing less symptoms from their 
weight and less concern about their weight.
In relation to the impact of the side effects of consuming too many fats 
whilst on orlistat, there were significant changes in the impact of these on beliefs 
over time. There was a significant increase in the side effects making them think 
about their behaviour and change their adherence and a decrease in the side 
effects making them change their diet behaviour. Therefore the side effects 
made them think about their behaviour more but also not to adhere as 
prescribed and they did not change their diet behaviour.
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III. Behaviour
Over the 6 month period there were significant changes in behaviour. There was 
a significant decrease in adherence therefore people were less likely to take 
orlistat as prescribed at 6 months compared to baseline. In terms of eating 
behaviour there was a significant increase in unhealthy snacks, unhealthy 
meals, unhealthy cooking, high fat food and fruit and vegetable consumption. 
There was a significant decrease in healthy snacks, healthy meals and healthy 
cooking. Therefore it appears overall participants eating behaviour has become 
unhealthier over the 6 month period.
For help seeking behaviour there were some significant changes over the 
6 month period. There was a significant decrease in seeing a practice nurse,
GP, hospital doctor, dietician, counsellor, psychologist and slimming club 
organiser, therefore help seeking overall decreased over the 6 month period. 
Also in terms of MAP, the telephone support helpline, there was a significant 
decrease in contacting MAP and a significant decrease in reporting their contact 
with MAP as positive. Finally in terms of weight loss methods attempted over the 
6 month period there was a significant decrease in weighing themselves and 
using more psychological methods, such as counselling and self help groups. 
There was a significant increase in exercise as a method of weight loss.
3. To examine predictors of outcomes
I. Predicting short term changes in BMi
Illness beliefs at follow up accounted for 19.7% of the variance in BMI with a 
decrease in BMI being predicted by greater treatment control over their weight, 
more personal control over their weight and less of a belief that their weight 
problem would last a long time at 6 month follow up. Changes in beliefs and 
behaviour accounted for 18.1% of the variance in BMI, with a decrease in BMI 
by 6 month follow up being predicted by a greater belief in the side effects
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making them think about their eating behaviour, a greater belief in the side 
effects just being part of taking the drug and a decrease in unhealthy food from 
baseline to 6 month follov^ up. Follow up beliefs and behaviour accounted for 
14.8% of the variance in BMI, with, a decrease in BMI by 6 month follow up 
being predicted by less unhealthy food at 6 month follow up. Changes in illness 
beliefs accounted for 14.5% of the variance in BMI with a decrease in BMI being 
predicted by greater treatment control, less belief that their weight problem will 
last a long time, greater personal, less concern, less identity and being less 
emotional about their weight problem from baseline to 6 month follow up. Eating 
behaviour at follow up accounted for 14.2% of the variance in BMI with a 
decrease in BMI being predicted by less unhealthy snacks, less high fat and less 
low fat at 6 month follow up. Baseline beliefs and behaviour accounted for
11.4% of the variance in BMI, with a decrease in BMI by 6 month follow up being 
predicted by lower endorsement of routine motivations, greater change in diet 
following the side effects and greater endorsement of a medical solution at 
baseline. Changes in eating behaviour accounted for 6.6% of the variance in 
BMI, with a decrease in BMI being predicted by less low fat, less high fat and 
fruit and vegetables from baseline to 6 month follow up. Eating behaviour at 
baseline accounted for 5.9% of the variance in BMI with a decrease in BMI by 6 
month follow up being predicted by less unhealthy snacks, more fruit and 
vegetables and less high fat at baseline. Illness beliefs at baseline accounted for 
4.4% of the variance in BMI with a decrease in BMI being predicted by greater 
treatment control for their weight problem at baseline.
II. Predicting short term changes in healthy eating
Changes in beliefs and behaviours accounted for 16.5% of the variance in 
healthy eating, with less healthy eating from baseline to 6 months being 
predicted by an increase in imposed control of orlistat, less belief in the side 
effects changing the way they thought about their behaviour and a decrease in 
the side effects making them change the way they think about the medication 
from baseline to 6 month follow up. Demographics only accounted for 1.7% of
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the variance in healthy eating with a decrease in healthy eating from baseline to 
6 months being predicted by lower age and more education at baseline.
III. Predicting short term changes in unhealthy eating
Changes in illness beliefs only accounted for 3.6% of the variance, with a 
decrease in unhealthy eating by 6 month follow up being predicted by greater 
personal control over their weight problem and less of a belief that their weight 
problem will last a long time by 6 month follow up.
IV. Predicting short term changes in adherence
Beliefs and behaviour at baseline accounted for 13.3% of the variance in 
adherence, with a decrease in adherence being predicted by less endorsement 
of a behavioural cause and imposed control at baseline. Beliefs and behaviour 
at follow up accounted for 10.8% of the variance in adherence, with a decrease 
in adherence being predicted by a greater belief in the side effects changing 
their diet behaviour at 6 months. Eating behaviour at follow up accounted for 
7.7% of the variance in adherence with a decrease in adherence being predicted 
by less low fat and unhealthier snacks at 6 months. Finally eating behaviour at 
baseline only accounted for 5.9% of the variance in adherence with a decrease 
in adherence being predicted by healthier cooking at baseline.
4. To examine experiencing side effects with the impact on adherence 
and diet change.
In relation to the self reported measures of diet change and adherence change 
due to the side effects, the majority reported the side effects made them change 
their diet behaviour but not change their adherence. This indicated that those 
who were successful in their weight loss adhered and changed their diet. This 
was also examined objectively by exploring whether those who experienced side 
effects at baseline adhered at baseline and changed their diet over the 6 month 
follow up. This analysis found that overall those who experienced side effects at
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baseline were not likely to change their diet behaviour, regardless of whether 
they adhered or not.
5. To examine the changes In endorsing a behavioural solution and the 
relationship to losing weight.
The majority of participants endorsed a behavioural solution to their weight 
problem at baseline and 6 month follow up. Also the results indicated that if an 
individual had a behavioural solution at both baseline and 6 month follow up 
then they were more likely to lose weight. Further more if they changed from not 
endorsing a behavioural solution at baseline to endorsing a behavioural solution 
at 6 month follow up they were also more likely to lose weight.
6. To examine changes in beiiefs about medicai solutions to their 
weight problem and relationship to iosing weight.
The majority of participants endorsed a medical solution at baseline and 6 
month follow up. Furthermore the second majority did not endorse a medical 
solution at baseline and 6 month follow up. This reflects that people tend to 
remain consistent in their beliefs over time. In relation to weight loss only those 
who had a medical solution at baseline and 6 month follow up were more likely 
to lose weight. As orlistat is a medical solution this may relate to them still 
endorsing orlistat as a weight loss method and therefore they are still adhering 
to medication as prescribed.
7. To explore changes In adherence and losing weight
The majority of participants adhered to orlistat at both baseline and 6 month 
follow up. The next highest majority were those who adhered at baseline and 
selectively adhered at 6 month follow up. In terms of success in weight loss the 
highest majority of those who lost weight adhered at baseline but only 
selectively adhered at 6 month follow up. The second highest majority adhered 
at both baseline and 6 month follow up. This indicates that initial adherence was
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important for weight loss, but adherence can become selective further down the 
line and weight loss can still continue or be maintained.
Links to literature
Weight loss over the 6 month period and a decrease in BMI, was predicted by 
less routine motivations to lose weight when they first began taking orlistat. This 
reflects Ogden and Sidhu’s (2006) study that found those with routine 
motivations to start losing weight tended not to be successful. At baseline 
participants tended to have a greater belief in the side effects changing their diet 
behaviour, thus the side effects seemed to be educating the participants, which 
was also found with Ogden and Sidhu. They found that the side effects act as an 
educational tool, to indicate what food should not be eaten, for those who were 
subsequently successful at losing weight. Those who lost weight also ate less 
unhealthy snacks and more fruit and vegetables at baseline, indicating they 
generally ate healthier at the beginning of them taking orlistat. Participants also 
described generally eating less unhealthy food at 6 months, which again 
indicated those who lost weight generally ate healthier at 6 months.
In terms of changes from baseline to 6 month follow up, weight loss over 
that period was predicted by changes in other variables. In terms of beliefs, 
weight loss was predicted by an increase in the side effects making them think 
about their behaviour, therefore it seems if the participant increased their belief 
that the side effects were an education and helped them to think about their 
behaviour then they were more likely to lose weight. This was also reflected in 
the change in eating behaviour. Weight loss was predicted by a decrease in • 
unhealthy food, decrease in high fat and decrease in low fat. This indicated that 
those who lost weight ate healthier after taking orlistat for 6 months than when 
they first started taking it. There was also a decrease in all fats consumed and 
this may be due to the mechanisms of orlistat in that it reduces the absorption of 
fats and if fats are eaten there are unpleasant consequences, therefore orlistat 
has an ‘antabuse’ effect (Finer, 2002).
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Changes in their illness beliefs were related to weight loss. Weight loss 
by 6 months was predicted by decrease in timeline and concern, increase in 
personal control and treatment control by 6 months. Therefore those who lost 
weight appeared to become less concerned with their weight problem and 
began to believe their weight problem would not continue for a very long time. 
There was an increase in overall control in their weight, both in terms of 
personal control and treatment control, this is in line with the increase in belief 
that their weight problem will not continue. Thus it seems if over the short time of 
taking orlistat if the individual believes they have more control over their weight, 
both personally and through taking orlistat, then they are more likely to lose 
weight. This suggests they were taking responsibility for their weight problem 
and understood it was their behaviour that was contributing to their weight 
problem. This reflects both Ogden and Hills (2008) and Ogden and Sidhu (2006) 
who found that those with a more behavioural model of their obesity are more 
successful in losing weight.
In relation to self reported measures of diet change and adherence 
change due to the side effects the majority reported the side effects made them 
change their diet behaviour but not change adherence. This fits in with Ogden 
and Sidhu’s (2006) study that found those who were successful in their weight 
loss attempts used the side effects as an educational tool to teach them what 
food they can and can not eat. Therefore those successful in weight loss 
adhered to orlistat and changed their diet. This effect was also examined 
objectively by exploring whether those who experienced side effects at baseline 
adhered at baseline and changed their diet over the 6 month follow up. This 
analysis found that overall those who experienced side effects at baseline were 
not likely to change their diet behaviour, regardless of whether they adhered or 
not. According to Ogden and Sidhu’s (2006) findings it would suggest that these 
people should then not lose weight although it is shown in this study that most
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people did lose weight. It may be however that these people will not be so 
successful in the long term when they stop taking orlistat.
The majority of participants endorsed a behavioural solution to their 
weight problem at baseline and 6 month follow up. Also the results indicated that 
if an individual had a behavioural solution at both baseline and 6 month follow 
up then they were more likely to lose weight. Several models are working here. 
There is consistency in beliefs about causes and solutions which is reflected in 
Leventhal et al.’s (1984, 1992, 1997) work which suggested that illness beliefs 
regarding a particular illness are consistent. Also Ogden and Sidhu’s (2006) 
study where participants who described their model of obesity as a behavioural 
model, where their eating and exercise behaviour were the main factors they 
attributed to their weight, were those successful in losing weight.
Those who changed from not endorsing a behavioural solution at 
baseline to endorsing a behavioural solution at 6 month follow up were more 
likely to lose weight. This is reflected in Ogden and Jubb (2008) who found that 
beliefs can be manipulated and can change. This indicates that the use of • 
orlistat had manipulated these participants beliefs about a behavioural solution 
and had subsequently led to them losing weight.
The majority of participants endorsed a medical solution at baseline and 6 
month follow up, with the next majority not endorsing a medical solution at 
baseline and 6 month follow up. This reflects that people tended to remain 
consistent in their beliefs over time. This indicates that in this sample, taking 
orlistat did not change the participants’ model of obesity as suggested in Ogden 
and Sidhu’s (2006) study. However this study only reflected the changes over a 
6 month period and Ogden and Sidhu’s study followed up participants’ after 1 
year, therefore this needs to be explored through the long term follow up study 
(chapter 5) and the process of change study (chapter 6).
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In relation to weight loss only those who had a medical solution at 
baseline and 6 month follow up were more likely to lose weight. As orlistat is a 
medical solution this may relate to them still endorsing orlistat as a weight loss 
method and therefore they are still adhering to the medication as prescribed.
The majority of participants adhered to orlistat at both baseline and 6 month 
follow up. The next highest majority were those who adhered at baseline and 
selectively adhered at 6 month follow up. In terms of success in weight loss the 
highest majority of those who lost weight adhered at baseline but only 
selectively adhered at 6 month follow up. The second highest majority adhered 
at both baseline and 6 month follow up. This indicates that initial adherence was 
important for weight loss, but adherence could become selective further down 
the line and weight loss could still continue or be maintained.
implications for practice and research
The results of this study have implications for health professionals who prescribe 
orlistat and the patients who are considering taking orlistat as a weight loss 
method. For health professionals the baseline predictors of weight loss are key 
as this is the point where the health professionals have the contact with the 
patient and therefore may have an impact on their success.
Health professionals need to discuss with their patients the reasons 
behind why they have decided to lose weight and if they are more routine 
motivations then the health professional needs to be conscious of the fact that 
this means they are less likely to lose weight. Therefore they alternatively need 
to highlight to the patient their risk of health problems due to their weight and 
thus the benefits of losing weight if they are prescribed orlistat to make the 
motivation for losing weight more salient.
Another key factor for health professionals is that those who believe the 
side effects change their diet behaviour when they first start taking orlistat are 
those who are more likely to lose weight. This would therefore be a key point for
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the health professional to point out to the patient and highlight the fact that these 
side effects are an indicator that they have eaten some food that is too high in 
fat and thus they need to change their diet and eating behaviour to eating more 
healthy food. Furthermore health professionals need to address patients 
concerns about their weight, as in the current study those with greater concern 
over their weight problem at baseline were more likely to put on weight. 
Therefore the health professionals should address the concerns of their patients 
and empower them to take control and do something about their weight problem 
by changing their behaviour.
For patients they need to endorse a behavioural model to their weight 
problem in order to successfully lose weight as the current study shows that 
those who endorse a behavioural model at both time points are more likely to 
lose weight. They need to be aware that they need to change their eating 
behaviour and that they need to take control of that and that orlistat will not 
impose control on what they eat but it will guide them in their food choices as a 
bad or unhealthy food choice will mean unpleasant consequences.
Patients also need to be aware that their weight problem can be 
controlled and does not need to continue for forever. They can change their 
behaviour and lose weight which can be maintained. They can change their 
eating behaviour, control what they eat and if they decide to start taking orlistat, 
to assist them in their weight loss, then this need to be conceptualised as a 
educational tool to assist them in changing their eating behaviour.
Conclusion
This study gives an insight into the mechanisms of successful weight loss during 
the short term use of orlistat. There are key variables that both health 
professionals and patients need to address in order for a successful outcome of 
the patient losing weight.
Understanding weight loss
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In terms of weight loss; initial motivations, decrease in the belief their weight 
problem would last forever, concern about their weight problem, unhealthy food, 
high fat food, low fat food and fruit and vegetables over the 6 month period were 
key predictors of weight loss.
The additional impact of orlistat
Orlistat functioned over the 6 months by the side effects making them change 
their dietary behaviour, therefore they ate healthier and they felt more in control 
of their weight. Whether the same variables are important in the long term will be 
examined for both future weight loss and weight maintenance.
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Chapter 6
Study 3: Long term behaviour change and weight loss since taking 
orlistat. From baseline to 18 month follow up.
6.1 Introduction
The previous chapter gave an insight into the mechanisms of short term 
changes in weight, beliefs and behaviour for those taking orlistat. The study 
showed that initial motivation and healthy eating were important predictors of 
weight loss in the short term. What orlistat adds to this is that the side effects 
act as an education to facilitate healthy eating and give the individual control 
over their weight. Whether these variables are important for long term changes 
will now be explored.
5.1.1 Background
Beliefs, behaviour and weight change have been examined in the short term but 
weight is also an issue that is relevant in the longer term. Avenell et al. (2004b) 
found that adding orlistat to a diet was associated with -3.26kg weight change 
after 2 years with beneficial changes on risk factors. This long term weight loss 
resulted in reduced risk of developing diabetes and may have been beneficial for 
cardiovascular disease. This study shows that long term weight loss is 
advantageous in terms of health benefits. Weight loss also needs to be 
examined in a population outside of a clinical trial environment. The 
psychological changes that occur in the long term after a short term 
pharmacological intervention for weight loss also need to be explored.
The impact of orlistat was examined in the short term (see chapter 4) and 
it will now be explored in terms of the long term effects after cessation of orlistat. 
Woo et al.’s (2003) study found that without further interventions, weight loss 
achieved whilst on orlistat is not maintained after cessation of orlistat. They 
found that a nutritionist-led lifestyle modification programme was effective in 
weight maintenance after treatment with orlistat and without this programme the
170
benefits of the drug treatment were lost. Therefore weight maintenance after 
cessation of orlistat needs to be explored to examine whether weight loss 
achieved whilst on orlistat can be maintained.
Elfhag and Rossner’s (2005) review of weight loss literature highlighted 
potential factors of importance in weight maintenance. They found that 
successful weight maintenance was associated with more initial weight loss, 
being physically active, eating regular meals including breakfast and healthy 
eating, better coping strategies, assuming responsibility in life and overall more 
psychological strength and stability. These factors need to be explored to 
determine if they are also key factors in weight maintenance after cessation of 
orlistat through a longitudinal quantitative study.
Some individuals’ are able to continue and maintain weight loss after 
cessation. The predictors of success therefore need to be addressed. Ogden 
and Hills (2008) conducted interviews with ‘success stories’ who had either lost 
weight through changes in diet and exercise or stopped smoking and maintained 
this for at least 3 years. The main finding of this study was that this sustained 
behaviour change was triggered by a significant life crisis relating to their health, 
relationships or salient milestones. The initial change was translated into 
sustained change if three conditions were met, which were the function of the 
unhealthy behaviour was disrupted, the individual perceived that their choice 
over carrying out the unhealthy behaviour was reduced and they adhered to a 
behavioural model of their problem. Furthermore these conditions enabled a 
process of reinvention whereby the participants shifted their identity to a new 
healthier self. These elements will be explored through this long term follow up 
of those who were prescribed orlistat at baseline.
Beliefs and behaviours at baseline can be examined and explored as to 
whether these impact on weight loss and weight maintenance in the long term. It 
can also be explored as to whether beliefs and behaviours change over the 18
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month period and whether these impact on weight. The main aim of the current 
study is to examine changes in weight, beliefs and behaviour in the long term. 
This study will describe beliefs, behaviour and weight at baseline and 18 month 
follow up. Furthermore the study will examine the relationship between beliefs, 
behaviour and weight over time and how these factors relate to each other.
5.1.2 Aims
The aim of this study is to examine the long term changes in weight, beliefs and 
behaviour. These long term changes will be examined from baseline to 18 
month follow up. Specifically the aims of this study are:
1. To describe participants’ demographics at baseline and 18 month
follow up.
2. To explore the changes over time in weight, beliefs and behaviour.
3. To examine predictors of outcomes.
4. To examine the changes in endorsing a behavioural solution and
the relationship to losing weight.
5. To examine changes in beliefs about medical solutions to their 
weight problem and the relationship to losing weight.
5.2 Methods
5.2.1 Design
The study used a longitudinal design with questionnaires concerning 
experiences of taking orlistat, weight, beliefs and behaviours, which were 
completed at baseline and 18 months.
5.2.2 Sample
The sample included people who had registered on the Xenical support system 
(MAP) over a four month period. 1582 questionnaires were returned at baseline 
and 519 were returned at 18 month follow up (response rate 33%). The
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University Ethics committee approved the study. The data presented here 
reflects the long term behaviour change over an 18 months period.
5.2.3 Procedure
MAP gained initial consent from participants to pass on their contact details to 
take part in the study. An information sheet and questionnaire were then sent 
out to participants by post with a freepost envelope for them to return it in. 
Participants who returned the first questionnaire were then sent a follow up 
questionnaire at 18 months by post, with a freepost envelope or by email with a 
link to the questionnaire online, if they provided their email address at baseline.
5.2.4 Measures
The questionnaire was based on previous qualitative research (Ogden & Sidhu, 
2006; Ogden & Hills, 2008). The questionnaire examined people’s weight, 
motivations, beliefs about obesity, side effects, diet and exercise in the past 
month along with profile characteristics. All participants were asked to complete 
a baseline questionnaire and a follow up questionnaire at 18 months (see 
methods section for details).
5.2.5 Inclusion/Exclusion Criteria
Participants were included if they initially rang up to register on the MAP 
program within a four month period, were 18 or over and were prescribed orlistat 
by their GP. Furthermore they returned a follow up questionnaire after 18 
months.
5.2.6 Data analysis
The data will be analysed to:
1. To describe partic ipants’ demographics at baseline and 18 month 
fo llow  up. Descriptive analysis will be conducted to explore:
I. Profile characteristics.
II. Taking orlistat
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III. Methods of weight loss
Further descriptive analysis of beliefs (causes, solutions, motivations, illness 
perceptions, side effects, implications and behaviour change) and behaviour 
(adherence, imposed control, eating behaviour, exercise and help seeking) are 
in appendix 5.
2. To explore the changes over the 18 months In weight, beliefs and 
behaviour. Repeated measures AN OVA's will be conducted to explore the 
changes in:
Weight
I. Weight change 
Beliefs
II. Beliefs about causes and solutions
III. Illness perceptions
IV. Side effects, implications and behaviour change 
Behaviour
V. Adherence and imposed control
VI. Eating behaviour
VII. Exercise
VIII. Help seeking
IX. Methods of weight loss
3. To examine predictors o f outcomes. Demographics, beliefs (cognitions 
and illness perceptions) and behaviour (exercise, adherence and eating 
behaviour) will be explored and multiple regressions will be conducted to explore 
the variance they account for in:
I. Predicting changes in BMi from:
Demographics
Baseline, 18 month follow up and changes in cognitions/behaviour 
Baseline, 18 month follow up and changes in illness perceptions
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Baseline, 18 month follow up and changes in eating behaviour
II. Predicting changes in healthy eating from:
Demographics
Baseline, 18 month follow up and changes in cognitions/behaviour
Baseline, 18 month follow up and changes in illness perceptions
III. Predicting changes in unhealthy eating from:
Demographics
Baseline, 18 month follow up and changes in cognitions/behaviour
Baseline, 18 month follow up and changes in illness perceptions
IV. Predicting changes in adherence from:
Demographics
Baseline, 18 month follow up and changes in cognitions/behaviour
Baseline, 18 month follow up and changes in illness perceptions
Baseline, 18 month follow up and changes in eating behaviour
4. To examine the changes in endorsing a behavioural so lution and the 
relationship to losing weight.
5. To examine changes in beliefs about medical so lu tions to the ir 
w eight problem and the relationship to losing weight.
Data transformation 
Demographics
For the multiple regressions age, sex and education remained as they were and 
ethnicity, job and marital status were recoded. Ethnicity was recoded into white 
(n=492) and other (n=20). Job was recoded into working (n=259) or not working 
(n=237). Marital status was recoded into living with someone (n=373) and living 
alone (n=133).
Behavioural so lu tion
For behavioural solutions several items were averaged to give the behavioural 
solution score (eating fewer calories, healthy eating, eating less fat, exercise.
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being more active and physical activity). Items were dichotomised using median 
split. “If then" analysis was then carried out to determine the differences 
between those who endorsed a behavioural solution or not at baseline and 6 
months and whether they lost weight.
Medical solution
For medical solutions several items were averaged to give the medical solution 
score (medication and surgery). Items were dichotomised using median split. “ If 
then” analysis was then conducted to determine the differences between those 
who endorsed a medical solution or not at baseline and 6 months and whether 
they lost weight.
5.3 Results
The results were analysed to describe the participants’ demographic 
characteristics.
5.3.1 Descriptions of demographics
I. Profile characteristics
The results were analysed to describe the participants’ demographic 
characteristics, these are shown in table 5.1.
The average age of participants in this sample was 51.28 years with a 
range from 18 to 77. The majority of participants were female, white, not 
working, married and were secondary school graduates. The average height 
was 1.66m; the average weight at baseline was 98.28kg and at 18 month follow 
up it was 95.62kg, giving an average weight lost between baseline and 18 
month follow up of 1.97 kg. The mean BMI at baseline was 35.67 and at 18 
month follow up was 34.82.
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Table 5.1; Demographics
Variable
Age (yrs) Mean = 51.28
(n=502) SD = 12.7 
Range = 18-77
Sex Male = 106 (21%)
(n=505) Female = 399 (79%)
Ethnicity White = 484 (96%)
(n=504) Black Caribbean = 3 (0.6%) 
Black African = 3 (0.6%) 
Asian = 6 (1.2%)
Other = 8 (1.6%)
Job Full time = 154 (31.6%)
(n=488) Part time = 104 (21.3%) 
Networking = 230 (47.1%)
Marital Status Married = 315 (63.3%)
(n=498) Divorced = 52 (10.4%)
Living with Partner = 52 (10.4%) 
Single = 59 (11.8%)
Widowed = 20 (4%)
Education Less than secondary = 53 (10.7%)
(n=494) Secondary School Grad = 148 (30%)
Some College = 135 (27.3%)
College Grad = 77 (15.6%)
Graduate = 32 (6.5%)
Postgraduate = 16 (3.2%)
Doctorate or Professional Degree = 33 (6.7%)
Height (m) Mean = 1.66
(n=494) SD = 0.09 
Range = 1.37-2.08
Baseline 18 month follow up 
n=486 n=473
Weight (kg) Mean = 98.28 Mean = 95.62 
SD = 19 SD = 19.77 
Range = 59.42-177 Range = 53.98-186 
Baseline 18 month follow up 
n=481 n= 458
BMI Mean = 35.67 Mean = 34.82
SD = 5.93 SD = 6.38
Range = 20.76-56.25 Range = 22.03-58.70
Weight lost T1-T4 (kg) Mean = 1.97
(n=451) SD = 8.72
Range = -26.31-34.93
Representativeness of the sample
In terms of the representativeness of the data, there was a significant difference 
in relation to age and education between responders and non-responders at 18 
months.
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Table 5.2: Responders compared to non-responders at baseline
Variable Responders Non-responders t /  .T* P
Age X = 51.28 X  = 47.24 5.731 .0001 '
SD = 12.68 
n ■ 502
S D =  13.14 
n = 1051
Sex Male = 106 (21%) 
Female = 399 (79%)
Male = 173 (16.4%) 
Female = 881 (83.6%)
4.867 .027 ’
Ethnicity White = 484 (96%)
Black Caribbean =  3 (0.8%) 
Black African = 3 (0.6%) 
Asian = 6(1.2%)
Other = 8(1.6% )
White =  1009 (95.5%)
Black Caribbean = 15 (1.4%) 
Black African = 6 (0.6%) 
Asian = 15 (1.4%)
Other = 12 (1.1%)
2.702 .609
Job Full time = 154 (31.6%)
Pait time = 104 (21.3%)
Not Workinq = 230 (47.1%)
Full time = 344 (33.4%)
Part time = 213 (20.7%)
Not Workinq =  473 (45.9%)
.510 .775
Marital
Status
Married = 315 (83.3%)
Divorced = 52 (10.4%)
Living with Patiner =  52 (10.4%) 
Single = 59 (11.8%)
Widowed = 20 (4%)
Married = 613 (59.6%)
Divorced =136  (13.2%)
Living with Partner =  110 (10.7%) 
Single =  130 (12.6%)
Widowed =  39 (3.3%)
3.077 .545
Education <  Secondary = 53 (10.7%)
Secondary School Grad = 148 (30%)
Some College = 135 (27.3%)
College Grad = 77 (15.6%)
Graduate = 32 (6.5%)
Postgraduate = 16 (3.2%)
Doctorate or Professional Degree =  33 (6.7%)
< Secondary = 140(14%)
Secondary School Grad =  362 (36.2%)
Some College = 237 (23.7%)
College Grad = 141 (14.1%)
Graduate = 76 (7.6%)
Postgraduate = 17 (1.7%)
Doctorate or Professional Degree = 28 (2,8%)
25.082 .0001 '
BMI X = 35.69 
SD = 5.94 
n = 480
X = 36.23 
SD =  5,95 
n = 995
-1.647 .100
II. Taking orlistat
The results were analysed to describe whether the participants’ were still taking 
orlistat and if they were not why they stopped, this is shown in table 5.3.
Table 5.3: Taking orlistat
Yes Nostill taking orlistat at 18 month n= 113 (21.8%) n= 406 (78.2%)
follow up (n=519)
Because doctor told me to n= 158 (39.9%) n= 238 (60.1%)
(n=396)
Because wasn’t helping n= 172 (43.5%) n= 223 (56.5%)
(n=395)
Because didn’t like side effects n= 119 (30.1%) n= 277 (69.9%)
(n=396)
The majority of the sample were not still taking orlistat at 18 months follow up, 
with the most common reason for stopping being because it wasn’t helping.
III. Methods of weight loss
Participants’ described the different methods they had tried to lose weight at 
baseline and 18 month follow up, which are described in table 5.4.
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Table 5.4: Methods of weight loss
Baseline 18 month follow up
Never Sometimes Very
Often
Never Sometimes Very
Often
Diet n=110 n=222 n=124 n=104 n=193 n=120
(24.1%) (48.7%) (27.2%) (24.9%) (46.3%) (28.8%)
Exercise n=112 n=209 n=169 n—124 n=167 n=183
(22.9%) (42.7%) (34.5%) (26.2%) (35.2%) (38.6%)
Weighing n=100 n=113 n=273 n=149 n=98 n=216
yourself (20.6%) (23.3%) (56.2%) (32.2%) (21.2%) (46.7%)
Psychological n=456 n=9 n=7 n=415 n=11 n=3
(96.6%) (1.9%) (1.5%) (96.7%) (2.6%) (0.7%)
Baseline 18 month follow up
Yes Maybe No Yes Maybe No
Had surgery n=1 n=506 n=5 n=507
(0.2%) (99.8%) (1%) (99%)
Would have n=23 n=13 n=464 n=35 n=14 n=462
surgery In the (4.6%) (2.6%) (92.8%) (6.8%) (2.7%) (90.4%)
future
When asked about methods of weight loss the majority reported sometimes 
dieting at baseline and 18 month follow up. The majority also reported 
sometimes exercising at baseline and very often at 18 month follow up. The 
majority reported weighing themselves very often at baseline and 18 month 
follow up. Furthermore they reported never using psychological methods (such 
as cognitive behaviour therapy) at baseline and 18 month follow up. Most had 
not had weight loss surgery at baseline and 18 month follow up. Also most 
reported not wanting it in the future; at baseline and 18 month follow up.
5.3.2 Changes over time
The data will now be analysed in terms of changes over time in weight, beliefs 
and behaviour using repeated measures ANOVAs.
Weight
I. Weight change
Participants’ weight and BMI at baseline and 18 month follow up are shown in 
table 5.5. The results show that there was a significant decrease in weight and 
BMI from baseline to 18 month follow up.
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Table 5.5: Weight change
Baseline 18 month 
follow up
F P Direction
Weight x= 97.73 x= 95.75 23.115 .0001 * 1 > 4
SD= 18.71 SD= 19.55
BMI x= 35.55 x= 34.83 22.453 .0001 * 1 > 4
SD= 5.88 SD= 6.26
Beliefs
II. Causes and solutions
Participants’ endorsement of behavioural and medical causes and solutions to 
their weight problem and how they changed over the 18 months are described in 
table 5.6.
Table 5.6: Beliefs
Baseline 18 month 
follow up
F P Direction
Behaviourai cause x= 3.46 
SD= 0.90
x= 3.44 
SD= 0.95
0.095 .758
Medical cause x= 2.20 
SD= 0.89
x= 2.26 
SD= 0.95
1.651 0,200
Behavioural solution x= 4.21 
SD= 0.701
x= 4.075 
SD= 0.804
11.11 .001 ■* 1 > 4
Medical solution x= 2.60 
SD= 0.93
x= 2.60 
SD= 1.08
0.017 .895
The results show there was a significant decrease in endorsement of a 
behavioural solution to their weight problem from baseline to 18 month follow up.
ill. Illness beliefs
Participants illness beliefs at baseline and 18 month follow up are shown in table 
5.7. The results show a significant decrease in consequences, personal control, 
treatment control, identity, concern, understanding and emotional response to 
their weight along with an increase in timeline from baseline to 18 month follow 
up.
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Table 5.7: Illness perceptions
Baseline 18 month 
follow up
F P Direction
Consequences x= 7.33 x= 6.41 76.14 .0001 * 1 > 4
SD= 2.17 SD= 2.72
Timeline x= 6.70 x= 7.07 9.08 .003 * 1 < 4
8D= 2.23 SD= 2.75
Personal control x= 5.63 x= 5.16 13.07 .0001 * 1 > 4
SD= 2.34 SD= 2.65
Treatment control x= 7.78 x= 5.59 183.92 .0001 * 1 > 4
SD= 2.25 SD= 3.56
Identity x= 5.82 x= 5.20 23.12 .0001 * 1 > 4
SD= 2.50 SD=2.79
Concern x= 8.55 x= 7.75 64.04 .0001 * 1 > 4
SD= 1.71 SD= 2.44
Understanding x= 7.52 x= 7.09 12.04 .001 * 1 > 4
SD= 2.33 SD= 2.71
Emotional response x= 6.84 x= 6.31 18.38 .0001 * 1 > 4
SD= 2.97 8 0= 3 .1 4
IV. Side effects, cognitions and behaviour change
Participants’ described whether they experienced side effects of taking orlistat 
along with the impact of these side effects on cognitions and behaviour at 
baseline and 18 month follow up, which is shown in table 5.8. The results 
showed there was a significant decrease in the side effects making them change 
their diet behaviour and a significant increase in the side effects making them 
selectively adhere to orlistat from baseline to 18 month follow up.
Table 5.8: Side effects
Baseline 18 month 
follow up
F P Direction
8ide effects x= 2.52 x= 2.39 2.307 .132
8D= 0.94 8D= 0.98
Behavioural cognitions x= 3.46 x= 3.62 1.61 .207
8D= 1.27 8D= 1.09
Medication cognitions x=2.33 x= 2.44 .793 .375
8D= 1.16 8D= 1.05
Diet behaviour change x= 4.11 x= 3.65 19.91 .0001 * 1 > 4
8D= 1.04 8D= 1.08
Adherence behaviour x= 1.21 x= 1.61 15.37 .0001 * 1 < 4
change 8D= 0.538 SD= 1.03
Behaviour
V. Adherence and imposed control
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Participants described whether they adhered to orlistat as prescribed and 
whether taking orlistat imposed control on what they ate, which is shown in table 
5.9.
Table 5.9: Medication
Baseline 18 month 
follow up
F P Direction
Adherence 
Imposed control
x= 4.48 
SD= 0.75 
x= 2.46 
SD= 1.09
x= 3.91 
SD= 0.94 
x= 2.37 
SD= 1.05
32.48
0.738
.0001 * 
.392
1 > 4
The results indicate a significant decrease in adherence from baseline to 18 
month follow up.
VI. Eating behaviour 
Participants' eating behaviour at baseline and 18 month follow up and the 
significance of changes is shown in table 5.10. The results show that there was 
a significant decrease in healthy snacks, healthy meals, healthy cooking and 
fruit and vegetable consumption, along with an increase in unhealthy snacks, 
unhealthy meals, unhealthy cooking and high fat foods from baseline to 18 
month follow up.
Table 5.10: Eating behaviour
Baseline 18 month 
follow up
F P Direction
Healthy snack x= 3,91 x= 3.45 82.76 .0001 * 1 > 4
SD= 1.06 SD= 1.07
Unhealthy snack x= 1.84 x= 2.48 188.56 .0001 * 1 < 4
SD= 0.74 SD= 0.99
Healthy meal x= 5.80 x= 5.64 7.86 .005 * 1 > 4
SD= 1.28 SD= 1.35
Unhealthy meal x= 1.94 x= 2.07 12.19 .001 * 1 < 4
SD= 0.85 SD= 0.83
Healthy cooking x= 3.40 x= 3.24 13.76 .0001 * 1 > 4
SD= 0.93 SD=0.91
Unhealthy cooking x= 2.07 x= 2.22 27.41 .0001 * 1 < 4
SD= 0.57 SD= 0.57
High fat food x= 1.48 x= 1.90 97.65 .0001 * 1 < 4
SD= 0.74 SD= 0.94
Low fat food x= 4.28 x= 4.25 0.122 .727
SD= 1.23 SD= 1.34
Fruit and vegetables x= 4.33 x= 4.02 16.69 .0001 * 1 > 4
SD= 1.53 SD= 1.64
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VII. Exercise
Participants’ described the intensity of exercise they took part in at baseline and 
18 month follow up and the significance of any changes are shown in table 5.11. 
Table 5.11; Exercise
Baseline 18 month 
follow up
F P Direction
Exercise x= 3.21 
SD= 1.17
x= 3.08 
SD= 1.17
7.37 .007 * 1 > 4
There was a significant decrease in exercise from baseline to 18 month follow 
up.
VIII. Help seeking
Participants’ reported the frequency they saw health professionals at baseline 
and 18 month follow up with the significance of any changes shown in table 
5.12.
Table 5.12; Help seeking
Baseline 18 month 
follow up
F P Direction
Practice nurse x= 2.33 x= 1.63 107.99 .0001 * 1 > 4
SD= 1.32 SD= 1.17
GP x= 2.82 x= 1.76 248.76 .0001 * 1 > 4
SD= 1.15 SD= 1.22
Hospital doctor x=1.34 x= 1.16 20.11 .0001 * 1 > 4
SD= 0.82 SD= 0.59
Dietician x= 1.83 x= 1.27 103.68 .0001 * 1 > 4
SD= 1.13 SD= 0.81
Counsellor x= 1.12 x=1.05 5.75 .017 * 1 > 4
SD= 0.51 SD=0.39
Psychologist x= 1.08 x= 1.02 12.56 .0001 * 1 > 4
SD= 0.45 SD= 0.23
Slimming club organiser x= 2.47 x= 1.59 155.85 .0001 * 1 > 4
SD= 1.42 SD= 1.28
Contact MAP x= 1.56 x= 1.19 3.46 .083
SD= 0.73 SD= 0.40
MAP positive x= 4.74 x= 4.29 2.53 0.14
SD= 0.62 SD= 0.66
There was a significant decrease in seeing a practice nurse, GP, hospital 
doctor, dietician, counsellor, psychologist and slimming club organiser from 
baseline to 18 month follow up.
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IX. Methods o f w eight loss
Participants’ described the methods of weight loss they had tried to lose weight 
at baseline and 18 month follow up, which are shown in table 5.13, along with 
the significance of any changes that occurred. There was a significant decrease 
in weighing themselves and having psychological help from baseline to 18 
month follow up.
Table 5.13: Methods of weight loss
Baseline 18 month 
follow up
F P Direction
Diet x= 3.01 x= 2.97 0.63 .429
SD= 0.84 SD= 0.87
Exercise x= 3.18 . x= 3.24 0.93 .336
SD= 1.07 SD= 1.21
Weigh yourself x= 3.54 x= 3.23 20.40 .000 * 1 > 4
SD= 1.26 SD= 1.38
Psychological x= 1.37 x= 1.27 9.81 .002 * 1 > 4
SD= 0.60 SD= 0.54
5.3.3 Predictors o f change
The data will now be analysed to assess whether demographics, beliefs 
(cognitions and illness perceptions) and behaviour (exercise, adherence and 
eating behaviour) account for any of the variance in long term changes in BMI, 
healthy eating, unhealthy eating and adherence change using multiple 
regressions.
i. Predicting change in BMi 
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) were analysed to examine their 
impact on BMI change from baseline to 18 month follow up.
Demographics
The results showed that a decrease in BMI by 18 months was predicted most by 
not being white, then by them not working , accounting for 3.2% of the variance 
(F=3.255, p=.004).
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Table 5.14; BMI change (T1 minus T4) and demographics
Variables Standardised 13. coefficient P
Age .020 .715
Sex .049 .334
Ethnicity -143 .004 *
Job -.153 .005 *
Marital Status -.018 .712
Education .008 .872
Adjusted = .032
Baseline beliefs and behaviour
Table 5.15: Change in BMI (T1 minus T4) and baseline beliefs/behaviour
Variables Standardised 13, coefficient P
Behavioural cause .060 .470
Medical cause -.027 .706
Behavioural solution .098 .230
Medical solution .024 .743
Routine motivation -.111 .131
Significant event motivation .139 .049 *
Symptom motivation .133 .071
Healthy food .013 .862
Unhealthy food .040 .584
Exercise -.021 .766
Side effects -.072 .356
Behavioural cognitions -.115 .195
Medication cognitions -.066 .371
Diet behaviour change -.107 .236
Adherence behaviour change -.036 .643
Imposed control -.032 .654
Adherence .136 .084
Adjusted R'^  = .068
The results showed that a decrease in BMi by 18 months was predicted most by 
more significant event motivations to lose weight, accounting for 6.8% of the 
variance (F=1.967, p=.015).
Follow up beliefs and behaviour
The results showed that a decrease in BMI by 18 months was predicted most by 
more adherence, then by less endorsement of a behavioural solution to their 
weight problem at 18 month follow up, accounting for 23.8% of the variance 
(F=2.651, p=.005).
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Table 5.16: Change in BMI (T1 minus T4) and 18 month follow up beliefs/behaviour
Variables Standardised (i coefficient P
Behavioural cause -.112 .410
Medical cause -.028 .826
Behavioural solution -.299 .034 *
Medical solution .212 .073
Healthy food -.002 .985
Unhealthy food -.082 .503
Exercise .219 .054
Side effects -.102 .404
Behavioural cognitions .095 .497
Medication cognitions -.085 .543
Diet behaviour change .041 .771
Adherence behaviour change -.148 .276
Imposed control -.067 .596
Adherence .307 .022 *
Adjusted = .238
Change in beliefs and behaviour
Table 5.17: Change in BMI (T1 minus T4) and change in beliefs/behaviour (T1 minus T4)
Variables Standardised R coefficient P
Behavioural cause .017 .921
Medical cause .241 .170
Behavioural solution -.083 .615
Medical solution .010 .954
Healthy food .300 .079
Unhealthy food .327 .113
Exercise -.156 .380
Side effects -.254 .132
Behavioural cognitions -.231 .262
Medication cognitions -.266 .114
Diet behaviour change .165 .362
Adherence behaviour change .094 .614
Imposed control .180 .333
Adherence .129 .583
Adjusted R'^  = .065
The analysis showed that this model accounted for 6.5% of the variance in 
change in cognitions and behaviour from baseline to 18 month follow up and a 
change in BMI from baseline to 18 month follow up but none of the factors were 
significant, nor was the overall model (F=1.220, p=.312).
Baseline illness perceptions
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Table 5.18: Change in BMI (T1 minus T4) and baseline illness perceptions
Variables Standardised (3 coefficient P
Consequences -.076 .245
Timeline -.036 .493
Personal control .015 .799
Treatment Control .034 .536
Identity .103 .091
Concern .049 .407
Understanding .114 .036 *
Emotional Response -.042 .478
Adjusted = .019
The results showed that a decrease in BMI by 18 months was predicted by more 
understanding of their weight problem at baseline, accounting for 1.9% of the 
variance (F=2.026, p=.042).
Follow up illness perceptions
Table 5.19: Change in BMI (T1 minus T4) and 18 month follow up illness perceptions
Variables Standardised R. coefficient P
Consequences -.083 .225
Timeline -.130 .014 *
Personal control .129 .011 *
Treatment Control .107 .024 *
Identity .021 .729
Concern -.069 .273
Understanding .006 .896
Emotional Response -.071 .260
Adjusted R = .105
The results showed that a decrease In BMI by 18 months was predicted most by 
more personal control, then less timeline and more treatment control of their 
weight problem at 18 month follow up, accounting for 10.5% of the variance 
(F=7.469, p=.0001).
Change in illness perceptions
Table 5.20: Change in BMI (T1 minus T4) and change in illness perceptions (T1 minus T4)
Variables Standardised ft coefficient P
Consequences .082 .133
Timeline .117 .015 *
Personal control -.113 .018 *
Treatment Control -.091 .056
Identity .115 .023
Concern .151 .004 *
Understanding .055 .243
Emotional Response .084 .099
Adjusted R = 1 3 3
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The analysis showed that a decrease in BMI by 18 months was predicted most 
by decrease in concern, then decrease in their weight lasting a long time, more 
personal control and then decrease in identity with their weight problem from 
baseline to 18 month follow up, accounting for 13.3% of the variance (F=9.023,
p=.0001).
Baseline eating behaviour
Table 5.21: Change In BMI (T1 minus T4) and baseline eating behaviour
Variables Standardised ft coefficient P
Healthy snack -.021 .715
Unhealthy snack -.069 .257
Home cooked meal -.024 .684
Unhealthy meal -.044 .450
Healthy cooking .022 .702
Unhealthy cooking .053 .349
High fat -.018 .753
Low fat -.066 .252
Fruit and vegetables .024 .675
Adjusted R = -.007
The results showed that this model accounted for 0.7% of the variance in eating 
behaviour at baseline and change in BMI from baseline to 18 month follow up 
but none of the factors were significant, nor was the overall model (F=.725,
p=.686).
Follow up eating behaviour
Table 5.22: Change in BMI (T1 minus T4) and 18 month follow up eating behaviour
Variables Standardised ft coefficient P
Healthy snack .128 .021 *
Unhealthy snack -.110 .061
Home cooked meal -.013 .807
Unhealthy meal -.030 .576
Healthy cooking .008 .878
Unhealthy cooking -.035 .520
High fat -.155 .006 *
Low fat -.170 .002 *
Fruit and vegetables .012 .822
Adjusted R'^  = .082
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The results showed that a decrease in BMI by 18 months was predicted most by 
less low fat food, less high fat food and then more healthy snacks at 18 month 
follow up, accounting for 8.2% of the variance (F=4.831, p=.0001).
Change in eating behaviour
Table 5.23; Change in BMI (T1 minus T4) and change in eating behaviour (T1 minus T4)
Variables Standardised ft coefficient P
Healthy snack -.118 .045 *
Unhealthy snack .074 .231
Home cooked meal .026 .644
Unhealthy meal -.017 .767
Healthy cooking -.056 320
Unhealthy cooking .114 .054
High fat .128 .026 *
Low fat .116 .051
Fruit and vegetables .049 .393
Adjusted = .055
The results showed that a decrease in BMI by 18 months was predicted by a 
decrease In high fat food and then by an increase in healthy snacks from 
baseline to 18 month follow up, accounting for 5.5% of the variance (F=3.107,
p=.001).
Summary of predictors of BMI
The results showed that a decrease in BMi by 18 months was predicted by more 
personal control, less timeline and more treatment control of their weight 
problem at 18 month follow up, accounting for 10.5% of the variance. Also a 
decrease in BMI was predicted by a decrease in concern, decrease in their 
weight lasting a long time, more personal control and a decrease in identity with 
their weight problem from baseline to 18 month follow up, accounting for 13.3% 
of the variance. Furthermore a decrease in BMI was predicted by less low fat 
food, less high fat food and more healthy snacks at 18 month follow up, 
accounting for 8.2% of the variance. These three models were all highly 
significant. Other significant models indicated that a decrease in BMI by 18 
months was predicted by a decrease in high fat food and an increase in healthy 
snacks from baseline to 18 month follow up, accounting for 5.5% of the
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variance. Also a decrease in BMI was predicted by not being white and not 
working, accounting for 3.2% of the variance. A decrease in BMi by 18 months 
was predicted by more adherence and less endorsement of a behavioural 
solution to their weight problem at 18 month follow up, accounting for 23.8% of 
the variance. A decrease in BMI by 18 months was predicted by more significant 
event motivations to lose weight, accounting for 6.8% of the variance, also by 
more understanding of their weight problem at baseline, accounting for 1.9% of 
the variance.
II. Predictors in changes in heaithy eating
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise and adherence) were analysed to examine their impact on change in 
healthy eating from baseline to 18 month follow up.
Demographics
Table 5.24: Change in healthy eating (T1 minus T4) and demographics
Variables Standardised ft coefficient P
Age -.123 .025 *
Sex .084 .101
Ethnicity .014 .785
Job -.126 .020 *
Marital Status -.033 .518
Education -.048 .353
Adjusted = .020
The results showed that a decrease in healthy eating by 18 months was 
predicted by not working and a lower age, accounting for 2% of the variance 
(F=2.323, p=.032).
Baseline cognitions and behaviour
The analysis showed that this model accounted for 0.6% of the variance in 
cognitions and behaviour at baseline and change in healthy eating from baseline 
to 18 month follow up but none of the factors were significant.
190
Table 5.25; Change in healthy eating (T1 minus T4) and baseline beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause .088 .264
Medical cause -.075 .265
Behavioural solution -.002 .981
Medical solution -.024 .732
Routine motivation .130 .066
Significant event motivation -.002 .977
Symptom motivation -.092 .189
Exercise -.034 .613
Side effects .035 .634
Behavioural cognitions .099 .244
Medication cognitions -.019 .788
Diet behaviour change -.001 .988
Adherence behaviour change -.005 .952
Imposed control -.113 .097
Adherence .056 .470
Adjusted R = .006
Follow up beliefs and behaviour
Table 5.26: Change in healthy eating (T1 minus T4) and 18 month follow up beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause .196 .156
Medical cause -.097 .441
Behavioural solution -.189 .196
Medical solution .185 .148
Exercise -.183 .116
Side effects .006 .961
Behavioural cognitions -.181 .250
Medication cognitions -.074 .596
Diet behaviour change .175 .249
Adherence behaviour change .125 .362
Imposed control -.312 .019 *
Adherence .172 .201
Adjusted R"^  = .080
The results showed that a decrease in healthy eating by 18 months was 
predicted by orlistat imposing less control on what they ate at 18 month follow 
up, accounting for 8% of the variance, but the overall model was not significant 
(F=1.538, p=.135).
Change in beliefs and behaviour
The results showed that this model accounted for 13.4% of the variance in 
change in cognitions and behaviour from baseline to 18 month follow up and
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change in healthy eating from baseline to 18 month follow up but none of the 
factors were significant.
Table 5.27; Change in healthy eating (T1 minus T4) and change in beliefs/behaviour (T1 minus 
T4)
Variables Standardised ft coefficient P
Behavioural cause -.080 .629
Medical cause -.041 .803
Behavioural solution .039 .814
Medical solution .096 .559
Exercise .085 .614
Side effects -.066 .707
Behavioural cognitions .332 .089
Medication cognitions .053 .747
Diet behaviour change -.079 .665
Adherence behaviour change .166 .377
Imposed control -.118 .475
Adherence -.067 .730
Adjusted = -.134
Baseline illness perceptions
Table 5.28: Change in healthy eating (T1 minus T4) and baseline illness perceptions
Variables Standardised ft coefficient P
Consequences .015 .825
Timeline -.017 .757
Personal control .019 .745
Treatment Control .033 .571
Identity .004 .953
Concern -.042 .504
Understanding .038 .496
Emotional Response .028 .653
Adjusted R = -.014
The analysis showed that this model accounted for 1.4% of the variance in 
illness perceptions at baseline and change in healthy eating from baseline to 18 
month follow up but none of the factors were significant.
Follow up illness perceptions
The results (see table 5.29) showed that this model accounted for 0.9% of the 
variance in illness perceptions at 18 month follow up and change in healthy 
eating from baseline to 18 month follow up but none of the factors were 
significant.
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Table 5.29: Change in healthy eating (T1 minus T4) and 18 month follow up illness perceptions
Variables Standardised ft coefficient P
Consequences .035 .654
Timeline -.014 .808
Personal control .033 .553
Treatment Control -.040 .444
Identity -.016 .817
Concern .003 .967
Understanding -.037 .497
Emotional Response .077 .267
Adjusted R = -.009
Change in iliness perceptions
Table 5.30: Change in healthy eating (T1 minus T4) and change in illness perceptions (T1 
minus T4)
Variables Standardised ft coefficient P
Consequences -.049 .424
Timeline -.011 .829
Personal control .000 .994
Treatment Control .059 .265
Identity .016 .779
Concern -.015 .804
Understanding .080 .136
Emotional Response -.056 .341
Adjusted R"^  = -.001
This model accounted for 0.1% of the variance in change in illness perceptions 
from baseline to 18 month follow up and change in heaithy eating from baseline 
to 18 month follow up but none of the factors were significant.
Summary of predictors of healthv eating
The only model that was significant in terms of healthy eating was 
demographics, with a decrease in healthy eating being predicted by not working 
and lower age, accounting for 2% of the variance.
III. Predictors of changes in unhealthy eating
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise and adherence) were analysed to examine their impact on unhealthy 
eating change from baseline to 18 month follow up.
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Demographics
Table 5.31: Change in unhealthy eating (T1 minus T4) and demographics
Variables Standardised ft coefficient P
Age .047 .402
Sex -.074 .163
Ethnicity -.090 .084
Job -.038 .496
Marital Status -.131 .013 *
Education .116 .031 *
Adjusted = .034
A decrease in unhealthy eating by 18 months was predicted most by not living 
with someone, then by more education, accounting for 3.4% of the variance 
(F=3.156, p=.005).
Baseline beliefs and behaviour
Table 5.32: Change in unhealthy eating (T1 minus T4) and baseline beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause -.121 .108
Medical cause -.017 .790
Behavioural solution -.050 .499
Medical solution .170 O il *
Routine motivation -.178 .009 *
Significant event motivation -004 .947
Symptom motivation .023 .736
Exercise -.016 .801
Side effects .183 .009 *
Behavioural cognitions -.122 .132
Medication cognitions .035 .601
Diet behaviour change -.029 .719
Adherence behaviour change -.097 .197
Imposed control -.066 .307
Adherence -.119 .109
Adjusted R^  = .091
The analysis showed that a decrease in unhealthy eating by 18 months was 
predicted most by less routine motivations to lose weight and more side effects 
from orlistat, then by greater endorsement of a medical solution to their weight 
problem at baseline, accounting for 9.1% of the variance (F=2.675, p=.001).
Follow up beliefs and behaviour
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The results showed that a decrease in unhealthy eating by 18 months was 
predicted by less endorsement of a behavioural cause to their weight problem at 
18 month follow up, accounting for 3% of the variance, but the overall model 
was not significant (F=1.183, p=.317).
Table 5.33: Change in unhealthy eating (T1 minus T4) and 18 month follow up beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause -.295 .047 *
Medical cause -.079 .567
Behavioural solution -.058 713
Medical solution -.084 .525
Exercise -.144 .239
Side effects -.028 .832
Behavioural cognitions -.100 .553
Medication cognitions .115 .435
Diet behaviour change .104 .536
Adherence behaviour change -.201 .184
Imposed control .136 .318
Adherence .038 .805
Adjusted R = .030
Change in beliefs and behaviour
Table 5.34: Change in unhealthy eating (T1 minus T4) and change in beliefs/behaviour (T1 
minus T4)
Variables Standardised ft coefficient P
Behavioural cause .297 .029 *
Medical cause -.054 .673
Behavioural solution .118 .369
Medical solution -.081 .559
Exercise .228 .108
Side effects .243 .086
Behavioural cognitions -.396 .010 *
Medication cognitions .116 .384
Diet behaviour change .186 .197
Adherence behaviour change .021 .891
Imposed control -.142 .282
Adherence -.481 .005 *
Adjusted R^  = .295
A decrease in unhealthy eating by 18 months was predicted most by a decrease 
in adherence, then by a decrease in the side effects making them think about 
their behaviour and an increase in the endorsement of a behavioural cause to 
their weight problem from baseline to 18 month follow up, accounting for 29.5% 
of the variance (F=2.817, p=.007).
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Baseline illness perceptions
Table 5.35: Change in unhealthy eating (T1 minus T4) and baseline illness perceptions
Variables Standardised ft coefficient P
Consequences -.070 .285
Timeline -.012 .828
Personal control -.200 .001 *
Treatment Control .009 .879
Identity .012 .854
Concern .070 .252
Understanding -.005 .935
Emotional Response -.110 .073
Adjusted R = .028
The results showed that a decrease in unhealthy eating by 18 months was 
predicted by less personal control over their weight problem at baseline, 
accounting for 2.8% of the variance (F=2.372, p=.017).
Follow up illness perceptions
Table 5.36: Change In unhealthy eating (T1 minus T4) and 18 month follow up illness 
perceptions
Variabies Standardised ft coefficient P
Consequences .116 .128
Timeline -.075 .190
Personal control .031 .574
Treatment Control -.073 .165
Identity -.081 .231
Concern -.048 .497
Understanding .067 .218
Emotional Response -.141 .042 *
Adjusted R'^  = .035
A decrease in unhealthy eating by 18 months was predicted by less emotional 
response to their weight problem at 18 month follow up, accounting for 3.5% of 
the variance (F=2.770, p=.005).
Change in illness perceptions
The results showed that a decrease in unhealthy eating by 18 months was 
predicted by an increase in personal control and understanding of their weight
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from baseline to 18 month follow up, accounting for 6.6% of the variance 
(F=4.353, p=.0001).
Table 5.37: Change in unhealthy eating (T1 minus T4) and change in illness perceptions (T1 
minus T4)
Variables Standardised ft coefficient P
Consequences -.058 .338
Timeline .065 .216
Personal control -.193 .0001 *
Treatment Control .032 .542
Identity .044 .437
Concern .113 .058
Understanding -.105 .046 *
Emotional Response .042 .479
Adjusted R"^  = .066
Summarv of predictors of unhealthv eating
In order of significance; a decrease In unhealthy eating by 18 months was 
predicted by an increase in personal control and understanding of their weight 
from baseline to 18 month follow up, accounting for 6.6% of the variance. Also a 
decrease in unhealthy eating was predicted by less routine motivations to lose 
weight, more side effects from orlistat and greater endorsement of a medical 
solution to their weight problem at baseline, accounting for 9.1% of the variance. 
A decrease in unhealthy eating by 18 months was predicted by not living with 
someone and more education, accounting for 3.4% of the variance. Furthermore 
a decrease in unhealthy eating was predicted by less emotional response to 
their weight problem at 18 month follow up, accounting for 3.5% of the variance. 
A decrease in unhealthy eating was also predicted by a decrease in adherence, 
a decrease in the side effects making them think about their behaviour and an 
increase in the endorsement of a behavioural cause to their weight problem from 
baseline to 18 month follow up accounting for 29.5% of the variance. Finally a 
decrease in unhealthy eating by 18 months was predicted by less personal 
control over their weight problem at baseline, accounting for 2.8% of the 
variance.
IV. Predictors in changes in adherence
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Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) were analysed to examine their 
impact on adherence change from baseline to 18 month follow up. 
Demographics
Table 5.38: Change in adherence (T1 minus T4) and demographics
Variables Standardised ft coefficient P
Age .062 .598
Sex -.058 .601
Ethnicity -.077 .478
Job .138 .226
Marital Status .039 .712
Education -.291 .009 *
Adjusted = .031
A decrease in adherence by 18 months was predicted by less education, 
accounting for 3.1% of the variance, but the overall model was not significant 
(F=1.478, p=.195).
Baseline beliefs and behaviour
Table 5.39: Change in adherence (T1 minus T4) and baseline beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause .239 .229
Medical cause .075 .702
Behavioural solution -.185 .349
Medical solution -.174 .349
Routine motivation .061 .739
Significant event motivation .058 .756
Symptom motivation -.086 .662
Healthy food .021 .910
Unhealthy food -.033 .856
Exercise .163 .366
Side effects -.099 .651
Behavioural cognitions .123 .609
Medication cognitions -.029 .886
Diet behaviour change -.052 .820
Adherence behaviour change -.245 .164
Imposed control -.065 .716
Adjusted R'^  = -.090
This model accounted for 9% of the variance in cognitions and behaviour at 
baseline and change in adherence from baseline to 18 month follow up but none 
of the factors were significant.
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Follow up beliefs and behaviour
Table 5.40: Change in adherence (T1 minus T4) and 18 month follow up beliefs/behaviour
Variables Standardised ft coefficient P
Behavioural cause .271 .051
Medical cause .184 .134
Behavioural solution -.105 .461
Medical solution .013 .914
Healthy food -.113 .345
Unhealthy food .084 .504
Exercise .008 .943
Side effects -.116 .336
Behavioural cognitions -.144 .307
Medication cognitions -.126 .344
Diet behaviour change .276 .056
Adherence behaviour change .419 .0001 *
Imposed control .059 .627
The results showed that a decrease in adherence by 18 months was predicted 
by the side effects from orlistat making them selectively adhere more, 
accounting for 17.5% of the variance (F=2.221, p=.019).
Change in beliefs and behaviour
Table 5.41: Change in adherence (T1 minus T4) and change in beliefs/behaviour (T1 minus T4)
Variables Standardised ft coefficient P
Behavioural cause .114 .372
Medical cause -.239 .042 *
Behavioural solution .027 .826
Medical solution -.162 .174
Healthy food .018 .875
Unhealthy food -.416 .002 *
Exercise .243 .054
Side effects .074 .548
Behavioural cognitions -.013 .932
Medication cognitions .057 .635
Diet behaviour change .042 .751
Adherence behaviour change -.388 .003 *
Imposed control -.191 .112
Adjusted = .451
A decrease in adherence by 18 months was predicted most by a decrease in 
unhealthy food, the side effects leading them to selectively adhere to orlistat and 
then in the endorsement of a medical cause to their weight problem, accounting 
for 45.1% of the variance (F=4.095, p=.0001).
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Baseline illness perceptions
Table 5.42; Change in adherence (T1 minus T4) and baseline illness perceptions
Variables Standardised ft coefficient P
Consequences .148 .272
Timeline .003 .981
Personal control .052 .666
Treatment Control .146 .211
Identity -.137 .290
Concern .016 .900
Understanding .112 .350
Emotional Response -.068 .587
Adjusted R = -.015
The analysis showed that this mode! accounted for 1.5% of the variance in 
illness perceptions at baseline and change in adherence from baseline to 18 
month follow up but none of the factors were significant.
Follow  up illness perceptions
Table 5.43: Change In adherence (T1 minus T4) and 18 month follow up illness perceptions
Variables Standardised ft coefficient P
Consequences .084 .600
Timeline .081 .501
Personal control .088 .477
Treatment Control .058 .598
Identity -.108 .432
Concern -.022 .874
Understanding .150 .211
Emotional Response .170 .227
Adjusted R = -.020
The results (see table 5.42) showed that this model accounted for 2% of the 
variance in illness perceptions at 18 month follow up and change in adherence 
from baseline to 18 month follow up but none of the factors were significant. 
Change in illness perceptions
Table 5.44: Change in adherence (T1 minus T4) and change in illness perceptions (T1 minus 
T4)
Variables Standardised ft coefficient P
Consequences .145 .277
Timeline -.077 .482
Personal control -.077 .528
Treatment Control .038 .752
Identity -.091 .448
Concern .017 .890
Understanding .049 .656
Emotional Response -.247 .062
Adjusted R = -.022
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This model accounted for 2.2% of the variance in change in illness perceptions 
from baseline to 18 month follow up and change in adherence from baseline to 
18 month follow up but none of the factors were significant.
Baseline eating behaviour
Table 5.45: Change in adherence (T1 minus T4) and baseline eating behaviour
Variables Standardised ft coefficient P
Healthy snack -.103 .417
Unhealthy snack .215 .075
Home cooked meal .201 .109
Unhealthy meal -.048 .676
Healthy cooking .217 .065
Unhealthy cooking -.113 .342
High fat -.137 .252
Low fat .126 .305
Fruit and vegetables -.032 .780
Adjusted R = .063
The results showed that this model accounted for 6.3% of the variance in eating 
behaviour at baseline and change in adherence from baseline to 18 month 
follow up but none of the factors were significant.
Follow up eating behaviour
Table 5.46: Change in adherence (T1 minus T4) and 18 month follow up eating behaviour
Variables Standardised ft coefficient P
Healthy snack -.222 .064
Unhealthy snack .052 .684
Home cooked meal .107 .399
Unhealthy meal .100 .384
Healthy cooking .117 .357
Unhealthy cooking -.075 .530
High fat -.010 .936
Low fat -.007 .950
Fruit and vegetables .042 .736
Adjusted R'^  = -.035
This model accounted for 3.5% of the variance in eating behaviour at 18 month 
follow up and change in adherence from baseline to 18 month follow up but 
none of the factors were significant.
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Change In eating behaviour
Table 5.47: Change in adherence (T1 minus T4) and change in eating behaviour (T1 minus T4)
Variables Standardised ft coefficient P
Healthy snack .207 .099
Unhealthy snack .057 .674
Home cooked meal -.035 .781
Unhealthy meal .015 .905
Healthy cooking -.011 .928
Unhealthy cooking -.004 .973
High fat -.140 .268
Low fat .129 .308
Fruit and vegetables -.352 .007 *
Adjusted = .068
The results showed that a decrease in adherence by 18 months was predicted 
by an increase in fruit and vegetables from baseline to 18 month follow up, 
accounting for 6.8% of the variance, but the overall model was not significant 
(F=1.621, p=.127).
Summarv of predictors of adherence
In terms of significant models and variables that changed over the 18 month 
period that predicted a decrease in adherence; these were unhealthy food, the 
side effects making them change their adherence behaviour and an increase in 
endorsement of a medical cause over the 18 month period, accounting for 
45.1% of the variance. Also in terms of variables at follow up, a decrease in 
adherence was predicted by the side effects making them change their 
adherence more at 18 months, accounting for 17.5% of the variance.
5.3.4 Changes in endorsing a behavioural solution and losing weight.
Changes in endorsing a behavioural solution to their weight problem or not and 
the relationship to losing weight was explored. Whether endorsing a behavioural 
solution to their weight problem changed over time was examined.
The 6 behavioural solution items were averaged and split into yes or no 
groups using median split. These were then explored in terms of whether they 
lost weight or not.
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Table 5.48: Changes in endorsing a behavioural solution from baseline to 18 month follow up.
Baseline
Behavioural solution Not behavioural solution
18
month
follow
up
Behavioural solution 
Not behavioural solution
n= 118 
34.2% 
n= 61 
17.7%
n= 45 
13% 
n= 121 
35.1%
163
182
179 166 345
The majority of participants remained consistent in their beliefs about the 
endorsement of a behavioural solution to their weight problem or not over an 18 
month period. The participants endorsement of a behavioural solution at 
baseline had a significant association with endorsing a behavioural solution or 
not at 18 month follow up (1, N=345) = 52.06, p<.0Q01).
Whether endorsing a behavioural solution at both time points or changing from 
not endorsing a behavioural solution to endorsing a behavioural solution was 
explored in relation to whether they lost weight from baseline to 18 month follow 
up.
Table 5.49: Impact of endorsing a behavioural solution on weight loss.
T1 Behavioural 
solution 
T4 Behavioural 
solution
T1 Not behavioural 
solution 
T4 Behavioural 
solution
T1 Behavioural 
solution
T4 Not behavioural 
solution
T1 Not behavioural 
solution
T4 Not behavioural 
solution
Lost weight n= 56 n= 19 n= 28 n= 51
T1 to T4 54.4% 48.7% 50% 43.2%
Not lost weight n= 47 n= 20 n= 28 n= 67
T1 to T4 45.6% 51.3% 50% 56.8%
Most people who endorsed a behavioural solution to their weight problem at 
baseline and 18 month follow up lost weight Furthermore those who did not 
endorse a behavioural solution at baseline and 18 month follow up were more 
likely to not lose weight.
The majority of participants who endorsed a behavioural solution at both time 
points lost weight and the majority of those who did not endorse a behavioural 
solution at both time points did not lose weight. The participants endorsement of
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a behavioural solution or not at both time points did not have a significant 
association with losing weight or not (1, N=221) -  2.74, p>.05).
Table 5.50 Correlation of the impact of endorsing a behavioural solution on weight loss.
T1 Behavioural 
solution 
T4 Behavioural 
solution
T1 Not behavioural 
solution
T4 Not behavioural 
solution
Lost weight 
T1 to T4
56 51 107
Not lost weight 
T1 to T4
47 67 114
103 118 221
5.3.5 Changes In beliefs about a medical so lution to the ir w eight problem 
and the relationship to iosing weight.
Changes in endorsing a medical solution to their weight problem or not and the 
relationship to losing weight was explored. Firstly whether people change their 
endorsement of a medical solution to their weight problem or not over time was 
examined.
The two medical solutions items were averaged and split into medical 
solution or not groups using median split. These were then explored in terms of 
whether they lost weight or not.
Table 5.51: Changes in endorsing a medical solution from baseline to 18 month follow up.
Baseline
Medical solution Not medical solution
18 Medical solution n= 202 n= 144 346
month 56.3% 40.1%
follow Not medical solution n= 8 n= 5 13
up ______________________ 2.2%_____________ 14%___________________
210 149 359
The majority of participants endorsed a medical solution to their weight problem 
at baseline and 18 months. The participants endorsement of a medical solution 
at baseline did not have a significant association with endorsing a medical 
solution or not at 18 month follow up ( j ^  (1, N=359) = .051, p>.05).
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Endorsement of a medical solution to their weight problem or not, at 
baseline and 18 month follow up was examined in relation to whether they lost 
weight from baseline to 18 month follow up.
Table 5.52: Impact of endorsing a medical solution on weight loss.
T1 Medical 
solution 
T4 Medical 
solution
T1 Not medical 
solution 
T4 Medical solution
T1 Medical solution 
T4 Not medical 
solution
T 1 Not medical 
solution 
T4 Not medical 
solution
Lost weight n= 98 n= 58 n= 3 n= 3
T1 to T4 53% 46% 42.9% 60%
Not lost weight n= 87 n= 68 n= 4 n= 2
T1 to T4 47% 54% 57.1% 40%
Of those who did not endorse a medical solution at baseline and follow up the 
majority lost weight, however not many people fell into this category (n=5). 
Table 5.53 Correlation of the impact of endorsing a medical solution on weight loss.
T 1 Medical solution 
T4 Medical solution
T1 Not medical 
solution 
T4 Medical solution
Lost weight 
T1 to T2
98 58 156
Not lost weight 
T1 to T2
87 68 155
185 126 311
The majority of participants who endorsed a medical solution at both time points 
lost weight and the majority of those who did not endorse a medical solution at 
both time points did not lose weight. The participants endorsement of a medical 
solution or not at both time points did not have a significant association with 
losing weight or not (1, N=311 ) = 1.45, p>.05).
5.4 D iscussion
This discussion will begin with summarising the results of this study, it will then 
go on to discuss these results in relation to background literature and the 
implications of these results in terms of successful weight loss and maintenance 
in the long term.
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1. To describe partic ipants’ demographics at baseline and 18 month 
fo llow  up.
I. Profile characteristics
The average age of participants in this sample was 51.28 years with a range 
from 18 to 77. The majority of participants were female, white, not working, 
married and were secondary school graduates. Average height was 1.66m; 
average weight at baseline was 98.28kg and at 18 month follow up 95.62kg, 
giving an average weight lost between baseline and 18 month follow up of 1.97 
kg. The mean BMI at baseline was 35.67 and at 18 month follow up was 34.82.
II. Taking orlis ta t
The majority of the sample was not still taking orlistat at 18 month follow up, with 
the most common reason for stopping being because it wasn't helping.
ill. Methods o f w eight loss 
When asked about methods of weight loss the majority reported sometimes 
dieting at baseline and 18 month follow up. Most also reported sometimes 
exercising at baseline and very often at 18 month follow up. The majority 
reported weighing themselves very often at baseline and 18 month follow, up. 
Furthermore they reported never using psychological methods (such as 
cognitive behaviour therapy) at baseline and 18 month follow up.
Most had not had weight loss surgery at baseline and 18 month follow up. Also 
most reported not wanting it in the future at baseline and 18 month follow up.
Participants were described in terms of their profile characteristics; taking 
orlistat and methods of weight loss at baseline and 18 month follow up. This 
analysis simply describes these constructs at the two time points, these 
constructs were also analysed to explore changes over time.
2. To explore the changes over tim e in weight, beliefs and behaviour.
I. W eight
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Over the 18 month follow up period there was a significant decrease in weight 
and BMI.
II. Beliefs
Over the 18 month follow up there was significantly less of an endorsement of a 
behavioural solution to their weight problem. For illness beliefs, over the 18 
month follow up, there was a significantly greater belief that their weight problem 
would continue for a long time. There was significantly less of a belief in 
consequences, personal control, treatment control, identity, concern, 
understanding and emotional response to their weight problem. Therefore there 
was less of a belief that their weight affected their life, that they had control over 
their weight, that orlistat could help control their weight, that they experienced 
symptoms from their weight, that they were concerned about their weight, that 
they understood their weight and less of a belief that their weight affected them 
emotionally.
The participants also reported significantly less of a belief that the side 
effects made them change their diet behaviour and less of a belief in the side 
effects making them selectively adhere to orlistat over the 18 month period.
III. Behaviour
Over the 18 month period there were several significant changes in behaviour. 
Participants adhered to orlistat significantly less at 18 months compared to 
baseline. Therefore overall those still taking orlistat at 18 months were more 
likely to selectively adhere rather.than take it as prescribed.
The participants also significantly changed their eating behaviour. Over 
the 18 months they ate significantly less healthy snacks, healthy meals, healthy 
cooking and fruit and vegetables. They also ate more unhealthy snacks, 
unhealthy meals, high fat foods and used more unhealthy cooking methods over 
the 18 months. Therefore overall over the 18 month period the majority of
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participants eating behaviour became unhealthier. They also generally exercised 
less over the 18 month period.
In terms of help seeking behaviour there were also some significant 
changes. Participants generally had less contact with a practice nurse, GP, 
hospital doctor, dietician, counsellor, psychologist and slimming club organiser 
over the 18 months. They also weighed themselves and had psychological help, 
such as counselling and self help groups, significantly less over the 18 month 
period.
These results show that weight, beliefs and behaviours significantly 
change over time. It is also useful to examine predictors of change to explore 
what variables at baseline, 18 month follow up and those that change over that 
period, predict change in key variables. The key variables that will be examined 
are BMI, healthy eating, unhealthy eating and adherence.
3. To examine predictors of outcomes.
I. Predicting changes in BMI
Follow up beliefs and behaviours accounted for 23.8% of the variance in BMI, 
with a decrease in BMI by 18 months being predicted by more adherence and 
less endorsement of a behavioural solution to their weight problem at 18 month 
follow up. Changes in illness beliefs accounted for 13.3% of the variance in BMI, 
with a decrease in BMI being predicted by a decrease in concern, decrease in 
their weight lasting a long time, more personal control and a decrease in identity 
with their weight problem from baseline to 18 month follow up. Illness beliefs at 
follow up accounted 10.5% of the variance in BMI, with a decrease in BMI by 18 
months being predicted by more personal control, less timeline and more 
treatment control of their weight problem at 18 month follow up. Eating 
behaviour at follow up accounted for 8.2% of the variance in BMI, with a 
decrease in BMI being predicted by less low fat food, less high fat food and 
more healthy snacks at 18 month follow up. Beliefs and behaviour at baseline
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accounted for 6.8% of the variance in BMI, with a decrease in BMi by 18 months 
being predicted by more significant event motivations to lose weight.
Changes in eating behaviour accounted for 5.5% of the variance in BMI, with a 
decrease in BMI by 18 months being predicted by a decrease in high fat food 
and an increase in healthy snacks from baseline to 18 month follow up. 
Demographics accounted for 3.2% of the variance in BMI, with a decrease in 
BMI was predicted by not being white and not working. Finally illness beliefs at 
baseline only accounted for 1.9% of the variance in BMI, with a decrease in BMI 
by 18 months was predicted by more understanding of their weight problem at 
baseline.
II. Predicting changes in healthy eating
Demographics only accounted for 2% of the variance in healthy eating with a 
decrease in healthy eating were not working and lower age.
III. Predicting changes in unhealthy eating
Changes in beliefs and behaviours accounted for 29.5% of the variance in 
unhealthy eating, with a decrease in unhealthy eating being predicted by a 
decrease in adherence, a decrease in the side effects making them think about 
their behaviour and an increase in the endorsement of a behavioural cause to 
their weight problem from baseline to 18 month follow up. Baseline beliefs and 
behaviour accounted for 9.1% of the variance in unhealthy eating, with a 
decrease in unhealthy eating being predicted by less routine motivations to lose 
weight, more side effects from orlistat and greater endorsement of a medical 
solution to their weight problem at baseline. Changes in illness beliefs 
accounted for 6.6% of the variance in unhealthy eating, with a decrease in 
unhealthy eating by 18 months being predicted by an increase in personal 
control and understanding of their weight from baseline to 18 month follow up. 
Follow up illness beliefs accounted for 3.5% of the variance in unhealthy eating, 
with a decrease in unhealthy eating being predicted by less emotional response 
to their weight problem at 18 month follow up. Demographics accounted for
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3,4% of the variance in unhealthy eating, with a decrease in unhealthy eating by 
18 months being predicted by not living with someone and more education. 
Finally baseline illness beliefs accounted for 2.8% of the variance, with a 
decrease in unhealthy eating by 18 months being predicted by less personal 
control over their weight problem at baseline.
IV. Predicting changes in adherence
Changes in beliefs and behaviours accounted for 45.1% of the variance in 
adherence, with a decrease in adherence being predicted by an increase in 
unhealthy food, an increase in the belief that the side effects made them change 
their adherence behaviour and an increase in the endorsement of a medical 
cause to their weight problem over the 18 month period. Furthermore follow up 
beliefs and behaviour accounted for 17.5% of the variance in adherence, with a 
decrease in adherence being predicted by more of a belief in the side effects 
making them change their adherence at 18 months.
4. To examine the changes in endorsing a behavioural so lu tion and the 
relationship to losing weight.
The results indicated that the majority of participants remained consistent in their 
beliefs about whether or not they endorsed a behavioural solution to their weight 
problem over the 18 month period. Most people who endorsed a behavioural 
solution to their weight problem at baseline and 18 month follow up lost weight. 
Furthermore those who did not endorse a behavioural solution at baseline and 
18 month follow up were more likely to not lose weight.
5. To examine changes in beliefs about medical so lu tions to their 
w eight problem and relationship to losing weight.
The majority of participants endorsed a medical solution to their weight problem 
at baseline and 18 months. The next highest majority were those who did not 
endorse a medical solution at baseline but then did at 18 month follow up. The 
majority of people who endorsed a medical solution to their weight problem at
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baseline and 18 month follow up lost weight. Furthermore those who endorsed a 
medical solution at baseline but did not at 18 months were more likely not to 
lose weight. It therefore appears that if an individual endorses a solution to their 
weight problem, whether behavioural or medical then they are more likely to lose 
weight.
Links to literature
Weight loss by 18 months was predicted by more significant event motivations 
at baseline. Therefore it appears that if people decided to lose weight due to a 
significant event then they were more likely to lose weight in the long term 
compared to those who decided to start losing weight just due to routine 
consequences of being overweight, such as low self-esteem and lack of 
confidence or due to experiencing symptoms from their weight. This is reflected 
in Ogden and Sidhu’s (2006) study where they conducted in depth interviews of 
individuals' experiences of being prescribed orlistat in the past year. Their study 
found that those who were successful in losing weight reported their motivations 
to lose weight as dramatic life crises. Therefore motivations appear to be an 
important factor in successful weight loss.
It important for individuals to fully adhere to orlistat to facilitate weight loss 
as those who adhered more at 18 months had a significant reduction in BMI 
over the long term. This is reflected in McDonald et al (2002) who report that 
non-adherence reduces the treatment benefits, which in the case of orlistat is 
less weight loss, but also biases the health professionals and patients 
perception of the effectiveness of the treatment. Therefore adherence is 
important to facilitate weight loss but also to indicate whether the drug is an 
appropriate weight loss method for the patient.
These results also indicate that more healthy snacks, less low and high 
fat at 18 months predict long term weight loss. Therefore healthier snack 
behaviour and eating less fat is predictive of weight loss. This indicates that the
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healthy snacks enable the individual to eat healthier and eat less fat. Orlistat 
facilitates the change in eating behaviour through its "antabuse" effect (Finer, 
2002), when fatty food is eaten whilst taking orlistat and the healthy snacks also 
facilitated the change in eating behaviour in order to enable weight loss in the 
long term.
For variables that changed over the 18 month period where participants 
were followed up, some of these variables predicted weight loss. Weight loss 
was predicted by individuals believing more in their weight problem not 
continuing forever, an increase in believing they had personal control over their 
weight problem and them being less concerned about their weight. This reflects 
the results of Ogden and Hills study (2008) where those who lost weight had a 
shift in identity to a new healthier self. In the current study people who lost 
weight were less concerned about their weight and felt it would not continue for 
much longer, therefore felt more positive about their weight. This is further 
reflected in Elfhag and Rossner’s (2005) study where better coping strategies, 
assuming responsibility in life and overall more psychological strength and 
stability were important for weight maintenance.
There were some changes in behaviour over the 18 months that 
predicted weight loss. Eating more healthy snacks by 18 months was predictive 
of weight loss, along with less high fat foods. Therefore the healthy snacks 
appear to facilitate the weight loss, this could be through reducing calorie and fat 
intake by not snacking on unhealthy foods but also by staving off hunger so that 
when people make choices about their main meals these are healthy choices as 
well.
The results indicated that the majority of participants remained consistent 
in their beliefs about whether or not they endorsed a behavioural solution to their 
weight problem over the 18 month period. The majority of people who endorsed 
a behavioural solution to their weight problem at baseline and 18 month follow
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up lost weight. Furthermore those who did not endorse a behavioural solution at 
baseline and 18 month follow up were more likely to not lose weight. This 
provides support for Ogden and Sidhu (2006) who found that those who hold a 
behavioural model to their obesity are more likely to be successful in losing 
weight.
Implications for practice and research
The results of this study have implications for long term weight loss. There are 
many variables that are predictors of change either at baseline, 18 months or 
those that change over the 18 month period.
For those who are beginning the process of losing weight there are 
several factors that should be considered, as this study shows they are 
predictors of weight loss. Firstly individuals need to consider their motivations for 
losing weight, as routine motivations for losing weight are not predictors of 
successful weight loss in the short or long term. When the individual is thinking 
why they want to lose weight it may be more useful to think of a significant life 
event such as a birthday or think about the health benefits of losing weight in 
terms of reducing the health risks of being overweight to make their motivations 
for losing weight more salient.
This study shows that those who increased their healthy snack 
consumption over the 18 months were more likely to lose weight. The healthy 
snacks may be a useful tool for individuals because not only are snacks easier 
to substitute for healthier options as individuals do not feel they are sacrificing 
too much but also they can help regulate appetite. The healthy snack will 
facilitate the individual is choosing their main meal as they will not be as hungry 
and thus may feel more in control and be able to choose healthier options, also 
they will not feel as hungry and therefore may not eat as much. This indicates 
individuals trying to lose weight should incorporate healthy snacks into their diet' 
to improve their chances of success.
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Another aspect for individuals trying to lose weight to consider is that 
those reporting their weight will not last for much longer are associated with 
losing weight. This indicates for individuals that having a positive mind set and 
believing their weight is something that will not continue forever, therefore is 
controllable, will be more successful in their weight loss. Although it may also be 
the fact that they have lost weight that makes them fee! more positive. But this is 
also something for individuals to be aware of as they will realise that by losing 
some weight they will begin to feel more positive about controlling their weight, 
therefore their weight loss and maintenance will continue.
It is important for individuals to fully adhere to orlistat to ensure weight 
loss, as those who reported more adherence at 18 months were more likely to 
lose weight. Therefore individuals who use orlistat as a weight loss method 
should understand its efficacy when adhered to as Avenell et al. (2004b) found 
significant weight loss with adding orlistat to diet. It appears believing in the 
treatment they are using will help them lose weight in the long term. Also 
understanding that their weight is controllable will facilitate long term weight loss.
Another belief to consider is concern for their weight problem, individuals 
whose concern for their weight decreased over the 18 months were more likely 
to lose weight. Concern appears to be important in both short and long term 
weight loss. A certain amount of concern would be required for the individual to 
consider action to do something about it but too much concern seems to be 
prohibitive in weight loss. Therefore the individual should not worry about their 
weight too much and should focus their energies on losing the weight through 
change in diet and exercise.
Finally individuals who decide to go back to orlistat after a break or those 
who continue with orlistat in the long term should be aware of the importance of 
adherence. Adherence at 18 months was predictive of weight loss; therefore if
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the individual is deciding to use orlistat as a weight loss method then they 
should take it as prescribed for success in weight loss.
Conclusions
Weight loss and maintenance is achievable, as overall the majority of 
participants who had used orlistat as a weight loss method had lost weight over 
the 18 month follow up period.
Understanding w eight loss
There are several factors that need to be taken into consideration to improve the 
individuals’ chances of losing weight. This study shows that for long term weight 
loss, a significant event motivation is important along with healthy snacks and 
less fatty foods. Furthermore the belief that their weight probiem will not 
continue forever and being less concerned with their weight is useful. These are 
all factors that can be addressed and used to facilitate long term weight loss. 
The additional im pact o f orlis ta t
Orlistat functions by showing the individual that their weight can be controlled, 
therefore they become less concerned and believe their weight problem will not 
last forever. Also by adhering fully to orlistat individuals lose weight and eat 
healthier, thus by incorporating healthy snacks this translates to long term 
weight loss.
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Chapter 6
Study 4: The process of behaviour change since beginning to take orlistat. 
From baseline through 6 month, 12 month and 18 month follow up.
6.1 Introduction
Short term (chapter 4) and long term changes (chapter 5) in weight, beliefs and 
behaviour have been examined. In the short term initial motivations and healthy 
eating are important and orlistat functions as an education whilst giving the 
individual control over their eating, in the long term significant event motivations 
are also important along with healthy snacks, less high and low fat. Orlistat 
functions over the long term by educating people in what they should be eating 
and shows them they can control their weight and they become less concerned 
about their weight. The process of change over the 18 months needs to be 
addressed therefore that will now be explored.
6.1.1 Background
In terms of weight change previous research suggests that early treatment 
response is a good indicator of subsequent behaviour change and success with 
weight loss. Stotland and Larocque (2005) who examined early treatment 
response as a predictor of ongoing weight loss in obesity treatment found that 
early improvements in eating behaviour and weight have an additive effect in 
predicting ongoing weight change. Therefore behaviour change appears to be a 
prerequisite of weight loss. One study (Sjôstrôm et al., 1998) that examined 
weight loss and maintenance after the use of orlistat found that those who were 
on orlistat for 1 year then continued to the end of year 2 on a placebo regained 
twice as much as those who continued on orlistat. This suggests there is a 
likelihood that participants will regain weight lost after cessation of orlistat. This 
will be explored in the current study over the 18 month follow up. This process of 
change needs to be explored in terms of beliefs and behaviour change.
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A study that reviewed weight loss literature, to highlight potential factors 
of importance in weight maintenance (Elfhag & Rossner, 2005), found that 
successful weight maintenance was associated with more initial weight loss, 
reaching a self-determined goal weight, being physically active, eating regular 
meals including breakfast and healthy eating, control of over-eating and self­
monitoring of behaviours. Furthermore they established weight maintenance 
was associated with an internal motivation to lose weight, social support, self 
efficacy, better coping strategies and the ability to handle life stresses, 
autonomy, assuming responsibility in life and overall more psychological 
strength and stability.
Beliefs are important to address especially in terms of illness beliefs. 
Leventhal’s self-regulatory model of illness behaviour (Leventhal et al., 1984, 
1992, 1997) suggests a theoretical framework to dealing with illness through 
cognitions and behaviour change and it indicates the importance of coherence 
between illness beliefs and treatment beliefs in order for behaviour to change. 
Behaviour change is a complex process with many variables playing a part. 
Ogden and Sidhu (2006) conducted a qualitative study to explore the process of 
behaviour change whilst taking orlistat, they found this process to involve a 
combination of factors which meant orlistat helped some to lose weight and 
others saw no change. In particular the initial motivation was important, along 
with why they thought they were overweight and how the side effects were 
conceptualised. They suggested that orlistat, through the highly visual side 
effects, changed peopie's beliefs about the cause of their obesity which made 
them more likely to change their behaviour. Therefore taking orlistat and 
subsequent weight loss were the consequence of experiencing the side effects 
and the realisation that their weight problem was the result of their own 
behaviour. This reflects what Ogden and Jubb (2008) found, in that beliefs can 
be manipulated and can change. They found that after manipulation a shift in 
beliefs about cause results in a parallel shift in beliefs about solution. Therefore 
through this study whether orlistat manipulates beliefs which leads to behaviour
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change needs to be explored. Furthermore the current study will examine 
whether initial weight loss over the first 6 months of treatment with orlistat has 
an impact on later weight loss or maintenance at 18 month follow up.
6.1.2 Aims
The aim of this study is to examine the process of behaviour change over an 18 
month period from when participants first start taking orlistat. Also to examine 
this process of change through changes in beliefs, behaviour and weight. 
Specifically the aims of this study are:
1. To describe participants’ demographics at baseline, 6 month, 12
month and 18 month follow up.
2. To explore the changes over time in weight, beliefs and behaviour.
3. To examine predictors of outcomes.
6.2 Methods
6.2.1 Design
The study used a longitudinal design with questionnaires concerning 
experiences of taking orlistat, beliefs, behaviours and weight, which were 
completed at 6 month intervals over an 18 month period.
6.2.2 Sample
The sample included people who had registered on the Xenical support system 
(MAP). Participants were included in this study if they returned the 
questionnaires at baseline (time 1), 6 months (time 2), 12 months (time 3) and 
18 months (time 4).
The University Ethics committee approved the study. The data presented 
here reflects the process of change over an 18 months period.
6.2.3 Inclusion/Exclusion Criteria
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Participants were included if they initially rang up to register on the MAP 
program within a four month period, were 18 or over and were prescribed orlistat 
by their GP. Furthermore they returned all questionnaires at baseline, 6, 12 and 
18 months.
6.2.4 Procedure
MAP gained initial consent from participants to pass on their contact details to 
take part in the study. An information sheet and questionnaire were then sent 
out to participants by post with a freepost envelope for them to return it in. 
Participants who returned the first questionnaire were then sent a follow up 
questionnaire at 6 months by post, with a freepost envelope or by email with a 
link to the questionnaire online, if they provided their email address at baseline. 
Those who returned a completed questionnaire were sent a further 
questionnaire at 12 months and likewise for 18 months (n=296, 19% response 
from baseline).
6.2.5 Measures
The questionnaire was based on previous qualitative research (Ogden & Sidhu, 
2006; Ogden & Hills, 2008). The questionnaire examined people’s weight, 
motivations, beliefs about obesity, side effects, diet and exercise in the past 
month along with profile characteristics. The measures for the baseline and 
follow up questionnaires are described in full in the methods section (chapter 2).
6.2.6 Data analysis
The data will be analysed to:
1. To describe participants’ demographics at baseline, 6,12 and 18 
month follow up.
Descriptive analysis will be conducted to explore:
I. Profile characteristics
II. Weight and BMI
III. Taking orlistat at baseline
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IV. Taking orlistat at follow up
V. Methods of weight loss
Further descriptive analysis of beliefs (causes, solutions, motivations. Illness 
perceptions, side effects, implications and behaviour change) and behaviour 
(adherence, imposed control, eating behaviour, exercise, help seeking and 
obesity surgery) are in appendix 5.
2. To explore the changes over the 18 months in weight, beliefs 
and behaviour.
Repeated measures ANOVA’s will be conducted to explore the changes in: 
Weight
I. Weight change 
Beliefs
II. Beliefs about causes and solutions
III. illness perceptions
IV. Side effects, implications and behaviour change 
Behaviour
V. Adherence and imposed control
VI. Eating behaviour
VII. Exercise
VIII. Help seeking
IX. Methods of weight loss
Post hoc analysis was conducted to determine where the changes occurred. 
With the post hoc analysis the significance level was set at .05, therefore the 
difference between the two time points had to have a lower p value than .05 to 
be accepted as significant.
3. To examine short term predictors of long term outcomes.
Demographics, short term changes in beliefs (cognitions and illness
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perceptions) and behaviour (exercise, adherence and eating behaviour) will be 
explored and multiple regressions will be conducted to explore the variance they 
account for in:
I. Predicting long term changes in BMI from:
Demographics
Short term change in beliefs/behaviour 
Short term change in illness beliefs 
Short term change in eating behaviour
II. Predicting long term changes in healthy eating from:
Demographics
Short term change in beliefs/behaviour 
Short term change in illness beliefs
ill. Predicting long term changes in unhealthy eating from:
Demographics
Short term change in beliefs/behaviour 
Short term change in illness beliefs
iV. Predicting long term changes in adherence from:
Demographics
Short term change in beliefs/behaviour 
Short term change in illness beliefs 
Short term change in eating behaviour
Data transformation
For the multiple regressions age, sex and education remained as they were and 
ethnicity, job and marital status were recoded. Ethnicity was recoded into white 
(n=280) and other (n=11). Job was recoded into working (n=142) or not working 
(n=139). Marital status was recoded into living with someone (n=222) and living 
alone (n=68).
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Short term changes are baseline variables minus 6 month follow up. Long 
term changes are baseline variables minus 18 month follow up.
6.3 Results
The results were analysed to describe the demographics throughout the 18 
month period.
6.3.1 Descriptions of demographics
i. Profile characteristics
The data will be described to address who is in the sample with their profile 
characteristics: this is shown in table 6.1.
Table 6.1: Demographics
Variable 
Age (yrs) 
(n=288)
Sex
(n=289)
Ethnicity
(n=287)
Job
(n=277)
Marital Status 
(n=286)
Education
(n=285)
Height (m) 
(n=284)
Mean = 53.05 
SO = 12.58 
Range = 18-77 
Male = 71 (24.6%)
Female = 218 (75.4%)
White = 276 (96.2%)
Black Caribbean -  1 (0.3%)
Asian = 4 (1.4%)
Other = 6 (2.1%)
Full time = 86 (31%)
Part time = 57 (20.6%)
Networking = 134 (48.4%)
Married = 189 (66.1%)
Divorced = 23 (8%)
Living with Partner = 31 (10.8%)
Single = 33 (11.5%)
Widowed = 10 (3.5%)
Less than secondary = 30 (10.5%)
Secondary School Grad = 88 (30.9%)
Some College = 76 (26.7%)
College Grad = 45 (15.8%)
Graduate = 21 (7.4%)
Postgraduate = 9 (3.2%)
Doctorate or Professional Degree = 16 (5.6%) 
Mean = 1.66 
SD = 0.093
Range = 1.37-1.91___________________
222
The average age of the sample was 53 years and the majority were female, 
white, not working, married and secondary school graduates. The mean height 
of the sample was 1.66m.
Representativeness of the sample
Table 6.2: Responders compared to non-responders at baseline
Variable Responders Non-responders t /  2" P
Age X = 52.99 
S D = 12.54 
n = 288
X = 47.54 
SD = 13.05 
n = 1265
6.438 .0001 "
Sex Mafe = 71 (24.6%) 
Female = 218 (75.43%)
Male = 208 (16.4%) 
Female = 1062 (83.6%)
10.746 .001 *
Ethnicity White = 276 (96.2%)
Black Caribbean = 1 (0.3%) 
Asian = 4 (1.4%)
Other = 6 (2.1%)
White = 1217 (95.5%)
Black Caribbean = 17 (1.3%) 
Black African = 9 (0.7%) 
Asian = 17 (1.3%)
Other = 14 (1.1%)
5.815 .213
Job Full time = 86 (31%)
Part time = 57 (20.6%)
Not Working = 134 (48,4%)
Full time = 412 (33.2%)
Part time = 260 (21 %)
Not Working = 569 (45.9%)
.647 .724
Marital
Status
Married = 189 (86.1%)
Divorced = 23 (8%)
Living with Partner = 31 (10.8%) 
Single = 33 (11.5%)
Widowed = 10 (3.5%)
Married = 739 (59.6%)
Divorced = 165 (13.3%)
Living with Partner = 131 (10.6%) 
Single = 156 (12.6%)
Widowed = 49 (4%)
7.181 .127
Education < Secondary = 30 (10.5%)
Secondary School Grad = 88 (30.9%)
Some College = 76 (26.7%)
College Grad =  45 (15.8%)
Graduate = 21 (7.4%)
Postgraduate = 9 (3.2%)
Doctorate or Professional Degree = 16 (5.6%)
< Secondary = 163 (13.5%)
Secondary School Grad = 422 (34.9%)
Some College = 296 (24.5%)
College Grad = 173 (14.3%)
Graduate = 87 (7.2%)
Postgraduate = 24 (2%)
Doctorate or Professional Degree = 45 (3.7%)
6.915 .329
BMi X = 35.61 
SD =  5.72 
n = 273
x = 36.16 
SD = 6.00 
n =  1202
-1.363 .173
In terms of the representativeness of the data, there was a significant difference 
in relation to age and sex between responders and non-responders over the 18 
months.
ii. Weight and BMI
The participants' weight and BMI at all 4 time points will be described, which is 
shown in table 6.3.
Table 6.3: Weight and BMI
Time 1 Time 2 Time 3 Time 4
Weight (kg) Mean = 97.63 Mean = 93.30 Mean = 93.47 Mean = 94.94
SD = 19.01 SD = 18.56 SD = 18.72 SD = 19.35
Range = 63.5- Range = 57.15- Range = 54.90- Range = 55-173.27
177 169 160.0
BMI Mean = 35.37 Mean = 33.82 Mean = 33.88 Mean = 34.42
SD = 5.60 SD = 5.59 SD = 5.70 SD = 5.96
Range = 26.53- Range = 24.74- Range = 21.99- Range = 22.03-54.69
54.69 58.48 53.53
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The average weight of the sample at time 1 was 97.63kg, at time 2 was 93.30kg, 
at time 3 was 93.47kg and time 4 was 94.94kg. The average BMI at time 1 was 
35.37, time 2 was 33.82, time 3 was 33.88 and time 4 was 34.42.
iii. Taking orlistat at baseline
The length of time participants were taking orlistat at baseline along with 
whether it was their first time taking it is described in table 6.4.
Table 6.4: Taking orlistat at baseline
Length of time taking orlistat Mean = 9.05 SD = 10.27
(weeks) Range = 1-130
First time? Yes No
n= 258 (87.5%) n= 37 (12.5%)
If no how many times before Mean = 1.4 SD = 0.604
Range = 1-3
The average amount of time participants had been taking orlistat when they 
completed the baseline questionnaire was 9.05 weeks and for the majority it was 
their first time taking orlistat. For those who had taken it before the mean 
amount of times they had taken it before was 1.4 times.
iv. Taking orlistat at follow up
Whether participants’ were still taking orlistat and if not why not is described in 
table 6.5.
Table 6.5: Taking orlistat at follow up
Time 2 Time 3 Time 4
Still taking orlistat Yes No Yes No Yes No
n= 194 n= 102 n= 113 n= 183 n= 80 n=216
(65.5%) (34.5%) (38.2%) (61.8%) (27%) (73%)
Because doctor told Yes No Yes No Yes No
me to n= 46 n= 45 n= 87 n= 91 n= 102 n= 109
(50.5%) (49.5%) (48.9%) (51.1%) (48.3%) (51.7%).
Because wasn’t Yes No Yes No Yes No
helping n= 39 n= 52 n= 70 n= 108 n= 86 n= 124
(42.9%) (57.1%) (39.3%) (60.7%) (41%) (59%)
Because didn’t like Yes No Yes No Yes No
side effects n= 31 n= 60 n= 44 n= 134 n= 57 n= 154
(34.1%) (65.9%) (24.7%) (75.3%) (27%) (73%)
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With the follow up questionnaires at time 2 the majority were still taking orlistat 
and of those who were no longer taking it, they stopped because the doctor told 
them to, but not because it wasn’t helping and not because they didn’t like the 
side effects. At time 3 the majority were no longer taking orlistat and of those 
who had stopped taking it they reported it was not because the doctor told them 
to, not because it wasn’t helping and not because they didn’t like the side 
effects. Finally at time 4 the majority were no longer taking orlistat and of those 
who stopped they reported it was not because the doctor told them to, not 
because it wasn’t helping and not because they didn’t like the side effects.
V. Methods of weight ioss
Participants’ described the different methods they had tried to lose weight at 
baseline, 6, 12 and 18 month follow up, which are described in table 6.6.
Table 6.6; Methods of weight loss
Time 1 Time 2
Never Sometimes Very
Often
Never Sometimes Very 
Often
Diet n=66 n=142 n=52 n=49 n=143 n=66
(25.4%) (54.6%) (20%) (19%) (55.4%) (25.6%)
Exercise n=75 n=118 n=88 n=58 n=100 n=129
(26.7%) (42%) (31.3%) (20.2%) (34.8%) (44.9%)
Weighing yourself n=57 n=67 n=159 n=62 n=72 n=146
(20.1%) (23.7%) (56.2%) (22.1%) (25.7%) (52.1%)
Psychological n=265 n=3 n=2 n=267 n=7 n=2
(98.1%) (1.1%) (0.7%) (96.7%) (2.5%) (0.7%)
Time 3 Time 4
Never Sometimes Very Never Sometimes Very
Often Often
Diet n=59 n=136 n=62 n=50 n=145 n=57
(23%) (52.9%) (24.1%) (19.8%) (57.5%) (22.6%)
Exercise n=71 n=80 n=128 n=76 n=94 n=106
(25.4%) (28.7%) (45.9%) (27.5%) (34.1%) (38.4%)
Weighing yourself n=70 n=63 n=140 n=89 n=57 n=129
(25.6%) (23.1%) (51.3%) (32.4%) (20.7%) (46.9%)
Psychological n=257 n=3 n=4 n=252 n=6 n=2
(97.3%) (1.1%) (1.5%) (96.9%) (2.3%) (0.8%)
For the types of methods of weight loss the participants had tried to lose weight 
over the 18 months, the majority reported sometimes dieting at all time points. 
The majority reported sometimes exercising at time 1 and very often exercising
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at time 2, 3 and 4. The majority reported weighing themselves very often at all 
time points. Finally the majority reported using psychological methods never at 
all time points.
6.3.2 Changes over time
The data was analysed through a series of repeated measures AN OVA to 
examine weight, beliefs and behaviour changes over time and the post hoc tests 
determined where those changes are.
Weight
I. Weight change 
Participants’ weight and BMI at baseline, 6, 12 and 18 month follow up are 
shown in table 6.7.
Table 6.7: Weight change
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Weight x= 97.63 x= 93.30 x= 93.47 x= 94.94 43.425 .0001 1 >2.3.4
SD= 19.01 SD= 18.56 SD= 18.72 SD= 19.35 4 > 2.3
BMI x= 35.37 x= 33.82 x= 33.88 x= 34.42 49.271 .0001 1 >2.3.4
SD= 5.60 SD= 5.59 SD= 5.70 SD= 5.96 4 > 2.3
Weight significantly changed over the four time points. Time 1 was significantly 
greater than time 2, 3 and 4. Furthermore time 4 was significantly greater than 
time 2 and 3. BMI significantly changed over the 4 time points. Time 1 was 
significantly greater than time 2, 3 and 4. Also time 4 was significantly greater 
than time 2 and 3.
Graph to show change in BMI over the 18 months:
33 5
6 monlht 12 moothi 18 tnonthi
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NOTE: This is a graph to show changes in weight over the 18 months, but this 
change can’t not be attributed to any one method of weight loss this simply 
shows the pattern of weight loss and regain of participants over that period.
Beliefs
II. Causes and solutions
Participants’ endorsement of behavioural and medical causes and solutions to 
their weight problem and how they change over the 18 months are described in 
table 6.8.
Table 6.8: Beliefs
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Behavioural x= 3.43 x= 3.41 x= 3.26 x= 3.42 3.547 .014 3 <1,2,4
cause SD= 19.48 SD= 0.91 SD= 0.93 SD= 0.94
Medical cause x= 2.26 x= 2.27 x= 2.29 x= 2.31 .339 .797 -
SD= 0.94 SD= 0.86 SD= 0.92 SD= 0.94
Behavioural x= 4,18 x= 4.03 x= 3.95 x= 4.05 7.358 .0001 1 > 2,3,4
solution SD= 0.71 SD= 0.71 SD= 0.77 SD= 0.80 4 > 3
Medical X— 2.58 x= 2.51 x= 2.52 x= 2.55 .474 .690 -
solution SD= 0.90 SD= 0.86 SD= 0.92 SD= 1.03
The endorsement of a behavioural cause to their weight problem significantly 
changed over the four time points. Time 3 was significantly less than time 1, 2 
and 4. Endorsement of a behavioural solution significantly changed over the four 
time points. Time 1 was significantly greater than time 2, 3 and 4. Furthermore 
time 4 was significantly greater than time 3.
III. Illness beliefs
Participants’ illness beliefs at baseline, 6,12 and 18 month follow up are shown 
in table 6.9. The consequences of their weight problem significantly changed 
over time with time 4 being significantly less than time 1, 2 and 3. Timeline 
significantly changed over time, with time 1 being significantly less than 3 and 4, 
furthermore time 3 was significantly greater than 2 and 4. Personal control 
significantly changed over time, with time 4 being significantly greater than time 
1, 2 and 3, furthermore time 1 was significantly greater than time 2 and 3. 
Treatment control significantly changed overtime with time 3 being significantly
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less than time 1 and 2, also time 4 was significantly less than 1, 2 and 3. identity 
significantly changed over time with time 4 being significantly less than time 1, 2 
and 3. Concern significantly changed over time with time 1 being significantly 
greater than time 3, also time 4 was significantly less than time 1, 2 and 3. 
Understanding significantly changed over time, with time 4 being significantly 
less than time 1, 2 and 3. Emotional response significantly changed over time 
with time 1 being significantly less than time 2, also time 4 was significantly less 
than time 1, 2 and 3.
Table 6.9: Illness perceptions
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Consequences x= 7.19 x= 7.03 x= 6.93 x=6.16 20.743 .0001 4 <1.2,3
SD= 2.21 SD= 2.55 SD= 2.65 SD= 2.76
Timeline x= 6.68 x= 6.92 x= 7.50 x= 7.05 10.113 .0001 1 <3,4
SD= 2.13 SD= 2.74 SD= 2.68 SD= 2.80 3 >2 ,4
Personal control x= 5.71 x= 6.05 x= 5.83 x= 5.25 8.156 .0001 4 > 1,2,3
SD= 2.38 SD= 2.62 SD= 2.65 SD= 2.64 1 >2,3
Treatment control x= 7.88 x= 7.64 x= 6.95 x= 6.09 39.058 .0001 3 < 1,2
SD= 2.18 SD= 2.94 SD= 3.33 SD= 3.47 4 <1,2,3
Identity x= 5.80 x= 5.79 x= 5.73 x= 5.10 8.651 .0001 4 < 1,2,3
SD= 2.47 SD= 2.77 SD= 2.83 SD= 2.83
Concern x= 8.58 x= 8.36 x= 8.22 x= 7.69 17.083 .0001 1 > 3
SD= 1.79 SD= 2.24 SD= 2.43 SD= 2.47 4 <1.2,3
Understanding x= 7.56 x= 7.51 x= 7.46 x= 7.11 3.200 .023 4 < 1,2,3
SD= 2.33 SD= 2.50 SD= 2.64 SD= 2.71
Emotional x= 6.53 x= 6.84 x= 6.75 x= 6.14 8.558 .0001 1 < 2
response SD= 3.09 SD=3.15 SD= 3.13 SD= 3.21 4 < 1.2,3
IV. Side effects, cognitions and behaviour change
Participants’ described whether they experienced side effects of taking orlistat 
along with the impact of these side effects on cognitions and behaviour at 
baseline, 6, 12 and 18 month follow up, which is shown in table 6.10.
Table 6.10: Side effects, cognitions and behaviour change
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Side effects x= 2.50 x= 2.48 x= 2.27 x= 2.39 1.839 0.150 -
SD= 0.92 SD= 0.85 SD= 0.88 SD= 0.92
Behavioural x= 3.29 x= 3.68 x= 3.64 x= 3.63 3.828 0.016 1 <2,3,4
cognitions SD= 1.19 SD= 1.01 SD= 0.96 SD= 1.04
Medication cognitions x= 2.39 x= 2.48 x= 2.20 x= 2.31 1.296 0.278 -
SD= 1.18 SD= 1.08 SD= 0.86 SD= 0.94
Diet behaviour x= 4.05 x= 3.82 x= 3.75 x= 3.58 5.249 0.002 1 >2,3,4
change SD= 1.00 SD= 1.03 SD= 0.98 SD= 1.11
Adherence behaviour x= 1.15 x= 1.33 x= 1.35 x= 1.46 3.059 0.037 1 <2,3,4
change SD= 0.43 SD= 0.71 SD= 0.72 SD= 0.89
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The side effects leading participants to think about their behaviour significantly 
changed over time, with time 1 being significantly less than time 2, 3 and 4. The 
side effects leading the participants to change their diet behaviour significantly 
changed overtime, with time 1 being significantly greater than 2, 3 and 4. The 
side effects leading participants to selective adhere to orlistat significantly 
changed over time, with time 1 being significantly less than time 2, 3 and 4.
Behaviour
V. Adherence and imposed control
Participants described whether they adhered to orlistat as prescribed and 
whether taking orlistat imposed control on what they ate, which is shown in table 
6 .11 .
Table 6.11: Medication
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Adherence x= 4.53 
SD= 0.73
x= 4.35 
SD= 0.72
x= 4.16 
SD= 0.78
x= 3.96 
SD= 0.90
11.708 0.0001 1 > 2,3,4
2 >3 .4  
3 > 4
Imposed
control
x= 2.35 
SD= 1.03
x= 2.37
SD= 0.96
x= 2.47 
SD= 0.89
x= 2.29 
SD= 0.96
0.767 0.514
Adherence significantly changed overtime, with time 1 being significantly less 
than time 2, 3 and 4, also time 2 was significantly greater than time 3 and time 4, 
furthermore time 3 was significantly greater than time 4.
Vi. Eating behaviour
Participants’ eating behaviour at baseline, 6, 12 and 18 month follow up and the 
significance of changes are shown in table 6.12. The consumption of healthy 
snacks significantly changed over time, with time 1 being significantly greater 
than time 2, 3 and 4. The amount of unhealthy snacks eaten significantly 
changed over time, with time 1 being significantly less than time 2, 3 and 4, also 
time 2 was significantly less than time 3 and 4. The amount of unhealthy meals 
significantly changed over time, with time 1 being significantly less than time 2, 3 
and 4. Healthy cooking significantly changed overtime, time 1 was significantly
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greater than 2, 3 and 4. Unhealthy cooking changed overtime, with time 1 being 
significantly less than time 4. High fat food consumption changed over time, time 
1 was significantly less than time 2, 3 and 4, also time 2 was significantly less 
than time 3 and 4.
Table 6.12: Eating behaviour
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Healthy x= 3.85 x= 3.58 x= 3.63 x= 3.55 10.222 0.0001 1 >2,3.4
snack SD= 1.07 SD=1.05 SD= 1.07 SD= 1.04
Unhealthy x= 1.82 x= 2.16 x= 2.28 x= 2.34 41.926 0.0001 1 <2.3,4
snack SD= 0.73 SD= 0.88 SD= 0.91 SD= 0.92 2 <3 ,4
Healthy meal x= 5.78 x= 5.61 x= 5.70 x= 5.65 1.899 0.128 -
SD= 1.22 SD= 1.26 SD= 1.31 SD= 1.28
Unhealthy x= 1.84 x= 1.99 x= 2.01 x= 2.02 7.188 0.0001 1 <2,3.4
meal SD= 0.86 SD= 0.91 SD= 0.89 SD= 0.84
Healthy x= 3.40 x= 3.23 x= 3.21 x= 3.20 7.376 0.0001 1 > 2,3,4
cooking SD= 0.90 SD= 0.86 SD= 0.89 SD= 0.88
Unhealthy x= 2.06 x= 2.09 x= 2.12 x= 2.17 3.784 0.010 1 < 4
cooking SD= 0.54 SD= 0.56 SD= 0.54 SD= 0.52
High fat food x= 1.46 x= 1.63 x= 1.77 x= 1.84 22.201 0.0001 1 <2,3,4
SD= 0.78 SD= 0.77 SD= 0.83 SD= 0.94 2 <3 ,4
Low fat food x= 4.28 x= 4.31 x= 4.25 x= 4.24 0.448 0.713 -
SD= 1.22 SD= 1.22 SD= 1.27 SD= 1.23
Fruit and x= 4.35 x= 4.38 x= 4.28 x= 4.27 0.759 0.511 -
vegetables SD= 1.54 SD= 1.67 SD= 1.55 SD= 1.63
VII. Exercise
Participants’ described the intensity of exercise they took part in at baseline, 6, 
12 and 18 month follow up and the significance of any changes are shown in 
table 6.13.
Table 6.13: Exercise
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Exercise x= 3.14 
SD= 1.15
x= 3.14 
SD= 1.22
x= 3.26 
SD= 1.14
x= 3.07 
SD= 1.16
3.329 0.019 3 > 1,4
The amount of exercise significantly changed over time, with time 3 being 
significantly greater than time 1 and time 4.
VIII. Help seeking
Participants’ reported the frequency they saw health professionals at baseline. 
6, 12 and 18 month follow up with the significance of any changes shown In 
table 6.14. The frequency of seeing a practice nurse significantly changed over
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time; time 1 was significantly greater than time 2, 3 and 4, also time 2 was 
significantly greater than time 3 and 4, furthermore time 3 was significantly 
greater than time 4. The frequency of seeing a GP significantly changed over 
time, with time 1 being significantly greater than 2, 3 and 4, also time 2 was 
significantly greater than 3 and 4, furthermore time 3 was significantly greater 
than time 4. The frequency of seeing a hospital doctor significantly changed over 
time, with time 1 being significantly greater than time 2, 3 and 4. The frequency 
of seeing a dietician significantly changed over time, time 1 was significantly 
greater than time 2, 3 and 4, also time 2 was significantly greater than time 3 
and 4. The frequency of seeing a psychologist significantly changed over time, 
time 1 was significantly greater than time 2 and 4. The frequency of seeing a 
slimming club organiser significantly changed over time with time 1 being 
significantly greater than time 2, 3 and 4, also time 2 was significantly less than 
time 4.
Table 6.14: Help seeking
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Practice nurse x= 2.34 x= 2.09 x= 1.82 x= 1.61 28.283 0.0001 1 >2,3.4
SD= 1.32 SD= 1.42 SD= 1.31 SD= 1.15 2 > 3,4
3 > 4
GP x= 2.90 x= 2.30 x= 2.03 x= 1.78 61.531 0.0001 1 >2,3 .4
SD= 1.13 SD= 1.37 SD= 1.36 SD= 1.25 2 >3 ,4
3 > 4
Hospital x= 1.35 x= 1.12 x= 1.15 x= 1.09 14.280 0.0001 1 >2,3 ,4
doctor SD= 0.78 SD= 0.54 SD= 0.59 SD= 0.40
Dietician x= 1.82 x= 1.41 x= 1.26 x= 1.26 33.800 0.0001 1 > 2,3,4
SD= 1.13 SD= 0.96 SD= 0.76 SD= 0.80 2 >3 ,4
Counsellor x= 1.09 x= 1.09 x= 1.08 x= 1.06 0.375 0.752 -
SD= 0.40 SD= 0.48 SD= 0.47 SD= 0.40
Psychologist x= 1.06 x= 1.02 x= 1.04 x= 1.01 4.128 0.016 1 >2 ,4
SD= 0.33 SD= 0.21 SD= 0.32 SD=0.13
Slimming club x= 2.39 x= 1.36 x= 1.43 x= 1.5.5 68.873 0.0001 1 >2,3 ,4
organiser SD= 1.36 SD= 1.01 SD= 1.13 SD= 1.24 2 < 4
Contact MAP x= 2.25 x= 1.75 x= 1 x= 1.25 3.105 0.082 -
SD= 0.96 SD= 0.50 SD= 0.00 SD= 0.50
MAP positive x= 4.38 x= 4.67 x= 4.42 x= 4.17 0.288 0.833 -
SD= 1.03 SD= 0.47 SD= 0.67 SD= 0.93
IX, Methods of weight loss
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Participants’ described the methods of weight loss they had tried to lose weight 
at baseline, 6, 12 and 18 month follow up, which are shown in table 6.15 along 
with the significance of any changes that had occurred.
Table 6.15: Methods of weight loss
Time 1 Time 2 Time 3 Time 4 F P Post hoc
Diet x= 2.98 x= 3.08 x= 3.04 x= 3.04 0.967 0.408 -
SD= 0.85 SD= 0.82 SD= 0.84 SD= 0.82
Exercise x= 3.08 x= 3.43 x= 3.37 x= 3.25 8.472 0.0001 1 <2,3,4
SD= 1.03 SD= 1.16 SD= 1,19 SD= 1.19 2 > 4
Weigh x= 3.51 x= 3.43 x= 3.37 x= 3.26 2.873 0.036 4 <  1,2
yourself SD= 1.25 SD= 1.28 SD= 1.34 SD= 1.32
Psychological x= 1.32 x= 1.25 x= 1.24 x= 1.26 1.596 0.189 -
SD= 0.49 SD= 0.51 SD= 0.54 SD= 0.52
Exercise as a method of weight loss tried significantly changed over time; time 1 
was significantly less than 2, 3 and 4, also time 2 was significantly greater than 
time 4. Weighing themselves as a method of weight loss used significantly 
changed over time; time 4 was significantly less than time 1 and 2.
6.3.3 Predictors of change
The variables that account for variance in key outcomes will be explored. 
Previous chapters have explored either short term changes or long term 
changes but this chapter will explore short term changes and their impact on 
long term changes. Therefore short term changes whilst taking orlistat and the 
impact in the long term after cessation of orlistat.
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) change from baseline to 6 months 
were put into multiple regression analysis to assess whether they accounted for 
any of the variance in BMI, healthy eating, unhealthy eating and adherence 
change from baseline to 18 month follow up.
i. Predicting change in BMI
Demographics, cognitions and behaviour, illness perceptions and eating 
behaviour were analysed to examine their impact on BMI change.
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Demographics
Table 6.16: Short term change In BMI (T1 minus T2) and demographics
Variables Standardised li coefficient P
Age -.048 .520
Sex -.012 .853
Ethnicity -.021 .764
Job .005 .948
Marital Status -.020 .759
Education -.142 .049 *
Adjusted R = -.007
An increase in BMI by time 4 was predicted by less education, but this only 
accounted for 0.7% of the variance and the overall model was not significant 
(F=.723, p=.631).
Demographics
Table 6.17 Long term change in BMI (T1 minus T4) and demographics
Variables Standardised R. coefficient P
Age .114 .125
Sex .044 .515
Ethnicity -.068 .311
Job -.059 .417
Marital Status -.045 .491
Education .068 .333
Adjusted = .002
The results showed that this model accounted for 0.2% of the variance in 
demographics and change in BMI from time 1 to time 4 and none of the factors 
were significant, nor was the overall model (F=1.084, p=.372).
Short term change in beliefs and behaviour
A decrease in BMI by time 4 was predicted by less imposed control on what they 
ate due to orlistat and less thinking the side effects were just part of taking the 
drug from baseline to time 2, accounting for 12% of the variance but the overall 
model was not significant (F=1.808, p=.055).
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Table 6.18 Long term change in BMI (T1 minus T4) and short term change in beliefs/behaviour
(T1 minus T2)
Variables Standardised 13, coefficient P
Behavioural cause -.030 .815
Medical cause .022 .849
Behavioural solution .143 .250
Medical solution .135 .236
Healthy food .045 .703
Unhealthy food .216 .052
Exercise -.216 .062
Side effects .052 .678
Behavioural cognitions -.071 .556
Medication cognitions -.244 .038 *
Diet behaviour change .017 .890
Adherence behaviour change .238 .083
Imposed control .244 .036 *
Adherence .083 .536
Adjusted = .120
Short term change in Illness beliefs
Table 6.19 Long term change in BMI change (T1 minus T4) and short term change in illness 
beliefs (T1 minus T2)
Variables Standardised 13, coefficient P
Consequences -.092 .246
Timeline .106 .107
Personal control -.110 .115
Treatment Control -.074 .278
Identity .241 .001 *
Concern -.019 .804
Understanding .008 .904
Emotional Response .130 .076
Adjusted R"^  = .055
A decrease in BMI by time 4 was predicted by less identity with their weight 
problem from time 1 to time 2, accounting for 5.5% of the variance (F=2.758,
p=.006).
Short term change In eating behaviour
The results showed that this model accounted for 0.1% of the variance in 
change in eating behaviour from time 1 to time 2 and change in BMI from time 1 
to time 4 but none of the factors were significant, nor was the overall model 
(F=1.026, p=.421).
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Table 6.20 Long term change in BMI (T1 minus T4) and short term change in eating behaviour
(T1 minus T2)
Variables Standardised R coefficient P
Healthy snack -.093 .234
Unhealthy snack .079 .346
Home cooked meal -.052 .483
Unhealthy meal -.064 .404
Healthy cooking -.085 .259
Unhealthy cooking .010 .898
High fat .100 .217
Low fat .052 .500
Fruit and vegetables -.013 .866
Adjusted = .001
Summary of predictors of BMI
Some of the individual items in these models were significant, but the overall 
models were not significant. One model that was significant indicated that a 
decrease in BMI by time 4 was predicted by less identity with their weight 
problem from time 1 to time 2, accounting for 5.6% of the variance.
ii. Predicting changes in healthy eating
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise and adherence) were analysed to examine their predictive 
associations with change in healthy eating.
Demographics
Table 6.21 Short term changes in healthy eating (T1 minus T2) and demographics
Variables Standardised (2, coefficient P
Age -.247 .001 *
Sex .024 .719
Ethnicity .008 .904
Job -.017 .808
Marital Status .044 .660
Education .042 .689
Adjusted R  ^ = .038
The results show that a decrease in healthy eating by time 2 was predicted by 
lower age, accounting for 3.8% of the variance (F=2.536, p=.021).
Demographics
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Table 6.22 Long term change in healthy eating (T1 minus T4) and demographics
Variables Standardised 12. coefficient P
Age -.093 .219
Sex .068 .309
Ethnicity -.019 .775
Job -.028 .701
Marital Status .069 .482
Education .089 .380
Adjusted R -  -.005
This model accounted for 0.5% of the variance in demographics and change in 
healthy eating from time 1 to time 4 and none of the factors were significant.
Short term change in beliefs and behaviour
Table 6.23 Long term change in healthy eating (T1 minus T4) and short term change in 
beliefs/behaviour (T1 minus T2)
Variables Standardised 12, coefficient P
Behavioural cause .216 .083
Medical cause -.073 .516
Behavioural solution -.139 .248
Medical solution .145 .182
Exercise -.095 .380
Side effects -.108 .382
Behavioural cognitions -.103 .389
Medication cognitions .068 .557
Diet behaviour change .037 .743
Adherence behaviour change .094 .422
Imposed control -.032 .771
Adherence -.025 .831
Adjusted R = -.040
The results showed that this model accounted for 4% of the variance in change 
in cognitions and behaviour from time 1 to time 2 and change in healthy eating 
from time 1 to time 4 but none of the factors were significant.
Short term change in illness beliefs
The results showed that an decrease in healthy eating by time 4 was predicted 
less personal control from time 1 to time 2, accounting for 2.3% of the variance, 
but the overall model was not significant (F=1.709, p=.097).
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Table 6.24 Long term change in healthy eating (T1 minus T4) and short term change in illness
beliefs (T1 minus T2)
Variables Standardised Q> coefficient P
Consequences -.086 .286
Timeline -.061 .359
Personal control .201 .005 *
Treatment Control -.051 .458
Identity .068 .373
Concern .041 .609
Understanding .022 .749
Emotional Response -.025 .736
Adjusted R  ^= .023
Summary of predictors of healthy eating
Some of the individual items in these models were significant, but the overall 
models were not significant. One model that was significant indicated that a 
decrease in healthy eating from baseline to 18 month follow up was predicted by 
lower age, but this only accounted for 3.8% of the variance.
iii. Predicting changes in unhealthy eating
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise and adherence) were analysed to examine their impact on unhealthy 
eating.
Demographics
The results show that a decrease in unhealthy eating by time 2 was predicted by 
not living with someone, accounting for 3.4% of the variance (F=2.303, p=.036). 
Table 6.25 Short term changes in unhealthy eating (T1 minus T2) and demographics
Variables Standardised 13, coefficient P
Age .027 .719
Sex -.108 .111
Ethnicity -.018 .787
Job -.137 .060
Marital Status -.201 .046 *
Education -.105 .310
Adjusted R'^  = .034
Demographics
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Table 6.26 Long term changes in unhealthy eating (T1 minus T4) and demographics
Variables Standardised 13» coefficient P
Age .040 .608
Sex -.045 .507
Ethnicity -.157 .021 *
Job -.069 .343
Marital Status -.214 .035 *
Education -.039 .715
Adjusted = .042
The results show that a decrease in unhealthy eating by time 4 was predicted by 
them not being white and not living with someone, accounting for 4.2% of the 
variance (F=2.573, p=.020).
Short term changes in beliefs and behaviour
The modei accounted for 5.6% of the variance in change in cognitions and 
behaviour from time 1 to time 2 and change in unhealthy eating from time 1 to 
time 4 but none of the factors were significant.
Table 6.27 Long term changes in unhealthy eating (T1 minus T4) and short term changes in 
beliefs/behaviour (T1 minus T2)
Variables Standardised 13, coefficient P
Behavioural cause -.062 .618
Medical cause .001 .993
Behavioural solution -.081 .512
Medical solution -.044 .697
Exercise .020 .862
Side effects .129 .314
Behavioural cognitions -.086 .483
Medication cognitions .174 .147
Diet behaviour change .087 .459
Adherence behaviour change -.065 .605
Imposed control .028 .806
Adherence -.061 .623
Adjusted R = -.056
Short term change in illness beliefs
The results showed that a decrease in unhealthy eating by time 4 was predicted 
by less concern and greater personal control of their weight problem from time 1 
to time 2, accounting for 2.6% of the variance, but the overall model was not 
significant (F=1.753, p=.088).
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Table 6.28 Long term changes in unhealthy eating (T1 minus T4) and short term change in
illness beliefs (T1 minus T2)
Variables Standardised 13 coefficient P
Consequences -.049 .555
Timeline .073 .305
Personal control -.142 .049 *
Treatment Control .022 .973
Identity -.157 .055
Concern .173 .042 *
Understanding -.011 .873
Emotional Response .004 .964
Adjusted R'^  = .026
Summary of predictors of unhealthy eating
A decrease in unhealthy eating from baseline to 18 month follow up was 
predicted by not being white and not living with someone, but this only 
accounted for 3.4% of the variance. Furthermore a decrease in unhealthy eating 
from baseline to 6 month follow up was predicted by not being married, 
accounting for 4.2% of the variance.
iv. Predicting changes in adherence
Demographics, beliefs (cognitions and illness perceptions) and behaviour 
(exercise, adherence and eating behaviour) were analysed to examine their 
impact on change in adherence.
Demographics
Table 6.29 Short term change in adherence (T1 minus T2) and demographics
Variables Standardised 13 coefficient P
Age .182 .036 *
Sex .146 .064
Ethnicity .025 .746
Job .029 .733
Marital Status .111 .410
Education .123 .374
Adjusted R'^  = .012
The results show that a decrease in adherence by time 2 was predicted by being 
older, accounting for 1.2% of the variance, but the overall model was not 
significant (F=1.331, p=.246).
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Demographics
Table 6.30 Long term change in adherence (T1 minus T4) and demographics
Variables Standardised 13 coefficient P
Age -.035 .814
Sex -.088 .516
Ethnicity -.037 .781
Job .056 .697
Marital Status .014 .952
Education -.086 .713
Adjusted = -.074
This model accounted for 7.4% of the variance in demographics and change in 
adherence from time 1 to time 4 and none of the factors were significant.
Short term change in beliefs and behaviour
Table 6.31 Long term change in adherence (T1 minus T4) and short term change in 
beliefs/behaviour (T1 minus T2)
Variables Standardised 13 coefficient P
Behavioural cause .449 .045 *
Medical cause -.254 .229
Behavioural solution -.109 .671
Medical solution -.008 .976
Healthy food .114 .627
Unhealthy food -.021 .928
Exercise .075 .710
Side effects .210 .480
Behavioural cognitions -.281 .299
Medication cognitions -.053 .840
Diet behaviour change -.030 .885
Adherence behaviour change -.106 .614
Imposed control -.119 .634
Adjusted R^  = -.114
The results showed that an increase in adherence by time 4 was predicted by 
lower endorsement in a behavioural cause to their weight problem from time 1 to 
time 2, accounting for 11.4% of the variance, but the overall model was not 
significant (F=.709, p=.738).
Short term change in illness beliefs
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This model accounted for 2.2% of the variance in change in illness beliefs from 
time 1 to time 2 and change in adherence from time 1 to time 4 but none of the 
factors were significant.
Table 6.32 Long term change in adherence (T1 minus T4) and short term change in illness 
beliefs (T1 minus T2)
Variables Standardised 13 coefficient P
Consequences .179 .233
Timeline .055 .682
Personal control .002 .989
Treatment Control .202 .128
Identity .125 .395
Concern -.090 .573
Understanding -.145 .303
Emotional Response -.031 .828
Adjusted R = -.022
Short term change in eating behaviour
Table 6.33 Long term change in adherence (T1 minus T4) and short term change in eating 
behaviour (T1 minus T2)
Variables Standardised 13 coefficient P
Healthy snack .046 .755
Unhealthy snack .130 .427
Home cooked meal -.098 .495
Unhealthy meal .125 .365
Healthy cooking .123 .376
Unhealthy cooking -.122 .389
High fat -.083 .605
Low fat .273 .083
Fruit and vegetables -.212 .148
Adjusted R"^  = .015
The results showed that this model accounted for 1.5% of the variance in 
change in eating behaviour from time 1 to time 2 and change in adherence from 
time 1 to time 4 but none of the factors were significant.
Summarv of predictors of adherence
Some of the variables put in the regressions to assess the amount of variance 
they accounted for in adherence were significant, but none of the overall models 
were significant.
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6.4. Discussion
This discussion will begin by summarising the results of this study through 
changes that occur over the four time points and then will summarise the 
changes that occur in the short term and how these predict changes in key 
variables in the long term. These results will then be discussed in relation to 
previous literature and the implications of these findings will be considered.
1. To describe participants’ demographics at baseline, 6 month, 12 
month and 18 month follow up.
I. Profile characteristics
The average age of the sample was 53 years and the majority were female, 
white, not working, married and secondary school graduates. The mean height 
of the sample was 1,66m.
II. Weight and BMI
The average weight of the sample at time 1 was 98.98kg, at time 2 was 93.40kg, 
at time 3 was 94.09kg and time 4 was 95.15kg. The average BMI at time 1 was 
35.70, time 2 was 33.73, time 3 was 34.09 and time 4 was 34.51.
ill. Taking orlistat at baseline
The average amount of time participants had been taking orlistat when they 
completed the baseline questionnaire was 9.05 weeks and for the majority it was 
their first time taking orlistat. For those who had taken it before, the mean 
amount of times they had taken it before was once.
IV. Taking orlistat at follow up
At time 2 most were still taking orlistat and of those who were no longer taking it 
they stopped because the doctor told them to, but not because it wasn't helping 
and not because they didn’t like the side effects. At time 3 the majority were no 
longer taking orlistat and of those who had stopped taking it they reported it was
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not because the doctor told them to, not because it wasn’t helping and not 
because they didn’t like the side effects. Finally at time 4 the majority were no 
longer taking orlistat and of those who stopped they reported it was not because 
the doctor told them to, not because it wasn’t helping and not because they 
didn’t like the side effects.
V. Methods of weight loss
For the type of methods of weight loss the participants had tried to lose weight 
over the 18 months, most reported sometimes dieting at all time points. The 
majority reported sometimes exercising at time 1 and very often exercising at 
time 2, 3 and 4. The majority reported weighing themselves very often at all time 
points. Finally most reported never using psychological methods at all time 
points.
2. To explore the changes over time In weight, beliefs and behaviour.
i. Weight
Weight was significantly less at time 2, 3 and 4 compared to baseline. However 
weight at 18 months was significantly greater at time 4 compared to time 2 and
3. BMI followed the same trend with BMI significantly greater at baseline 
compared to time 2, 3 and 4 with weight at time 4 being significantly greater at 
time 2 and 3.
NOTE: It is not clear exactly when people stopped taking orlistat, as at each 
time point people were asked if they were still taking orlistat or if they stopped 
within the last month. Therefore there is a 5 month window when people may 
have stopped, which needs to be taken into account when interpreting the 
results.
ii. Beliefs
For beliefs about the causes of their weight problem there was significantly less 
of an endorsement of a behavioural cause at time 3 compared to time 1, 2 and
4. For a solution to their weight problem there was a significantly greater
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endorsement of a behavioural solution at time 1, compared to time 2, 3 and 4. 
However the. endorsement of a behavioural solution at time 4 was significantly 
greater than time 3.
For illness beliefs, people reported that their weight affected their life 
greater at time 4 compared to time 1, 2 and 3. A belief in their weight continuing 
forever was less at time 1 compared to time 3 and 4, but time 3 was greater than 
time 2 and 4. Personal control was greater at time 4 compared to time 1, 2 and 
3, with time 1 being greater than time 2 and 3. Treatment control was less at 
time 4 compared to time 1, 2 and 3, with time 3 being less than time 1 and 2. In 
terms of whether they reported experiencing symptoms from their weight this 
was less at time 4 compared to time 1, 2 and 3. Participants reported more 
concern at time 1 than time 3, but at time 4 they reported less concern than time 
1, 2 and 3. Participants reported less understanding of their weight problem at 
time 4 than other time points. Finally they reported their weight affecting them 
emotionally less at time 4 than other time points but more at time 2 than time 1.
iii. Behaviour
Participants reported the side effects made them think about their behaviour 
more at time 2, 3 and 4 than time 1. The side effects also made them change 
their diet behaviour more at time 1 than time 2, 3 and 4. With the side effects 
also making them change whether they adhered to orlistat less at time 1 than 
the other time points. Participants adhered more at time 1 than other time points, 
but also more at time 2 than time 3 and 4 and more at time 3 than time 4.
In terms of eating behaviour, participants reported consuming more 
healthy snacks at time 1 than at all other time points. The majority reported 
consuming less unhealthy snacks at baseline compared to all other time points; 
however they also reported eating less at time 2 than time 3 and 4. Most 
reported eating less unhealthy meals at baseline compared to ail other time 
points. Participants reported using more healthy cooking methods at baseline
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compared to all other time points and iess unhealthy cooking at baseline 
compared to the 18 month follow up. Participants reported eating less high fat 
food at time 1 compared to all other time points and less at time 2 compared to 
time 3 and 4.
For the amount of exercise, participants reported doing more at time 3 
than time 1 and 4. In relation to help seeking behaviour participants reported 
seeing the practice nurse and GP more at time 1 than time 2, 3 and 4, more at 
time 2 than time 3 and 4 and more at time 3 than time 4. They reported seeing 
the hospital doctor more at baseline than all other time points. Participants 
reported seeing a dietician more at baseline than all other time points and more 
at time 2 than time 3 and 4. They reported seeing a psychologist more at 
baseline than time 2 and 4. Finally they reported seeing a slimming club 
organiser more at baseline than all other time points and more at time 4 than 
time 2.
Participants were also asked about weight loss methods they had tried 
and they reported using exercise less at baseline than ali other time points and 
more at time 2 than time 4. Finally in terms of weighing themselves they 
reported they did this less at time 4 than time 1 and 2.
3. To examine predictors of outcomes.
I. Predicting changes in BMI
Short term changes in illness beliefs accounted for 5.5% of the variance in long 
term changes in BMI, with a decrease in BMI by time 4 being predicted by less 
Identity with their weight problem from time 1 to time 2.
II. Predicting changes in healthy eating
Demographics accounted for 3.8% of the variance in short term changes in 
healthy eating, with a decrease in healthy eating from baseline to 18 month 
follow up being predicted by lower age.
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III. Predicting changes in unhealthy eating
Demographics accounted for 4.2% of the variance in long term changes in 
unhealthy eating, with a decrease in unhealthy eating from baseline to 6 month 
follow up being predicted by not being married. Demographics also accounted 
for 3.4% of the variance in short term changes in unhealthy eating, with a 
decrease in unhealthy eating from baseline to 18 month follow up being 
predicted by not being white and not living with someone.
IV. Predicting changes in adherence
Some of the variables put in the regressions to assess the amount of variance 
they accounted for in adherence were significant, but none of the overall models 
were significant.
Links to literature
An initiai decrease in identity over the first 6 months of taking orlistat was 
predictive of weight loss over the 18 month period. Therefore those who had an 
initial decrease in experiencing symptoms from their weight over the first 6 
months indicated weight loss in the long term. The decrease in identifying with 
the symptoms of their weight problem was reflected in Ogden and Sidhu’s 
(2006) study where those who had a shift in identity to a new healthier self were 
successful in their weight loss.
In terms of weight loss, it appears that overall, irrespective of how long 
the participants were taking orlistat, people generally lost weight over the first 6 
months from starting to take orlistat but that this weight was gradyually regained. 
This was shown by weight at baseline was significantly higher than at all other 
time points but that weight at 18 months was significantly higher than at 6 and 
12 months. This pattern of weight loss and regain is reflected in a randomised 
placebo trial of orlistat by Sjostrom et al. (1998). Participants were initially 
assigned to receive either orlistat or placebo for 1 year alongside a hypocaloric
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diet, then in a further 52 week double-blind period patients were assigned to 
either a placebo or orlistat group with a weight maintenance diet (eucaioric). The 
results showed that in year 1 the orlistat group lost, on average, more weight 
than the placebo group. Also in year 2, patients who continued on orlistat 
regained, on average, half as much weight as those who switched to the 
placebo group. Therefore in year 2 weight regain was reduced greater by orlistat 
compared to placebo and those who ceased taking orlistat experienced a 
marked rebound effect in terms of their weight. Therefore it appears that after 
taking orlistat there is a high chance of weight regain, as found in the current 
study. However as already stated it is not clear exactly how long the participants 
were on orlistat but the patterns of those still taking orlistat and weight loss 
seems to indicate this is what is happening.
Conclusion
This study explored data collected from participants at baseline, 6, 12 and 18 
month follow up. The results show a steady decline in weight over the first 6 
months but then a gradual regain.
Understanding weight loss
The results of this study indicate the patterns of change in weight, beliefs and 
behaviour over the 18 month period. It highlights short term changes in 
identifying with their weight problem can facilitate long term weight loss and 
maintenance. Long term weight loss was predicted by a decrease in 
experiencing symptoms from their weight over the first 6 months. However the 
overall picture for weight loss in the long term is that people tend to have initial 
success when trying to lose weight but that this weight loss is not maintained 
and the weight loss is regained.
The additional impact of orlistat
Orlistat facilitates the initial weight loss and those who experience fewer 
symptoms from their weight in this time are successful in their long term weight 
loss. Therefore orlistat functions to facilitate weight loss and improve health 
status. However the pattern of weight loss and weight regain maps onto the
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amount of people taking orlistat, therefore as the numbers of those taking orlistat 
reduces the average weight increases. Therefore it appears unless people make 
changes in their lifestyle whilst on orlistat then they will not maintain the weight 
loss after treatment has ceased.
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Chapter 7
Study 5: Experiences o f those who have failed to lose w eight in the long 
term  after drug therapy: A qualitative study
7.1 Introduction
The previous longitudinal studies have shown that in terms of weight loss most 
lose weight whilst on orlistat but after cessation the weight is gradually regained. 
Those who were successful in maintaining their weight loss had initial significant 
event motivations to iose weight, decreased the amount of unhealthy food, 
increased the amount of healthy snacks and ate less fat. Orlistat functioned by 
educating some through the side effects in what they should not eat and also 
facilitated the belief that they do have control over their weight, which enabled 
them to be successful in the longer term. For some, however, orlistat did not 
function in this way and they went on to regain the weight they had lost and also 
put more weight on. Why orlistat did not have the desired effect on these 
individuals is the focus of this final empirical chapter.
7.1.1 Background
Weight loss maintenance is a complex phenomenon that is only achieved by a 
small minority. Orlistat is used as a pharmacological method of weight loss by 
reducing the amount of fat that is absorbed from food eaten. Although often 
prescribed by doctors there is marked variability in terms of people who 
successfully lose weight and those who do not. One study which examined the 
experiences of those taking orlistat was conducted by Ogden and Sidhu (2006). 
They conducted an exploratory study examining individuals’ experiences of 
taking orlistat (Ogden & Sidhu, 2006) and found that successful weight loss was 
related to participants’ model of the causes of their obesity, their motivations for 
weight loss and the side effects of taking orlistat in terms of both how they 
managed the side effects and made sense of them. The themes from these 
interviews indicate the components involved in successful weight loss.
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Research has also explored successful changes In behaviour, including 
that which results in weight loss maintenance from a broader perspective. For 
example, Ogden and Hills (2008) interviewed ‘successful’ individuals who had 
either lost weight or stopped smoking. This study highlighted some other key 
themes indicating that behaviour change is triggered by a significant life crisis 
relating to their health, relationships or salient milestones which translate into 
sustained change if the function of the unhealthy behaviour is disrupted, the 
individual perceives their choice for carrying out the unhealthy behaviour is 
reduced and they adhered to a behavioural model of their problem. The changes 
enabled the individual to reinvent themselves and thus shift their identity to a 
new healthier self. This study involved descriptions from those who have been 
successful in their behaviour change and maintained it in the long term.
To date, however, little research has directly explored the experiences of 
those who have not been successful in their weight loss attempts. This was the 
focus, of the current study. Furthermore as the people in this study will be 
discussing their failure to lose weight by reflecting on their experiences of taking 
orlistat, whether they adhered to taking it as prescribed will also be explored.
The health belief model suggests that adherence is a function of motivation and 
response selection, with motivation conceived as a product of the perception of 
vulnerability to the disease times the perception on its negative consequences.
In addition, it highlights response selection as a function of the perceived 
benefits and costs of each of the available self-protective actions (Becker, 1974; 
Rosenstock, 1974). In the case of obesity and orlistat the health belief model 
would predict that the individual who fails to see themselves as vulnerable to the 
consequences of obesity would be less motivated to adhere to their medication 
along with the healthy lifestyle regimen than someone who accepts this 
vulnerability. However, someone who is motivated may be non adherent if they 
perceive the costs and benefits of orlistat treatment as unfavourable in 
comparison to some other method even if that method is ineffective. This cost
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benefit analysis will be examined in the interviews of those who have been 
unsuccessful in their weight loss attempts with orlistat.
Adherence will be explored in terms of whether the participants took 
orlistat as prescribed but there also may be other factors involved in why the 
individual had failed in their weight loss attempt. The individuals’ weight 
management attempts will also be explored in terms of how they described 
themselves and whether there are factors that they feel interrupt their weight 
loss attempts.
As previous qualitative research has focussed on successful behaviour 
change and subsequent weight loss, unsuccessful behaviour change and weight 
regain will be examined. This will be explored through adherence to orlistat, 
along with factors that have interrupted their weight loss attempts. This will be 
examined using a qualitative design as it is an exploratory research question 
and this study intends to give a clearer picture of the perspective of the 
individual who has failed to lose or maintain weight loss after having taken 
orlistat.
7.1.2 Aims
The present study used in depth interviews as a means to access the 
experiences of people taking orlistat who fail to lose weight in the long term. 
These experiences were explored from the perspective of the individual to 
examine the mechanisms involved in failing to lose weight after the use of 
orlistat.
7.2 Methods
7.2.1 Design
This study used a qualitative methodology involving in depth interviews 
assessing experiences of taking orlistat and beliefs about the reasons why
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orlistat did not help the participants to lose weight. These interviews were 
analysed using Interpretative Phenomenological Analysis (IPA, Smith, 1996).
7.2.2 Sample
The sample included people who had registered on the Xenical support system 
(MAP) and had taken part in both the baseline and the 18 month stages of the 
longitudinal study and are described in Chapter 5 who also indicated on the 
questionnaire that they would be willing to take part in an interview about their 
experiences of taking orlistat. If participants returned questionnaires at baseline 
and 18 month follow up and gained weight then they were called to be included 
in the study. People were contacted in order of who had regained the most 
weight, starting with the highest first. Of the 13 people contacted 3 declined and 
10 took part (77% acceptance rate). The ten participants were males (n=2) and 
females (n=8) between 33 to 72 years of age (mean = 51.7 years). Majority were 
not working, married, with at least some college education (see table 1 for 
details). The University Ethics committee approved the study.
Table 7.1: Demographics
Sex Age Job Marital status Education
1 Sue F 54 NotvvorHng Single Masters degree
2 Anne F 60 Networking Married -
3 Jan F 72 Part time Widowed Doctorate or professional degree
4 Rob M 48 Full time Married Secondary school graduate
5 Michelle F 53 Not working Married College graduate
6 Lesley F 60 Not working Married Secondary school graduate
7 Rulh F 33 Notworldng Living with partner -
8 Eve F 37 Not working Single Some college
9 Sarah F 39 Fulltime Married Some college
10 Henty M 61 Not working Married Less than secondary school
7.2.3 Inclusion/Exclusion Criteria
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Participants were included if they returned the 18 month follow up questionnaire 
which had indicated that they had failed to maintain the weight they had lost 
whilst on orlistat.
7.2.4 Procedure
MAP gained initial consent from participants to pass on their contact details to 
take part in the study. An information sheet and questionnaire were then sent 
out to participants by post with a freepost envelope for them to return it in. 
Participants who returned the first questionnaire and gave consent to take part 
in an interview were contacted around 18 months after joining MAP.
The interviews were conducted over the telephone as participants came 
from all over England and lasted on average 20 minutes. They were recorded 
verbatim for transcription purposes. In total 10 interviews were conducted and 
analysed using Interpretative Phenomenological Analysis (IPA, Smith, 1996).
7.2.5 Interview schedule
Interviews were semi-structured and included the following open ended 
questions and prompts:
1) Are you still taking Xenical?
2) How did you find taking Xenical?
3) Do you think it helped you to lose weight?
4) If so, how?
5) If not, why not?
6) Do you intend to take it again in the future?
7) Do you feel you still have a weight problem?
7.2.6 Data analysis
The interviews were analysed using I PA (Interpretative Phenomenological 
Analysis), this involves transcribing the interviews then reading and re-reading
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the interviews and interpreting the data to find emerging themes and sub themes 
apparent across all interviews.
I PA ailows the participant to describe their experiences from their own 
perspective. This will therefore allow us to explore the participants’ perspective 
of why they had failed to maintain the weight they lost whilst on orlistat. I PA also 
acknowledges the role of the researcher in processing the data analytically and 
interpreting the patients’ world. This method has been employed for this data set 
as it is exploratory therefore it is data driven and this analysis allows the data to 
be examined first from a descriptive level and then for further in-depth 
interpretation. This method also allows us to examine each individual case in 
depth, which is why there is a small sample size. Therefore the data presented 
here reflects an in depth look at peoples long term experiences of taking orlistat.
7.2.7 Themes
The participants described their failure to lose weight with orlistat in terms of 
three broad areas: alternative methods, mechanisms of orlistat and barriers to 
weight loss. These areas will be described individually and their implications for 
faiiure to lose weight will be discussed. The participants’ characteristics in terms 
of sex, age, baseline weight (kg), weight at 18 month follow up (kg), their highest 
ever weight (kg), their lowest ever weight (kg), whether they are still taking 
orlistat (yes/no), whether they are currently losing weight (yes/no), whether they 
have tried alternative methods to orlistat (yes/no), whether they experienced any 
side effects, such as liquid stools, whilst taking orlistat (yes/no) and whether they 
reported any barriers to their weight loss attempts (yes/no) are presented in 
table 2.
Half of the participants interviewed were currently trying to lose weight 
and one of the participants had gone back to taking orlistat. There was a mix of 
people who had experienced the side effects whilst taking orlistat whilst others
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had not. All participants had tried alternative methods of weight loss, reported 
barriers to them losing weight and stiil had a weight problem.
Table 7.2: Summary of participants
Sex Age Baseline
weigW
16
mondes
vmiglil
Highest
K eig lt
Loweÿ
W g N
Still
îahing
ortstst
C iirm #
losing
weight
ÀHemetivo
meihocis
Side
elfects
Baitiers Still hsvo 
8 weight 
problem
1 Sii& F 54 17640 18600 196 00 • No No Yes Mo Yes Yes
2 Anm F 60 111.13 120.66 111.13 6688 No Mo Yes Yes Yes Yes
3 vfgn F 72 80.29 9208 8890 5625 No No Yes No Yes Yes
4 Rob M # 111.13 120.68 119.75 73.03 No No Yos No Yos Yos
6 Wchetle F 53 02.53 102.06 11113 6885 No Yes Yes Yes Yes Yes
6 W e y F 60 02.99 io4.?a 10314 5987 No Yes Yes Yes Yes Yes
7 R # F 33 10206 11521 10795 - No Yes Yes Yes Yes Yes
8 Evo F 37 112,26 159.21 146.06 53.98 Yes Yes Yes Yes Yos Yes
9 âarah 39 86.6 100.34 9980 78CÎÔ No No Yes Yes Yes Yes
10 HeniV h\ 61 110.00 133.00 * 88.90 Ho Yes Yes Yes Yos Yes
7.3 Results
7.3.1 Descriptive Analysis
The results were analysed to describe the participants’ demographic 
characteristics and changes over 18 months in weight. The participants had a 
mean age at baseline of 51.7 years, were majority female, married, not working 
and had a least some college furthermore all described themselves as white 
ethic group (see table 3).
Table 7.3: Demographics
Vaiiable
Age (yis) 
(n=10)
Mean = 51.7 SD = 12.40 Range =  33-72
Sex
(n=10j
Male = 2 (20%) Female =  8 (B0%)
Elhnicily
(n=10)
While =  10(100%)
Job Full lime = 2 (20%) Part lime = 1 (10%)
(n=10) Not Woikinj = 7 (70%)
Marital Status Married =  6 (B0%) Living with Partner= 1 (10%)
(n=10) Single =  2 (20%) VWdov/ed =  1 (10%)
Education Less than secondary = 1 (12.5%) Secondary School Grad = 3 (25%)
(n=B) Some College = 2  (25%) Coliego Grad= 1 (12.5%)
Postgraduate =  1 (12.5%) Doctorate/Professional Degree =  1 (12.5%)
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At baseline the mean weight was 108.4kg and this rose to 123.4kg by 18 
months. In line with this, BMI at baseline was 40, which puts participants in 
obese class II which rose to 45.6 at 18 months, putting them in obese class III. 
At baseline and 18 month follow up none of the participants had had obesity 
surgery, at baseline none would consider having it in the future but by 18 
months follow up some said they would consider it (n=3) but the majority still felt 
they would not. See table 7.4 for details.
Table 7.4: Weight change
Baseline 18 months
Weight (kg) Mean = 108.4 
SD = 27.0 
Range = 80 .29-176.4
Mean = 123.4 
SD = 29.2 
Range = 92,1 -18 6 .0
BMI Mean = 40.0 
(Obese Class II) 
SD = 7.3 
Range = 30 .2 -5 5 .7
Mean = 45.6 
(Obese Class III) 
SD = 8.7 
Range = 34 .7 -59 .9
Had obesity 
surgeiy
n = 10 
No = 10(100%)
n = 10 
No = 10(100%)
Obesity 
surgery In 
the future
n = 9 
No = 9 (100%)
n = 10 
Yes = 3 (30%) 
No = 7 (70%)
7.3.2 Themes
The main theme emerging from the data related to the participants’ failure to 
lose weight and how this reflected how orlistat works which did not suit the 
participants needs. The individuals also described barriers to their weight loss 
attempts with orlistat and other methods that restricted their success. There was 
also some discussion of alternative methods to orlistat that had been successful 
and also failed in the past and present. These three themes were the main 
topics of discussion amongst the participants in the interviews, but there were 
also some overarching concepts that covered all three main themes relating to a 
self-fulfilling prophesy and self identity (see table 5 for an illustration of the 
model). A self-fulfilling prophesy related to the individuals mind set when 
beginning their weight loss attempts as they expected to fail and then in line
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with this showed weight regain. Self-identity covered all three main themes and 
related to the individuals identifying themselves as a dieter or someone who 
tries and fails to lose weight. These themes will now be described and illustrated 
with exemplar quotes.
Table 7.5: Model of failure to lose weight with orlistat
Self-identity
Barriers Alternative
methods
Mechanisms 
of orlistat
Seif-fulfilling
prophesy
7.3.3 Mechanisms of orlistat
Throughout the interviews participants had described their failure to lose weight 
in terms of the mechanisms of orlistat. They discussed the mechanisms of 
orlistat in terms of how it hadn’t worked for them due to the function of orlistat 
through reducing the absorption of fat along with the impact of the side effects 
and selective adherence.
Some described how orlistat did not work for them because of the 
function of orlistat, for example Rob, who did not experience the side effects of 
orlistat described:
“well, if I’m .. if I’m honest, we don’t consume a lot of fat in our diet 
anyway, if you see what 1 mean ... and I think Xenical really only works if you’re 
consuming a lot of fat
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This illustrates that for Rob orlistat did not work for him due to the function of the 
drug. He described how he did not have much fat in his diet therefore the role of 
orlistat in reducing the amount of fat absorbed was not suitable for him. The 
mechanisms of orlistat, in terms of it stopping the absorption of fat, is why some 
felt orlistat was not suitable for them and this was their rational for why orlistat 
did not help them to lose weight.
Others described experiencing side effects but did not associate them 
with their diet and felt that orlistat did not help them to lose weight as they felt 
they had a diet low in fat. For example, Ruth, who had experienced the side 
effects associated with taking orlistat and consuming high fat foods, described; 
“no, it (orlistat) didn’t (w ork).... my diet was pretty good, so I don’t know 
what it was .... I think because I don’t have much fat in my diet. I probably 
eat a lot, well obviously I do eat a lot of food .... but actually fats I don’t 
eat. But when I started on the Xenical I had started obviously my healthier 
eating plan so I wasn’t eating fats and .... stuff like that so it couldn’t get 
rid of fats that I wasn’t having".
They describe how the mechanisms of orlistat are the reasons why they fail to 
lose weight. They had not attributed the side effects to their eating behaviour 
and rather had rationalised it as just being part of the drug. However others were 
more aware of the role of orlistat and had acknowledged its role in assisting 
them with losing weight. For example Jan, who did not experience the side 
effects, reported:
“although I was on a low fat diet, it was sort of taking out even more fat 
.... combined with the exercise I think it did uhh .. pretty well” .
The main role of orlistat in blocking the absorption of fat, was recognised by 
some and they understood that this was helping to reduce the absorption of fat 
in their diet even though they may have a healthy diet and were not 
experiencing the side effects. This example indicates that some endorsed
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orlistat as a weight loss method and understood how it works and that it can 
work for them.
Participants described the side effects they experienced whilst on orlistat 
in their accounts, but it was the context of them experiencing the side effects 
that illustrated mechanisms as to why they would fail in their weight loss 
attempts. For example Ruth, described;
“sometimes you have to be a little bit careful if you break wind".
This illustrated that they were aware of the side effects of the drug when fatty 
food is consumed but that they are careful about not breaking wind rather than 
not eating fat which causes the side effects. Another example of describing the 
side effects as a consequence of taking the drug rather than a consequence of 
eating fatty food is Sarah who described;
“don’t break wind just in case you got an oily stool, ...waiting to surprise you”.
This description suggests it is the side effects of the drug that they are cautious 
about rather than not consuming too much fat. Others were conscious of the 
cause of the side effects and took ownership of it, for example Henry described 
“it obviously upset my bowel movements .... I don’t keep to a strict diet".
There is an acknowledgement that the side effects are self inflicted due to their 
diet.
Others however maintained that the side effects were just part of the drug but it 
was something they could put up with. For example Michelle described;
“it did make me run several times, but umm .. nothing too major . . so l  
decided to continue with it".
The side effects of consuming too much fat whilst on orlistat were seen as just 
part of taking the drug and losing weight. However the benefits of losing weight
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outweighed the cost of the side effects. For others this consequence of taking 
the drug was not acceptable and therefore they decided to stop taking it. As Eve 
described:
“it wasn’t particularly long (that I was taking orlistat), I gave up because of 
the side effects’’.
The reason for them stopping to take orlistat was the side effects, they were only 
taking orlistat for a short period of time and had not tried to change their 
behaviour, instead they just stopped taking it. Others reported stopping to take 
orlistat because the drug did not agree with them, for example Lesley described: 
“at the end umm .. you know, of me taking it, it just wasn’t agreeing with 
me, I had a sore stomach. Not so much, ok yes, I did have a couple of 
diarrhoea problems but I had, you know, grumbling pains all the time in 
your stomach”.
This shows that some believed that the drug just did not agree with them. 
Therefore the side effects of orlistat were attributed to the drug itself rather than 
their own behaviour, with the solution to this being to stop taking orlistat rather 
than stop eating the food that triggered the side effects. Some described the 
side effects as a source of fear, for example Sarah, who was not currently trying 
to lose weight, described:
“only once I got it wrong with the fat count and I had a bit of diarrhoea .... 
but that was enough to leave me paranoid, I was feeling, sort of you 
know, don’t break wind just in case you got an oily stool, ...waiting to 
surprise you .... so that’s the main reason I came o ff.
Some acknowledged the reason behind experiencing the side effects was their 
own behaviour. They described how they were aware that the side effects were 
caused by eating too much fat but the consequences of that were not 
acceptable. The fear of eating something they should not was constantly on their 
mind and they felt it would happen inevitably therefore they came off orlistat so
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as not to experience the consequences. There is an element of self-fulfilling 
prophesy in that they are expecting to eat the wrong food at some point and 
therefore rather than experience the consequences of that whilst on orlistat they 
just stopped taking the drug. Another aspect of the side effects not being an 
acceptable part of taking the drug is in terms of the side effects being due to 
orlistat letting them down, for example Michelle, who was currently trying other 
methods of weight loss, described:
“because I was always slightly concerned that umm .. it was going to 
make me run to the loo .... at any given time you know, it did worry me to 
continuing to take it, you know, cause you always had that fear in the 
back of your mind it was going to let you down".
This indicates the side effects were causing fear but there was no 
acknowledgement of taking responsibility for the side effects through their diet. 
Rather they described the side effects as part of the drug and that they occurred 
when the drug “let you down".
Others described the side effects functioning by making them more aware 
of what they were eating. The role of the side effects was as an education; 
therefore they used the side effects as an indicator that they had eaten 
something they should not. There was an awareness of becoming conscious of 
the fat in their diet that they controlled the fat in order to control the side effects. 
For example Rob described:
“so, you know, it has brought fat into the forefront of my mind ... taking 
Xenical obviously made me very aware of what food had fat in it and what 
food didn’t have fat in i t .... and also encouraged me to remove the fat off 
meat”.
Orlistat was encouraging them to address their eating behaviour and to make 
good food choices such as “to remove the fat off meat". Others also described
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orlistat as an education and that the fear of the side effects imposed control on
their diet. For example Sarah described:
“it kept you on the straight and narrow, you knew if you ate something
too fatty .... that you’d pay for it”.
The awareness that the side effects were a consequence of eating fatty foods 
meant that they adjusted their diet to ensure they would not experience the 
unpleasant consequences. This is in contrast to the previous descriptions which 
indicated some felt the side effects were part of the drug and did not take 
ownership of the cause of the problem. Others managed the side effects in 
another way and that was by selectively adhering to orlistat therefore they did 
not take orlistat when they were about to eat a fatty meal. Therefore some 
selectively adhered to orlistat in order to manage the side effects, for example 
Sarah described:
“if you wanted to cheat, and have something more fatty than you should 
have had, you just don’t take the tablet”.
The selective adherence was a result of them being aware of the consequences 
of consuming too much fat whilst taking orlistat, they made the choice to not 
take the drug rather than not eat the fatty food. They weighed up the cost and 
benefit of not eating the fatty food or not taking the drug and eating the fatty food 
wins out as a short term benefit but the long term cost is that they will not lose 
the weight. The focus is on the short term reward of eating the fatty food they 
enjoy rather than focussing on the long term reward of losing weight, which is 
why they are taking orlistat in the first place. There is a general lack of taking 
responsibility for their weight and this is shown by them attributing the side 
effects to being just part of the drug. There is a feeling that the drug should fit in 
with their lifestyle; for example Eve, who was currently back taking orlistat to 
help her to lose weight described:
“I always try and eat a low fat meal but if for any reason something’s gone 
wrong I don’t take it. You know occasionally you might like a take away.
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you know, with your friends I don’t take it then, if I know that what 1 have
eaten is a bit over, a bit over in the fat department”.
For some they would rather not take orlistat occasionally in order for them to be 
able to eat what they want. This is another example of selective adherence 
where they manage the side effects rather than changing her diet. This suggests 
the inevitable failure to lose weight using orlistat again. Selective adherence 
may mean in the short term they can eat the food they want without the side 
effects and also lose some weight, but if they do not change their diet whilst on 
orlistat then they won’t have suitable eating habits afterwards to continue and 
maintain the weight loss in the long term. Orlistat is only a short term solution, 
most people only take it for 6 months, therefore in order to reap the benefits 
after cessation of orlistat they need to change their eating behaviour whilst on it 
rather than selectively adhere in order to manage the side effects.
This theme shows that the mechanisms of orlistat vary for different 
people which relates to how some experience side effects whilst others do not. 
When someone experiences these side effects they either use these side effects 
as a tool to educate them into what foods they should not be consuming whilst 
others fear the side effects and do not take orlistat at all or selectively adhere to 
ensure they do not experience the side effects. This relates to Ogden and 
SIdhu’s (2006) study which found that peoples model of obesity vary which 
maps onto how they conceptualise the side effects of orlistat when too much fat 
is eaten. Ogden and Sidhu identify that people either have a behavioural model 
which means they believe their weight problem is due to their behaviour 
therefore the side effects are the results of them eating food with too much fat in. 
The other model is the medical model which suggests that the individual 
believes their obesity is due to medical reasons; therefore they identify the side 
effects they experience as just a consequence of taking the drug.
7.3.4 Barriers
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In terms of reasons why the participants had failed to lose weight, all described 
barriers to changing their behaviour to enable them to change their lifestyle and 
lose weight. Some believed their eating behaviour was a barrier to them losing 
weight. For example Sue, who was not currently losing weight but had tried 
many different methods of weight loss described:
“My problem would be, that I would be having umm .. masses and 
masses of homemade vegetable soup, no doubt far too much emmmm .. 
lentils and vegetables etcetera, taking brown wholemeal bread with that”.
The need to consume a large volume of food had lead to the weight problem 
and stopped them from losing weight. Some identified themselves as having a 
good diet and eating healthily but that they just eat too much. It is the quantity of 
food that they consume that is the barrier to her losing weight. In a similar vein, 
Anne, who was also not currently losing weight but had tried many other 
methods, described:
“I go to gym, but I still have food. I’m still eating you see .... so I’m no 
better for going to the gym really, to be honest, cause I’m still eating .... 
I’m eating the wrong food ... if you know what I mean”.
Eating behaviour was again the reason for the lack of weight loss, even though 
some were physically active. They described going to the gym which is a good 
tool for losing weight but the wrong foods were also being eaten which 
counteracted the benefits of going to the gym. In this case the food being eaten 
was the barrier to losing weight, however for others it was when they were 
eating that was the problem. This is related to what they are eating and when, 
therefore their eating pattern, for example Sarah described:
“I don’t eat all day and then I’ll have a big meal because I’m so hungry I 
just eat all wrong”.
The lack of a regular eating pattern was the reason behind why some were 
struggling to lose weight. Some describe an eating pattern of feast and famine.
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where they “don’t eat all day” and the hunger they experience means they 
overindulge in the evening, which is inhibiting the weight loss. Not having a 
regular eating pattern means when the food choice is being made they are 
hungry therefore do not think about what they are eating and make bad food 
choices.
Others describe health problems as the reason behind their failed weight 
loss attempts. These include health problems that are stopping them from doing 
exercise and as reasons for failed weight loss attempts. For example Sue 
described a short term illness that meant she regained the weight she had lost:
“I was severely depressed with the flu and run down for about 3 months 
and .. in that 3 months I wasn’t going swimming ...and the weight that I 
had come off went back on again unfortunately ”.
The illness that Sue had experienced meant she wasn’t being as active 
therefore she put the weight on. Lack of exercise rather than their eating 
behaviour is what they attribute their weight regain to. Others described longer 
term illnesses that they felt prevented them from losing weight, for example 
Anne described:
"well. I’m always fighting it, but uhh .. I’ve also got an underactive thyroid, 
and uhh .. I have had two hip operations -  my muscles are pretty weak at 
the moment so I'm not getting around so much. I’m not finding it easy to 
lose at all”.
The long term illness is what they feel is preventing them from losing weight and 
therefore they described “I’m not finding it easy to lose”. There is the identity of 
someone who was “always fighting it”, therefore it appears their weight was a 
constant battle. There is also an element of self-fulfilling prophesy as they 
described expecting to regain any weight lost at some point therefore it is no 
surprise when they do regain the weight. Others described chronic conditions 
that they felt caused them difficulty in losing weight, for example Rob described
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“1 have diabetes and of course that makes it a little bit more difficult I 
believe
They identified diabetes as the reason for not losing weight rather than taking 
ownership of their weight problem by acknowledging it may be due to their 
behaviour and therefore within their control. The solution to their weight problem 
had been attributed to a variable that is out of their control. Others described a 
similar theme to their weight problem in that their illnesses make them put on 
weight. There is the belief that it is the illness that had created their weight 
problem rather than their own behaviour, for example Henry described:
“because I suffer with depression .... I, umm .. I get down .... and the 
weight’s piled back on to me".
Their self-identity is embedded in the depression and it is the depression that led 
them to having a weight problem and regaining any weight that is lost rather 
than his eating behaviour. They had externalised the source of the weight 
problem so that it was not something within their control and was the trigger to 
putting on weight. Some described medications for their illnesses that they felt 
made them regain weight, for example Eve described:
“previous to Xenical I had lost 14 stone .... then, cause I’ve got loads of 
mental health problems, and the medicine is renowned for making you 
put on weight - and its happened again and again and again, now this 
time i t .. just feels painfully slow, and umm .. I just feel that I just need to 
shift that next bit of weight to keep me going. I do have an under active 
thyroid, and the GP said to give it time”.
They described previous success at weight loss but the current circumstances 
with the various health problems and associated medications mean they do not 
believe they will have the same success this time. They believe these health 
problems mean they will not be successful in their weight loss attempt which 
may be a self-fulfilling prophesy. This description highlights how they feel the
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process of losing weight was “painfully slow” as the medication being taken was 
making them put on weight. This is another example where the cause of the 
weight problem had been externalised, in that it is the medication that was being 
taken that was making them not lose weight. This externalisation means their 
weight is out of their control, rather than acknowledge their eating behaviour can 
have an impact and that it is something in their control.
There was also an element of collusion with the patient and doctor in 
justifying their lack of weight loss whilst on orlistat. Some describe the doctor as 
giving their patients justification for not losing weight and continuing to prescribe 
orlistat even though they have not lost weight whilst on it nor address the issue 
of why they have not lost weight, for example Michelle described:
“the first couple of times I did (lose weight) .. and then I seemed to be 
staying pretty static and the doctor said to me. you know well umm .. you 
are supposed to have lost some weight but umm .. but this week I’m 
weighing you and you’ve got your shoes on and last time I weighed you - 
you didn’t have your shoes on .. so umm .... and was giving me the 
benefit of the doubt”.
The lack of weight loss was made acceptable by the doctor colluding with the 
patient, this may be in an attempt to support the patient but it is also putting 
them under the false illusion that they are on track and doing what they should
be rather than addressing areas they can improve in order to help them to lose
(weight. This just reinforced the belief that it was the drug that was not working 
rather than it being down to the patients’ behaviour. Others described how their 
doctor did not even address the issue that they were not losing weight and 
simply gave them another prescription of orlistat, for example Michelle 
described:
“well yes, I think that every time I went, the first couple of times I had lost 
a few pounds and she (the doctor) was quite oh “that’s good" you know, 
"you are doing really doing a good program, whatever you are doing its
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working” and then after that when I was just the same each time it was 
“oh well, that’s disappointing try again for next time” and it just wasn’t 
happening for me”.
The doctor was not addressing the patients failure to lose weight therefore the 
doctor was colluding with the patient by being dismissive and not addressing the 
underlying issue of why they are not losing weight. It appears the doctor is giving 
the patient another prescription and feel they are helping the patient or just 
doing something to end the consultation, rather than discuss with the patient the 
reasons why they are not losing the weight and what areas the patient needs to 
alter in order to be successful in their weight loss. There was an element of 
conflicting feedback from health professionals, therefore the doctor was 
colluding with the patient and continuing to give them a prescription whereas the 
nurse who weighs the patient was explaining they should not continue to be on 
orlistat if they are not losing weight. For example Anne described;
“the nurse weighed me, and cause I had put 2 lbs on she took me off 
them .... she said it was too expensive for me to put weight back on ... 
you know ... so anyway -  well I went back to the doctor and she put me 
back on them -  but it just didn’t work, I just put all my weight back on”.
The nurse had identified the problem that orlistat alone is not helping the patient 
to lose weight; thus there must be other factors that need to be addressed. But 
when the patient goes back to the doctor they just put them back on orlistat in 
the hope that it will work then next time, but as Anne described “it just didn’t 
work”. The nurse identified that orlistat was not working for this patient as they 
were not changing their eating behaviour and losing weight but the doctor 
overlooked this and gave the patient the prescription again rather than address 
what the key issue was. Others described their partner as the reason behind 
their failure to losing weight, for example Anne explained one of her reasons for 
regaining the weight she had lost was:
“since I’ve been with my husband I’ve just piled it on -  I think its content”.
268
The barrier described by Anne to losing weight was her partner, it may not have 
been he was stopping her losing the weight but she felt weight loss was no 
longer a priority as being happy with her husband was now the focus. This 
description shows that their energy was focussed on being happy with their 
husband which meant not being aware of eating habits to enable them to lose 
weight.
For successful behaviour change to occur any barriers that arise must be 
overcome in order to maintain the change in behaviour. As in Prochaska and 
DiClemente’s (1982) stages of change model perceived barriers can stop 
someone from moving from the preparation to the action phase and also from 
the action to the maintenance stage. People need to develop coping strategies 
to overcome these barriers and to carry out and maintain the new healthier 
behaviour. They also need to see the benefits of changing their behaviour as 
higher than the costs of not carrying out their old behaviour. In terms of the 
people interviewed for this study they highlighted many barriers to their weight 
loss attempts that they have not overcome. Some described their eating 
behaviour as a barrier to losing weight which as shown in the previous area they 
sometimes change whilst on a ‘diet’ but this is only a short term change and is 
not maintained. They expect themselves to go back to their old eating habits at 
some point and through a self-fulfilling prophesy their prediction comes true. It 
seems the cost of changing their eating habits is too high in the long term 
therefore they resort back to their desired eating habits. Others describe health 
as a barrier to both exercise and dietary behaviour change, they have not 
developed coping strategies to overcome these health issues to help them 
change their eating behaviour or to carry out more exercise in order to lose 
weight. Finally some describe an element of collusion with others as a barrier to 
change. This is a major barrier to success because if the doctors and family 
members are reinforcing the belief that the diet won’t work or that it is the drug
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that is not working rather than them changing their eating behaviour then this is 
a major barrier for the individual to change their behaviour and lose weight.
7.3.5 Alternative Methods
Participants described the many alternative methods of weight loss that they had 
tried in the past and failed along with methods they were using at present and 
potential future methods. In terms of past attempts many described numerous 
failed attempts; such as “I done mostly all the diets” (Ruth) and “I mean I’ve tried 
all sorts” (Henry).
Some described success they had in the past with alternative methods. 
For example Lesley described
"I’ve done Weight Watchers in the p a s t.... well I do lose weight with them 
... if I can stick to it, I can find the willpower to stick to it, why I put weight 
on again is sheer umm .. just let yourself go and a lot of it is umm .. from 
my own point of view is umm ..a  lot of it can be a comfort eat thing”.
They described how they have some success with the method but appear to 
give up at a certain point. They expect to put the weight back on at some point 
and feel the diet is just a short term measure, therefore it is a self-fulfilling 
prophesy. They also identified themselves as a dieter, as in dieting is just part of 
who they are and when they “just let yourself go” they begin to assess what diet 
to try next.
Some also described alternative methods in terms of the methods they 
were employing at present, these included traditional methods of weight loss. 
The methods they were currently trying seemed to be successful at the moment, 
for example Michelle, who was currently trying to lose weight, described:
“I’m currently on the Weight Watchers Plan .... and umm that appears to 
be working for me .... it has given me a whole new outlook to food ....
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with their point system. I think this Weight Watchers Plan at the moment 
is keeping me more structured".
The current method of weight loss they were using was a method that was 
working “at the moment" but the individual was not convinced of its long term 
success. They were expecting to fail at some point which related to the self- 
fulfilling prophesy that if they expect to fail then this is the inevitable outcome. 
Others also described alternative methods that were being currently used with 
some success, for example Lesley, who was successfully losing weight at the 
time, described:
“I go to Slimming World now, and being a Scot, you know, if you pay for it 
you gotta do it, you know (laughs) .... its psychological, and I have lost 
weight with them. I’ve lost about 2 34 stone”.
The cost of the current weight loss method meant they felt more invested in it 
and meant it was enabling them to be successful. They described themselves as 
someone who was sticking to this method because of the financial commitment 
and the weight loss was a bonus. However this may lead to another failed 
attempt when the prepaid classes run out and the financial investment has 
ended. Another interviewee who was trying an alternative method which was 
successful at the time was Ruth, who described:
“I’ve gone back onto Slimming World now .... I’ve lost 2 stone so fa r .... 
not too bad this time, it’s working anyway, so that’s something!”
For some, returning to a weight loss method tried in the past was leading them 
to be successful this time round and they described it was “not too bad this 
time”. There is a negative tone to this in that it appears to be successful at the 
moment but there was not the shift in identity that they are in control of their 
weight. Describing “it’s working” indicated they feel it was the current weight loss 
method that was making them lose weight rather than changing their behaviour. 
Others described returning to trying orlistat again in an attempt to lose weight.
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for example Eve described how it was “my third attempt at taking it (orlistat)” 
therefore she was attempting to lose weight with orlistat but did not appear to be 
committed fully to the attempt. It seems she has a short term view on weight 
loss in that it works for a while then she gives up, but comes back to orlistat at a 
later date. It is implied that it works for her as she comes back to it several 
times, but the weight loss achieved whilst on orlistat is not maintained and there 
is regain which leads her to go back to orlistat again.
Some described alternative methods they may try in the future, therefore 
they are expecting their weight problem to continue and will need to use another 
method. For example Sue, who had tried alternative methods in the past but 
was not currently losing weight, described
“I had actually looked at having bariatric surgery”.
They are thinking of another weight loss method to address their weight problem 
because what they feel they are doing at present would eventually fail. They 
described believing they are someone who will always struggle to lose weight 
therefore they are thinking of a more drastic weight loss method. Another 
example of the individual already thinking ahead to an alternative weight loss 
method they may try in the future is Eve, who was currently back taking orlistat 
to try to help her to lose weight, who also described
“having surgery is now an option”.
It appears they are preparing to fail to lose weight with orlistat and so are 
contemplating alternative methods for when this outcome becomes apparent. 
This reflects a self-fulfilling prophesy of expecting to fail with their current weight 
loss attempt and this belief is confirmed when they do fail to lose weight at some 
point.
Participants who had failed to lose weight on orlistat described their 
experiences of their recent failure to lose weight within the context of other past
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and present similarly failed attempts. However they had also failed with orlistat 
and were still currently trying alternative methods along with thinking about 
future attempts. It seems that the participants expect to fail and therefore it is a 
self-fulfilling prophecy. Their identity seems to be embedded in the concept that 
they are always dieting and that is just part of who they are, as described above.
In the study by Ogden and Hills (2008) those who successfully maintained the 
behaviour change in quitting smoking and losing weight shifted their identity to a 
new healthier self. Whereas in the current study it appears that those who fail to 
maintain the new healthy lifestyle still have the identity of a yo-yo dieter where i
I
they are continually “dieting” rather than a shift in identity to a permanent state of 
living a healthy lifestyle. They are describing current success with alternative 
methods but there is also the undertone that this is working “at the moment”, it 
appears they conceptualise it as a short term solution but that inevitably they will 
cease to lose weight and will begin to regain the weight. There is the element of 
self-fulfilling prophesy in that they expect to fail and this is embedded in their 
identity as a dieter and that is part of who they are.
7.4 Discussion and conclusion
The main themes emerging from the data related to mechanisms of orlistat, 
barriers to weight loss and alternative methods. Participants were describing 
alternative methods of weight loss that they had tried in the past and present 
and succeeded and failed in but they were only conceptualised as short term 
measures, they were only working “at the moment” and some were already 
thinking of future methods they may use to try to lose weight when the inevitable 
happened and they put back on the weight they had lost. They had the identity 
of someone who diets, that was who they were and there was the inevitability of 
them regaining the weight which was a self-fulfilling prophesy.
The interviewees discussed the mechanisms of orlistat as the reason for 
their failure. Whether it was that they didn’t eat any fat so that was why it didn’t 
work for them or part of taking the drug was experiencing side effects therefore
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they either selectively adhered or stopped taking it. They had identified 
themselves as a healthy eater therefore orlistat wasn’t going to work for them as 
it only worked on the fat in their diet, therefore they thought it wasn’t going to 
work for them anyway which was a self-fulfilling prophesy. However some did 
acknowledge that the side effects were a consequence of them eating too much 
fat and for these people orlistat was an education. Although they were now 
aware of the fat in their diet some people still chose to eat the fatty foods as they 
saw the short term reward of eating something they enjoyed rather than the long 
term cost of them putting on weight.
Finally there was the theme of barriers to their weight loss. Many 
described numerous barriers to their weight loss. In terms of their eating 
behaviour these barriers included eating too much healthy food and not eating 
all day then having a large meal at night. They also described health problems 
as barriers to their weight problem, it was these health problems such as 
depression, diabetes and under active thyroid that were inhibiting them to lose 
weight rather than anything in their control such as their eating behaviour. There 
was also an element of collusion with others such as doctor or partner that was 
a barrier to them losing weight. The doctor was justifying their lack of weight loss 
and allowing their patient to not take responsibility for the problem and their 
partners were making them feel their weight was not an issue that was a 
problem therefore they became happy that they were not losing weight.
7.4.1 Overarching themes
The main areas that emerged in the interviews of participants who had failed to 
lose weight since taking orlistat were described in terms of alternative methods 
of weight loss, mechanisms of orlistat and barriers to weight loss. In terms of 
these three broad areas there were also two overarching themes that arose in 
all areas relating to self-fulfilling prophesy and self identity.
7.4.2 Self-fulfilling prophesy
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Self-fulfilling prophesy is the concept that a belief or expectation can influence 
the way a person behaves. In terms of the present study the results indicated 
that many participants started each new weight loss attempt with the expectation 
that it would fail which in itself influenced the outcome. In terms of alternative 
methods the concept of self-fulfilling prophesy appeared in many of the 
interviews in terms of; they had tried and failed in the past therefore they 
expected to not lose weight on the current method and were already thinking of 
other methods to try. For example Sarah, who was not currently on orlistat nor 
currently trying to lose weight described
“so sort of I drop a couple of stone off and then it goes back on and I stop 
at that then".
Also Eve, who was currently taking orlistat was also thinking of other methods to 
try to lose weight, as she described
"actually having surgery is now an option”.
In terms of orlistat it seems the patients do not have high hopes for the efficacy 
of the drug to begin with which falls into a self-fulfilling prophesy. They seem to 
feel this method won't work for them before they have even started taking it. For 
example Michelle, who was currently trying to lose weight through other 
methods described:
“it just didn’t do it for me, and I know it, you know, the doctor said that it 
was doing it for other people and that’s good but umm .. it just didn’t work 
for me at that time”.
Along a similar vein Lesley, who was also currently trying to lose weight through 
alternative methods described
“I suppose it’s like every other drug you take, some things agree with 
people and some things don’t and that particular one just didn’t agree 
with me”.
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Self fulfilling prophesy also arose in terms of barriers to weight loss. It appears 
that their weight is something they are at war with and constantly battling. For 
example Jan, who was not currently losing weight, described 
“I’m always fighting it’’.
The interviews indicate that most of these participants who have failed to lose 
weight and maintain it after the use of orlistat have a specific mind set that 
seems to enable their failure. Their mind set of the self-fulfilling prophesy fits in 
with their concept of constantly trying different methods of weight loss that 
ultimately do not work. It seems that something significant, in terms of a 
significant life event or something that disrupts the health behaviour they are 
trying to change, needs to happen in order for a change to occur that is 
maintained in the long term. This supports Ogden and Hill’s study (2008) of 
those who had been successful in their weight loss and smoking cessation 
attempts which found that this sustained behaviour change was triggered by a 
significant life crisis. This trigger translated into sustained behaviour change if 
the function of the unhealthy behaviour was disrupted, the individual perceived 
that their choice over carrying out the unhealthy behaviour was reduced and 
they adhered to a behavioural model of their problem. This initial trigger and 
subsequent conditions enabled a process of reinvention whereby the 
participants shifted their identity to a new healthier self. Self identity was another 
key theme that arose amongst the other areas discussed.
7.4.3 Self identity
The second over-arching theme that covered all the areas described is self 
identity. Many of the participants described their attempts at alternative methods 
in terms of it being part of being the kind of person who is always on a diet. For 
example Anne who was not currently trying to lose weight but has tried many 
different methods described
“I’m not really very good at dieting or owt like that at all”.
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In a similar vein Michelle, who is currently trying to lose weight described 
“I am always trying to diet”.
It seems their identity is consumed by the concept that they are constantly trying 
diets but that they do not work therefore do not help them to lose weight and 
maintain that weight loss. In terms of the mechanisms of orlistat it seems that 
they do not identify themselves as having much fat in their diet therefore that is 
one of the reasons orlistat did not work for them. For example Rob, who was no 
longer taking orlistat and not currently losing weight described:
“well, if I'm .. if I’m honest, we don’t consume a lot of fat in our diet
anyway, if you see what I m ean and I think Xenical really only works
if you’re consuming a lot of fa t ..”
Within barriers to weight loss there was also an over arching theme of self- 
identity which was similar to that discussed in Throsby’s study (2007). They 
found one of the main discourses their participants drew on to resist the 
construction of their fatness as a moral failure was that of the fat prone body. 
This was also described by the participants in the current study, for example 
Lesley, who is currently trying to lose weight, described:
“but I think I’m prone to be overweight, I think I would be overweight 
anyway , I’m a little tubby Scot”.
In a similar thread Henry, who is also currently trying to lose weight, describes 
“she can eat biscuits and doesn’t put an ounce of weight on her I just got 
to look at one or two, and I umm .. I notice that uhh .. in a matter of a 
month I can put a stone on. I’ve always had a bit of a weight problem. I’ve 
had this weight problem for many years”.
Therefore it seems that the people in this study who have failed to maintain 
weight loss by taking orlistat, have also failed at other methods but that seems 
to be part of their identity. Diets are something that they do and something that
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they are always trying. Also the mechanisms of orlistat, in that it reduces the 
absorption of fat, does not fit with their self- identity as they do not see 
themselves as a fat person and they do not eat fatty foods therefore that is why 
orlistat does not work for them. Finally in terms of barriers to weight loss it 
seems to be they feel one of the major barriers to the weight loss is that they 
have a fat prone body, therefore they feel even if they did lose weight they would 
put it back on as that is just part of their identity with their fat prone body.
7.4.4 Summary of results
This study explored the experiences of those who had taken orlistat in an 
attempt to lose weight but in the long term follow up had failed to maintain any 
weight loss achieved. The interviews highlighted three main areas in terms of 
describing their failed weight loss attempt. Firstly they had described alternative 
methods tried in the past and present, along with potential future methods they 
may try. They also discussed the mechanisms of orlistat in terms of the impact 
of the side effects and selective adherence, along with reducing the absorption 
of fat as reasons behind their failure to lose. They also discussed the barriers to 
them losing weight, these included their eating behaviour, health problems and 
collusion with health professionals and significant others. These were the main 
themes that arose in the 10 interviews conducted however there were also two 
over arching themes that covered all three of these areas and these were self- 
fulfilling prophecy and self-identity.
In relation to previous research on successful weight loss the findings of 
this study on those who fail reflects the same concepts. In the study by Ogden 
and Hills (2008) those who successfully maintained the behaviour change in 
quitting smoking and losing weight shifted their identity to a new healthier self. In 
the current study it appears that those who fail to maintain the new healthy 
lifestyle still have the identity of a yo-yo dieter where they are continually 
“dieting” rather than a shift in identity to a permanent state of living a healthy 
lifestyle. They are describing current success with alternative methods but there
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is also the undertone that this is working “at the moment", it appears they 
conceptualise it as a short term solution but that inevitably they will cease to lose 
weight and will begin to regain the weight. There is the element of self-fulfilling 
prophesy in that they expect to fail and this is embedded in their identity as a 
dieter and that is part of who they are.
In relation to the mechanisms of orlistat previous research has explored 
those who have been successful in the weight loss and the mechanism of 
success. Ogden and SIdhu (2006) explored people’s experiences of taking 
orlistat and found that peoples model of obesity vary which maps onto how they 
conceptualise the side effects of orlistat when too much fat is eaten. They 
identify that people either have a behavioural model which means people 
believe their weight problem is due to their behaviour therefore the side effects 
are the results of them eating food with too much fat in. The other model is the 
medical model which suggests that the individual believes their obesity is due to 
medical reasons; therefore they identify the side effects they experience as just 
a consequence of taking the drug. The current study reflects the similar themes 
found in Ogden and Sidhu. This study found that the mechanisms of orlistat vary 
for different people, therefore some experience side effects whilst others do not. 
When someone experiences these side effects they either use these side effects 
as a tool to educate them into what foods they should not be consuming 
whereas others fear the side effects or believe it is just part of taking the drug, 
therefore they do not take orlistat at all or selectively adhere to ensure they do 
not experience the side effects.
The interviewees in this study identified many barriers to their 
weight loss which they use to explain their failure. Previous research suggests 
that for successful behaviour change to occur any barriers that arise must be 
overcome in order to maintain the change in behaviour. Prochaska and 
DiClemente’s (1982) stages of change model suggests perceived barriers can 
stop someone from moving from the preparation to the action phase and also
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from the action to the maintenance stage. People need to develop coping 
strategies to overcome these barriers and to carry out and maintain the new 
healthier behaviour. They also need to see the benefits of changing their 
behaviour as higher than the costs of not carrying out their old behaviour. In 
terms of the people interviewed for this study they highlighted many barriers to 
their weight loss attempts that they have not overcome. Some of the barriers 
they described included their eating behaviour, health problems and collusion 
with others. Those who fail to lose weight maintain the identity of someone who 
diets and fails, either through alternative methods not working, or the 
mechanisms of the pharmacological treatment not working or there being too 
many barriers in their way for them to overcome. These all prevent the individual 
from moving from the action to maintenance stage of behaviour change 
therefore the new eating behaviours are not maintained and they move on to an 
alternative method of weight loss.
7.4.5 Implications for research
By addressing the individuals’ experiences 18 months after starting to take 
orlistat it has given the individuals’ time to reflect on their experiences and 
behaviours and therefore give their perspective on why the treatment did not 
work for them. This gave a rich data set to explore the different themes and 
address reasons for their failure to maintain the weight loss achieved.
The design of this study has enabled insight into the experiences of a 
small number of individuals who have failed to maintain weight loss achieved 
whilst taking orlistat. The small number of participants fit in with the chosen 
methodology for analysis of the data (IPA, Smith, 1996). However it would also 
be useful to examine whether this is also the case in the rest of the large 
number of people who try orlistat as a method of weight loss but fail to either 
lose weight initially or succeed in the short term but fail to maintain this initial 
weight loss. This could be achieved by using these themes to inform a 
quantitative study, for a large scale representative data set.
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7.4.6 Implications for those considering taking orlistat for weight loss
The results of this study indicate that self-fulfilling prophesy is a key issue when 
someone is considering a new method of weight loss. The patient needs to be 
made aware of the efficacy of the drug and its benefits compared to diet alone.
In Sjostrom et al’s (1998) study, those on orlistat lost more weight on average 
compared to those taking the placebo. Furthermore the total cholesterol, low 
density lipoprotein (LDL) cholesterol, LDL/high-density lipoprotein ratio, and 
concentrations of glucose and insulin decreased more in the orlistat group 
compared to the placebo group. This is important as plasma total cholesterol 
and LDL-cholesterol concentrations fell further In those taking orlistat than would 
be expected from weight loss alone. Therefore patients should be made aware 
of this in order to give them a positive outlook on their weight loss with orlistat.
In respect of the mechanisms of orlistat patients should be made aware 
that the side effects are a result of them eating food that is too high in fat rather 
than simply a side effect of the drug. Furthermore even if they do report they 
have no fat in their diet, this is impossible and there must be some element of fat 
in their diet however low and orlistat will help reduce the absorption of what fat 
they do eat. However on the other hand if the patient reports they have no fat in 
their diet then the health professional needs to address whether orlistat is the 
right method of weight loss they should be prescribing. There are other drugs 
available or maybe it is a matter of the patient requiring a more active lifestyle 
therefore maybe the GP referral scheme for exercise would be more suitable for 
that patient.
This study also highlights the issue that health professionals need to 
address the barriers to the patients’ lifestyle changes when advising on methods 
of weight loss. If the patient is unable to employ suitable coping strategies to 
overcome these barriers themselves then the health professional will need to
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address this issue with them and try and assist the patient in devising 
appropriate coping strategies.
There is also the issue of identity that needs to be addressed in terms of 
those considering taking or prescribing orlistat for weight loss. If the patient sees 
themselves as someone who is “prone to be overweight" (Lesley) or is “always 
fighting it” (Jan), then this needs to be addressed for the patient to have a 
successful attempt at weight loss with orlistat and for that weight loss to be 
maintained in the longer term. These patients need to go through a process of 
reinvention, as in Ogden and Hills study (2008), to a new healthier self and 
health professionals need to be aware of this process and to try and facilitate it.
Self identity is a major barrier to a successful attempt at weight loss with 
orlistat because if the patient sees themselves as someone who will not lose 
weight then they will not make the appropriate lifestyle changes to enable the 
success in weight loss and subsequently maintain changes in the longer term.
7.4.7 Conclusion
This study explored individuals who had failed to lose weight after treatment with 
orlistat at 18 month follow up. They described how they had tried and failed with 
other methods of weight loss; believed orlistat did not help them to lose weight 
and described many barriers to their weight loss. Overarching themes were self- 
identity, in that having a weight problem was part of who they were and self- 
fulfilling prophesy, which meant that they expected to fail in their weight loss 
attempts that was inevitably confirmed.
Understanding weight loss
Failure to lose weight was related to maintaining the identity of someone who 
tries and fails to lose weight, not believing the efficacy of the current method of 
weight loss and not overcoming barriers to their weight loss. Self-fulfilling 
prophecy is a key element of those who fail to lose weight, they expect to fail in 
whatever method they choose and they feel any barriers cannot be overcome.
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The additional impact of orlistat
This study shows that for some orlistat alone is not enough to facilitate changes 
in beliefs and behaviour to enable weight loss. For those who conceptualise the 
side effects of orlistat as just part of taking the drug do not make the connection 
between their behaviour and their weight therefore maintain the identity of 
someone who can not lose weight. They attempted to lose weight with a method 
that they did not fully endorse, which lead to a self-fulfilling prophesy. Orlistat 
can be used to break the cycle of failed weight loss attempts but only if they 
overcome the barriers to their weight loss attempts. This study shows that 
orlistat itself works but that the individual needs to facilitate the process by 
understanding the mechanisms of orlistat, over coming barriers to their weight 
loss and break the cycle of failing at weight loss by changing their identity to 
someone who can control their weight and believes they can succeed.
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Chapter 8 
Discussion
This final discussion will first provide a brief summary of results in the context 
of the stated hypotheses and will also describe how these findings relate to 
previous literature. The overall summary of results will then be discussed and 
the implications for theory, practice and research will be outlined. This 
discussion will then present an analysis of the overall conclusions of this 
thesis.
8.1 Summary of results
The key results of the longitudinal quantitative study on people’s experiences 
of taking orlistat and those from the qualitative study of those who failed to 
lose weight will now be described.
8.1.1 Quantitative study
• Over the first 12 months after starting to take orlistat weight and BMI 
significantly decreased but by 18 months most showed weight regain, 
but their weight was still less than at the beginning.
® Those who were successful at weight loss had significant event 
motivations for weight loss, adhered to orlistat and perceived greater 
control both personally and by the treatment.
• Orlistat functioned by facilitating healthier food choices and showed 
them that their weight can be controlled.
8.1.2 Qualitative study; Experiences of those who have failed to lose 
weight in the long term after drug therapy:
This study explored participants who had failed to lose weight after treatment 
with orlistat at 18 month follow up.
• People who had failed to lose weight described that they believed orlistat 
did not help them to lose weight, described many barriers to their weight 
loss and highlighted how they had tried and failed with alternative 
methods of weight loss.
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® Overarching themes were self-identity, in that having a weight problem 
was part of who they were and self-fulfilling prophesy, which meant that 
they expected to fail in their weight loss attempts that was inevitably 
confirmed.
# This study indicates that in order to reduce weight loss failure people 
need to have a shift in identity to someone who can control their weight 
and not expect to fail. They therefore need improved self efficacy. 
Furthermore they need to invest in their weight loss and believe they will 
succeed, endorse their current method of weight loss by believing in its 
efficacy whilst trying to overcome barriers to their weight loss.
8.2 Hypotheses tested
Hypotheses were described in the introduction section, alongside stated 
research aims, which were generated from the reviewed literature. These 
hypotheses were tested in the data analysis of the longitudinal studies and 
will now be discussed.
Primary hvootheses:
1. Those that show greater weight loss, over the short and long term, 
will have more significant life event motivations along with endorsing a 
behavioural model to their obesity.
The short term follow up indicated that less routine motivations were 
associated with short term weight loss. However, more significant event 
motivations were associated with greater weight loss in the long term. 
Therefore these results support part of the hypothesis where having a 
significant event motivation for losing weight was a better indicator ,of future 
weight loss, however endorsing a behavioural model to their obesity does not 
appear to play a significant role in weight loss. Although endorsement of a 
behavioural model is more predictive of adherence, as in the short term 
follow up a decrease in adherence was predicted by less of an endorsement 
of a behavioural cause to their weight problem and in the long term follow up 
a decrease in adherence was predicted by an increase in the endorsement of 
a medical cause to their weight problem.
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2. Those that change from endorsing a medical model to their weight to a 
behavioural model will lose more weight than those who maintain their 
endorsement of a medical model.
As the constructs of medical and behavioural models are not mutually 
exclusive, the analysis of the models was explored in terms of endorsement 
of both types of model independently. In the short term follow up those who 
changed from not endorsing a behavioural model to endorsing it were more 
likely to lose weight (although the number of people falling into this category 
was small, n= 48) and those who changed from endorsing a medical solution 
to not endorsing a medical solution were less likely to lose weight. However, 
those who lost weight were also more likely to endorse a medical solution at 
both time points. This indicates that endorsing a solution, whether medical or 
behavioural, is important for success in weight loss. In the longer term follow 
up, those who endorsed a medical solution at both time points were more 
successful. It appears that endorsing a solution to their weight problem is 
important for weight loss but that this doesn’t have to be a behavioural 
solution.
3. Those that adhere to orlistat, eat healthier food and exercise more will 
lose more weight.
In the short term follow up study, the results indicated that less unhealthy 
food, specifically less high and low fat along with less unhealthy snacks were 
predictive of short term weight loss. Furthermore those who reported 
adherence at both time points were more likely to lose weight. The long term 
study suggests more adherence at follow up was predictive of weight loss, as 
well as more healthy snacks and less high fat. The results therefore support 
part of the hypothesis that adherence and healthy eating is important for 
weight loss but exercise does not appear to be a significant factor.
Secondary hvpotheses:
1. Participants will be consistent in their beliefs about causes and 
solutions to their weight problem.
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At baseline the majority of participants were consistent in their beliefs about 
the causes and solutions to their weight problem tending to focus on a 
behavioural model. However there were also a minority with inconsistent 
beliefs about the causes and solutions with them endorsing behavioural 
causes but a medical solution. Therefore this hypothesis is supported by the 
majority of participants in this study.
2. Of those who experience side effects from taking orlistat, those who 
fully adhere will also change their eating behaviour.
Over the short term when most participants were still taking orlistat, the 
majority confirmed that they changed their diet due to the side effects of the 
drug. Furthermore the majority reported that the side effects had not 
influenced their adherence to the drug. However when this was explored 
through more objective measures, of those who experienced side effects the 
majority adhered but did not change their diet, with the next majority of 
participants reporting not adhering and not changing their diet. There was no 
significant association between adherence and changing dietary behaviour. 
Therefore this hypothesis is supported through self report but not from the 
objective measures.
3. Those who endorse a more behavioural model to their weight problem 
will be more successful in losing weight than those who endorse a 
more medical model.
The analysis over the short and long term indicated that endorsement of a 
medical or behavioural model were not significant predictors of weight loss. 
However as referred to above in the context of the second primary 
hypothesis, in the short term study, those who endorsed a medical or 
behavioural solution at both time points were more likely to lose weight than 
those who did not endorse a solution at both time points. Therefore in the 
short term it appears endorsing a solution to their weight problem is important 
regardless of how it is categorised. This was also shown in the multiple 
regressions in the short term follow up, where behavioural and medical 
solutions were significant predictors of weight loss. In the long term study
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those who were consistent with their endorsements of a solution were more 
likely to lose weight and of those who did not endorse a behavioural solution 
at both time points, the majority did not lose weight. But of those who did not 
endorse a medical solution at both time points the majority did lose weight 
but the number of people that fell in this category was very small (n=5) 
therefore this result needs to be treated with caution. Thus it appears that this 
hypothesis is not supported by the results, rather it seems that endorsing a 
solution to their weight problem is important rather than the type of model of 
their weight problem that they hold.
4. Those who report more routine motivations to begin losing weight will 
be less successful in losing weight than those who report more 
significant event motivations.
This hypothesis was supported from the results of the long term follow up 
studies, which showed that greater significant event motivations to start 
taking orlistat to lose weight were a significant predictor of weight loss in the 
longer term.
5. Those who fully adhere to orlistat will lose more weight than those who 
selectively adhere.
In the multiple regressions in the short term study, adherence did not appear 
as a significant factor in weight loss. However with further analysis those who 
adhered at both time points were more likely to lose weight than those who 
did not adhere. In the longer term follow up study adherence at 18 months 
was a significant predictor of long term weight loss, therefore greater 
adherence was associated with greater weight loss in the longer term. Thus 
this final hypothesis was supported by the results of the longer term 
assessment in this longitudinal study.
8.3 Links to literature
The results from the present study showed a consistent role for motivations 
in predicting weight loss. However, in line with previous qualitative work 
(Ogden & Sidhu, 2006) dramatic life events were seen to be a more effective
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motivation for weight loss than routine factors such as low self esteem and 
lack of confidence. The small qualitative study indicated that those who were 
successful in their weight loss reported their motivations for weight loss as 
dramatic life crises. Likewise in both Ogden and Sidhu and the current 
research those who were motivated to lose weight due to routine, everyday 
consequences of being over weight such as low self esteem, were less likely 
to be successful in their weight loss attempts. This was also reflected in the 
study by Ogden and Hills (2008) who found that sustained behaviour change, 
for both smoking cessation and weight loss, was triggered by significant life 
crises. This is also reflected in the success of those taking orlistat for weight 
loss. In the current research those who decided to start taking orlistat, found 
that if their motivations were significant life events then they were more 
successful in their weight loss compared to those whose motivations were 
routine consequences of being overweight. This also finds reflection in the 
Ogden and Sidhu (2006) study who explored the experiences of those taking 
orlistat and those who were successful were those who described a 
significant life event as a motivation for losing weight. In the current study the 
significant life event was the trigger to them starting to take orlistat to address 
their weight problem. Orlistat then enabled them to take control of their 
weight problem and take responsibility for changing their dietary behaviour to 
lose weight. Through taking orlistat there was the new belief that they could 
control their weight and this control related to the initial trigger of the 
significant event motivation. Those who failed to lose weight had a routine 
motivation and were stuck in the identity of someone who failed to lose 
weight and were always dieting. Likewise in the study by Ogden and Sidhu 
(2006) the significant event triggered the individual to use orlistat to help 
them to lose weight and to take control of their weight problem and assume 
the identity of a new healthier self.
The individuals’ model of obesity was also shown to be an important 
factor for successful behaviour change and subsequent weight loss. In 
particular endorsing a solution, whether medical or behavioural, to their 
weight problem was important for weight loss. This finds reflection in
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Leventhal’s (1992) self regulatory model which suggests stages for regulation 
of illness behaviour, the first of which being interpretation and the second is 
coping. Coping with the illness incorporates what they feel the best solution is 
and if the individual feels there is a solution then they will adhere to the 
medication or change their behaviour to facilitate them getting better. In the 
case of orlistat if they endorse a solution to their weight problem then they 
are more likely to employ coping strategies of adherence and behaviour 
change as a tool to control their weight. Therefore weight loss alone is more 
successful when the individual holds a solution to their obesity and in line 
with taking orlistat, promotes adherence and behaviour change to work with 
the drug to promote weight loss.
The impact of the side effects was described by Garrow (1998) when 
orlistat was first licensed for prescription in the UK. He commented that it 
would be the side effects and the subsequent change in dietary behaviour 
that would lead to weight loss rather than the mechanisms of the drug itself. 
The current research suggests that there is a complex relationship with the 
mechanisms of the drug along with subsequent behaviour change that is the 
key to successful weight loss in the long term. People, whether they change 
their diet or not will lose weight whilst on the drug, but it is the associated 
change in dietary behaviour, specifically the reduction in fat intake, that leads 
to successful weight loss in the long term after cessation of orlistat. Orlistat is 
therefore the trigger for endorsing a solution to their obesity, shifting their 
identity to someone who can control their weight and therefore make the 
required behaviour change to facilitate weight loss in the long term.
In the current research greater personal and treatment control was 
related to greater weight loss. Personal control is the focus of much research 
in relation to behaviour change. In Leventhal’s self-regulatory model of illness 
behaviour the first stage of dealing with the illness is interpretation. This 
interpretation includes representation of the health threat which involves cure 
or control which feeds into the coping strategies employed. Therefore it 
would appear that if the individual interprets their weight problem that they
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themselves can control then they are more likely to be successful in their 
weight loss. In relation to orlistat, In the current research, those who 
endorsed orlistat as a useful tool for weight loss and reported treatment 
control over their weight problem were more likely to adhere and be 
successful in their weight loss. This finds reflection in the study by Horne and 
Weinman (2002) which explored non-adherence to preventer medication and 
found that beliefs about treatment, therefore doubts about the necessity of 
medication, were strong predictors of adherence. This reflects the findings of 
the current research in that belief in treatment control over their weight 
problem was related to greater weight loss which is the primary outcome of 
this study. Those who choose to control their adherence to control the side 
effects rather that control their dietary behaviour are those who do not lose 
weight.
In terms of personal control which this current research has shown to 
be important for weight loss, this has also been found in other research. 
Elfhag and Ressner (2005) found that weight maintenance was associated 
with self-efficacy, autonomy and assuming responsibility in life. Therefore 
both previous research and the current research indicates that personal 
control is a key component in successful weight loss. Other research that has 
shown the importance of control in changing health behaviours was that of 
French, Cooper and Weinman (2006). They found that attendance at cardiac 
rehabilitation following an acute myocardial infarction was strongly predicted 
by beliefs about cure or control. Therefore those who felt their condition was 
more controllable were more likely to attend the clinic. In relation to the 
function of orlistat this is a similar story. The current research suggests that 
orlistat's role is as a trigger to facilitate the belief that the individual has 
control over their weight, whether it is personal control or treatment control, 
and this leads to more success in losing weight. It appears that orlistat 
functions by showing the individual they can lose weight and be in control of 
their weight, which facilitates the individual to adhere to the medication and 
change their behaviour. The control that orlistat has given them over their
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weight when they adhere to the medication enables them to change their 
weight to continue to be in control of their weight through dietary change.
The findings of the interview study are reflected in other research into 
weight loss. Elfhag and Rossner (2005) found that potential risk factors for 
regaining weight included weight cycling. The participants in the current 
research indicated a series of alternative weight loss methods they have tried 
and failed. This has put them in the mind set of failing and with a self-fulfilling 
prophesy what they expect to come true inevitably does. Self-identity was 
also a key factor in the interview study, in that their identity was embedded in 
the concept of being a “yo yo" dieter. Part of what makes them who are they 
are is that they are constantly dieting but never make a sustained change. 
This is also reflected in Ogden and Hills (2008) study which found that 
sustained behaviour change was a result of a shift in identity to a new 
healthier self. This shift in identity enabled the individuals to sustain their 
change in behaviour and maintain their weight loss or cessation of smoking. 
Therefore those who had failed to lose weight had not made that shift and 
had not reinvented themselves therefore were still stuck in their current 
identity which was a barrier to their weight loss. For these individuals orlistat 
had not featured as a trigger to them feeling in control of their weight nor that 
they felt it helped them to lose weight at all. Orlistat was just another method 
of weight loss they had tried and failed, reinforcing the belief that their weight 
is a constant battle that they will not overcome. They had not adhered to 
orlistat as prescribed and therefore it had not facilitated their weight loss to 
enable them to feel in control of their weight and shift their identity to 
someone who can control their weight through orlistat nor through changing 
their behaviour.
8.4 Overall summary
Overall, the results from the longitudinal study suggest that endorsement of a 
behavioural cause influences whether participants adhere to orlistat or not, 
as decreased adherence over the first 6 months of taking orlistat related to 
less of an endorsement of a behavioural cause. Also in the long term a
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decrease in adherence was related to an increase in endorsing a medical 
cause to their weight problem. This indicates that endorsing a behavioural 
cause to their weight problem promotes adherence and that orlistat functions 
to promote the behavioural model of obesity. Those who fail to adhere 
endorse a medical cause to their weight problem. Such participants do not 
seem to take ownership of their weight problem and blame the drug for their 
lack of weight loss and rationalise this by stating that the drug did not work 
for them.
In relation to weight loss, motivation to start losing weight is important 
for long term weight loss success. Decrease in BMI over the short term is 
related to less routine motivations and long term weight loss is related to less 
routine motivations and more significant event motivations. As with all weight 
loss methods the motivations to lose weight are an important factor in 
success. Those who had failed to lose weight had not been motivated to lose 
weight by a salient factor and therefore seemed to be just giving another 
method a try without believing fully in the efficacy of the method. 
Subsequently they succumbed to a self-fulfilling prophesy. Those who were 
successful had a salient motivation and orlistat functioned to facilitate their 
weight loss to improve their success.
In terms of illness beliefs personal control over their weight is 
important for long term weight loss with decrease in BMI in the long term 
being predicted by a short term increase in personal control and a long term 
increase in treatment control. A belief in control over their weight is an 
important factor for weight loss. Orlistat functions to promote this feeling of 
personal control over the short term which leads to long term weight loss. 
Those who do not succeed in their weight loss attempts believe methods of 
weight loss are merely a short term measure that will eventually fail and they 
are stuck in the identity of someone who ‘diets’. They fall into a self-fulfilling 
prophesy as they, are expecting to fail with whatever method they are 
currently trying.
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There is a complex relationship in terms of successfully losing weight 
with orlistat. Firstly the motivations for losing weight need to be salient 
therefore a significant event. They need to endorse a behavioural cause in 
order for them to adhere and eat less fat in order to lose weight. Also they 
need to believe both orlistat and themselves can control their weight problem 
in order for them to lose weight. The results indicate that there are many 
predictors of success for weight loss, including motivations, model of obesity 
and control. Orlistat functions to facilitate these predictors by endorsing a 
behavioural cause to their weight problem through promoting them eating 
less fat and by showing the individual they can control their weight by 
facilitating weight loss through its mechanisms.
The complex nature of weight loss is also reflected in the interviews of 
those who had failed to lose weight in the long term after drug therapy. Their 
self-identity was embedded in them failing to lose weight and they were 
unable to use orlistat as a tool to show them their weight could be controlled 
because they did not adhere to orlistat as prescribed and believed the side 
effects were just part of taking the drug and that the drug just did not agree 
with them. They believed orlistat was not for them as they had a good diet 
and this identity was a barrier to their weight loss. There was also an element 
of self-fulfilling prophesy in that they expected any weight loss attempt to fail, 
including orlistat, therefore they were not conscious of the functions of orlistat 
to educate them in new dietary behaviours and to show them their weight 
could be controlled. They used barriers to their weight loss as the reason 
behind their failure that they could not overcome; therefore they would 
always fail whatever method they chose.
As shown there is variability in terms of success when orlistat is used 
as a method of weight loss. Previous literature has shown the importance of 
motivations for behaviour change, the model of obesity held and feelings of 
control. However the longitudinal study shows that as orlistat is seen as a 
medical solution some endorse a behavioural cause but also endorse a 
medical solution whilst still changing their behaviour to lose weight. Therefore
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coherence in causes and solutions to their weight problem is not a necessity 
for behaviour change and weight loss. Orlistat is Important for giving the 
individual a renewed feeling of control over their weight by educating them in 
to new dietary behaviour which promotes weight loss in the long term.
Understanding weight loss
In the first study the baseline characteristics of the participants were 
examined. At baseline the majority were consistent in endorsing a 
behavioural model of their weight problem which are good indicators for 
weight loss. Over the first 6 months, from when they started taking orlistat 
participants had lost a significant amount of weight. In relation to predictors of 
weight loss; initial motivations, decrease in the belief their weight problem 
would last forever, concern about their weight problem, unhealthy food, high 
fat food, low fat food and fruit and vegetables over the 6 month period were 
key predictors. At the 18 month follow up, when most were no longer taking 
orlistat, most weighed significantly less than baseline. The best predictors of 
long term weight loss were significant event motivations to lose weight along 
with eating more healthy snacks and less fat. Also the belief that their weight 
problem will not continue forever and being less concerned with their weight 
were related to weight loss. This process of change over the 18 months was 
examined in study 4. The results showed a steady decline in weight over the 
first 6 months but then a gradual regain. Long term weight loss was predicted 
by a decrease in experiencing symptoms from their weight problem over the 
first 6 months from starting to take orlistat. The final qualitative study added 
to the understanding of the processes involved in failed weight loss. Failing to 
lose weight was embedded in the self-identity of someone who could not 
control their weight and the self-fulfilling prophesy of expecting to fail. It 
therefore appears that endorsing the efficacy of the method of weight loss 
and overcoming barriers to losing weight are an important part of the process 
of weight loss.
The additional impact of orlistat
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Orlistat had the impact at baseline of causing a conflict in beliefs. Most 
endorsed a behavioural model to their weight problem, however there were 
some who were in conflict by endorsing a behavioural cause but a medical 
solution. Orlistat also appeared to be functioning by facilitating healthy food 
choices, as of those who adhered most had a healthier diet. Over the first 6 
months, whilst most people were still taking orlistat, people ate healthier and 
felt more in control of their weight. At 18 months, most were no longer taking 
orlistat but it still had a long term impact. Whilst they were taking orlistat 
those who used the side effects as an education used that knowledge in the 
long term and orlistat also worked by showing them that their weight can be 
controlled, which they were able to do in the long term. Study 4 showed that 
this process of change, through the impact of orlistat, functioned by giving the 
individual personal control over their weight, which reinforced the belief in a 
behavioural model to their weight problem which enabled them to change 
their diet and lose weight in the long term. The final qualitative study gave an 
insight into the variability in the impact of orlistat. Orlistat works by blocking 
the fat absorbed but the variability arises when it comes to the impact of 
orlistat to change beliefs and behaviour. For those who do not believe in the 
efficacy of orlistat, believe the side effects are just part of taking the drug and 
are expecting to fail do not make the shift in beliefs and behaviour to enable 
weight loss in the long term after cessation of orlistat.
8.5 Implications for theory
Leventhal’s (1992) self regulatory model suggests stages for regulation of 
illness behaviour, the first of which being interpretation therefore 
interpretation of the cause of their illness. Interpretation of the cause of their 
illness relates to how they cope with their illness. The current research 
supports this theory in relation to the use of orlistat for weight loss. When the 
individual interprets their illness as being caused by their behaviour then they 
will employ coping strategies that enable them to change their behaviour in 
order to lose weight. Long term weight loss relies on the individual changing 
their behaviour and to take the identity of a new healthier self. Orlistat 
facilitates the individual to acknowledge they can control their weight and
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therefore change their behaviour in order to achieve this. Orlistat’s role is to 
show the individual when they have made bad dietary choices, through visual 
feedback, therefore the individual becomes aware that their behaviour can be 
modified to initially reduce the side effects and to subsequently facilitate 
weight loss.
Research suggests that coherence in terms of their model of obesity is 
important for behaviour change and weight loss. Ogden and Sidhu (2006) 
found that those who were successful in their weight loss with orlistat 
associated their obesity with a more behavioural model; therefore they 
endorsed both a behavioural cause and a behavioural solution. The current 
research suggests that it is how they conceptualise the cause of their weight 
problem that is the key factor when seeking a medical intervention for their 
weight loss. Whether they endorsed a behavioural or medical solution was 
not a key predictor of weight loss, but control over their weight problem was. 
This inconsistency in their beliefs about causes and solutions was also 
observed by Ogden and Flanagan (2008) with lay people. It seems that 
acknowledging a behavioural cause to their weight problem is key but that 
when solving their weight problem, believing it can be controlled is important 
rather than whether that control is personal or through the medication. The 
individual has to endorse the current method of weight loss in order for them 
to succeed otherwise it will be a self-fulfilling prophesy. Thus in relation to 
individuals seeking a medical intervention to their weight loss, the source of 
the solution to their weight problem is not the key factor it is whether they feel 
there is a solution and that their weight can be controlled that is fundamental.
The component of control being significant to addressing their health 
problem is also found in individuals who have experienced an acute 
myocardial infarction. French, Cooper and Weinman (2006) found that 
attendance at cardiac rehabilitation was strongly predicted by beliefs about 
cure or control. Therefore beliefs about control are important for addressing 
an illness and in the current research to enable the individual to control their 
weight. This reflects the study by Elfhag and Rossner (2005) where weight
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maintenance was associated with self-efficacy, autonomy and assuming 
responsibility in life. It appears the feelings of control are fundamental in the 
individual taking control of their weight and changing their behaviour to 
achieve that. Orlistat functions to promote this feeling of control by the 
individual using the side effects as a education. Those who fail in their weight 
loss attempts do not assume the identity of someone who can control their 
weight and are always expecting to fail at their current method of weight loss, 
which is a self-fulfilling prophesy.
8.6 Implications for practice
Research shows that orlistat helps to reduce weight (Sjostrom et al. 1998) 
however there is variability in successful outcomes. The current research 
indicates that it Is the psychological processes and subsequent behaviour 
change that vary. This research confirms previous research and highlights 
the issue of initial motivations for weight loss. Those with a significant event 
motivation were more likely to lose weight. This would be a key area for 
health professionals to address therefore they should discuss with their 
patients the rationale behind why they had chosen to address their weight 
problem. If the individual reports more everyday consequences of being 
overweight, then the health professional should address this and point out to 
the individual the health benefits of weight loss and the health implications if 
they do not lose the weight. This may trigger the individual to see the 
importance of them losing weight and make the issue more salient and 
therefore something they will be motivated to resolve.
Another key area for the health professionals to address when 
contemplating the use of orlistat for weight loss is the model of obesity that 
the patient holds, especially in terms of what they believe to be the cause of 
their weight problem. If the individual endorses a behavioural model then 
they are more likely to adhere to the medication and change their behaviour 
in order to lose weight. If the health professional discusses the patients 
model with them and it is more focussed on medical causes such as it being 
genetic or hormones, the health professional needs to address this belief and
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provide the patient with the knowledge that only a small number of people 
suffer with syndromes that cause obesity (e.g. Prada-Willi) and that the 
health professional needs to investigate this possibility and disregard this 
possibility in order to assist the patient to acknowledge their weight has a 
behavioural cause, in order to improve their weight loss outcomes through 
the use of orlistat. Orlistat does function to promote the endorsement of a 
behavioural cause to their weight problem, but the health professional also 
has a part to play in assisting the patient to make this shift in identity.
The current study highlights the importance of addressing the 
significance of the side effects of orlistat as a tool for weight loss rather than 
something just to be endured. Health care professionals should discuss this 
with their patients when they prescribe it to them. The less side effects the 
patients experiences the more success they will have with their weight loss. 
The side effects should be used as visual feedback to facilitate behaviour 
change. The side effects are an indicator that the individual has eaten food 
that is too high in fat therefore the side effects act to educate the individual in 
regard to what fat should not be consumed. The health professional should 
emphasize this to the patient so the patient then feels empowered to address 
the occurrence of side effects rather than conceptualise the side effects as 
something to be put up with as they are just part of taking the drug. Orlistat 
can function to promote the feeling of control over their weight problem but it 
has to be adhered to and changes made to their diet to facilitate weight loss. 
Selective adherence to reduce the side effects and the belief that the side 
effects are just part of the drug and therefore the drug does not agree with 
them is not a productive mindset. Those who think this way will just stop 
taking the drug and that will be another failed method of weight loss that the 
individual has tried which will reinforce the identity of a dieter, who tries 
different methods but they inevitably fail and the weight is regained. The 
health professional needs to work with orlistat to promote the side effects as 
an educational tool that is an important factor in them gaining control of their 
weight.
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Finally the element of control is important for practice. By prescribing 
orlistat to patients, health care professionals can empower patients to feel 
they can control their weight through taking orlistat but also through changing 
their diet. Their weight problem is not part of their identity, is does not make 
them who they are, this is something that can be controlled and concern over 
their weight can become part of their old identity, with a shift to a new identity 
where they can control their weight. Orlistat facilitates the shift in identity to a 
new person who can control their weight rather than it being out of their 
control.
8.7 Implications for research
The main limitation of this study is that the baseline data is not a true 
baseline in that it did not assess participants on the day they first started to 
take orlistat. Due to the recruitment procedure, participants were generally 
completing the questionnaires within the first 3 months of them taking orlistat. 
This means the data has to be explored tentatively with this in mind. The 
baseline data is therefore in the beginnings of them starting to take orlistat 
but not at the very beginning. Future research should aim to recruit 
participants just before they take their first prescription of orlistat in order to 
gain a true baseline.
Another issue to address is that the data does not show exactly when 
the participants came off orlistat or exactly how long they had been on it. 
Within each of the quantitative studies at each time point it is known whether 
the participants are currently taking the drug, or if they stopped within the last 
month, however it is not known exactly when they have come off it. Therefore 
there is a 5 month window when they may have stopped taking it, but it is not 
known exactly when. As a result although we are looking at the impact of 
orlistat on changes on beliefs and behaviour we have no clear marker of 
when orlistat was stopped therefore it is not clear exactly how it was driving 
the changes. Differences in patient experiences of the orlistat may be related 
to the duration of time they took the treatment, but this is not known. This
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needs to be taken into account when interpreting the data. This is an issue 
that could be addressed if this were to be replicated in a future study.
In this study the response rate was around 30% which is in line with 
other postal questionnaire research studies and other long term studies of 
those taking orlistat. High attrition rates are common in studies examining 
pharmacological interventions for weight loss. Some authors attempt to 
address this by carrying forward last observations for weight to the further 
time points (Padwal, Li & Lau, 2003). However this may not always be 
accurate as mostly patients who come off treatment programs tend to put 
weight back on, normally to the start weight. Therefore in our study, due to 
the large numbers of participants, participants were excluded from certain 
studies if they did not return a completed questionnaire.
In terms of there being no control group in this study there are a few 
points to consider. Firstly financial and time constraints meant that a large 
number of participants who were taking orlistat were used rather than having 
to half the number of those taking orlistat in order to compare them with a 
control group. Also the main aim of these studies were to examine the 
experiences of those taking orlistat therefore a large number of participants 
talking orlistat was sought and explored. Furthermore participants were 
examined in terms of how beliefs and behaviours change over time with the 
use of orlistat therefore the use of a control group who had not taken orlistat 
would be inappropriate as participants were their own control. Finally if a 
control group of those who were not taking orlistat was used this would mean 
a different research question to the one asked in this thesis. This thesis was 
exploring the experiences of those taking orlistat both quantitatively and 
qualitatively, not exploring the efficacy of the drug itself, which is the type of 
study that would require a control group and this research question has 
already be explored extensively.
In terms of interpreting the results of this research it needs to be 
highlighted that both diet and weight were reported using self-reported
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measures. This means that there may be inaccuracies in the reporting of 
these variables, but they were the best means of measuring these variables 
for a large scale nation wide study as part of a postal questionnaire. A more 
objective measure would be for either the researcher to measure the weight 
of the participants in person or for a health professional to measure their 
weight at appropriate intervals and for the data to be passed onto the 
researcher, however both these options would have both time and financial 
costs that would be prohibitive especially with the ethical process of allowing 
the health professional to pass on this data and for them to commit their time 
to taking the measurements. Furthermore there is the possibility that getting 
an objective measure of weight would be time consuming for participants as 
well, which would increase drop out rates. The only objective measure of diet 
would be for the participants to consume all meals in a laboratory 
environment which would not be appropriate for a longitudinal study. 
Therefore in terms of implications of these results to research it would be 
appropriate to use similar measures as a tool for measuring diet but if 
barriers for obtaining an objective measure of weight were overcome this 
would improve the reliability of the results.
Other areas that would have been useful to explore was whether the 
participants had other health problems and examine how that may interact 
with how the drug changes beliefs and behaviours along with whether it 
impacts on the primary outcome measure of weight loss over time. The 
questionnaire also did not address pregnancy, which is a factor in weight 
regain and subsequent loss over a long term period. Finally the diet measure 
was very general and did not account for specialist diets such as non-dairy, 
therefore this could be accounted for in subsequent studies to accurately 
assess participants’ diets.
Based on the findings of this research an intervention to address 
motivations, model of obesity, conceptualising the side effects and control in 
patients being prescribed orlistat would be of use. This intervention could 
address these key components both before the patient starts to take orlistat
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and also when they come in for their repeat prescriptions. Beliefs and 
behaviours can be addressed in order to facilitate behaviour change and 
promote a shift in cognitions in order for the individual to feel in control of 
their weight through their new behaviour. This intervention should evaluate 
whether addressing these components will increase success rates with the 
use of orlistat and reduce the variability in outcomes.
8.8 Conclusion
The quantitative longitudinal studies and the qualitative study gave an insight 
into the processes involved in successful weight loss and the additional 
impact of orlistat.
Understanding weight loss
Successful weight loss relied on significant event motivations for weight loss, 
eating healthier and a belief that their weight can be controlled. Failure to 
lose weight is embedded in a participant’s belief that they will not lose weight 
as there are too many barriers stopping them from doing so.
The additional impact of orlistat
Orlistat is of benefit to those attempting to lose weight as it educates them 
about what foods should not be eaten and shows them that their weight can 
be controlled. It therefore gives the individual the belief that their weight is 
controllable and that they can lose weight.
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Appendix 2: information sheet
Participant Information Sheet
Study title: Patients' experiences of taking Xenical.
‘You are being Invited to take part in a research study. Before you decide it is important for you to understand why 
the research is being done and what It will Involve. Please take time to read the following information carefully. Talk 
to others about the study if you wish.
• Part 1 tells you the purpose of this study and what will happen to you if you take part.
•  Part 2 gives you more detailed Information about the conduct of the study.
Ask us if there Is anything that is not clear or if you would tike more Information. Take time to decide whether or not 
you wish to take part.
Part 1.
1. What is the purpose of the study?
Previous research has shown that people have different experiences of taking Xenical. These differences also 
relate to why people started taking Xenical in the first place. We are interested in why you started taking Xenical 
and your experiences of taking the drug so far. Some of the results from this study will be used In a student 
research project.
2. Why have 1 been chosen?
You have been chosen to take part in this study because you registered on the MAP programme within the time 
period that we are looking for participants and have agreed to being sent this information.
3. Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will have this information sheet to keep and 
will have the questionnaire to complete. You are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard of care you receive.
4. What will happen to me if I take part?
You will be asked to fill out the enclosed questionnaire send It back to us In the freepost envelope provided. If you 
agree, you will be sent 4 follow up questionnaires every 6 months to see how you are getting on. The 
questionnaires should take about 15 minutes each to complete.
5. What do I have to do?
Please read the Information sheet, please then complete the questionnaire and send it back to us in the freepost 
envelope. Once you have sent back the completed questionnaire you will be sent follow up questionnaires at 6 
month Intervals over 2 years.
6. What are the other possible disadvantages and risks of taking part?
There are no foreseen disadvantages to taking part in this study. The only inconvenience will be the time It takes to 
complete the questionnaire, which should be a maximum of 15 minutes, and then posting this back to us In the 
freepost envelope provided.
7. What are the possible benefits of taking part?
The information we receive will help us to understand people's experiences of taking Xenical. This could help to 
improve patient care in the future. It will also give you a chance to share your experiences of taking Xenical.
8. What happens when the research study stops?
Once the research study stops you will be sent no more questionnaires and your involvement will be complete.
9. What if there is a problem?
Any complaint about the way you have been dealt with during the study will be addressed, detailed Information on 
this is given in Part 2.
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10. Will my taking part in the study be kept confidential?
Yes. All the information about your participation in this study wiil be kept confidential. The details are included In 
Part 2.
11. Contact Details:
If you would like any further information on the study please contact Amelia Hollywood, the main researcher, by 
telephone on 01483 686883 or by email at a.hollywood@surrey.ac.uk.
This completes Part 1 of the Information Sheet.
If the information in Part 1 has interested you and you are considering participation, please continue to read 
the additional information in Part 2 before making any decision.
Part?
12. What wiil happen if I don’t want to carry on with the study?
if you withdraw from the study, we will destroy all your Identifiable details, but we will need to use the data collected 
up to your withdrawal.
13. What if there is a problem?
Complaints;
If you have a concern about any aspect of this study, you should ask to speak with Amelia Hollywood, the main 
researcher, who will do her best to answer your questions (01483 686883). If you remain unhappy and wish to 
complain formally, you can do this through the University of Surrey. Details can be obtained from the University.
14. Will my taking part in this study be kept confidential?
All information which Is collected about you during the course of the research wiil be kept strictly confidential. All 
personal data relating to participants is held and processed In the strictest confidence, and in accordance with the 
Data Protection Act (1998).
Your answers to the questions in the questionnaire will be put Into a data base by the main researcher and your 
responses will be coded to ensure they are anonymous. This will be stored securely and anonymously and only 
used for the purposes of this study. Ail personal information will be encoded and anonymous as far as is possible 
and consistent with the needs of the study, and as early as possible after collection. This applies to both paper and 
electronic records.
Only the main researcher will have access to view identifiable data. The research data will be retained intact for a
period of at least five years from the date of any publication which Is based upon It. All Information which is
collected about you during the course o f the research will be kept strictly confidential.
15. What will happen to the results of the research study?
The results from this research project will make up part of the thesis of the main researcher, Amelia Hollywood. The 
results are also Intended to be published in academic journals and other publications. Participants wiil not be 
Identified In any report/publication.
16. Who is organising and funding the research?
The University of Surrey will be responsible for conducting this research study, it has been funded by a non-
dlrectlonal research grant from Roche UK.
17. Who has reviewed the study?
This study has been given a favourable ethical opinion by the University of Surrey.
Thank you for taking time to read this sheet.
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Appendix 3: Baseline questionnaire 
How do you feel about taking Xenical?
We are interested in your experiences of taking Xenical and your weight history. We would be 
grateful if you could answer the following questions as honestly as possible by circling the 
answer which best describes your experiences. All answers will be treated with the strictest 
confidence. Please remember that there are no right or wrong answers we are only interested
in your views.
Please answer ALL questions 
SECTION 1 These first questions are about taking Xenical.
1) How long have you been taking Xenical for? __________________________________
2) Is this the first time you have been prescribed Xenical? Yes □  No □
3) If no, how many times have you been prescribed Xenical for weight loss?_____________
4) To what extent do you think that your weight problem is caused by the following?
Not at all Totally
Eating too much 1 2 3 4 5
Not enough exercise 1 2 3 4 5
Eating the wrong foods 1 2 3 4 5
Genetics/inheritance 1 2 3 4 5
Glands/hormone problem 1 2 3 4 5
Slow metabolism 1 2 3 4 5
5) To what extent do you think the following would help you to lose weight?
6) What motiva
Not at all Totally
Exercise 1 2 3 4 5
Medication 1 2 3 4 5
Eating fewer calories 1 2 3 4 5
Healthy eating 1 2 3 4 5
Being more active 1 2 3 4 5
Surgery 1 2 3 4 5
Physical activity 1 2 3 4 5
Eating less fat 1 2 3 4 5
ed you to start taking Xenical?
Not at all Totally
Low self-esteem 1 2 3 4 5
Lack of confidence 1 2 3 4 5
Feeling unattractive 1 2 3 4 5
Major medical problem 1 2 3 4 5
Significant event e.g. birthday 1 2 3 4 5
Relationship breakdown 1 2 3 4 5
Feeling unhealthy 1 2 3 4 5
Feeling breathless 1 2 3 4 5
Pains in your knees 1 2 3 4 5
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SECTION 2 Please now think about your feelings, experiences and behaviour In the
PAST MONTH
Since starting to take Xenical how often have you experienced the following:1)
Not at all Totally
Liquid stools 1 2 3 4 5
An urgency to go to the toilet 1 2 3 4 5
Diarrhoea 1 2 3 4 5
Bloating 1 2 3 4 5
Wind 1 2 3 4 5
2) To what extent have these side effects (i.e. diarrhoea, urgency etc) made you think 
the following: (in the PAST MONTH)
Not at all Totally
They have helped me to think about my diet 1 2 3 4 5
They have helped me to think why I’m overweight 1 2 3 4 5
They have made me realise what is in different foods 1 2 3 4 5
They are just something 1 have to put up with 1 2 3 4 5
They are a necessary part of weight loss 1 2 3 4 5
They are a necessary part of taking the drug 1 2 3 4 5
3) To what extent have these side effects made you: fin the PAST MONTH)
Not at all Totally
Eat healthier 1 2 3 4 5
Reduce fat intake 1 2 3 4 5
Change the way you eat 1 2 3 4 5
Stop taking Xenical 1 2 3 4 5
Take Xenical only occasionally 1 2 3 4 5
Not take Xenical if you want to eat fattier foods 1 2 3 4 5
4) To what extent do you think Xenical:
Not at all Totally
Limits what you can eat 1 2 3 4 5
Limits what you want to eat 1 2 3 4 5
Makes you eat food you do not enjoy 1 2 3 4 5
5) To what extent do the following describe how you take Xenical: (in the PAST 
MONTH)
Not at all Totally
1 take it religiously 1 2 3 4 5
1 miss doses sometimes 1 2 3 4 5
1 stop taking it before a fatty meal 1 2 3 4 5
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For the following questions, please circle the number that best corresponds to your 
views over the PAST MONTH:
6) How much does your weight affect your life? 
no affect 
at all
0 1 2 3 4 5 6 7 8
severely 
affects my life 
10
7) How long do you think your weight problem will continue? 
a very short time
0 1 2 3 4 5 6 7 8
forever
10
8) How much control do you feel you have over your weight?
absolutely
no control
0 1 2 3 4 5 6 7 i
extreme amount 
of control 
9 10
9) How much do you think taking Xenical can help your weight? 
not at all
0 1 2 3 4 5  6 7  8
extremely helpful 
9 10
10) How much do you experience symptoms from your weight? 
no symptoms 
at ail
0 1 2  3 4 5 6  7 8
many severe 
symptoms 
10
11 ) How concerned are you about your weight?
not at all
concerned
0 1 2 3 4 5 6 7
extremely
concerned
10
12) How well do you feel you understand your weight? 
don't understand 
at all
0 1 2 3 4 5 6 7 8
understand 
very clearly 
10
13) How much does your weight affect you emotionally? (e.g. does it make you angry, 
scared, upset or depressed?
not at ail affected extremely affected
emotionally emotionally
0 1  2 3 4  5 6  7 8 9  10
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SECTION 3 The following questions are about your diet and exercise over the PAST
MONTH
1) SNACKS:
Never or less Less than Once a 
week
2-4 days 
a week
5-6 days Once a 2-3 times More than 3
than once a once a a week day. a day. times a day.
month week every day everyday every day
Rice cakes, crackers or 
breadsticks □ □ □ □ □ □ □ □
Chips □ □ □ □ □ □ □ □
Raw vegetables and 
salad □ □ □ □ □ □ □ □
Crisps or savoury snacks 
(Walkers, Pringles etc) □ □ □ □ □ □ □ □
Cakes, biscuits and other □sweet pastries
Confectionery (chocolate, 
sweets) □ □ □ □ □ □ □ □
Fruit □ □ □ □ □ □ □ □
Cereal bars □ □ □ □ □ □ □ □
2) MEALS AT HOME & EATING OUT:
Please indicate how often you have you done the following in the PAST MONTH:
Never or less Less than 
than once a once a 
month week
Once a 
week
2-4 da>s 
a week
5-6 days Once a 2-3 times More than 3
a week day, a day, times a day,
_________ everyday everyday everyday
Cooked meals at home □
Ate processed foods □ □ □
Ate ready meals □ □ □
Ate takeaways □
3) COOKING:
Please indicate how often you have used the following cooking methods in the PAST MONTH:
Never SeldotTi Occasionally Frequently Often
Deep try in oii/tat □ □ □
Shallow fry in oil/lat □
Roast/bake □ □
Boil □
Steam □ □
Dry try
4) FAT:
Please indicate how often you have eaten the following foods in the PAST MONTH:
Never or less Less than Once 2-4 Once a 2-3 times a More than 3
than once a once a a days a 5-6 days day. day, every times a day, 
month week week week a week everyday ' day______ every day
Ful cream milk □
Semi-skimmed/skimmed milk □
Ful tatbutterfmarganne □ □ □
Low fat butter/marganne □
Ful fat cheese (hard)
Low fat cheese □ □ □
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5) FRUIT & VEGETABLES:
How many portions of fruit or vegetables have you usually had on an average day in the 
PAST MONTH:?
N one□ □ 7 +□
6) EXERCISE:
Which of the following best describes how active you have been over the PAST MONTH 
(PLEASE TICK ONE BOX)
Sedentary  
(no exercise)
O c ca s io n a l m ild exerc ise R eg u lar m ild exercise O cca s io n a l vigorous exercise R eg u lar vigorous exercise
(i.e , c lim b stairs, w a lk (i.e., c lim b stairs, brisk (i.e., w ork or recreation for (i.e., w ork or recreation tor
15 m inutes) w alk ing) 3 0  m inutes) 3 0  m inutes)
□ □ □ □ □
SECTION 4 The following questions are about what you have tried In the past to
lose weight.
1) Have you ever tried any of the following methods as a means to lose weight?
Never Seldom Sometimes Often Very Often
Calorie controlled diet 1 2 3 4 5
Food avoidance 1 2 3 4 5
Food weighing 1 2 3 4 5
Low fat diet 1 2 3 4 5
Healthy eating 1 2 3 4 5
Never Seldom Sometimes Often Very Often
High fibre diet 1 2 3 4 5
Exercise 1 2 3 4 5
Weighing yourself 1 2 3 4 5
Counselling 1 2 3 4 5
Cognitive Behaviour Therapy 
(with a ciinical psychologist)
1 2 3 4 5
Self help group 1 2 3 4 5
2) Have you ever had weight loss surgery (e.g. gastric band, stomach bypass etc)? 
Yes □  No n
3) Do you intend to have weight loss surgery in the future? 
□
Yes □ No
326
4) How much contact have you ever had with the following professionals to help you lose 
weight?
None Rarely Sometimes Regularly Frequently
Practice nurse 1 2 3 4 5
GP 1 2 3 4 5
Hospital doctor 1 2 3 4 5
Dietician 1 2 3 4 5
Counsellor 1 2 3 4 5
Psychologist 1 2 3 4 5
Slimming club organiser 1 2 3 4 5
Section 5 The following questions are about your weight history.
1. What is your present weight?
2. What is your present height?.
3. What was your highest weight ever (excluding pregnancy)?
4. What was your lowest weight since 18yrs?______
5. What weight would you like to be?_________________
6. What is the most weight you have ever lost?_______
7. How long did/have you maintained this weight loss for? (months/years)
8. Are you currently trying to lose weight? YES I NO
9. How old were you when you first became overweight?_______ (yrs)
10. How old were you when you first tried to lose weight?_______ (yrs)
11. How many years have you been trying to lose weight for? (yrs)
Please complete the following AGE/W EIGHT record as accurately as possible from when you 
were 18yrs, using whatever measure o f weight you are happy with (lbs, stones or kgs). 
PLEASE PUT A WEIGHT FOR EACH AGE UP TO THE AGE YOU ARE NOW. GUESS IF YOU ARE 
NOT SURE.
AGE WEIGHT
18 _______
20 ______
22 ______
24 _______
26 _______
28 _______
30
AGE
32
34
36
38
40
42
44
WEIGHT AGE WEIGHT
46 _______
48 _______
50 _______
52 _______
54 _______
56 _______
58
AGE WEIGHT
60 _______
62 _______
64 _______
66 ______
68 ______
70 _______
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Section 6 Please now think about the telephone support service.
1. In the PAST month how often have you contacted the MAP telephone support 
service?
N ev er or less than  
o n c e  a m onth
Less than  
o n c e  a w e e k
O n c e  a 2 -4  da>s 
w e e k  a w e e k
5 -6  days 
a w e e k
O n c e  a day, 
everyd ay
2 -3  tim es  a 
day, every day
M o re  than 3  tim es  
a day, every day
□ □ □  □ □ □ □ □
327
2. To what extent do the following describe how you have found the telephone support 
service:
Not at all Totally
Helpful 1 2 3 4 5
Caring 1 2 3 4 5
Personal 1 2 3 4 5
Informative 1 2 3 4 5
Understanding 1 2 3 4 5
Supportive 1 2 3 4 5
Black Caribbean □
Neither, I am not
Section 7 The final questions are about you.
1. Age:________
2. Sex: Male □  Female □
3. Which of the following best describes you?
White □  Black African □
Asian □  Other □
4. Do you work? Full time □  Part time □  
working at the moment □
5. Marital Status: Married □  Divorced/Separated □  Living with partner □
Single □  Widowed □
6. Level of Education: a) less than Secondary school □
b) Secondary school graduate □
c) Some college □
d) College graduate □
e) Undergraduate degree □
f) Masters degree □
g) Doctoral or Professional Degree □
Please provide further contact details for us to send you future information on this study.
Email address: __________________________________________________
Would you like to take part in a short telephone interview, at a later date, to discuss you 
experiences further?
Yes □  No □
If YES please write your telephone number: ___________________________________
Thank you for your help with this study. Please return the questionnaire in the freepost 
envelope provided.
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Appendix 4: Follow up questionnaire 
How do you feel about taking Xenical? □ □ □ □ □
We are interested in your experiences of taking Xenical and any weight changes. We would 
be grateful if you could answer the following questions, even if you are no longer taking 
Xenical, as honestly as possible by circling the answer which best describes your 
experiences. All answers will be treated with the strictest confidence. Please remember that 
there are no right or wrong answers we are only interested in your views.
Please answer ALL guestions
SECTION 1 Please think about your feelings, experiences and behaviour In the
PAST MONTH
1) To what extent do you think that your weight problem is caused by the following?
Not at all Totally
Eating too much 1 2 3 4 5
Not enough exercise 1 2 3 4 5
Eating the wrong foods 1 2 3 4 5
Genetics/inheritance 1 2 3 4 5
Glands/hormone problem 1 2 3 4 5
Slow metabolism 1 2 3 4 5
2) To what extent do you think the following would help you to lose weight?
Not at all Totally
Exercise 1 2 3 4 5
Medication 1 2 3 4 5
Eating fewer calories 1 2 3 4 5
Healthy eating 1 2 3 4 5
Being more active 1 2 3 4 5
Surgery 1 2 3 4 5
Physical activity 1 2 3 4 5
Eating less fat 1 2 3 4 5
3) Are you still taking Xenical?
4) If NO why did you stop?
Yes n
If YES go to question 5.
No n
Because the doctor told me to Yes n No n
Because it wasn’t helping Yes □ No n
Because 1 didn't like the side effects Yes n No n
If vou stopped less than a month ago please continue to question 5, if you stopped
longer than a month ago please go to question 10.
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5) Whilst taking Xenical how often have you experienced the following in the PAST 
MONTH:
Not at all Totally
Liquid stools 1 2 3 4 5
An urgency to go to the toilet 1 2 3 4 5
Diarrhoea 1 2 3 4 5
Bloating 1 2 3 4 5
Wind 1 2 3 4 5
6) To what extent have you felt the following about these side effects of taking Xenical: 
(in the PAST MONTH)
Not at all Totally
They have helped me to think about my diet 1 2 3 4 5
They have helped me to think why I'm overweight 1 2 3 4 5
They have made rrie realise what is in different foods 1 2 3 4 5
They are just something 1 have to put up with 1 2 3 4 5
They are a necessary part of weight loss 1 2 3 4 5
They are a necessary part of taking the drug 1 2 3 4 5
7) To what extent have these side effects made you: (in the PAST MONTH)
Not at all Totally
Eat healthier 1 2 3 4 5
Reduce fat eaten 1 2 3 4 5
Change the way you eat 1 2 3 4 5
Stop taking Xenical 1 2 3 4 5
Take Xenical only occasionally 1 2 3 4 5
Not take Xenical if you want to eat fattier foods 1 2 3 4 5
8) To what extent do you think Xenical: (in the PAST MONTH)
Not at all Totally
Limits what you can eat 1 2 3 4 5
Limits what you want to eat 1 2 3 4 5
Makes you eat food you do not enjoy 1 2 3 4 5
9) To what extent do the following describe how you take Xenical: (in the PAST 
MONTH)
Not at all Totally
1 take it religiously 1 2 3 4 5
1 miss doses sometimes 1 2 3 4 5
1 stop taking it before a fatty meal 1 2 3 4 5
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10) How often have you tried any of the following methods as a means to lose weight in 
the PAST MONTH?
Never Seldom Sometimes Often Very Often
Calorie controlled diet 1 2 3 4 5
Food avoidance 1 2 3 4 5
Food weighing 1 2 3 4 5
Low fat diet 1 2 3 4 5
Healthy eating 1 2 3 4 5
High fibre diet ■I 2 3 4 5
Exercise 1 2 3 4 5
Weighing yourself 1 2 3 4 5
Counselling 1 2 3 4 5
Cognitive Behaviour Therapy 
(with a clinical psychologist)
1 2 3 4 5
Self help group 1 2 3 4 5
11 ) How much contact have you had with the following professionals to help you lose 
weight in the PAST MONTH?
None Rarely Sometimes Regularly Frequently
Practice nurse 1 2 3 4 5
GP 1 2 3 4 5
Hospital doctor 1 2 3 4 5
Dietician 1 2 3 4 5
Counsellor 1 2 3 4 5
Psychologist 1 2 3 4 5
Slimming club organiser 1 2 3 4 5
12) Have you had weight loss surgery (e.g. gastric band, stomach bypass etc)?
Yes □  No □
13) Do you intend to have weight loss surgery in the future?
Yes □  No □
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Section 2 For the following questions, please circle the num ber that best 
corresponds to your views in the PAST MONTH:
1 ) How much does your weight affect your life? 
no affect 
at all
0 1 2 3 4 5 6 7 8
severely 
affects my life 
9 10
2) How long do you think your weight problem will continue? 
a very short time forever
0 1 2 3 4 5 6 7 8 9  10
3) How much control do you feel you have over your weight?
absolutely
no control
0 1 2  3 4 5  6 7  8
extreme amount 
of control 
9 10
4) How much do you think taking Xenical can help your weight?
not at all extremely helpful
0 1 2 3 4 5  6 7  8 9  10
5) How much do you experience symptoms from your weight? 
no symptoms 
at all
0 1 2  3 4 5 6  7 8
many severe 
symptoms 
9 10
6) How concerned are you about your weight?
not at all
concerned
0 1 2 3 4 5 6
extremely 
concerned 
9 10
7) How well do you feel you understand your weight? 
don't understand 
at all
0 1 2 3 4 5 6 7
understand 
very clearly 
9 10
8) How much does your weight affect you emotionally? (e.g. does it make you angry, 
scared, upset or depressed?
not at all affected extremely affected
emotionally emotionally
0 1  2 3 4  5 6  7 8 9  10
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SECTION 3 Tiw following questions are about your diet and exercise over the PAST MONTH
1) SNACKS:
Please indicate how often you have snacked on the following foods in the PAST MONTH:
N ever or less 
than o n c e  a 
m onth
Less than  
o n c e  a 
w e e k
O n c e  a 
w e e k
2 -4  days 
a w e e k 5 -6  days a w e e k
O n c e  a 
day, 
eveiy day
2 -3  tim es  
a day, 
everyd ay
M o re  than 3  j 
tiiTies a day, | 
everyd ay i
Rice cakes, c tackeis or 
breadstlcks □ □ □ a □ □ □ □  Ii
Chips □ □ □ □ □ □ □  :
R a w  vegetables and 
sa lad □ □ □ □ □ □ °  i
Crisps or savouty sn acks  
(W alkeis , Pringles etc) □ □ □ a □ □ □ 1
C akes, biscuils and other 
s w e e t pastries □ □ □ □ □ □ O □ 1
Confectionery (chocolate, 
sw eets) □ □ □ o □ □ □ !
Fruit □ □ □ a n □ □ □ 1
C ereal bars □ □ □ □ □ □ □ □
2) MEALS AT HOME & EATING OUT:
Please indicate how often you have you done the following in the PAST MONTH:
1
Never or less 
than once a 
month
Less than j 
once a I 
week !
Once a 
weeir
2-4 days 
a week 5-6 days a week
Once a 
day, 
every day
2-3 times 
a day, 
every day
More than 3 ; 
times a day, ; 
every day !
1 Cooked meals at home □ □  1 □ □ □ □ □ □  I
1 Ale processed toods □ □ □ □ □ □ □ □
1 Ate ready meals □ n  i □ □ □ □ □ n  1
1 Ate takeaways □ □  1 □ □ □ □ □ □  I
3) COOKING:
Please indicate how often you have used the following cooking methods in the PAST MONTH:
i N ever 1 Seldom I O ccasionally Frequently i O ften i
D ee p  try in oil/tat □ □ i O □ □  1
, Shallow  fry in oil/tat □ □ ! o □ □ i
1 R oast/bake i ° 1 ° : □ °  ; °  1
i Boil 1 □ 1 □ i □ □ ; □
i S team ; □ n ! a □ ' □  i
; Dry fry : □ ! □ i □ □  I □ 1
4) FAT:
1
!11
N ever or 
less than 
once a 
m onth
Less than  
once a . 
w e e k  :
O n c e  a 
w e e k
2-4  days 
a w e e k
6 -6  days 
a w e e k
O n ce  a 
day, 
every day
2 -3  tim es a 
day, every 
day
M o re than  
3  tim es a 
day, every 
day
1 Full cream  milk □ □ □ □ □ □ □ □
1 Sem i-skimim edfekimmed m ilk □ □  ' □ □ □ □ □ □
j Full fat butter/margarine □ □  : □ □ □ □ □ □
1 Low  fat butter/margarine □ □  ! n □ □ □ □ □
I Full fat cheese (hard) □ a □ O O □ □ □
; Low  tat cheese □ □ □ □ □ □ □ □
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6) FRUIT & VEGETABLES:
How many portions of fruit or vegetables have you usually had on an average day in the 
PAST MONTH:?
None 1 2 3 4 5 6 7 +
□ □ □ □ □ □ □ □
7) EXERCISE:
Which of the following best describes how active you have been over the PAST MONTH 
(PLEASE TICK ONE BOX)
Sedentary  
(no exercise)
O cca s io n a l m ild exercise R egu lar m ild exercise O cca s io n a l vigorous exercBe R egu lar vigorous
(i.e. c lim b stairs, w a lk (i.e. clim b stairs, w alking (i.e. w ork or recreation for exercise (i.e. w ork or
15 m ins) for 15 tpins) 3 0  mins) recreation for 3 0  rp in ^
□ □ □ □ □
Section 4 - This section refers to your weight and use of the telephone support service. 
1. What is your present weight?_________ (Please state Nwhether lbs / stone I kgs)
Do you still have contact with MAP?
Yes □ No n
If YES go to question 3 i If ^  please go to the end.
3. In the PAST month how often have you had contact with the MAP telephone support
service?
Never or 
less than 
once a 
month
Once a 2-3 times More
Less than 
once a 
week
Once a 
week
2-4 days 
a week
5-6 days 
a week
day. 
every day
a day, than 3 
every day times a 
day, 
every day
□ □ □ □ □ □ □  □
4. To what extent do the following describe how you have found the telephone support 
service?
Not at all Totally
Helpful 1 2 3 4 5
Caring 1 2 3 4 5
Personal 1 2 3 4 5
Informative 1 2 3 4 5
Understanding 1 2 3 4 5
Supportive 1 2 3 4 5
Thank you for your help with this study. Please return the questionnaire in the freepost 
envelope provided.
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Appendix 5: Further descriptive analyses 
Study 2: Short term changes in individuals taking orlistat From baseline 
to six months follow up.
I. Beliefs about causes, solutions and motivations.
Baseline 6 month follow up
Variable No Not sure Yes No Not sure Yes
Behavioural cause n=69 n=179 n=219 n=81 n=181 n=206
(14.8%) (38.3%) (46.9%) (17.3%) (38.7%) (44%)
Medical cause n=271 n=96 n=45 n=277 n=95 n=57
(65.8%) (23.3%) (10.9%) (64.6%) (22.1%) (13.3%)
Behavioural solution n=14 n=79 n=370 n=21 n=96 n=336
(394) (17.1%) (79.9%) (4.6%) (21.2%) (74.2%)
Medical solution n=191 n=195 n=61 n=204 n=189 n=52
(42.7%) (43.6%) (13.6%) (45.8%) (42.5%) (11.7%)
T1 Routine n=180 n=91 n=191
motivation (39%) (19.7%) (41.3%)
T1 Significant event n=380 n=52 n=8
motivation (66.4%) (9.1%) (1.4%)
T1 Symptom n=160 n=127 n=178
motivation (34.4%) (27.3%) (38.3%)
II. Illness beliefs
Baseline 6 month follow up
Item Low Not sure High Low Not sure High
Consequences n=29 n=126 n=405 n=54 n=162 n=350
(5.2%) (22.5%) (72.3%) (9.5%) (28.6%) (61.8%)
Timeline n=46 n=251 n=270 n=59 n=193 n=311
(8.1%) (44.3%) (47.6%) (10.5%) (34.3%) (55.2%)
Personal control n=124 n=231 n=209 n=111 n=238 n=216
(22%) (41%) (37.1%) (19.6%) (42.1%) (38.2%)
Treatment control n=30 n=119 n=416 n=86 n=133 n=343
(5.3%) (21.1%) (73.6%) (15.3%) (23.7%) (61%)
Identity n=110 n=210 n=242 n=139 n=188 n=236
(19.6%) (37.4%) (43.1%) (24.7%) (33.4%) (41.9%)
Concern n=11 n=64 n=492 n=27 n=65 n=474
(1.9%) (11.3%) (86.8%) (4.8%) (11.5%) (83.7%)
Understanding n=41 n=137 n=387 n=51 n=159 n=355
(7.3%) (24.2%) (68.5%) (9%) (28.1%) (62.8%)
Emotional response n=91 n=106 n=368 n=86 n=115 n—363
(16.1%) (18.8%) (65.1%) (15.2%) (20.4%) (64.4%)
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III. Side effects, cognitions and behaviour change.
Baseline 6 month follow up
Variable No Not sure Yes No Not sure Yes
Side effects n=276 n=152 n=50 n=214 n=121 n=31
(57.7%) (31.8%) (10.5%) (58.5%) (33.1%) (8.5%)
Behavioural cognitions n=103 n=116 n=272 n=55 n=86 n=242
(21%) (23.6%) (55.4%) (14.4%) (22.5%) (63.2%)
Medication cognitions n=310 n=85 n=82 n=227 n=83 n=51
(65%) (17.8%) (17.2%) (62.9%) (23%) (14.1%)
Diet behaviour change n=57 n=67 n=395 n=44 n=67 n=267
(11%) (12.9%) (76.1%) (11.6%) (17.7%) (70.6%)
Adherence behaviour n=449 n=18 n=15 n=311 n=30 n=14
change (93.2%) (3.7%) (3.1%) (87.6%) (8.5%) (3.9%)
IV. Adherence and imposed control
Baseline 6 month follow up
Variable No Not sure Yes No Not sure Yes
Imposed control n=289 n=154 n=68 n=223 n=102 n=51
(56.6%) (30.1%) (13.3%) (59.3%) (27.1%) (13.6%)
Adherence n=0 n=11 n=326 n=0 n=4 n=212
(0%) (3.3%) (96.7%) (0%) (1.9%) (98.1%)
V. Eating behaviour
Baseline 6 month follow up
Variable Never Sometimes Often Never Sometimes Often
Healthy snack n=33 n=389 n=121 n=65 n=380 n—83
(6.1%) (71.6%) (22.3%) (12.3%) (72%) (15.7%)
Unhealthy n=441 n=93 n=2 n=335 n=202 n=6
snack (82.3%) (17.4%) (0.4%) (61.7%) (37.2%) (1.1%)
Healthy meal 11=5 n=69 n=489 n=11 n=84 n=464
(0.9%) (12.3%) (86.9%) (2%) (15%) (83%)
Unhealthy n=422 n=108 n=2 n=399 n=139 n=5
meal (79.3%) (20.3%) (0.4%) (73.5%) (25.6%) (0.9%)
Healthy n=77 n=387 n=64 n=97 n=381 n=60
cooking (14.6%) (73.3%) (12.1%) (18%) (70.8%) (11.2%)
Unhealthy n=441 n=91 n=0 n=400 n=137 n=1
cooking (82.9%) (17.1%) , (0%) (74.3%) (25.5%) (0.2%)
High fat food n=469 n=49 n=1 n=453 n=66 n=7
(90.4%) (9.4%) (0.2%) (86.1%) (12.5%) (1.3%)
Low fat food n=43 n=259 n=238 n=45 n=247 n=254
(8%) (48%) (44.1%) (8.2%) (45.2%) (46.5%)
Baseline 6 month follow up
Fruit & Mean; SD: 1.502 Range: Mean: 4.51 SD: 1.683 Range:
vegetables 4.33 1-7 0-7
VI. Exercise
Baseline 6 month follow up
Variable Sedentary Regular
mild
vigorous Sedentary Regular
mild
vigorous
Exercise n=169
(30%)
n=199
(35.3%)
n=195
(34.6%)
n=183
(32.7%)
n=188
(33.6%)
n=189
(33.8%)
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VII. Help seeking
Baseline 6 month follow up
Profession None Sometimes Frequently None Sometimes Frequently
Practice nurse n=310 n=98 n=119 n=342 n=53 n=144
(58.8%) (18.6%) (22.6%) (63.5%) (9.8%) (26.7%)
GP n=218 n=174 n=145 n=317 n=88 n=135
(40.6%) (32.4%) (27%) (58.7%) (16.3%) (25%)
Hospital doctor n=466 n=24 n=15 n=496 n=12 n=10
(92.3%) (4.8%) (396) (95.8%) (2.3%) (1.9%)
Dietician n=409 n=70 n=49 n=468 n=30 n=26
(77.5%) (13.3%) (9.3%) (89.3%) (5.7%) (5%)
Counsellor n=487 n=14 n=4 n=506 n=7 n=4
(96.4%) (2.8%) (0.8%) (97.9%) (1.4%) (0,8%)
Psychologist n=499 n=3 n=2 n=513 n=1 n=0
(99%) (0.6%) (0.4%) (99.8%) (0.2%) (0%)
Slimming club n=259 n=137 n=141 n=443 n=27 n=50
organiser (48.2%) (25.5%) (26.3%) (85.2%) (5.2%) (9.6%)
Baseline 6 month follow up
0>1 day 
a week
1-4 days a 
week
5 days a 
week<3 times a 
day everyday
0>1 day 
a week
1-4 days a 
week
5 days a 
week<3 times a 
day everyday
Contact MAP n=546
(96.6%)
n=18
(3.2%)
n=1
(0.2%)
n=48
(98.4%)
n=9
(1.6%)
n=0
(0%)
Not at all Somewhat Totally Not at 
all
Somewhat Totally
MAP positive n=32
(6.5%)
n=76
(15.3%)
n=388
(78.2%)
n=67
(13.2%)
n=85
(16.7%)
n=356
(70.1%)
Study 3: Long term behaviour change and weight loss since taking 
orlistat. From baseline to 18 month follow up.
Beliefs about causes, solutions and motivations.
Baseline 18 month follow up
Variable No Not sure Yes No Not sure Yes
Behavioural cause n=64 n=159 n=189 n=71 n=153 n=200
(15.5%) (38.6%) (45.9%) (16.7%) (36.1%) (47.2%)
Medical cause n=256 n=89 n=38 n=255 n=96 n=46
(66.8%) (23.2%) (9.9%) (64.2%) (24.2%) (11.6%)
Behavioural solution n=12 n=72 n=338 n=15 n=90 n=312
(2.8%) (17.1%) (80.1%) (3.6%) (21.6%) (74.8%)
Medical solution n=175 n=179 n=60 n=172 n—173 n=66
(42.3%) (43.2%) (14.5%) (41.8%) (42.1%) (16.1%)
Baseline Routine n=163 n=79 n=172
motivation (39.4%) (19.1%) (41.5%)
Baseline Significant n=350 n=40 n=7
event motivation (88.2%) (10.1%) (1.8%)
Baseline Symptom n=161 n=107 n=152
motivation (38.3%) (25.5%) (36.2%)
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II. Illness beliefs
Baseline 18 month follow up
Item Low Not sure High Low Not sure High
Consequences n=16 n=11 n=79 n=49 n=38 n=98
(15.1%) (10.4%) (74.5%) (26.5%) (20.5%) (53%)
Timeline n=13 n=27 n=141 n=35 n=28 n=92
(7.2%) (14.9%) (77.9%) (22.6%) (18.1%) (59.4%)
Personal control n=50 n=54 n=147 n=95 n=49 n=140
(19.9%) (21.5%) (58.6%) (33.5%) (17.3%) (49.3%)
Treatment control n=13 n=14 n=65 n=128 n=30 n=87
(14.1%) (15.2%) (70.7%) (52.2%) (12.2%) (35.5%)
Identity n=52 n=50 n=122 n=102 n=45 n=132
(23.2%) (22.3%) (54.5%) (36.6%) (16.1%) (47.3%)
Concern n=3 n=2 n=28 n=25 n=19 n=52
(9.1%) (6.1%) (84.8%) (26%) (19.8%) (54.2%)
Understanding n=21 n=10 n=74 n=37 n=24 n=71
(20%) (9.5%) (70.5%) (28%) (18.2%) (53.8%)
Emotional response n=68 n=22 n=50 n=81 n=27 n=90
(48.6%) (15.7%) (35.7%) (40.9%) (13.6%) (45.5%)
I. Side effects, cognitions and behaviour change.
Baseline 18 month follow up
Variable No Not sure Yes No Not sure Yes
Side effects n=240 n=152 n=52 n=72 n=26 n=15
(54.1%) (34.2%) (11.7%) (63.7%) (23%) (13.3%)
Behavioural n=96 n=110 n=249 n=22 n=29 n=72
cognitions (21.1%) (24.2%) (64.7%) (17.9%) (23.6%) (58.5%)
Medication n=280 n=88 n=72 n=64 n=28 n=23
cognitions (63.6%) (20%) (16.4%) (55.7%) (24.3%) (20%)
Diet behaviour n=48 n=66 n=355 n=17 n=27 n=78
change (10.2%) (14.1%) (75.7%) (13.9%) (22.1%) (63.9%)
Adherence n=409 n=16 n=7 n=97 n=5 n=8
behaviour change (94.7%) (3.7%) (1.6%) (88.2%) (4.5%) (7.3%)
IV. Adherence and imposed control
Baseline (n=459) 18 month follow up (n=123)
No Not sure Yes No Not sure Yes
Imposed control n=254 n=130 n=75 n=68 n=34 n=21
(55.3%) (28.3%) (16.3%) (55.3%) (27.6%) (17.1%)
Baseline (n=412) 18 month follow up (n=109)
Adherence n=68 n=344 n=37 n=72
(16.5%) (83.5%) (33.9%) (66.1%)
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V. Eating behaviour
Baseline 18 month follow up
Variable No Sometimes Often No Sometimes Often
Healthy snack n=33 n=310 n=150 n=69 n=332 n=87
(6.7%) (62.9%) (30.4%) (14.1%) (68%) (17.8%)
Unhealthy snack n=379 n=105 n=3 n=244 n=216 n=21
(77.8%) (21.6%) (0.6%) (50.7%) (44.9%) (4.4%)
Home cooked meal n=10 n=68 n=436 n=14 n=73 n=421
(1.9%) (13.2%) (84.8%) (2.8%) (14.4%) (82.9%)
T akeaway/processed/ n=378 n=100 n=4 n=351 n=137 n=3
ready meal (78.4%) (20.7%) (0.8%) (71.5%) (27.9%) (0.6%)
Healthy cooking n=88 n=158 n=232 n=119 n=176 n=192
(18.4%) (33.1%) (48.5%) (24.4%) (36.1%) (39.4%)
Unhealthy cooking n=388 n=92 n=5 n=347 n=127 n=12
(80%) (19%) (1%) (71.4%) (26.1%) (2.5%)
High fat food n=420 n=52 n=3 n=366 n=104 n=8
(88.4%) (10.9%) (0.6%) (76.6%) (21.8%) (1.7%)
Low fat food n=35 n=236 n=219 n=37 n=241 n=207
(7.1%) (48.2%) (44.7%) (7.6%) (49.7%) (42.7%)
Fruit and vegetables Mean: 4.33 SD: 1.54 Range:
0-7
Mean: 4.02 SD: 1.638 Range:
0-7
VI. Exercise
Baseline 18 month follow up
Variable Sedentary Regular
mild
vigorous Sedentary Regular
mild
vigorous
Exercise n=155 n=173 n=185 n=169 n=160 n=175
(30.2%) (33.7%) (36.1%) (33.5%) (31.7%) (34.7%)
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VIL Help seeking
Baseline 18 month follow up
Profession None Sometimes Frequently None Sometimes Frequently
Practice nurse n=282 n=84 n=114 n=401 n=41 n=65
(58.8%) (17.5%) (23.8%) (79.1%) (8.1%) (12.8%)
GP n=197 n=158 n=136 n=385 n=59 n=63
(40.1%) (32.2%) (27.7%) (75.9%) (11.6%) (12.4%)
Hospital doctor n=421 n=25 n=19 n=477 n=16 n=11
(90.5%) (5.4%) (4.1%) (94.6%) (3.2%) (2.2%)
Dietician n=359 n=73 n=50 n=468 n=19 n=20
(74.5%) (15.1%) (10.4%) (92.3%) (3.7%) (3.9%)
Counsellor n=446 n=10 11=6 n=496 n=3 n=5
(96.5%) (2.2%) (1.3%) (98.4%) (0.6%) (1%)
Psychologist n=454 n=5 n=5 n=499 n=2 n=3
(97.8%) (1.1%) (1.1%) (99%) (0.4%) (0.6%)
Slimming club n=244 n=128 n=113 n=421 n=22 n=61
organiser (50.3%) (26.4%) (23.3%) (83.5%) (4.4%) (12.1%)
Baseline 18 month follow up
0>1 day 1 -4 days a 5 days a 0>1 day 1-4 days a 5 days a
a week week week<3 a week week week<3
times a day times a day
everyday everyday
Contact MAP n=492 n=17 11=0 n=16 n=0 n=1
(96.7%) (3.3%) (0%) (94.1%) (0%) (5.9%)
Baseline
18 months still Yes No
in contact with n=18 n=489
MAP (3.6%) (96.4%)
Baseline 18 month follow up
Not at all Somewhat Totally Not at all Somewhat Totally
MAP positive n=33 n=75 n=344 n=0 n=1 n=14
(7.3%) (16.6%) (76.1%) (0%) (6.7%) (93.3%)
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study 4: The process of behaviour change since beginning to take orlistat. 
From baseline through 6 month, 12 month and 18 month follow up.
Weight history
Highest weight ever Mean = 107.81 SD = 21.29
(kg) Range = 63.5-184
Lowest weight since 18 yrs (kg) Mean = 68.32 SD = 15.84
Range = 38.1-120.66
Desired weight Mean = 72.14 SD = 12.60
(kg) Range = 50.80-125.00
Most weight lost Mean = 17.08 SD = 9.73
(kg) Range = 1.13-50.80
How long maintained Mean = 24.08 SD = 37.17
(months) Range = 0-360
Currently trying to lose weight Yes No
n= 290 (99.7%) n= 1 (0.3%)
Age first overweight Mean = 26.55 SD = 14.50
(yrs) Range = 1-72
Age first tried to lose weight (yrs) Mean = 30.03 SD = 14.62
Range = 2-75
Years trying to lose weight Mean = 17.47 S D = 13.46
Range = 0-58
ii. Beliefs about causes, solutions and motivations
Time 1 Time 2
Variable No Not sure Yes No Not sure Yes
Behavioural cause n=34 n=100 n=103 n=40 n=100 n=117
(14.3%) (42.2%) (43.5%) (15.6%) (38.9%) (45.5%)
Medical cause n=142 n=52 n=25 n=156 n=61 n=21
(64.8%) (23.7%) (11.4%) (65.5%) (25.6%) (8.8%)
Behavioural solution n=9 n=45 n=186 n=10 n=58 n=178
(3.8%) (18.8%) (77.5%) (4.1%) (23.6%) (72.4%)
Medical solution n=101 n=105 n=29 n=106 n=119 n=26
(43%) (44.7%) (12.3%) (42.2%) (47.4%) (10.4%)
Time 1 Routine motivation n=105 n=46 n=86
(44.3%) (19.4%) (36.3%)
Time 1 Significant event n=201 n=27 n=2
motivation (87.4%) (11.7%) (0.9%)
Time 1 Symptom n=94 n=66 n=82
motivation (38.8%) (27.3%) (33.9%)
Time 3 Time 4
Variable No Not sure Yes No Not sure Yes
Behavioural cause n=52 n=106 n=88 n=45 n=101 n=111
(21.1%) (43.1%) (35.8%) (17.5%) (39.3%) (43.2%)
Medical cause n=160 n=50 n=24 n=147 n=64 n=29
(68.4%) (21.4%) (10.3%) (61.3%) (26.7%) (12.1%)
Behavioural solution n=13 n=74 n=162 n=10 n=58 n=177
(5.2%) (29.7%) (65.1%) (4.1%) (23.7%) (72.2%)
Medical solution n=112 n=104 n=25 n=102 n=108 n=38
(46.5%) (43.2%) (10.4%) (41.1%) (43.5%) (15.3%)
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iii. Illness beliefs
Time 1 Time 2
Item Low Not sure High Low Not sure High
Consequences n=18 n=69 n=203 n=29 n=82 n=161
(6.2%) (23.8%) (70%) (10.7%) (30.1%) (59.2%)
Timeline n=20 n=121 n=153 n=34 n=97 n=140
(6.8%) (41.2%) (52%) (12.5%) (35.8%) (51.7%)
Personal control n=62 n=115 n=115 n=53 n=114 n=112
(21.2%) (39.4%) (39.4%) (19%) (40.9%) (40.1%)
Treatment control n=15 n=58 n=221 n=33 n=61 n=156
(5.1%) (19.7%) (75.2%) (13.2%) (24.4%) (62.4%)
Identity n=60 n=107 n=123 n=67 n=101 n=116
(20.7%) (36.1%) (42:4%) (23.6%) (35.6%) (40.8%)
Concern n=4 n=39 n=250 n=13 n=37 n=201
(1.4%) (13.3%) (85.3%) (5.2%) (14.7%) (80.1%)
Understanding n=22 n=59 n=212 n=22 n=72 n=173
(7.5%) (20.1%) (72.4%) (8.2%) (27%) (64.8%)
Emotional response n=59 n=53 n=181 n=53 n=64 n=152
(20.1%) (18.1%) (61.8%) (19.7%) (23.8%) (56.5%)
Time 3 Time 4
Item Low Not sure High Low Not sure High
Consequences n=37 n=86 n=143 n=51 n=95 n=144
(13.9%) (32.3%) (53.8%) (17.6%) (32.8%) (49.7%)
Timeline n=25 n=74 n=148 n=38 n=76 n=175
(10.1%) (30%) (59.9%) (13.1%) (26.3%) (60.6%)
Personal control n=60 n=117 n=104 n=80 n=109 n=102
(21.4%) (41.6%) (37%) (27.5%) (37.5%) (35.1%)
Treatment control n=56 n=59 n=133 n=75 n=64 n=151
(22.6%) (23.8%) (53.6%) (25.9%) (22.1%) (52.1%)
Identity n=74 n=92 n=116 n=89 n=104 n=98
(26.2%) (32.6%) (41.1%) (30.6%) (35.7%) (33.7%)
Concern n=14 n=52 n=179 n=26 n=52 n=213
(5.7%) (21.2%) (73.1%) (8.9%) (17.9%) (73.2%)
Understanding n=27 n=76 n=155 n=35 n=68 n=187
(10.5%) (29.5%) (60.1%) (12.1%) (23.4%) (64.5%)
Emotional response n=59 n=61 n=150 n=67 n=77 n=147
(21.9%) (22.6%) (55.6%) (23%) (26.5%) (50.5%)
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iv. Side effects, cognitions and behaviour change
Time 1 Time 2
Variable No Not sure Yes No Not sure Yes
Side effects
Behavioural cognitions
Medication cognitions
Diet behaviour change
Adherence behaviour 
change______________
n=138
(54.3%)
n=62
(24.4%)
n=148
(58.5%)
n=27
(10.1%)
n=235
(95.1%)
n=90
(35.4%)
n=65
(25.6%)
n=60
(23.7%)
n=39
(14.6%)
n=10
(4%)
n=26
(10.2%)
n=127
(50%)
n=45
(17.8%)
n=202
(75.4%)
n~2
(0.8%)
n=125
(58.4%)
n=32
(14.3%)
n=139
(64.1%)
n=22
(10%)
n=195
(91.1%)
n=70
(32.7%)
n=57
(25.6%)
n=45
(20.7%)
n=45
(20.4%)
n=13
(6 .1%)
n=19
(8.9%)
n=134
(60.1%)
n=33
(15.2%)
n=154
(69.7%)
n=6
(2 .8%)
Time 3 Time 4
Variable No Not sure Yes No Not sure Yes
Side effects
Behavioural cognitions
Medication cognitions
Diet behaviour change
Adherence behaviour 
change______________
n=79
(66.9%)
n=19
(15.3%)
n=82
(69.5%)
n=14
(11.2%)
n=106
(89.8%)
n=27
(22.9%)
n=28
(22 .6%)
n=23
(19.5%)
n=29
(23.2%)
n=10
(8.5%)
n=12
(10.2%)
n=77
(62.1%)
n=13
(11%)
n=82
(65.6%)
n=2
(1.7%)
n=54
(65.1%)
n=15
(17.4%)
n=49
(59%)
n=16
(18.6%)
n=73
(90.1%)
n=16
(19.3%)
n=21
(24.4%)
n=20
(24.1%)
n=16
(18.6%)
n=4
(4.9%)
n=13
(15.7%)
n=50
(58.1%)
n=14
(16.9%)
n=54
(62.8%)
n=4
(4.9%)
V. Adherence and imposed control
Time 1 (n=261) Time 2 (n=220)
No Not sure Yes No Not sure Yes
Imposed control n=146 n=81 n=34 n=135 n=62 n=23
(55.9%) (31%) (13%) (61.4%) (28.2%) (10.5%)
Time 3 (n=125) Time 4 (n=89)
No Not sure Yes No Not sure Yes
Imposed control n=68 n=42 n=15 n=53 n=24 n=12
(54.4%) (33.6%) (12%) (59.6%) (27%) (13.5%)
Time 1 (n=237) Time 2 (n=208)
Adherence n=37 n=200 n=37 n=171
(15.6%) (84.4%) (17.1%) (82.2%)
Time 3 (n=116) Time 4 (n=81)
Adherence n=28 n=88 n=27 n=54
(24.1%) (75.9%) (33.3%) (66.7%)
343
vi. Eating behaviour
Time 1 Time 2
Variable No Sometimes Often No Sometimes Often
Healthy snack n=20 n=184 n=78 n=32 n=188 n=58
(7.1%) (65.2%) (27.7%) (11.5%) (67.6%) (20.9%)
Unhealthy snack n=224 n=56 n=1 n=177 n=100 n=5
(79.7%) (19.9%) (0.4%) (62.8%) (35.5%) (1.8%)
Home cooked meal n=5 n=35 n=254 n=7 n=45 n=238
(1.7%) (11.9%) (86.4%) (2.4%) (15.5%) (82.1%)
T akeaway/processed/ n=224 n=47 n=3 n=220 n=59 n=5
ready meal (81.8%) (17.2%) (1.1%) (77.5%) (20.8%) (1.8%)
Healthy cooking n=49 n=99 n=128 n=59 n=113 n=110
(17.8%) (35.9%) (46.4%) (20.9%) (40.1%) (39%)
Unhealthy cooking n=224 n=52 n=0 n=217 n=62 n=3
(81.2%) (18.8%) (0%) (77%) (22%) (1.1%)
High fat food n=235 n=33 n=2 n=247 n=34 n=3
(87%) (12.2%) (0.7%) (87%) (12%) (1.1%)
Low fat food n=22 n=134 n=128 n=20 n=135 n=131
(7.7%) (47.2%) (45.1%) (7%) (47.2%) (45.8%)
Fruit and vegetables Mean: SD: 1.55 Range: Mean: SD: 1.66 Range:
4.36 0-7 4.36 0-7
Time 3 Time 4
Variable No Sometimes Often No Sometimes Often
Healthy snack n=26 n=197 n=58 n=30 n=201 n=51
(9.3%) (70.1%) (20.6%) (10.6%) (71.3%) (18.1%)
Unhealthy snack n=170 n=104 n=8 n=154 n=113 n=7
(60.3%) (36.9%) (2.8%) (56.2%) (41.2%) (2.6%)
Home cooked meal n=6 n=46 n=238 n=7 n=37 n=245
(2.1%) (15.9%) (82.1%) (2.4%) (12.8%) (84.8%)
T akeaway/processed/ n=212 n=67 n=4 n=207 n=73 n=2
ready meal (74.9%) (23.7%) (1.4%) (73.4%) (25.9%) (0.7%)
Healthy cooking n=63 n=110 n=103 n=70 n=109 n=100
(22.8%) (39.9%) (37.3%) (25.1%) (39.1%) (35.8%)
Unhealthy cooking n=216 n=58 n=2 n=214 n=65 n=3
(78.3%) (21%) (0.7%) (75.9%) (23%) (1.1%)
High fat food n=215 n=54 n=1 n=214 n=59 n=4
(79.6%) (20%) (0.4%) (77.3%) (21.3%) (1.4%)
Low fat food n=26 n=125 n=128 n=22 n=137 n=124
(9.3%) (44.8%) (45.9%) (7.8%) (48.4%) (43.8%)
Fruit and vegetables Mean: SD: 1.55 Range: Mean: SD: 1.64 Range:
4.26 0-7 4.25 0-7
vii. Exercise
Time 1 Time 2
Variable Sedentary Regular mild vigorous Sedentary Regular mild vigorous
Exercise n=94 
(32%)
n=104
(35.4%)
n=96 n=101 
(32.7%) (34.8%)
n=86
(29.7%)
n=103
(35.5%)
Time 3 Time 4
Variable Sedentary Regular mild vigorous Sedentary Regular mild vigorous
Exercise n=80
(27.4%)
n=104
(35.6%)
n=108 n=105 
(37%) (36.3%)
n=85 
■ (29.4%)
n=99
(34.3%)
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viii. Help seeking
Time 1 Time 2
Profession None Sometimes Frequently None Sometimes Frequently
Practice nurse n=160 n=47 n=69 n=183 n=29 n=75
(58%) (17%) (25%) (63.8%) (10.1%) (26.1%)
GP n=107 n=91 n=84 n=166 n=50 n=65
(37.9%) (32.3%) (29.8%) (59.1%) (17.8%) (23.1%)
Hospital doctor n=241 n=16 n=11 n=262 n=6 n=6
(89.9%) (6%) (4.1%) (95.6%) (2.2%) (2.2%)
Dietician n=206 n=39 n=28 n=24t n=20 n=19
(75.5%) (14.3%) (10.3%) (86.1%) (7.1%) (6.8%)
Counsellor n=256 n=4 n=2 n=266 n=3 n=3
(97.7%) (1.5%) (0.8%) (97.8%) (1.1%) (1.1%)
Psychologist n=258 n=4 n=1 n=272 n=0 n=1
(98.1%) (1.5%) (0.4%) (99.6%) (0%) (0.4%)
Slimming club n=145 n=79 n=54 n=245 n=12 n=17
organiser (52.2%) (28.4%) (19.4%) (89.4%) (4.4%) (6.2%)
Time 3 Time 4
Profession None Sometimes Frequently None Sometimes Frequently
Practice nurse n=213 n=21 n=56 n=230 n=23 n=38
(73.4%) (7.2%) (19.3%) (79%) (7.9%) (13.1%)
GP n=196 n=38 n=53 n=220 n=33 n=37
(68.3%) (13.2%) (18.5%) (75.9%) (11.4%) (12.8%)
Hospital doctor n=275 n=4 n=6 n=277 n=10 n=3
(96.5%) (1.4%) (2.1%) (95.5%) (3.4%) (1%)
Dietician n=267 n=10 n=10 n=271 n~8 n=12
(93%) (3.5%) (3.5%) (93.1%) (2.7%) (4.1%)
Counsellor n=279 n=3 n=3 n=286 n=2 n=2
(97.9%) (1.1%) (1.1%) (98.6%) (0.7%) (0.7%)
Psychologist n=281 n=2 n=1 n=289 n=1 n=0
(98.9%) (0.7%) (0.4%) (99.7%) (0.3%) (0%)
Slimming club n=253 n=10 n=23 n=247 n=11 n=32
organiser (88.5%) (3.5%) (896) (85.2%) (3.8%) (11%)
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ix. Contact and experiences of MAP
Time 1 Time 2
0>1 day a 1-4 days 5 days a 0>1 day 1-4 days a 5 days a week<3
week a week week<3 times a a week week times a day
day everyday everyday
Contact n=280 n=10 n=0 n=286 n=3 n=(3
MAP (96.6%) (3.4%) (0%) (99%) (1%) (0%)
Time 3 Time 4
0>1 day a 1-4 days 5 days a 0>1 day 1-4 days a 5 days a week<3
week a week week<3 times a a week week times a day
day everyday everyday
Contact n=21 n=0 n=1 n=8 n=0 n= 1
MAP (95.5%) (0%) (4.5%) (88.9%) (0%) (11.1%)
Time 3 Time 4
Yes No Yes No
Stiil in contact with n=21 n=272 n=10 n=280
MAP (7.2%) (92.8%) (3.4%) (96.6%)
Time 1 Time 2
Not at ail Somewhat Totally Not at all Somewhat Totally
MAP positive n=19 n=54 n=189 n=31 n=48 n=194
(7.3%) (20.6%) (72.1%) (11.4%) (17.6%) (71.1%)
Time 3 Time 4
Not at all Somewhat Totally Not at all Somewhat Totally
MAP positive n=1 n=6 n=16 n=0 n=1 n=7
(4.3%) (26.1%) (69.6%) (0%) (12.5%) (87.5%)
X . Obesity surgery
Time 1 Time 2
Yes Maybe No Yes Maybe No
Had surgery n=1 n=288 n=2 n=292
(0.3%) (99.7%) (0.7%) (99.3%)
Would have surgery in the n=10 n=5 n=271 n=11 n=1 n=281
future (3.5%) (1.7%) (94.8%) (3.8%) (0.3%) (95.9%)
Time 3 Time 4
Yes Maybe No Yes Maybe No
Had surgery n=1 n=292 n=1 n=290
(0.3%) (99.7%) (0.3%) (99.7%)
Would have surgery in the n=17 n=4 n=271 n=16 11=5 n=269
future (5.8%) (1.4%) (92.8%) (5.5%) (1.7%) (92.8%)
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